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Abstract 
Background 
Cholangiocarcinoma (CC) is a malignancy of the bile ducts and mortality is high as 
patients present too late for curative surgery. In most cases of CC the aetiology is 
unknown, whilst diagnosis and staging are challenging. The hepatobiliary system 
excretes carcinogenic toxins and genetic mutations in biliary transporters lead to 
dysfunction and cholestasis, potentially contributing to cholangiocarcinogenesis. 
Polymorphisms in the NKG2D receptor have previously been associated with CC in 
primary sclerosing cholangitis (PSC). Such a role has not been investigated in sporadic 
CC. CC is difficult to diagnose, particularly in those with PSC. The transition from 
benign to malignant biliary disease is likely to be reflected in changes to the plasma 
proteome. However, current plasma biomarkers do not reliably distinguish benign from 
malignant biliary strictures. Elevation of neutrophil gelatinase-associated lipocalin 
(NGAL) has been demonstrated in the bile of patients with CC but has not been 
investigated as a plasma protein biomarker. Staging of CC is inaccurate, with only a 
minority of operated patients cured. Higher resolution MRI would improve diagnosis 
and staging. The work presented in this thesis represents a multimodality approach to 
enhance the diagnosis of CC:  
Genetic studies 
Genetic variation in major biliary transporter proteins, and the NKG2D receptor, were 
investigated. Single nucleotide polymorphisms (SNPs) in candidate genes were 
selected using HapMap. DNA from 173 CC patients and 265 healthy controls was 
genotyped. SNPs in ABCB11, MDR3 and ATP8B1 were nominally associated with 
altered susceptibility to CC, suggesting a potential role in cholangiocarcinogenesis. 
The previous association of NKG2D variation with CC in PSC was not replicated in 
sporadic CC, suggesting a possible difference in pathogenesis. 
Protein studies 
Plasma from subjects with CC, benign disease, and from healthy controls was studied. 
Two proteomic techniques, liquid chromatography-tandem mass spectrometry (LC-
MS/MS) and surfaced enhanced laser desorption ionization time-of-flight MS (SELDI-
TOF MS), were utilised. Differentially expressed proteins were identified where 
possible. LC-MS/MS fully identified six proteins that were differentially expressed in CC 
compared to gall stone disease patients. SELDI-TOF MS identified seven m/z peaks 
that showed significant utility in discriminating CC from PSC controls. An ELISA 
approach was used to study plasma NGAL levels in CC. Although differentially 
expressed between CC and healthy control groups, the utility of NGAL in discriminating 
CC from PSC was limited. 
Imaging studies 
An endoscope-mounted MR coil and intraductal MR detector coil were developed. 
Quantitative resolution and signal-to-noise-ratio (SNR) testing, and qualitative tissue 
discrimination appraisal, were undertaken. Sub-0.7mm resolution and excellent SNRs 
have been demonstrated. High-resolution has been demonstrated in imaged tissue. 
Imaging with the new devices compares favourably with endoscopic ultrasound 
imaging. 
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1. Introduction 
Cholangiocarcinoma (CC) was first described in 1840. Dr Max Durand-Fardel, a 
French physician, published a monograph on four patients with jaundice who rapidly 
succumbed to their disease. In three cases, post mortem examination revealed 
tumours of the pancreas obstructing the bile duct. In the final case he reported ‘a soft, 
whitish, cancerous material, completely filling the bile duct that did not extend beyond 
the wall of the duct’. Durand-Fardel concluded that this represented a primary cancer 
of the extrahepatic bile duct.[1] CC is a cancer that arises in the epithelial cells of the 
bile ducts and has features of cholangiocyte differentiation.[2] 
1.1 Epidemiology 
Worldwide, CC is the second commonest primary liver tumour, after hepatocellular 
carcinoma (HCC). CC is the commonest cause of death from primary liver cancer in 
the UK, with over 1000 deaths per year.[3] It occurs in both sexes with a slightly higher 
incidence in men.[4] In Western European countries, such as the United Kingdom, the 
median age at diagnosis of CC is 65 years and it rarely presents before the 5th decade, 
except in patients with primary sclerosing cholangitis (PSC) or uncommon genetic 
diseases of the biliary transporter proteins.[5] CC incidence varies hugely between 
regions and countries of the world. Incidence in Australia is relatively low, at 0.2 
cases/100,000 men. The population of northern Thailand, and of other areas along the 
course of the Mekong River from the Yunnan Province of China to the Lao Peoples’ 
Democratic Republic, has a very high rate - 96 cases/100,000 men (100-fold that of the 
UK). This very high rate has been clearly associated with endemic liver fluke 
infestation, with an earlier age of presentation than in Europe.[5] Although geographical 
variation in CC incidence is largely attributable to the prevalence of environmental risk 
factors, it is likely that ethnic or genetic factors may also contribute. Studies of the US 
population have shown wide variation between different ethnic groups with rates of 
1.22/100,000 in Hispanic Americans and 0.3/100,000 in African Americans.[6]  
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Since 1968, there has been a 15-fold increase in mortality from CC in the UK, with a 
similar global trend across industrialised countries.[7-9] In most epidemiological studies, 
this is ascribed to increasing incidence of intrahepatic CC (CC developing proximal to 
the liver hilum), with extrahepatic CC rates remaining stable. A proportion of this rise in 
IHCC has been attributed to misclassification of hilar CC as IHCC.[10] However, it is 
likely that this accounts for only part of the increase in IHCC. Increasingly sophisticated 
diagnostic tools, and a global increase in the prevalence of IHCC risk factors, such as 
cirrhosis of any cause, may have also contributed to this increase.[11] 
The mortality rate of CC is equal to its incidence. Mortality from CC is so high as most 
patients present too late for complete surgical resection, the only cure, and the cancer 
is generally resistant to chemotherapy and radiotherapy. The prognosis of CC is short, 
with median survival of 3-6 months in patients receiving palliative care.[12] Overall, 
median survival in developed countries is less than two years.[12, 13] 
1.2 Risk factors 
Most cases of CC are sporadic, with no known predisposing risk factor. The prevalence 
of risk factors, and hence their influence on CC incidence rates, varies with geography 
and ethnicity.  
1.2.1 Inflammatory risk factors 
Known risk factors for CC in Western populations include PSC, chronic secondary 
cholangitis and choledocholithiasis.[14-16] PSC is the commonest known cause of CC in 
the West but still only accounts for around 10% of CC cases.[17] Worldwide, chronic 
infestation of the biliary tree with the parasitic liver fluke Opisthorchis viverrini (OV) is a 
major risk factor for CC. In Northern Thailand a 5 to 15-fold increased risk of CC is 
described in OV infested individuals.[18, 19] Hepatolithiasis, in which calcium bilirubinate 
calculi form within the intrahepatic biliary tree, has been shown to increase risk of CC 
substantially in Western and Asian populations.[20, 21] It is rare in the West but has a 
high prevalence in some Southeast Asian countries such as Taiwan (20%).[22] 
Introduction 
 25 
Hepatolithiasis has proven to be a major risk factor for IHCC in Taiwanese, Chinese 
and Korean studies.[20, 23, 24] Anatomical anomalies in the biliary tree caused by Caroli’s 
syndrome (discussed below) and unresected choledochal cyst carry a lifetime risk CC 
of around 15%.[25, 26] All of these conditions cause structural bile duct abnormalities 
including dilatation and irregularity. These are thought to lead to biliary stasis, reflux of 
pancreatic juice into the bile duct, deconjugation of biliary toxins and predisposition to 
chronic secondary bacterial cholangitis. Each of these mechanisms, or a combination 
of them, may result in biliary epithelial injury and inflammation.[26-28] 
The viral hepatitides have been investigated as potential risk factors for CC. Hepatitis 
C infection has been examined in multiple case-control studies and found to confer a 
relative risk of CC between 2.55 and 9.7, well above the background population risk.[14, 
15, 29-34] A pathologic study of 1058 explanted livers sought evidence of dysplastic, 
precursor intrahepatic biliary lesions in patients with chronic hepatitis C (n=511), 
alcohol (n=112) or both (n=85) as well as chronic liver disease of other aetiology 
(n=216) and acute liver failure (n=134). A total of 1058 explanted livers were examined 
and 19 (1.8%) were found to have dysplastic biliary lesions. All the dysplastic changes 
were found in patients with hepatitis C (10/19), alcohol abuse (5/19) or both (4/19). In 
all cases, the dysplasia was multifocal.[35] Hepatitis B has also been investigated and, 
in the majority of published case-control studies, associated with an increased risk of 
CC.[15, 23, 24, 33, 34] HIV positivity was associated with a modest increase in CC risk in one 
study, but the strength of this finding is limited.[5] Non-alcoholic fatty liver, as well as 
diabetes and obesity without demonstrable liver disease, have recently been linked 
with increased risk of CC.[22] Cirrhosis of any cause increases the risk of CC, with a 
number of case-control studies producing relative risk estimates of between 5 and 
27.[14, 15, 24, 32, 36] Causative mechanisms have not been elucidated for these risk factors, 
but chronic inflammation of the liver is a feature common to them all. 
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1.2.2 Toxic risk factors 
Pro-mutagenic DNA adducts have been identified in CC-adjacent human tissue, 
indicating prior exposure to DNA-damaging exogenous toxins.[37] A variety of toxins 
and occupational risks have been implicated in CC, with varying strength of evidence. 
Thorotrast, an α particle-emitting radiological contrast containing thorium oxide, was 
used and subsequently proscribed in the middle of the last century. Thorium oxide has 
a long half-life and is concentrated in the reticuloendothelial system. It has been 
incontrovertibly linked with CC and a number of other malignancies, with a latency 
period of 20-35 years.[38, 39] Thorotrast exposure increases the risk of CC to 300 times 
that of the general population.[5] Epidemiological studies have implicated tobacco 
smoking and alcohol use, although conflicting evidence also exists.[14, 16, 33, 40, 41] 
Occupational exposure to the manufacture of rubber, petrochemicals and varnishes 
has been identified as an independent risk factor for CC.[42] These associations have 
been ascribed to exposure to chemical by-products, including dioxins and 
nitrosamines.[42] A proposed common pathway of these environmental risks is 
exposure of the biliary epithelium to oncogenic substances, which are concentrated in 
the bile, causing a sequence of genetic mutations and thereby initiating and promoting 
neoplastic change.[37]  
1.2.3 Genetic risk factors for CC 
1.2.3.1 Genetic diseases as risk factors for CC 
Lynch syndrome (HNPCC) and biliary papillomatosis, which are both genetic 
conditions, increase risk of CC.[43] Biliary papillomatosis carries a huge (85%) lifetime 
risk of progression to CC.[44] These genetic diseases appear to offer an epithelial 
substrate that is highly vulnerable to subsequent oncogenic factors. Caroli’s disease 
and syndrome represent a spectrum of bile duct ectasia, dilatation and congenital 
hepatic fibrosis, and increase the risk of CC (discussed in section 1.2.1, above). 
Caroli’s disease and syndrome appear to be inherited as autosomal recessive traits. 
The genetics of these conditions is incompletely understood, but there is a close 
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association with autosomal recessive polycystic kidney disease (ARPKD). The gene 
responsible lies on chromosome 6 and has been named PKHD1 (polycystic kidney and 
hepatic disease 1). The protein encoded by PKHD1 is expressed predominantly in the 
kidney, less so in the liver and in low abundance in the pancreas and lungs. The 
protein is found on the primary cilia and centrosome complex of renal tubule cells and 
cholangiocytes and appears to play a role in cell adhesion and proliferation.[45-47] 
Genetic defects leading to congenital abnormalities in bile salt transporter proteins 
such as bile salt exporter pump, (BSEP/ABCB11), familial intrahepatic cholestasis 
protein 1 (FIC1/ATP8B1) and multidrug resistant protein 3 (MDR3/ABCB4) cause 
cholestatic disease in infants. These defects result in unstable bile content and 
deconjugation of xenobiotics, previously conjugated in the liver.[9, 48, 49] Very early onset 
hepatocellular carcinoma and CC have been reported in children with progressive 
familial cholestasis type II (PFIC II), caused by BSEP/ABCB11 deficiency.[50-52] 
1.2.3.2 Specific genetic polymorphisms as risk factors for CC 
1.2.3.2.1 Specific polymorphisms and CC risk factors 
1.2.3.2.1.1 Genetic risk factors for gallstone disease (GSD) 
Cholelithiasis is a very common, but weak, risk factor for CC. In a large Scandinavian 
twin study, genetic factors were calculated to account for 25% of the gallstone risk 
among the twins.[53] Polymorphisms in UGT1A1 (implicated in Gilbert’s syndrome) may 
predispose to pigment gallstone formation. ABCG8, encoding part of cholesterol 
transporter, was unambiguously associated with an increased gallstone risk.[54, 55] 
Association has also been made between variants of NR1H4 (the gene that encodes 
the nuclear bile salt receptor FXR) and SLC10A2 (encoding the apical sodium-
dependant bile acid transporter) and cholelithiasis.[56, 57] Recent studies have 
demonstrated a number of polymorphisms in other biliary transporter genes, including 
ABCB4 and ABCB11, which increase the risk of cholelithiasis.[58-61]  
1.2.3.2.1.2 Genetic risk factors for PSC 
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Genetic factors in primary sclerosing cholangitis (PSC), the major risk factor for CC in 
Western populations, have been investigated extensively. Genetic variation in the 
human leukocyte antigen (HLA) complex on chromosome 6p21 has been repeatedly 
associated with PSC.[62, 63] Studies of specific genes have been small and negative to 
date, including a study of ABCB11 and ABCB4 (n= 37).[64] A recent national genome 
wide association study (GWAS) in Norway demonstrated associations between 
polymorphisms in HLA-B, macrophage-stimulating 1 (MST1), G protein-coupled bile 
acid receptor 1 (GPBAR1) and PSC.[65] A large-scale international GWAS in PSC is 
underway. 
1.2.3.2.2 Specific genetic polymorphisms and risk of CC 
A number of studies of candidate genes in CC, each examining between 30 and 216 
cases, have reported a positive association with the disease. All have yet to be 
replicated in validation cohorts. These studies, and their principal findings are 
summarised in Table 1.1. 
1.2.3.2.2.1 Xenobiotic metabolism, folate metabolism and DNA repair 
These studies have been performed on populations exclusively from the Far East. 
Polymorphisms affecting enzymes of xenobiotic metabolism that have been associated 
with CC include glutathione S-transferase (GST01), N-acetyltransferase 2 (NAT2) and 
cytochrome P450 1A2 (CYP1A2). Polymorphisms in methylenetetrahydrofolate 
reductase (MTHFR), involved in folate metabolism, and XRCC1, involved in DNA 
repair mechanisms, have also been implicated in single studies.[66-69] Several of these 
studies included gallbladder cancer, and even ampullary tumours, with CC cases.  
1.2.3.2.2.2 Alpha-1 antitrypsin (A1AT) 
In a German cohort, alpha-1-antitrysin (α1AT) Z heterozygosity was found to be over-
represented in patients with CC suggesting a potential contribution of aberrant α1AT 
function or excretion in biliary carcinogenesis.[70] 
1.2.3.2.2.3 MRP2 
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A recent German study, in a cohort of 60 patients, found a polymorphism in multidrug 
resistance-associated protein 2 gene (MRP2/ABCC2) to be associated with CC.[71] 
MRP2 is an ATP-binding cassette biliary transporter expressed on the apical 
membrane of hepatocytes and cholangiocytes. The c.3972 C>T SNP genotype was 
significantly more frequent in CC (39.2%) vs. controls (26.0%, p = 0.022) OR of 1.83 
(95% CI = 1.09 - 3.08). MRP2 is a reasonable candidate susceptibility protein as it 
plays a critical role in the excretion of xenobiotics and polymorphisms in ABCC2 have 
been associated with HCC. This is the only published study to date of genetic variation 
in biliary transporter proteins as risk factors for CC.  
1.2.3.2.2.4 Natural killer cell protein G2D (NKG2D)  
Genes modifying Natural Killer cell activation (natural killer cell receptor G2D, NKG2D) 
have been implicated in a number of neoplasms. This gene has been investigated in a 
cohort of Scandinavian PSC patients. 2 of the seven SNPs studied were associated 
with altered susceptibility to CC in PSC.[72] Polymorphisms in NKG2D are yet to be 
investigated in sporadic CC. 
1.3 Pathogenesis 
CC results from malignant transformation of cholangiocytes, although some CCs 
appear to arise from hepatic progenitor cells.[73, 74] In comparison to other 
gastrointestinal tract malignancies, the pathway of cholangiocyte transformation is 
poorly understood. There is evidence of a stepwise process, with non-invasive pre-
malignant precursor states now described. Biliary intraepithelial neoplasia (BilIN) 
lesions have been defined, and intraductal papillary mucinous neoplasm (IPMN) 
appears to be a less common precursor, similar to the same lesions found in the 
pancreas.[75, 76] Recent work on the molecular pathways involved, including gene 
expression studies, has been fruitful. There is now a reasonable consensus on some of 
the molecular events that contribute to cholangiocarcinogenesis. Common features of 
many disease risk factors for CC are chronic cholestasis and inflammation of the biliary 
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tree. It is postulated that such inflammation increases cell turnover, overwhelms local 
tissue repair pathways, and is intrinsically pro-oncogenic. Chronic inflammation and 
cholestasis have been shown to trigger release of cytokines and growth factors 
including hepatocyte growth factor (HGF), epidermal growth factor (EGF), platelet 
derived growth factor (PDGFs), TGF-B, TNF-a and IL-6. Abnormal bile acid signaling 
transactivates EGFR and induces the COX-2 pathway. The cytokine cascade induces 
inducible nitric oxide synthase. iNOS up-regulation leads to increased levels of reactive 
nitrogen oxide species that cause DNA breakage, gene and protein mutation, and 
suppression of DNA repair enzymes.[77, 78] Cholangiocyte hyperplasia, dysplasia and 
aneuploidy are the result. Ongoing damage to the biliary epithelium enhances 
cholangiocyte exposure to endogenous mutagens, such as hydrophobic bile acids and 
oxygen free radical species, as well as exogenous carcinogens that are concentrated 
and excreted in the bile.[77] The acquisition of subsequent mutations of genetic and 
epigenetic pathways that affect cell cycling, apoptosis, proliferation, angiogenesis and 
invasion contribute to the evolution of an overtly malignant lesion. This cascade is 
summarised in Figure 1.1, below (adapted from Sirica et al 2008).[79] There follows a 
summary of the factors currently implicated in cholangiocarcinogenesis. Whether these 
factors and pathways are truly pathogenic, or are bystander events is frequently 
unclear. 
1.3.1 Inflammatory mediators, growth factors and 
cholangiocarcinogenesis 
1.3.1.1 Interleukin-6 (IL-6) and its receptor, IL6R 
IL-6 is a cytokine that is released by injured tissue and has pro-inflammatory and anti-
inflammatory effects. IL-6 is usually undetectable in the healthy liver.[80] It appears to 
play a number of critical roles in cholangiocarcinogenesis. It is secreted principally by 
macrophages and T-cells but also by periportal stromal cells, including stellate cells, 
and cholangiocytes themselves. It acts in an autocrine loop, promoting proliferation of 
cholangiocytes and well as inducing nitric oxide synthase.[81, 82] IL-6 activates the signal 
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transducer and activator of transcription-3 (STAT-3) receptor. The binding of IL-6 to the 
gp130 receptor triggers STAT3 phosphorylation by JAK2. Phosphorylation of this 
receptor kinase activates nuclear transcription of a variety of mitogenic and anti-
apoptotic factors.[83, 84] IL-6 also acts to down-regulate bcl-2–associated X protein 
(Bax), thereby inhibiting cholangiocyte apoptosis.[80] IL-6 is markedly elevated in animal 
models of bile duct injury.[80] It has been shown to stimulate cholangiocyte DNA 
synthesis, is elevated in the serum of patients with cholangiocarcinoma as well as in 
the bile of patients with cholangitis.[85, 86] IL-6 also triggers increased expression of HGF 
and c-met[87, 88], induces COX-2 expression[89] and increases telomere length[90], all of 
which contribute to choangiocarcinogenesis and are considered in more detail below.  
1.3.1.2 Hepatocyte growth factor (HGF) and its receptor, c-met 
The HGF ligand and its tyrosine kinase receptor, c-met, are not expressed in normal 
biliary tissue. Activation of c-met by HGF leads to transduction of numerous pathways 
including the RAS (scattering, proliferation and branching morphogenesis), PI3K (cell 
motility, adhesion, cytoskeletal reorganisation and cell survival) and STAT3 (discussed 
above) pathways. Activation of HGF/c-met is normally limited to stem and progenitor 
cells, or healing tissues. It is upregulated in bile duct injury models.[80, 91, 92] The proto-
oncogene, c-met, encodes the c-met receptor. Increased c-met expression has been 
identified in numerous studies of CC tissue, as well as other solid cancers.[93-96] A high 
level of c-met expression has been associated with particularly poor prognosis and is 
known to co-activate EGFR, and vice versa.[97] Co-expression of c-met and EGFR has 
been found in a variety of cancer cells lines.[98]  
1.3.1.3 Epidermal growth factor (EGF) and its receptor, EGFR 
EGF acts by binding with its receptor on the cell surface and stimulating the intrinsic 
protein-tyrosine kinase activity of the receptor. This initiates a signal transduction 
cascade, increases the expression of certain genes, including the gene for EGFR. 
EGF/EGFR activation results in cellular proliferation, differentiation, and survival.[99] 
EGF levels are elevated in inflamed biliary epithelium and EGFR/ErbB1 induction has 
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been demonstrated in CC tissue.[99, 100] Activation of EGFR increases COX-2 
expression and, in a positive feedback loop, COX-2 ezymatic product prostoglandin-E2 
(PGE2), transactivates EGFR.[101] EGF/EGFR interaction also activates the STAT-3 
pathway, already discussed in 1.3.5, above. 
1.3.1.4 Cyclooxygenase-2 (COX-2) and its product, prostoglandin-E2 
(PGE2) 
COX-2, an enzyme that synthesises prostaglandin species, is minimally expressed in 
normal biliary tissue but is upregulated in inflammatory states. Cytokines such as 
TNFα, IFNγ, IL-6 and IL-1β all induce COX-2 expression.[102] As discussed in 1.3.2, 
above, EGFR and COX-2 cross-upregulate each other, in a positive feedback loop. 
Hydrophobic bile acids, known to promote cholangiocarcinogenesis in mouse models, 
are now known to induce COX-2 expression via EGFR.[103-106] Enhanced COX-2 
expression has been demonstrated in dysplastic cholangiocytes, cholangiocytes from 
PSC affected subjects and in cholangiocarcinoma cells.[107-109]  
COX-2/PGE2 attenuates the mitotic inhibitory effect of TGF-β[110] and also enhances 
the pro-mitotic effects of IL-6 and HGF.[111] In vitro, PGE2 application to CC cell lines 
promotes cell division and reduces apoptosis.[112, 113] PGE2 has been shown to promote 
tumour growth and upregulates myeloid leukaemia cell differentiation protein (Mcl-1), 
an anti-apoptotic member of the Bcl-2 family.[102]  
1.3.1.5 Transforming growth factor-β1 (TGF-β1) 
TGF-β1 is involved in tumour progression by promoting angiogenesis and suppressing 
the immune system. TGF-β1 also has a growth-inhibitory effect on epithelial cells 
including carcinoma cells via the SMAD and DAXX pathways.[114] This anti-mitotic 
effect is abrogated by COX-2/PGE2 activity in cell line models of 
cholangiocarcinogenesis.[110] TGF-β1 also exerts immunomodulatory effects on T-
lymphocytes and natural killer (NK) cells, reducing their activity in tumour 
surveillance.[115-117] 
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1.3.1.6 Tissue necrosis factor-α (TNF-α) and its receptor, NF-kappaB 
High levels of TNFα can be identified in the bile of patients with cholangitis.[85] TNFα 
activates NF-kappaB, leading to upregulation of the Snail pathway, consequent 
repression of E-cadherin in cholangiocarcinoma, promoting migration and invasion.[118] 
1.3.1.7 Inducible nitrogen oxide synthase (iNOS) 
iNOS catalyses nitric oxide (NO) from L-arginine. It is induced by a wide range of 
cytokines and plays a central role in the mediation of inflammation. It is thought to 
contribute to cholangiocarcinogenesis in a variety of ways. NO directly damages DNA 
via oxidation and inhibits DNA repair mechanisms. It can nitrosylate thiol and tyrosine 
residues in proteins, disrupting or modifying their function, and plays a critical role in 
activation of the Notch pathway, reducing apoptosis in cholangiocytes.[119] NO also 
upregulates COX-2 expression, as discussed in 1.3.1.4, above.[120] 
1.3.2 Somatic genetic changes in cholangiocarcinogenesis 
The inflammatory milieu in the bile duct is thought to contribute to initiation of genetic 
mutations that drive cellular proliferation, decreased senescence, decreased apoptosis 
and invasion.[121, 122] The innately toxic nature of bile contributes to this vicious cycle of 
inflammation and also contributes directly to further DNA damage.[37] Molecular studies 
of dysplastic biliary and CC tissues have demonstrated cumulative genetic mutations in 
the epithelium. Dysregulation of oncogenes (K-Ras, c-myc, c-neu, c-erbB-2, c-met, 
CCND1) and tumour suppressor genes (p53, DPC4/Smad4, CDKN2A, APC, 
p16INK4a)[123-125] has been demonstrated. However, the frequency of such mutations 
varies widely with ethnicity, tumour stage, tumour location and pre-existing biliary 
pathology.[126] The sequence of genetic changes and their role in initiation and 
progression of CC in not clear.[127, 128]  
1.3.3 Epigenetic changes in cholangiocarcinogenesis 
Recent studies have demonstrated a range of epigenetic factors in carcinogenesis. 
Promoter hypermethylation, histone deacetylation and altered microRNA (mir) 
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signalling have all been implicated in CC. Methylation of DNA within gene promoter 
region CpG islands can downregulate or silence associated gene transcription. In CC, 
this mechanism of down regulation of tumour suppressor genes has been repeatedly 
demonstrated, including APC, p16INK4a and p73.[129] Histone acetylation also mediates 
suppression of associated DNA transcription and thereby tumour suppressor genes.[130] 
Mir modulates the transcription of genes. Many genes that encode mir are located 
within malignancy-associated regions of the genome. Various studies have associated 
abnormal mir transcription, and thereby modified transcription of tumour 
promoting/suppressing genes, with cancer. Over expression of mir-141, mir-200b and 
mir-21, and downregulation of mir-29b mir-370, have been specifically associated with 
cholangiocarcinogenesis.[129] 
1.4 Histopathology 
1.4.1 Histological classification 
More than 90% of CCs are adenocarcinomas, the reminder are squamous cell 
carcinomas. CC can be classified as well, moderately or poorly differentiated. All 
subtypes have a propensity for local invasion, indolent growth, peri-neural spread and 
mucin production.[131] Three distinct histological subtypes of CC have been described - 
sclerosing, nodular and papillary. A substantial majority are of the sclerosing type, 
characterised by an intense desmoplastic reaction. Invasion along and through the bile 
duct wall is an early feature.[131, 132] Presentation is generally at a late stage and 
prognosis is particularly poor. Sclerosing CC has a radiological appearance similar to 
that of benign strictures of the bile duct, complicating diagnosis and management 
further.[133] 
1.4.2 Precursor lesions 
Two distinct pre-malignant biliary intraepithelial lesions have been defined, that are 
thought to precede invasive intrahepatic and hilar CC.[134] Biliary intraepithelial 
neoplasia (BilIN) is a flat or micro-papillary dysplastic biliary epithelial lesion.[135] It has 
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been demonstrated in hepatic explant series of patients suffering from PSC, 
hepatolithiasis and choledochal cysts.[136] Intraductal papillary neoplasm of the bile duct 
(IPNB) is characterized by prominent papillary growth of atypical biliary epithelium with 
distinct fibrovascular cores and mucin over-production.[137, 138] BilIN and IPNB are 
regarded as biliary counterparts of pancreatic intraepithelial neoplasia (PanIN) and 
pancreatic IPMN. [75, 139] 
1.4.3 Anatomical classification 
The anatomical site of any CC is of critical importance as this determines resectability, 
the nature of any surgery and the likelihood of its success. About 65% are hilar or 
perihilar (Klatskin tumours), 25% in the distal bile duct (defined as beyond the point at 
which the bile duct passes posterior to the duodenum) and 10% are within the 
peripheral liver.[2] Perihilar and distal lesions are classified as extrahepatic while lesions 
proximal to the hilum are classified as intrahepatic. In planning surgery, further detailed 
anatomical classification of perihilar CC is made into Bismuth-Corlette categories 
(Figure 1.2). CC, cancer of the gallbladder and cancer of the ampulla of Vater are now 
widely considered to be separate entities - in both clinical research studies and clinical 
practice.[140] 
1.4.4 Pathological diagnosis 
1.4.4.1 Diagnostic histology 
The fibrotic, paucicellular nature of CC makes successful sampling for histology or 
cytology very difficult. In small or early lesions, percutaneous biopsy often reveals 
normal or fibrotic tissue only. The intimate relation of most CCs to large bile ducts, and 
their adjacent blood vessels, means that percutaneous or laparoscopic biopsy carry 
significant risk of damaging critical structures. Very large, or peripheral lesions may be 
highly amenable to percutaneous biopsy. Seeding of malignant cells from a CC 
through a biopsy track is a theoretical possibility and has been demonstrated in studies 
of HCC.[141] It is therefore avoided in cases where curative resection is thought 
possible, as is EUS guided FNA. 
Introduction 
 36 
1.4.4.2 Diagnostic cytopathology 
Collection of cytology samples from biliary strictures is possible, using a brush or 
biopsy forceps at ERCP. The desmoplastic nature of most CCs means that these 
techniques offer a low yield of material for analysis. The cellular inflammatory response 
in conditions such as PSC complicates analysis further as atypical cells are seen in 
both conditions. In clinical studies, the sensitivity of these techniques (or combinations 
of them) ranges from 40 to 64% and specificity from 90 to 100%.[142-144] These studies 
included patients with a mixture of diseases, including metastatic and pancreatic 
cancers compressing the bile duct. Subgroup analyses suggest that cytological 
sampling is more likely to yield the diagnosis in lesions that originate in the bile duct, 
i.e. CC. Differential sensitivities for CC and pancreatic cancer of 80% and 35% 
respectively have been shown.[142] Cytological diagnosis is fraught with variability in 
technique, for both endoscopist and cytopathologist. In the studies considered here, 
gold-standard technique and expert operators were used.[145-147] Real-world 
performance is likely to be substantially worse. 
1.4.4.3 Cytopathological markers 
Immunohistochemistry has been unhelpful in the differentiation of CC from other 
malignancies, as no specific markers have been identified. However, the use of DNA 
proliferation measures shows promise. Cytokeratin, CEA and mucin staining of biopsy 
tissue are suggestive of the diagnosis, but are non-specific. Testing of K-ras and p53 
mutation in cells collected for cytology has been investigated in clinical studies and 
shown not to improve sensitivity or specificity.[148-150]  
1.4.4.3.1 Digital image analysis (DIA) and fluorescent in situ hybridisation (FISH) 
DIA measures the quantity of nuclear DNA in cells whilst FISH labels DNA with a 
fluorescent marker, permitting visualisation of chromosomal abnormalities. The use of 
DIA or FISH can improve the sensitivity and specificity of biliary stricture cytology in 
patients with and without PSC. In one study, DIA demonstrated sensitivity and 
specificity of 39% and 77% compared with 18% and 98% with standard cytology.[151] In 
Introduction 
 37 
patients with PSC, DIA has sensitivity of 43% and specificity of 87%. FISH has 
sensitivity of 47% and specificity of 100% in such patients.[152, 153] 
1.4.4.4 Cytopathology in PSC 
False positivity of cytopathological analysis is more common in patients with PSC and, 
in combination with the confounding radiological findings in PSC, can lead to incorrect 
diagnosis and therapy.[154]  
1.4.4.5 Cytopathology in Immunoglobulin G4 (IgG4) cholangiopathy 
The absence of malignant cells and the presence of a lymphoplasmacytic infiltrate rich 
in IgG4-positive cells is diagnostic and can be sought in biliary brushings, ampullary 
biopsies or FNA samples.[155]  
1.5 Clinical features 
Symptoms of icterus and pruritus are common, but occur only once bile outflow is 
almost completely obstructed. A minority of patients report a dull right upper abdominal 
pain. Non-specific features include lethargy, weight loss and low-grade pyrexia. The 
long latency before presentation is thought to contribute to the advanced stage at 
diagnosis and, therefore, poor prognosis.[156] Physical signs of CC include jaundice, 
right upper abdominal mass or hepatomegaly and only occur when the lesion is 
extensive enough to cause palpable mass effect or substantial biliary obstruction.[157] 
Where the patient suffers from pre-existing benign biliary disease such as PSC, 
progressive jaundice, weight loss and malaise may accompany deterioration of that 
underlying disease or herald the development of a CC. It is also impossible to clinically 
distinguish the presenting symptoms and signs of CC from those of hepatocellular 
carcinoma, pancreatic cancer or metastatic cancer of the liver.[158] Clinical and imaging 
findings in Immunoglobulin G4 (IgG4) associated cholangiopathy may closely mimic 
those of CC. IgG4 cholangiopathy is part of a recently described, and increasingly 
diagnosed, multisystem inflammatory disorder. The disease is non-malignant and 
generally steroid responsive. Many patients with IgG4 cholangiopathy present with 
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biliary strictures and jaundice, making it an important differential diagnosis.[155] 
Differentiating between these conditions and CC is critical for accurate diagnosis, 
management and prognostication in patients presenting with obstructive jaundice. 
1.6 Laboratory tests 
1.6.1 Serum biochemistry 
Standard liver function tests including bilirubin, alkaline phosphatase (ALP) and 
transaminases are usually elevated at the time of diagnosis. Peripheral IHCC often 
causes no elevation in bilirubin, as the volume of liver obstructed by the lesion does not 
affect the total excretory capacity of the liver significantly.[158] Elevated bilirubin and 
ALP are associated with all benign and malignant cholestatic diseases. Progressive 
deterioration of these indices in patients with PSC may indicate an evolving CC.[156]  
1.6.2 Tumour markers 
Carbohydrate antigen 19-9 (CA19-9) is the most widely used tumour marker in the 
diagnosis of CC.[140] The defining antibody reacts with mucin glycoproteins that are 
coated with sialylated blood-group epitopes such as sialyl Lewisa.[159] Large studies 
have demonstrated sensitivity and specificity of up to 75% and 85% respectively.[160] 
However, specificity is greatly reduced in the presence of cholestasis or cholangitis. In 
studies of PSC cohorts, sensitivity and specificity have ranged hugely; 38-80% and 50-
98% respectively.[159, 161] The selection criteria of cases studied and the CA19-9 cut-off 
value used account for this wide variation. Most importantly, the elevation of CA19-9 
has been shown to occur late in the development of CC. In a longitudinal study of PSC 
patients undergoing screening for CC with CA19-9, only 2/14 patients who developed 
CC were candidates for curative treatment.[162] CA19-9 is also elevated in gastric 
cancer, pancreatic cancer, primary biliary cirrhosis and individuals who smoke. 7% of 
the population are Lewis-negative and are unable to express CA19-9 at all.[163]  
Carcinoembryonic antigen (CEA) has been investigated extensively but is only positive 
in about 30% of patients with CC.[126] Some studies have suggested that CEA can 
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enhance sensitivity and specificity when used in conjunction with CA19-9 but this has 
not been validated in prospective clinical studies.[159] 
1.6.3 Serum IgG4 
Elevated serum IgG4 is a feature of IgG4 cholangiopathy. Many patients with IgG4 
cholangiopathy present with biliary strictures and obstructive jaundice, making CC an 
important differential diagnosis. In a study of 126 CCA and 50 IgG4 cholangiopathy 
patients, 17 (13.5%) of the CC cohort had elevated IgG4 and 4 (3.2%) had a >2-fold 
increase. PSC was present in 31/126 CC patients, of whom 7 (22.6%) had elevated 
IgG4 and 2 (6.5%) had a >2-fold elevation. Of the 50 IgG4 cholangiopathy patients, 39 
(78.0%) had elevated IgG4 and 25 (50.0%) had a >2-fold increase. In a validation 
cohort of 161 CC and 47 IgG4 cholangiopathy patients, the results were consistent with 
those of the test cohort. The authors concluded that, although very useful, IgG4 
elevation alone does not exclude the diagnosis of CC.[164] In the absence of clear 
radiological or cytopathogical diagnosis, serum IgG4 quantification is likely to prove 
helpful in identifying the small subset of patients that may have IgG4 cholangiopathy 
rather than CC. 
1.7 Imaging in the diagnosis and staging of CC 
A variety of imaging techniques is used in the assessment of biliary strictures and 
hepatic mass lesions. Imaging is the mainstay of diagnosis and staging of CC and 
most patients undergo three or more imaging techniques before their lesion is 
considered fully characterised.[140] Recent advances include detection of perfusion 
characteristics of benign and malignant lesions, liver specific contrast agents and 
enhanced signal detector technology. Standard imaging techniques can reliably 
distinguish malignant from some common benign causes of biliary obstruction, such as 
choledocholithiasis. However, discrimination between benign and malignant strictures 
of the bile ducts is more difficult.[165] Cholangiography is the most accurate way to 
delineate the site and intraductal extent of any stricture. This can be obtained via 
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endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic 
cholangiogram (PTC) or magnetic resonance cholangiopancreatography (MRCP) with 
equal accuracy.[140]  
In the context of background PSC, diagnostic imaging of CC is particularly challenging. 
Approximately 70% of patients with PSC have cholangiographic evidence of both intra- 
and extra-hepatic ductal involvement – including stricturing and dilatation.[166, 167] New, 
malignant strictures may be superimposed on these benign strictures, making accurate 
detection difficult.[168] This is a major problem - in one study of 125 PSC patients who 
were followed up for ten years, 45% developed a benign dominant stricture at some 
point.[169] In a 6 year prospective study of 230 patients with PSC, 10% were diagnosed 
with CC. The use of CA19-9 alone was less sensitive than a combination of CA19-9 
and cross sectional imaging. However, the addition of US or CT imaging did not 
improve specificity, positive predictive value (PPV) or negative predictive value (NPV). 
The addition of cholangiography (as MRCP or ERCP) did improve specificity and 
PPV.[170]  
Even with the full range of imaging technologies discussed in the following sections, 
accurate diagnosis and staging of CC is often impossible.  
1.7.1 Ultrasound (US) 
1.7.1.1 Transabdominal B-mode US 
Transabdominal ultrasound  (US) is a quick, widely available and safe test. 
Transabdominal B-mode US is highly sensitive for the detection of bile duct dilatation 
and, in this context and skilled hands, delineating the site of any obstruction.[171-173] 
However, US is operator dependent and has low sensitivity and specificity for CC 
detection and is inaccurate in estimating local tumour extent. Sensitivity for detection of 
hepatic masses of any type ranges from 37-87%.[174, 175]  
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1.7.1.2 Contrast enhanced US (CEUS) 
Developments in ultrasound technology, and associated ultrasound contrast agents, 
have led to major advances in characterisation and detection of liver lesions. These 
contrast agents are microbubbles, and contain an inert gas (typically a perfluorocarbon 
compound) with a stabilising outer phospholipid shell. The bubbles are 3-5µm in 
diameter and remain intact in the circulation for up to 20 minutes, but only have an 
optimum window of use of 5 minutes sonographically. When exposed to US energy, 
these bubbles generate specific harmonic signals that can be distinguished separately 
from the returning fundamental signals. The two signals are used to generate a 
separate side-by-side image or are displayed as an image overlay. These agents 
remain purely within the vascular space and thus allow the continuous assessment of 
the vascular perfusion of liver lesions from the arterial and portal phases right through 
to the late phase.[176] This technique has significantly improved the ability of ultrasound 
to accurately characterise liver lesions, including small IHCCs. On CEUS examination, 
IHCCs are typically hypovascular in the arterial and portal phases and remain as a 
defect in the delayed phase after contrast administration.[133] This characteristic is 
shared with metastatic liver cancers, but a discriminating factor is that CC masses tend 
to expand the intrahepatic ducts. This is not entirely reliable, as mass-forming types of 
CC appear identical to metastases. Finally, this hypovascularity allows CC masses to 
be distinguished from HCC, which enhance avidly in the arterial phase, or benign 
vascular lesions. Unfortunately, CEUS is less accurate at diagnosing the commonest, 
extra-hepatic infiltrating form of CC, especially in patients with PSC.[177]  
1.7.2 Computed Tomography (CT) 
New multi-detector CT (MDCT) has reduced the time required to image the whole liver 
by a factor of three, imaging the whole body in less than 1 minute. This permits 
repeated imaging through the different vascular phases and multiplanar reformats, 
thereby improving lesion characterisation. It can be difficult to distinguish duct dilatation 
due to a small CC or a calculus and therefore a pre contrast scan is extremely useful. 
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As with CEUS, CCs do not enhance in the arterial phase but this phase is important in 
delineating the anatomical vascular supply to the liver. In the portal and delayed 
phases, CCs typically shows a higher enhancement than the adjacent normal liver 
thought to be related to the abundant fibrous stroma of this type of tumour.[178]  
Small hilar lesions can be difficult to detect on CT. Although CT is highly sensitive for 
biliary dilatation and identification of the site of biliary obstruction, the accuracy of 
characterising sub centimetre hypoattenuating lesions is poor.[179] Older studies have 
suggested that CT has low sensitivity and specificity for CC, is inaccurate at estimating 
local tumour extent and predicts resectability with accuracy of only 60%.[180] However, 
the advent of MDCT allowing improved resolution has been reported to substantially 
improve on these disappointing results.[181]  
Although MDCT does not have a very high specificity for distinguishing CC from other 
liver malignancies and pathologies it remains the modality of choice for disease 
staging, particularly in the detection of distal metastases in the chest, abdomen and 
pelvis and also in assessing vascular invasion.[140, 179] 
1.7.2.1 Positron emission tomography and CT (PET/CT) 
Several studies have considered the use of P-[18F]-2-deoxy-glucose PET/CT to resolve 
indeterminate cases as benign or malignant disease.[140, 179] In one study, PET/CT had 
sensitivity of 93% and specificity of 80% for IHCC. For the more common, extrahepatic, 
CC this fell to 55% and 33% respectively. Sensitivity and specificity for regional lymph 
node metastases were 12% and 96%.[182] Another study found sensitivity of 85% for 
nodular forms of CC but a dismal 18% for the commoner infiltrating type. Sensitivity for 
previously undetected extrahepatic metastases was 65%.[183] PET/CT was found to 
alter management significantly in the majority of patients in a study of a non-PSC CC 
cohort.[184] False positivity is common in patients with inflammatory biliary diseases.[185] 
Despite disappointing performance of PET/CT in the clinical management of CC, it 
maintains a limited role. Its positive predictive value in regional nodal disease of non-
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PSC patients being staged prior to curative resection (or transplantation) may avoid 
inappropriate surgery for incurable lesions.[184] 
1.7.3 Magnetic resonance imaging (MRI) and magnetic resonance 
cholangiopancreatography (MRCP) 
MRI is the cross-sectional imaging modality of choice in assessing the biliary tree as it 
provides superior soft tissue resolution when compared with CT and US. MRCP 
provides a good overall anatomical assessment of the biliary system and, in addition, 
contrast-enhanced images of the liver parenchyma allow improved detection and 
characterisation of smaller lesions as well as periductal extension of tumour.  
Typical Liver MRI normally includes T1-weighted and varying heavily T2 weighted 
sequences as well as n-phase/out-of phase spoiled gradient echo sequence. This is 
usually supplemented with dynamic fat-saturated T1-weighted gadolinium enhanced 
sequences to allow tumour enhancement pattern characterisation and estimation of 
extent. This, together with the MRCP sequence, is very helpful in assessing periductal 
infiltration as well as distinguishing benign from malignant strictures. CCs are typically 
low signal on T1 weighted sequences and moderately hyperintense on the T2 weighted 
sequences. They demonstrate an enhancement pattern similar to that seen on CT and 
CEUS but it is the periductal high signal oedematous change that is helpful in 
distinguishing ductal from other pathology. Therefore high resolution and varying T2 
weighted sequences are employed.[133] MR is also particularly useful at detecting 
satellite intra-hepatic liver metastases. Studies have reported that extra-hepatic CCs 
show slow homogeneous enhancement into the late phase of scanning, while intra-
hepatic lesions tend to enhance peripherally initially, with prolonged retention of 
contrast in the late phase.[186, 187] Contrast MRI assessment of vascular invasion is 
comparable to traditional angiography.[188]  
The use of specific MR liver contrast agents such as ferumoxide has also been 
reported to improve the sensitivity of MRI studies for CC. Liver specific MRI agents 
consist of hepatocyte specific and reticuloendothelial agents which are taken up by 
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Kupffer cells. Older hepatocyte specific contrasts were manganese based agents such 
as Teslascan but more recently the development of bimodal gadolinium agents such 
Multihance/Gd-BOPTA (Bracco) and Gadoxetate, Primovist (Bayer-Schering), not only 
permit assessment of arterial and portal phase enhancement characteristics but also 
undergo biliary excretion and provide additional detail of the biliary tree.[189] 
Reticuloendothelial based or superparamagnetic iron oxide (SPIO) agents are very 
helpful in distinguishing benign from malignant lesions and thus improve the accuracy 
of MRI. These agents, for example Ferumoxide (Guerbet) or Resovist (Bayer-
Schering), shorten the T1 weighted signal in normal liver which demonstrates Kupffer 
cell activity thereby appearing as low signal while malignant lesions such as CC return 
a higher normal signal when compared with the adjacent liver post SPIO 
administration. 
Although contrast enhanced sequences are useful it is the MRCP that is key. MRCP 
provides high-resolution cholangiography, is non-invasive and rivals ERCP. It requires 
no contrast and utilises MR imaging data accrued with heavily T2-weighted sequences. 
The high water content of bile acts as an endogenous contrast medium. On these 
sequences, CCs are seen as shouldered stenotic or sclerosing ductal lesions. Subtle 
duct wall thickening, nodular or papillary filling defects may be seen. MRCP is highly 
sensitive for biliary obstruction and its localisation but is slightly less accurate than 
ERCP for differentiating benign from malignant biliary strictures.[190] Although MRCP 
can detect proximal ductal extent more accurately than ERCP, it can underestimate the 
extent of hilar and distal ductal lesions.[191]  
Recent developments in MR sequences include diffusion-weighted imaging (DWI) 
which utilises Brownian motion of water molecules and their diffusion characteristics 
within biological tissue in vivo. This has been shown to help distinguish benign from 
malignant lesions where cancerous lesions typically show a restriction in movement of 
fluid, likely due to the high cellular density and consequent effect of cell membrane 
restriction of water movement.[192] This degree of diffusion is calculated as an apparent 
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diffusion coefficient (ADC) and can be displayed graphically as well as numerically. 
However, the sensitivity changes with differing diffusion sensitivity coefficient (b value) 
scan parameters.[193] A recent study by Cui et al, assessing CCs with DWI and 
histopathological correlation, concluded that the b-value of 800 s/mm2 was the best in 
DWI of extrahepatic cholangiocarcinoma and that the lesion ADC value declined as the 
degree of cancerous tissue differentiation decreased.[194] Overall, the combination of 
cholangiography and extra-ductal information provided by a MRI/MRCP, with all the 
additional information with contrast enhancement and DWI, makes it the investigation 
of choice for diagnosis and local staging of CC.[133] Of course, MRCP offers no 
opportunity for tissue sampling, or therapeutic intervention (cf. ERCP). 
1.8 Endoscopic techniques in the diagnosis and staging of CC 
1.8.1 Endoscopic retrograde cholangiopancreatography (ERCP)  
ERCP is still considered the gold standard for cholangiography and is widely available 
in developed countries. After passing a duodenoscope to the ampulla of Vater, the bile 
duct is cannulated and contrast is instilled under endoscopic and fluoroscopic control. 
High-resolution cholangiograms are obtained in which biliary strictures can be reliably 
detected and differentiated from other obstructing pathologies such as 
choledocholithiasis. Differentiation between benign and malignant strictures can remain 
problematic. Features that favour malignancy include stricture length of >10mm, a 
ragged contour, abrupt transition (shouldering) or fixed filling defect. Strictures at the 
hilum are highly suspicious and warrant particularly aggressive investigation for 
malignancy.[195]  
Tissue sampling can be undertaken at ERCP using a variety of techniques including 
cytology brushing, forceps biopsy and bile aspiration for cytology. Additional devices 
can be introduced at ERCP, including a choledochoscope or RFA catheter (see 
sections below). Therapy, such as stent insertion, can be delivered at ERCP. However, 
ERCP provides only two-dimensional imaging of the bile duct and gives no extraductal 
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information.[133] It carries a significant risk of serious morbidity, particularly 
pancreatitis.[196] 
1.8.2 Choledochoscopy (e.g. SpyGlassTM system) 
Recent technological advances have reignited interest in this technique. The procedure 
requires insertion of a small, fibreoptic endoscope through the biopsy channel of a 
standard duodenoscope (or a percutaneous system) into the bile duct. First, second 
and third order bile ducts can be accessed and visualised. Modern systems permit 
biopsy of biliary lesions under direct endoscopic vision. Mucosal appearances that are 
suggestive of malignancy include nodularity, papillomatosis and ulceration.[197-199] 
These systems can facilitate stent insertion and targeted biopsy of specific 
strictures.[200, 201]  
A number of case-series have been reported that examined the use of 
choledochoscopy to assess indeterminate strictures. A recent prospective study 
examined 76 patients with indeterminate biliary strictures after non-invasive imaging. 
22/38 (58%) of malignant strictures were correctly characterised by ERCP alone. The 
addition of choledochoscopy with targeted biopsy increased the sensitivity for 
malignancy to 38/38 (100%). 7 of the 38 benign strictures were the result of PSC, and 
one of these cases was falsely categorised as malignant after choledochoscopy and 
biopsy.[202] A further case series of 255 indeterminate strictures claimed that relevant 
information was garnered by choledochoscopy and biopsy in 68% of cases, changing 
the diagnosis in 10%. However, malignancy was only demonstrated by 
choledochoscopy and biopsy in 10% of the lesions that were subsequently proven to 
be cancerous at excision.[203] In a study of 53 patients with PSC and indeterminate 
dominant stricture, sensitivity and specificity for CC both exceeded 90%.[199]  
Some centres have employed confocal microscopy, which is established in the 
endoscopic assessment of gastric and colonic neoplasms, to assess biliary strictures at 
choledochoscopy. Fluorescein solution is instilled into the bile duct through the channel 
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of the choledochoscope. This is followed by a catheter-based microscope that allows 
visualisation of the pattern of cells and vessels in the stricture. Lesions are classified 
using criteria similar to those used in the confocal microscopic assessment of other GI 
lesions. In a group of patients with previously indeterminate lesions, sensitivity for 
malignancy of ERCP alone, with the addition of choledochoscopy or with the addition 
of choledochoscopy and confocal microscopy were 56%, 59% and 83% 
respectively.[204] Other groups have examined biliary strictures experimentally using 
narrow-band imaging technology.[205] These techniques of in vivo pathological 
classification show some promise but remain experimental at present. 
Modern choledochoscopy appears very promising but has several disadvantages. The 
double scope systems are expensive and expertise is currently limited to a few highly 
specialist centres. The fibreoptic imaging bundle is extremely fragile and the image 
transmitted, at best, is suboptimal in comparison with the images produced by modern 
digital endoscopes. Choledochoscopy is invasive and gathers no information beyond 
the lumen of the bile duct and so does not contribute to staging of the disease. The 
risks of choledochoscopy exceed those of standard ERCP as the catheter is large and 
relatively inflexible, increasing risk of bile duct injury and cholangitis. 
1.8.3 Endoscopic Ultrasound (EUS) 
EUS requires a modified endoscope, with an ultrasound probe built into its tip. The bile 
duct can be imaged reliably to the bifurcation of right and left hepatic ducts, through the 
wall of the stomach or duodenum. EUS permits sampling of suspected CC by fine-
needle-aspiration (FNA). The two largest case series examining EUS + FNA reported 
sensitivities of 86% and 89% for CC. However, this strategy is avoided in the 
assessment of potentially resectable lesions, as there is a risk of tumour seeding.[206, 
207] EUS is highly sensitive for local nodal disease and this has been studied in trials of 
liver transplantation for CC. Of 47 patients, 17% were found to have local lymph node 
disease on EUS and FNA, precluding transplant.[206] The exclusion of such patients 
from inappropriate transplantation has contributed to hugely improved outcomes in 
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transplantation for irresectable CC. EUS is hampered by limited range so is unhelpful 
in imaging lesions extending proximal to the hilum and intrahepatic lesions. It is highly 
operator dependent and requires very costly systems. 
1.8.4 Intraductal ultrasound (IDUS) 
IDUS requires the passage of a catheter mounted US probe into the bile duct through 
an endoscope or percutaneous biliary drain. This allows radial imaging of the biliary 
tree. Various characteristics correlate with malignancy, particularly IDUS evidence of 
bile duct wall disruption.[208] A small (n=30) retrospective study demonstrated sensitivity 
and specificity of 92% in categorising strictures as benign or malignant – superior to 
ERCP in this particular study.[209] Use of IDUS to enhance cytology yield, in 
combination with ERCP, may improve overall accuracy to >90%.[209, 210] Some centres 
are now using contrast enhancement techniques with IDUS.[211] However, these studies 
on indeterminate biliary strictures have been on a heterogeneous group, with only 
small numbers of PSC patients included. Current IDUS technology has only limited 
ability to evaluate the layers of the bile duct and infiltration of surrounding structures 
such as lymph nodes.[212, 213] IDUS is only available in a very limited number of centres, 
and is highly operator dependent. The catheter based system is very delicate and 
expensive. Introduction of the catheter requires ERCP or PTC, with the attendant risks 
of these invasive procedures.  
1.9 Screening for cholangiocarcinoma in high risk groups 
Even though groups at high risk of CC may be readily identified, such as PSC patients 
and populations living in areas with high levels of endemic OV infection, there is 
currently no proven benefit in screening for CC in these groups. Criteria for an effective 
formal screening program were published by Wilson and Junger in 1968 and are 
retained by the WHO today. Two of these are not currently met in the case of CC risk 
groups; i) that there should be an accepted and effective treatment available for 
patients with the disease ii) that the screening test detects disease at an earlier stage, 
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when treatment is more effective.[214] Patients with advanced benign liver diseases 
(such as PSC, hepatolithiasis or chronic OV infection) patients are especially unlikely 
to be candidates for curative resection of CC. In most healthcare systems, the 
diagnosis of CC contraindicates liver transplant. A number of longitudinal studies of 
formal screening protocols in PSC have utilised CA19-9, ultrasound, MRCP and ERCP 
with cytology.[170, 215, 216]  Although some protocols have achieved respectable sensitivity 
and specificity, outcomes remain unaltered. Many centres in resource-rich systems do 
carry out informal screening for CC in PSC – varying from regular LFT measurement to 
regular CA19-9 estimation to US or MR liver imaging. Such approaches are not 
currently evidence based. Areas of highest OV prevalence are generally healthcare 
resource constrained and the cost of imaging based CC screening programmes would 
be prohibitive. More cost effective public health strategies may include population 
screening for OV infection with faecal antigen testing and subsequent eradication, 
public education against high-risk dietary habits and efforts to eradicate animal 
reservoirs of OV.[217-219] In the future, the development of a clinically useful vaccine 
against OV would be of huge benefit, although this currently remains an aspiration.[218] 
Until refined diagnostic tools permit earlier diagnosis, or new treatments that improve 
outcome become available, formal screening programs for CC in those subpopulations 
at high risk of CC are unlikely to lead to improved survival.[220]  
1.10 Staging of cholangiocarcinoma 
Staging of CC is currently poor. Even in cases where curative resection is attempted, 
survival rates are low as CC is a highly invasive tumour with early vascular and 
perineural invasion. Imaging is the mainstay of pre-operative staging, supplemented 
with staging laparoscopy in indeterminate cases.[140] Perihilar lesions are particularly 
difficult to stage correctly and often resectability can only be determined at surgery.[221] 
Survival after diagnosis with CC is dependent on complete surgical resection with clear 
margins, known as R0 resection.[222-224]  
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Accurate staging is principally required to determine resectability, and thereby allocate 
individual patients to the most appropriate treatment pathway. Staging is also important 
for the design and conduct of clinical trials and in prognostication. A number of CC 
staging systems have been used, these are generally based on tumour-node-
metastases (TNM) criteria, the American Joint Committee on Cancer (AJCC) TNM 
criteria being the most widely used. Such systems are based on some parameters that 
require pathological examination of an excised lesion for precise classification, 
although pre-operative imaging, biopsy or operative staging findings may be used to 
define a provisional stage prior to resection. It has become clear that different staging 
systems are required for intra-hepatic, peri-hilar and distal CC due the different 
patterns of tumour extension, prognosis and therapeutic approaches.[225] Historically, 
intra-hepatic CC (IHCC) has been staged according to the same criteria as 
hepatocellular carcinoma (HCC) using the 6th edition of the AJCC TNM system. The 7th 
edition of these criteria refined these for IHCC by adding vascular invasion, tumour 
number and lymph node status. Other systems, such as those of the National Cancer 
Centre of Japan (NCCJ) and Liver Cancer Study Group of Japan (LCSGJ), are also in 
widespread use.[226, 227] Unmodified, these systems are not appropriate for staging of 
extra-hepatic CC, as they do not take account of features of extra-hepatic CC that 
inform management such as precise ductal distribution of hilar CC; hepatic function; 
hepatic atrophy and vascular invasion. The Memorial Sloan-Kettering system adds 
biliary extent, vascular encasement and liver atrophy to the TNM criteria. Correlation 
with R0 resection, nodal spread and survival is somewhat improved using this 
system.[228] The 7th Edition of the AJCC/UICC system also incorporates these criteria 
and now addresses hilar extrahepatic and distal extrahepatic disease separately in its 
staging algorithm. All current staging systems for CC have their weaknesses and have 
proven imperfect in determining prognosis and response to therapy in patients with CC. 
As new prognostic factors emerge from multivariate analysis of different CC subtypes, 
further refinements of these imperfect systems are proposed. Expert groups are 
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currently refining and validating systems that include factors such as depth of invasion, 
jaundice and performance status.[229, 230] Even when staged as operable, clear margins 
are achieved in only 20-50% of patients undergoing curative resection for CC. In those 
patients with clear margins, the 5-year survival rate is 19-47%. Those undergoing 
resection with positive margins have 5-year survival of 0-12%.[222, 231] This indicates that 
that even with high quality expert imaging, current preoperative staging is poor and 
does not predict resectability of CC or survival.[232, 233] 
1.11 Treatment 
1.11.1 Surgery 
Surgery is the only therapy that can cure CC. Survival correlates strongly with negative 
margins (R0 resection), absence of vascular invasion and absence of lymph node 
involvement.[158, 234-240] Resection is usually only attempted with curative intent, as 
palliative or debulking resections confer no survival benefit.[228] Contraindications to 
surgery include proven distant metastases, malignant ascites, bilateral vascular or 
biliary involvement, advanced cirrhosis or PSC. In a large case-series, resection was 
feasible in distal, intrahepatic and perihilar lesions in 91, 60 and 56% of cases 
respectively.[158] Mono-focal intrahepatic CC can be resected in a segmental fashion 
with 5-year survival rates of 22-44%. Surgery for peri-hilar lesions is determined by 
Bismuth-Corlette criteria (Figure 1.2). Patients with Bismuth I and II lesions undergo en 
bloc resection of the extrahepatic bile ducts, gall bladder and hilar lymph nodes with 
formation of a hepatojejunostomy.  Type III and IV lesions require lobectomy or 
hemihepatectomy of the corresponding liver.[241-244] Distal lesions are resected with a 
pylorus preserving pancreaticoduodenectomy (Whipple’s procedure).[158] R0 resection 
of peri-hilar CC carries a five-year survival of 11%-41% and for distal CC 27%-37%.[158, 
223, 228, 245-247] Overall 5-year survival for R0 resections remains <50%.[245] It is likely that 
some of these studies underestimate current outcomes as survival rates after CC 
resection have improved in the last decade - most likely due to improved staging and 
patient selection.[248]  
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1.11.1.1 Surgery for PSC patients with CC 
Resection of CC in patients with PSC has higher associated morbidity and mortality 
than in patients with sporadic CC in a normal background liver. The underlying liver 
function is generally inadequate to withstand resection of the required volume of liver. 
Resection for extrahepatic lesions requires the formation of a biliary-enteric 
anastomosis, which can exacerbate the on going cholangitis, and is an additional risk 
factor for CC.[249, 250] Finally, PSC patients with CC are likely to have multifocal CC, or 
at least multifocal biliary dysplasia, that makes early recurrence or development of a 
new lesion common. Outcomes for patients with PSC who develop intrahepatic or 
perihilar CC and undergo resection are dismal.[251, 252] 
1.11.1.2 Orthotopic liver transplantation (OLT) 
Historically, orthotopic liver transplant (OLT) for unresectable CC achieved appalling 
outcomes, with early tumour recurrence and very short survival the rule. In the last two 
decades, a handful of centres in the United States of America (USA) have attempted 
liver transplantation in highly selected patients with CC. Protocols comprise extensive 
preoperative assessment, including EUS with lymph node FNA and a staging 
laparotomy with lymph node biopsy. Suitable candidates progress to preoperative 
chemotherapy, external beam radiotherapy and intraductal brachytherapy. Patients 
with irresectable disease confined to the liver, and who tolerate the neoadjuvant 
regime, undergo transplantation. In the largest published series, the cohort that actually 
underwent transplantation had 1-, 3-, and 5-year survival after OLT of 90%, 80%, and 
71%. These figures are comparable to those achieved with OLT for other 
indications.[253] The excellent survival figures are, in part, a result of the meticulous 
selection of appropriate cases. Even in centres where it available, only a minority of 
patients with CC actually undergoes OLT. Encouragingly, OLT seems to have been 
particularly successful in patients with PSC related CC where resection is almost never 
successful.[253-258] The strict exclusion criteria, the cost of protocols and the small 
donor pool mean that OLT is likely to remain an option for only a small proportion of 
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CC patients. Where permitted and available, live related liver donation may mitigate 
some of this restriction. For now, CC remains a contraindication to OLT in most 
healthcare systems worldwide – including patients with PSC related CC. Outcome data 
from the more numerous USA and European centres that are now using OLT in CC is 
emerging, demonstrating comparable outcomes.[259]  
1.11.1.3 Neoadjuvant therapy 
Neoadjuvant chemoradiotherapy is rarely feasible as CC patients are often jaundiced 
with poor performance status at presentation. Small series of patients have been 
studied with complete responses in 20-30% and partial responses in the remainder.[260, 
261] Cases of irresectable CC being downstaged and then resected successfully have 
been reported.[261] However, prospective clinical studies are required and neoadjuvant 
therapy remains feasible in only a minority of patients. 
1.11.1.4 Adjuvant therapy 
Adjuvant chemotherapy, in conjunction with R0 resection of CC, has not been proven 
to improve recurrence or survival rates.[260] Many centres offer 5FU or gemcitabine 
based adjuvant chemotherapy and this is the subject on ongoing clinical trials. Routine 
adjuvant chemoradiotherapy has been studied in small retrospective case-series, 
which have suggested a modest survival benefit.[262, 263] However, a prospective RCT of 
a mixed group of biliary, ampullary and pancreatic neoplasms showed no benefit of 
chemoradiotherapy in the CC subgroup.[264] In patients with positive margins at surgery, 
there is stronger evidence in support of adjuvant chemoradiotherapy. Small 
retrospective series have demonstrated improved 5-year survival (34 vs. 14%) and 
median survival (21 months vs. 8 months).[265, 266] Postoperative chemoradiotherapy is 
therefore generally recommended to patients with positive resection margins.[157] 
1.11.2 Palliative therapy 
In the 50-90% of CC patients that have unresectable disease at diagnosis, palliative 
therapy is the mainstay.[158] With full palliative treatment, median survival of 6 months is 
achieved, versus 2 months with expectant care.[267] The major morbidity is related to 
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biliary obstruction. The resultant jaundice can be debilitating and obstruction rapidly 
leads to deterioration of liver function and death.[268] 
1.11.2.1 Endoscopic palliation 
1.11.2.1.1 Stents 
Endoscopic insertion of biliary stents is the principal palliative therapy for CC. Plastic or 
metal stents can be deployed through strictures at ERCP and can reliably decompress 
the biliary tree. The choice of metal or plastic stent depends on the security of the 
malignant diagnosis, the predicted prognosis and local resources. Metal stents do not 
improve survival compared to plastic.[269] Plastic stents have an average patency of 2 
months, with metal stents lasting up to a year.[269, 270] Uncovered metal stents are very 
difficult to remove once placed, so are only used when unresectable CC has been 
proven.[271] Increasingly, fully covered metal stents are being placed as the primary 
endoscopic management of biliary strictures distal to the liver hilum. These maximise 
biliary decompression, minimise risk of stent occlusion and do not complicate future 
surgery. They can be removed endoscopically and have proven useful in benign 
stricturing disease. Covered metal stents have a slightly higher rate of migration that 
uncovered metal stents and cannot be deployed across the hilum, as contra-lateral 
biliary obstruction may result.[270, 272] 
1.11.2.1.2 Photodynamic therapy (PDT) 
After systemic delivery of a photosensitising hematoporphyrin derivative (HPD) such as 
Photosan-3® or Photofrin II®, high intensity light at a wavelength of 630 nm is applied to 
the bile duct lumen via a catheter.[273] This induces injury to any exposed biliary lesion 
to a depth of 6-8mm. PDT in generally undertaken before immediate placement of a 
metal stent. Improvement in duration of stent patency, and patient survival, has been 
demonstrated.[274, 275] Side effects include a higher rate of cholangitis than is seen in 
standard ERCP and the unwanted dermatological sequelae of photosensitisation.[13] 
The HPD drugs have become increasingly expensive in recent years, limiting their use 
in some healthcare systems. The most recent large clinical trial of PDT in CC, 
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published only in abstract form to date, had disappointing results, with earlier mortality 
in the PDT group compared to the control arm. Overall survival was 5.6 months for 
PDT plus stenting versus 8.5 months for stenting alone (HR 1.82, p=0.027). Although 
overall survival was improved among those who had chemotherapy compared to those 
who did not (11.1 vs. 4.8 months, p=0.001), adjusting for this only reduced the PDT 
plus stenting hazard ratio from 1.8 to 1.6, suggesting that failure to receive subsequent 
chemotherapy did not fully explain the excess risk in the PDT cohort. Some 
commentators suggest that flaws in the study methodology may have resulted in a 
spurious finding of inferiority in the PDT group but, in the absence of further RCT data, 
PDT should be regarded as of doubtful benefit in CC.[276] 
1.11.2.1.3 Intraductal radiofrequency ablation (RFA)  
Recent technical advances, led by engineers and clinicians at Imperial College 
London, have permitted the direct delivery of radiofrequency ablation (RFA) into the 
bile duct. This is undertaken at ERCP and requires the transpapillary introduction of a 
specially designed electrode catheter. RF energy is delivered, causing heating and 
coagulative necrosis of adjacent tissues, to a depth of 5-8mm. Initial studies have 
confirmed utility and safety of this approach when combined with stent insertion.[272] 
Unblocking of obstructed metal stents has also been demonstrated. There is a 
suggestion that stent patency and duration of patient survival may be improved.[277, 278] 
Randomised controlled trials are awaited. The principal advantage of the RFA 
approach over PDT is the avoidance of systemic photosensitisation, with the 
associated costs and side effects. 
1.11.2.2 Radiological palliation 
Percutaneous transhepatic cholangiography (PTC), with placement of drains (PTD) or 
metal stents, is frequently necessary to relieve jaundice. This is generally indicated 
when ERCP and stent delivery is impossible due to anatomical factors, such as 
duodenal obstruction, or patient factors, such as cardiorespiratory instability.[140] PDT 
and intraductal RFA catheters can also be deployed via the percutaneous route. Direct 
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percutaneous RFA of peripheral IHCC is also feasible, as in HCC management. 
Radiologic embolisation of extensive intrahepatic disease with chemotherapeutic or ß-
particle emitting microspheres (yttrium-90) has also been reported.[279] 
1.11.2.3 Surgical palliation 
There is no role for surgical debulking.[242] Laparoscopic biliary bypass surgery is 
sometimes required for palliative relief of jaundice. However, ERCP or PTC 
decompression is generally preferred as the associated morbidity is lower.[280] 
1.11.2.4 Oncological palliation 
Chemotherapy with gemcitabine and cisplatin has utility in patients with unresectable 
CC, with prolongation of median survival from 8 to 26 weeks.[267] Studies have 
incorporated intrahepatic CC, hilar CC, gallbladder cancer and extrahepatic CC as one 
entity. This is a flaw, and expert groups are now advocating separate clinical studies in 
each of these groups. Palliative external beam radiotherapy, with or without 
chemotherapy, may reduce biliary obstruction and pain but does not confer any 
survival benefit.[262, 281-283] Small studies of high dose radiotherapy with chemotherapy, 
including intraductal brachytherapy, have shown increased 2-year survival (48 vs 
0%).[284] However, prospective studies have not been performed and complication rates 
with high intensity chemoradiotherapy are high. 
1.12 Published guidelines for the diagnosis and management of CC 
Detailed guidelines for the diagnosis and management of CC were first published by 
the British Society of Gastroenterology (BSG) in 2002.[140] A summary of the diagnostic 
criteria for CC included in this guideline is provided in Table 1.2. An updated version of 
these guidelines was published in 2012. Other guidelines have been published by 
learned societies including the European Society for Medical Oncology (ESMO) 
guidelines on the diagnosis and management of CC (2011) and the IHPBA, AHPBA 
and EHPBA consensus documents on CC published in 2008.[285-287] The use of such 
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guidelines is helpful, but clearly local policies, patient needs and healthcare economics 
must be considered in their interpretation. 
1.13 Summary: Unmet needs and thesis aims 
Current understanding of the aetiology of cholangiocarcinogenesis is limited. Our 
knowledge of the aetiology of sporadic CC is particularly poor. Diagnostic and staging 
tests are inadequate. These factors combine in the current appalling prognosis of this 
disease. My overarching aim is to contribute to the knowledge of the aetiology of 
cholangiocarcinoma and to enhance its diagnosis and staging. In my thesis I will 
explore and elucidate the following three specific areas.  
1.13.1 Germline genetic risk factors for CC 
It is likely that genetic factors affect risk of CC development. Incidence of CC varies 
with ethnicity – independent of geography or environment. Genetic diseases such as 
Lynch syndrome and bile salt transporter defects carry a high risk of CC development. 
A number of genetic factors have been strongly implicated in the pathogenesis of PSC 
and cholelithiasis, the two major risk factors for CC in the West. NKG2D has been 
shown to be associated with CC risk in PSC patients. Greater understanding of 
relevant polymorphisms may clarify the pathogenesis of CC, aid diagnosis and perhaps 
permit identification of an at risk subpopulation. In Chapters 2 and 3 of my thesis I aim: 
i) To investigate the role of genetic variation in biliary transporter proteins as a 
risk factor for sporadic cholangiocarcinoma 
ii) To investigate the role of genetic variation in the NKG2D receptor as a risk 
factor for sporadic CC  
1.13.2 Plasma protein markers of CC  
CC is notoriously difficult to diagnose, particularly on the background of chronic bile 
duct inflammation, the major known predisposing factor. Liver transplantation is 
accepted therapy for HCC or severe PSC. Conversely, once CC has developed (as it 
does in up to 30% of PSC cases) transplantation is contraindicated. Therapy for these 
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diagnoses is radically different, potentially involving surgical resection, liver 
transplantation, endoscopic intervention, chemotherapy or palliation. Serum tumour 
markers CA19-9 and CEA have poor specificity and sensitivity and are usually only 
positive once the disease has become unresectable.[140] Therefore, there is a need for 
sensitive and specific biomarkers that become positive at an early stage of the disease 
and can distinguish CC from benign biliary disease, as well as from other liver tumours. 
In Chapters 4 and 5 of my thesis I aim: 
i) To establish protein profiles of plasma from patients with cholangiocarcinoma 
and define potential new biomarkers 
ii) To investigate the potential of neutrophil gelatinase-associated lipocalin (NGAL) 
as a plasma biomarker of CC 
1.13.3 Deficiencies in the imaging diagnosis and staging of CC 
Diagnosis of CC currently relies on imaging with CT or MRI.[140] However, these 
modalities cannot reliably distinguish benign from malignant biliary strictures, or 
differentiate CC from other liver tumours, such as metastases or HCC. Current imaging 
technology is inadequate in the staging of CC, leading to some patients with 
irresectable disease undergoing futile radical surgery, others undergoing inadequately 
radical surgery - reducing the chance of R0 resection. In Chapter 6 of my thesis I aim: 
i) To develop, validate and optimise a miniature detector coil for intraductal MR 
imaging of the biliary tree 
ii) To develop, validate and optimise a MR compatible duodenoscope, with 
integrated MR detector coils, for imaging of the biliary tree 
iii) To integrate 1 & 2 in an imaging system and demonstrate utility in imaging ex 
vivo specimens 
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1.14 Chapter 1 Tables and Figures 
Table 1.1: Summary of studies of genetic polymorphisms as risk factors for CC 
Gene polymorphism Study Function Country Cases - n Controls - n Odds ratio (95% CI) 
GST01*A140D Marahatta et al, 2006[66] Detoxification Korea 30 98 8.5 (2.1-37.8) 
NAT2* 12,*6B,*7A Prawan et al, 2006[69] Detoxification Thailand 216 233 0.38 (0.1-0.9) 
CYP1A2 Prawan et al, 2006[69] Detoxification Thailand 216 233 0.28 (0.1-0.9) 
MTHFR 677CC/ TSER 2R+ Ko et al, 2006[68] Folate metabolism Korea 47 204 5.38 (1.2-23.6) 
XRCC1 194W Huang et al, 2008[288] DNA repair China 127 786 1.9 (1.1 – 3.5) 
XRCC1 R280H Huang et al, 2008[288] DNA repair China 127 786 0.5 (0.3-0.9) 
NKG2D rs11053781 Melum et al, 2008[72] NK cell activation Norway 46 (PSC + CC) 319 (PSC) 2.08 (1.31-3.29) 
NKG2D rs2617167 Melum et al, 2008[72] NK cell activation Norway 46 (PSC + CC) 319 (PSC) 2.32 (1.47-3.66) 
MICA 5.1 allele Melum et al, 2008[72] NKG2D ligand Norway 46 (PSC + CC) 319 (PSC) 0.3 (0.20-0.95) 
PTGS2 Ex10 +327T>C Sakoda et al, 2006[289] COX-2 enzyme China 127 786 1.8 (1.2-2.7) 
α1AT rs28929474 Mihalache et al, 2011[70] α1AT function Germany 182 350 2.46 (1.14–5.32) 
MRP2 c.3972C>T Hoblinger et al, 2009[71] Biliary xenobiotic excretion Germany 60 73 1.83 (1.1-3.1) 
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Table 1.2: Summary of clinical features and recommended investigations 
for diagnosis, BSG Guideline on CC 2001[140] 
Clinical Features Serum Radiology Invasive Investigations 
Jaundice Bilirubin USS ERCP 
Pale Stools ALP Contrast triple phase helical CT  PTC 
Dark Urine GGT MRI EUS 
Pruritis ALT/AST MRCP Histology 
Malaise CA-125 (PET)  
Fatigue CA19-9   
Loss of Appetite CEA   
Weight Loss (IgG4)   
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Figure 1.1: Molecular events in cholangiocarcinogenesis 
Legend: Chronic biliary inflammation and cholestasis lead to cellular changes leading 
to cholangiocarcinoma development and progression. Inflammatory cytokines induce 
iNOS (inducible nitric oxide synthase) in cholangiocytes, favouring mutagenesis, 
impaired DNA repair, and COX-2 up-regulation. Aberrant bile acid signalling 
contributes to the promotion of cholangiocyte growth via transactivation of the 
epidermal growth factor receptor (EGFR), and is also linked to activation of the COX-2 
pathway. Alterations in various genetic and epigenetic molecular pathways selectively 
depicted in the figure then combine to promote the features of immortalization, evasion 
of apoptosis, autonomous proliferation, and invasion and metastasis characteristic of 
malignant cholangiocytes. MMP, matrix metalloproteinase; PDGF, platelet-derived 
growth factor; TGF, transforming growth factor; TNF, tumour necrosis factor. Adapted 
from Sirica et al 2008[79]. 
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Figure 1.2: Bismuth-Corlette classification of hilar CC 
Legend: This categorisation is based on ductal extent of the lesion. Type I: limited to 
the common hepatic duct, not involving the confluence of right and left hepatic ducts. 
Type II: involves the confluence. Type IIIa: type II plus involvement of the right hepatic 
duct. Type IIIb: type II plus involvement of the left hepatic duct. Type IV: extending to 
both right and left hepatic ducts. (Adapted from Sainani et al, 2008[290]) 
Chapter 2 – Biliary transporter genetics 
 63 
2. Polymorphisms of biliary transporter genes as risk 
factors for CC 
2.1 Background 
As discussed in Chapter 1, a variety of different diseases and environmental factors 
are known to increase an individual’s risk of CC. Some of these diseases, such as 
hepatitis C and gallstone disease, are very common. The hepatobiliary system is the 
major route of metabolism and excretion for exogenous and endogenous toxins, many 
of which are genotoxic and potentially carcinogenic. Exposure to environmental toxins 
has increased in the past few decades, and may well play an important role in 
cholangiocarcinogenesis.[291-293] Exposure to exogenous toxins is widespread, and 
biliary exposure to endogenous toxins such as hydrophobic bile acids is universal. 
Despite these highly prevalent disease and environmental risk factors, only a small 
percentage of Western populations develop CC. In common with many other complex 
diseases, it is highly likely that host susceptibility factors, many of which are genetically 
determined, will modify an individual’s response to these stimuli and their risk of 
cholangiocarcinogenesis. A number of genetic diseases that are risk factors for CC, 
including abnormalities in bile duct transporter proteins, have already been reviewed in 
section 1.2.3, where I also discuss the expanding evidence of strong genetic influences 
on risk of gallstone disease and PSC. 
Hepatobiliary excretion of bile salts and toxins is performed by a variety of transporters 
that are expressed on the apical surface of hepatocytes and cholangiocytes.[294] These 
transporters, their substrates and functions in the excretion of bile constituents are 
discussed in the following section and are illustrated in Figure 2.1 (adapted from Geier 
et al, 2006[295]). Their names, encoding genes, known functions and associated 
diseases are listed in Table 2.1 (adapted from Wadsworth et al, 2011[296]). 
The function of these transporters governs the rate of bile flow and their dysfunction is 
known to cause cholestasis and biliary injury. Bile flow and constituents vary between 
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individuals. Genetic polymorphisms in biliary transporters can lead to reduced 
expression, or function, or both.[297, 298] A reduction in the flow of bile (cholestasis) may 
result in increased exposure of cholangiocytes lining the biliary epithelium to 
xenobiotics and endogenous mutagens, such as hydrophobic bile acids. Hydrophobic 
bile acids have a strong detergent action that disrupts cell membranes. The formation 
of bile acids, phosphatidyl choline (PtC) and cholesterol into stable micelles in the bile 
protects the hepatobiliary system from damage. There is extensive experimental 
evidence that relative under or over representation of bile constituents, such as PtC 
and bile acids, leads to unstable biliary micelles and thereby failure of physiological 
biliary protective mechanisms. The sequelae of this are deconjugation of toxic species 
leading to the formation of ‘toxic bile’ and bile duct damage.[294, 299]  
2.1.1 Biliary canalicular transporter proteins 
2.1.1.1 Bile salt exporter pump (BSEP, ABCB11)  
BSEP, encoded by the ABCB11 gene, is a member of the superfamily of ATP-binding 
cassette (ABC) transporters. ABC proteins transport various molecules across extra- 
and intra-cellular membranes. BSEP is responsible for the active transport of bile acids 
across the hepatocyte canalicular membrane, and secretion of these bile acids is the 
major determinant of bile flow.[49, 297] Under-expression of BSEP is implicated in 
progressive familial intrahepatic cholestasis Type 2 (PFIC2).[300] PFIC2 has been 
associated with very early onset of HCC and CC in children. 
2.1.1.2 Multidrug resistance protein 3 (MDR3, ABCB4) 
MDR3 is encoded by the ABCB4 gene and is a phosphatidylcholine floppase that 
translocates PtC from the inner to the outer leaflet of the canalicular membrane. PtC is 
critical to the formation of lipids and bile acids into stable micelles in the bile. 
Polymorphisms in ABCB4 can lead to a reduction in MDR3 protein function and biliary 
PtC levels, resulting in unstable micelle formation.[301] MDR3 deficiency has been 
implicated in PFIC Type 3 (PFIC3).[302] 
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2.1.1.3 Multidrug resistance-associated protein 2 (MRP2, ABCC2) 
MRP2 is encoded by the ABCC2 gene, is a member of the MRP subfamily and plays a 
key role in drug elimination and drug resistance. It is expressed in the canalicular, 
apical membrane of the hepatocyte and exports numerous conjugated anionic species 
into the bile, including bilirubin and many drugs and toxins.[294, 303] A recent study in a 
German cohort reported an association between a polymorphism in ABCC2 and CC.[71] 
2.1.1.4 Familial intrahepatic cholestasis protein 1 (FIC1, ATP8B1) 
FIC1 is a member of the P-type cation transport ATPase family and belongs to the 
subfamily of aminophospholipid-transporting ATPases. It is highly expressed in 
cholangiocytes and the canalicular membranes of hepatocytes and is also found in the 
small intestine.[304] FIC1 transports phosphatidylserine and phosphatidylethanolamine 
from the outer membrane leaflet to the inner, maintaining the correct distribution of 
these lipids in the membrane and thereby membrane integrity.[305] FIC1 dysfunction is 
associated with the disease PFIC Type 1 (PFIC1).[306, 307]  
2.1.1.5 Farnesoid X receptor (FXR, NR1H4) 
FXR is encoded by the NR1H4 gene. It is a nuclear receptor and is expressed at high 
levels in the human liver and intestine. It is not a biliary canalicular transporter protein 
per se. However, chenodeoxycholic acid and other bile acids are natural ligands for 
FXR. When activated, FXR translocates to the cell nucleus and binds to hormone 
response elements on DNA. It thereby up- or down-regulates the expression of other 
genes. FXR suppresses the production of cholesterol 7 α-hydroxylase (CYP7A1), 
which is a crucial enzyme in bile acid synthesis. Synthesis of bile acids is thereby 
inhibited, when cellular bile acid levels are high.[308] Importantly, FXR also modifies the 
expression of other genes, including ABCB11 and ABCB4.[309, 310] 
2.1.2 Rationale for study 
Genetic polymorphisms in biliary transporters are known to lead to reduced transporter 
expression, or function, or both. Subsequent disequilibrium of excreted biliary 
constituents leads to cholestasis, micellar instability, failure of biliary epithelial 
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protective mechanisms and the formation of toxic bile – with deconjugation of 
genotoxic species.[294] Such a genetic predisposition may enhance the effect of other 
risk factors - known or unknown, genetic, disease or environmental. 
2.2 Hypothesis and study aim 
2.2.1 Hypothesis 
I hypothesised that variation in the genes that encode the biliary transporters BSEP, 
MDR3, MRP2 and FIC1, and the nuclear receptor FXR, is associated with altered 
susceptibility to sporadic cholangiocarcinoma. 
2.2.2 Study aim 
To investigate the role of polymorphisms in BSEP (ABCB11), MDR3 (ABCB4), MRP2 
(ABCC2), FIC1 (ATP8B1) and FXR (NR1H4) as risk factors for sporadic 
cholangiocarcinoma. 
2.3 Materials and methods 
2.3.1 Ethics 
The study protocol conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki. I sought and obtained approval of this study from the St Mary’s Research 
Ethics Committee and NHS R&D Department (Ref 09/H0712/82). 
2.3.2 DNA from CC patients 
I collected blood samples from 172 subjects with CC. Cases were confirmed by a) pre- 
or post-operative histology or b) multidisciplinary team consensus on the basis of ≥2 
imaging modalities, clinical course and serum markers. All cases collected were from 
Caucasian patients. 
2.3.2.1 Prospective collection 
I collected blood samples prospectively from 44 consecutive consenting patients with 
CC. These subjects were recruited at Imperial College Healthcare NHS Trust.  
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2.3.2.2 Archived samples 
I obtained blood samples from 128 subjects with CC from the hepatobiliary biobank 
archives of Imperial College Healthcare NHS Trust and University College Hospitals 
NHS Foundation Trust. These blood samples had been collected as part of other 
recent studies into CC and were stored with appropriate donor informed consent for 
retention and use in future, REC approved, studies.  
2.3.3 Control DNA 
I obtained blood samples from 265 control subjects with no liver disease. These were 
archived blood samples from a prior study, with informed consent for retention and use 
in future, REC approved, studies. The control blood samples were all from Caucasian 
patients and I selected them to form a cohort that was as well matched to the case 
group as possible in terms of sex and age. 
2.3.4 Power calculation 
I undertook an a priori power calculation, using statpages (Statpages.org, Albemarle, 
USA)[311].  
The SNPs selected had a minimum mean allele frequency (MAF) ≈10%. Therefore the 
expected control group allele frequency was set at 0.1, case group allele frequency of 
0.2 (i.e. an estimated odds ratio of 2). A required power of ≥80% to detect any 
difference, with a p value <0.05, was set.  Case and control groups were initially 
assumed to be of equal size.  
Using standard formulae[312], the number (n) required in each group was calculated as: 
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Where p1 is the expected/known proportion in control population; p2 is the estimated 
proportion in case population (assuming a difference); cp1power is a constant defined by 
the values chosen for the desired P value and power (defined by a standard 
nomogram, common values shown in Table 2.2[313]) 
I anticipated collecting 160 case samples, and had ready access to a larger number of 
control than disease samples. Therefore, I further calculated for unequal sample sizes:  
k!=!n!/!(2no!–!n)!
k!=!197.5!/!((2!x!160)!–!197.5)!
k!=!1.61!
kno!=!1.61!x!160!=!257.6!
Where n is the calculated required (equal group) sample size, n0 is the known minimum 
case group size, kno is the size of the required expanded control group, to maintain the 
same power (80%) at the same alpha (p=<0.05).[314] 
So, with a CC group of at least 160 and a control group of at least 258, the study had 
80% power to detect the hypothesised difference between cases and controls.  
2.3.5 DNA preparation 
I used two different DNA extraction techniques on samples from CC patients, 
depending on the provenance of the sample. The format of collection and storage was 
different for archived and prospectively collected samples, mandating different 
approaches to DNA extraction.  
DNA was extracted from the control blood samples using a third technique. The format 
of these samples was different (1-2mL of whole blood) and time pressures meant that I 
was unable to extract the DNA from these myself. KBioscience Ltd (Hoddesdon, 
Hertfordshire, UK) undertook these extractions. 
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All three techniques used are established, validated proprietary systems. As DNA is 
highly conserved, introduction of any bias due to differing extraction technique is highly 
unlikely. I undertook a number of DNA quality control (QC) measures, and these are 
outlined in 2.3.5.4, below.  These indices, and the genotyping failure rates, were 
compared between samples collected and processed with different techniques.  
2.3.5.1 Extraction of DNA from prospectively collected blood samples  
I collected samples prospectively from CC subjects using a sample collection SOP, 
which I authored (Appendix 1). The sample for genetic studies was taken into an EDTA 
tube, in which the blood does not clot. On centrifugation, a buffy coat layer can be 
readily identified and isolated. I extracted DNA from the blood leucocytes within the 
buffy coat layer using the QIAamp DNA blood mini kit (QIAGEN Ltd, Crawley, UK) 
using adapted manufacturer’s protocols.[315] This is a kit based, column adhesion 
technique. It is an economic, high throughput system, but is only applicable to samples 
that have been anticoagulated at collection. 
2.3.5.1.1 Method of DNA extraction from prospectively collected samples 
I adapted this methodology from the reagent manufacturer’s published guidance.[315] All 
reagents were obtained from QIAGEN.  
i. After collection, each 5mL EDTA blood sample was centrifuged at 2000g for 10 
min, before removing the buffy coat layer with a pipette. This was frozen at -
20oC in readiness for batch DNA extraction 
ii. 30 min before DNA extraction, samples thawed to room temperature 
iii. 200µL of buffy coat placed into a centrifuge tube and added 20µL of QIAGEN 
proteinase K solution 
iv. 200µL of Buffer AL added to each sample and vortexed for 15s 
v. Sample incubated at 56oC for 10 min 
vi. 200µl of ethanol added to the samples, before vortexing for 15s 
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vii. Resulting solution transferred into the QIAamp mini spin column, held within a 
2mL collection tube 
viii. The collection tube, column and solution were centrifuged at 6000g for 1 min, 
drawing the solution through the column 
ix. The filtrate was discarded, and 500µL of buffer AW1 added to the top of the 
column. This was again centrifuged at 6000g for 1 minute, within a clean 2mL 
centrifuge tube 
x. The filtrate was discarded, 500µL of buffer AW2 was added to the top of the 
column and the column centrifuged at 6000g for 1 min, within a clean 2mL 
centrifuge tube 
xi. The filtrate was discarded. 200µL of buffer AE was added to the column and 
incubated within a 1.5mL centrifuge tube for 5 min. The column was then 
centrifuged at 6000g for 1 min  
xii. The resulting filtrate, containing the eluted DNA in buffer AE, was stored at 
-20oC, pending preparation for genotyping 
2.3.5.2 Extraction of DNA from archived blood samples from CC patients 
The archived samples from CC subjects had been collected in serum separation tubes 
(SST) - in which blood clots. This initially posed a problem, as DNA extraction from 
mature clot usually requires manual or ultrasonic fragmentation of the sample. DNA 
yields from such samples are often low.  Moreover, such techniques are unsafe, as 
they require the use of a scalpel blade on the clot, or nebulisation of the sample with 
increased risk to the operator of mucosal splash.  
I identified a safer, high yield technique in the literature. This required the use of 
Clotspin Baskets and the Gentra Puregene Blood Kit (QIAGEN). This system allowed 
me to use a centrifuge and a basket within the sample processing tube to shred the 
clotted sample. The manufacturer states that the protocol permits purification of high 
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molecular weight DNA with purification steps that remove contaminants.  They state 
that purified DNA typically has an A260/A280 ratio between 1.7 and 1.9 and is up to 
200kb in size. The protocol is optimised for purification of DNA from 5–7mL of clotted 
blood. I obtained the protocol from the QIAGEN website, to which no modifications 
were required. I trialled the technique in six samples successfully, and confirmed DNA 
yield and quality using low volume spectrophotometry.  
Once I had demonstrated its utility, I applied this extraction technique to all the 
archived samples that had been collected in SST tubes.  
2.3.5.2.1 Method for DNA extraction from archived samples 
I adapted this methodology from the manufacturer’s published guidance.[316] All 
solutions and reagents used in the following protocol were purchased in kit form from 
QIAGEN. 
i) Each frozen, clotted blood sample was thawed out quickly in a water bath at 
37°C and then placed on ice. The SST tube was inverted several times to 
loosen the clot 
ii) The blood clot was poured into the Clotspin Basket, held within a 50mL tube  
iii) The blood sample was centrifuged, within the basket and 50mL tube, at 2000g!
for 10 min. This forced the clot through the perforations in the basket, shredding 
it 
iv) 15mL of red blood cell lysis solution was added to the basket to rinse residual 
clot material through 
v) The basket was removed from the 50mL tube and a pipette used to transfer 
remaining clot material from the basket into the 50mL tube, before discarding 
the basket 
vi) The resultant solution was vortexed for 3 s and then placed on a tube rotator for 
5 min at room temperature (15–25°C)  
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vii) The tube was vortexed again for 3 s, at high speed  
viii) The solution was centrifuged again, at 2000g for 5 min, to form a pellet of white 
blood cells and clot fragments at the bottom of the tube 
ix) The supernatant was poured off, retaining the pellet in the tube  
x) A further 5mL of red blood cell lysis solution was added to the pellet, and 
vortexed for 3 s at high speed  
xi) The tube was incubated on a rotator for 5 min at room temperature  
xii) The sample was centrifuged, at 2000g for 5 min, to pellet the white blood cells 
and clot fragments  
xiii) The supernatant was discarded, leaving behind 200µL of residual liquid and the 
pellet  
xiv) The tube was vortexed vigorously at high speed to disperse the pellet in the 
liquid 
xv) 5mL of cell lysis solution and 25µL of Puregene Proteinase K (20mg/mL) were 
added and the solution vortexed for 10 s  
xvi) The sample was incubated at 55°C overnight, vortexing for 10 s three times 
during the incubation  
xvii) To terminate cell lysis and proteinase activity, the samples were incubated on 
ice for 5 min  
xviii) 1.67mL of protein precipitation solution was added to the cell lysate, and 
vortexed for 20 s  
xix) The sample was centrifuged at 2000g for 10 minutes and then incubated on ice 
for 2 min 
xx) 5mL of isopropanol and 10µL of glycogen solution (20 mg/mL) were pipetted 
into a fresh 50mL centrifuge tube  
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xxi) The supernatant from step xix was decanted into the isopropanol/glycogen 
solution, discarding the pellet of precipitated protein and the original tube! 
xxii) The solution was mixed by inverting the tube 50 times  
xxiii) The tube was centrifuged at 2000g! for 3 min, at which point the DNA became 
visible as a small white pellet at the bottom of the tube  
xxiv) The supernatant was discarded and the tube drained onto a clean filter paper, 
retaining the DNA pellet in the tube 
xxv) 5mL of 70% ethanol was added to the tube, with washing of the DNA pellet by 
inverting the tube 5 times 
xxvi) The solution was centrifuged at 2000g for 1 min 
xxvii) The supernatant was discarded, again draining the tube onto a clean filter 
paper, retaining the DNA in the tube  
xxviii) The DNA was allowed to air dry at room temperature for 10 min  
xxix) 500µL of DNA hydration solution was added to the DNA pellet  
xxx) The DNA was incubated at 65°C for 1 hour until dissolved  
xxxi) The DNA was incubated overnight at room temperature overnight with gentle 
shaking before transferring to archive tubes and freezing at -20oC, pending 
preparation for genotyping 
2.3.5.3 Extraction of DNA from archived blood samples from control 
subjects 
KBioscience undertook DNA extraction from the archived control samples using a well-
established, robotised technique. The cells were lysed chemically and the resultant 
solution passed through a column of DNA binding silica particles, mediated by the 
chaotrope guanidinium isothiocyanate. After rinsing with a sequence of different buffers 
to remove any contaminants, the DNA was eluted into a low salt buffer. Samples were 
then transferred to storage tubes, and frozen at -20oC pending genotyping. 
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2.3.5.4 DNA quality control (QC) 
I performed a number of DNA QC measures. These permitted me to compare DNA 
quality and yield between extraction techniques and prepare correct concentrations of 
samples for genotyping – reassuring me that the subsequent genotyping step would be 
successful. 
2.3.5.4.1 Low volume spectrophotometry 
I performed Nanodrop low volume spectrophotometry (Thermo Fisher Scientific Inc. 
Waltham, MA, US) on all samples. This system quantifies the DNA concentration and 
260/280 ratio – a measure of the purity of DNA. It requires only 0.5µl of sample, so is 
minimally destructive of the DNA resource. It has a wide range of accuracy for DNA 
concentration (2-15000 ng/µL). 
2.3.5.4.2 Gel electrophoresis 
DNA gel electrophoresis permits estimation of DNA quality in terms of fragmentation. 
Highly fragmented samples are less likely to be successfully genotyped. I subjected a 
subset of samples to DNA gel electrophoresis. These were selected randomly from 
amongst the samples within the lowest quartile of concentration and quality on 
spectrophotometry.  
2.3.5.5 Presentation of DNA for genotyping 
Using DNA concentration data obtained in 2.3.5.2, I placed samples into 96 well plates 
with a total volume of 135µl solution per sample at a concentration of 7ng/µl. The 
required concentration was achieved by diluting an appropriate volume of each DNA 
sample with a matched volume of Buffer AE (QIAGEN). 
2.3.6 SNP selection 
I selected the polymorphisms to be genotyped in the 5 candidate genes. I used 
HaploView (v4.1, Broad Institute, Boston MA, USA) to search HapMap data (v2, 
release 22, NCBI) from genomic regions of interest within, and 5KB up and down 
stream of, each candidate gene. Markers with a minor allele frequency (MAF) of less 
than 5% were excluded. I also excluded markers that were not in Hardy-Weinberg 
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equilibrium in the HapMap cohort, with a p-value threshold of 0.001. I then used the 
application tagger within HaploView to select SNPs that captured the maximum genetic 
variation around each locus with the minimum number of SNPs. Pair-wise comparisons 
only were used with an R2 cut-off of ≥0.8. R2 is an index of linkage disequilibrium (LD) 
between two SNPs. This resulted in 23 SNPs to be genotyped in ABCB11, 15 SNPs in 
ABCB4, 9 in ABCC2, 21 in ATP8B1 and 5 in NR1H4. These SNPs are listed in Table 
2.3.  
I performed primer design by collating the corresponding DNA sequence from the 
NCBI dbSNP database for each SNP shortlisted. These are listed in Table 2.4. I 
reverse checked all DNA primer sequences by searching the NCBI basic local 
alignment search tool (BLAST). I then input these sequences into ‘PrimerPicker’ 
(KBioscience). This is proprietary, web-based software that generates designs for the 
oligonucleotides necessary for the KASPar genotyping process. 
2.3.7 KASPar genotyping 
KBioscience undertook primer preparation and genotyping. They used a competitive 
allele-specific PCR SNP genotyping system known as KASPar and which utilises 
FRET quencher cassette oligonucleotides. The KASPar system has demonstrated 
superior reliability to Taqman systems and is substantially cheaper.[317] KASPar is a 
homogeneous fluorescent endpoint genotyping system. It comprises two components - 
an assay mix and a reaction mix. The assay mix is the SNP-specific component, 
containing three unlabelled primers. The reaction mix contains a universal fluorescent 
reporting system (fluorescent dyes FAM, VIC and ROX as a control) and Taq 
polymerase. The two mixes were applied to each DNA sample and 20 PCR thermo 
cycles undertaken. A fluorescent plate reader was then used to measure signal 
intensity from each well. Data were plotted in KlusterCaller software and the genotype 
determined by the relative signal intensity from each fluorescent marker. 
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Raw data from the genotyping process was returned to me in comma separated values 
(csv) format.  
2.3.8 Analysis 
I managed and manipulated the raw genotyping data with Excel (Microsoft, Redmond, 
USA). Differences between groups were considered significant when p<0.05. 
2.3.8.1 Hardy-Weinberg equilibrium (HWE) 
I confirmed HWE in all genotyped SNPs using Pearson’s χ2 test in PLINK (V1.07, MAC 
OS 10.5.8.). I used a p-value threshold of 0.001, in line with standard practice and the 
HWE p-value criteria set in the tagger algorithm during SNP selection. I determined 
that any SNPs that breached this HWE threshold in the control cohort would be 
excluded from further analysis. 
2.3.8.1.1 HWE testing in PLINK 
PLINK is a programme run from the command line in Unix. I taught myself how to use it 
using online resources and trial and error. It was necessary to reformat my genotyping 
data into the prescribed matrices. The first of these is the PLINK-DATA file, containing 
only the subject labels and allele calls in chromosomal order. And example of the 
PLINK-DATA file, for ABCB11, is reproduced in Figure 2.2. The second is a PLINK-
MAP file, listing the rs number of each SNP in chromosomal order. An example of the 
PLINK-MAP file, for ABCB11, is given in Figure 2.3. Finally, I had to write a short 
command line script to run the programme in each gene. An example script, for the 
confirmation of HWE in ABCB11, is reproduced here: 
>plink --ped plinkabcb11dataccafricanandpscexclusion.txt --1 -
-no-fid --no-parents --no-sex --allow-no-sex --map 
plinkabcb11mapccafricanandpscexclusion.txt   --hardy 
2.3.8.2 Allelic association testing (χ2) 
I used a χ2 test to perform a basic comparison of allelic frequencies between case and 
control groups using PLINK. Estimated odds ratios (with 95% confidence intervals) 
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were also calculated at this stage. The same PLINK data and MAP matrices were used 
as for HWE testing, above. I wrote the necessary PLINK scripts. As an example, the 
script for ABCB11 is reproduced here: 
>plink --ped plinkabcb11dataccafricanandpscexclusion.txt --1 -
-no-fid --no-parents --no-sex --allow-no-sex --map 
plinkabcb11mapccafricanandpscexclusion.txt --assoc --ci 0.95 
2.3.8.3 Cochran-Armitage trend testing (CATT) 
I then compared observed versus expected genotype frequencies with Cochran-
Armitage trend testing (CATT) using PLINK. CATT is a modified form of χ2 test, which 
examines the relationship between variable 1, with two categories, and variable 2, with 
n categories where the n categories represent what is thought to be a continuum – e.g. 
‘high’, ‘medium’ and ‘low’ doses of a drug in a clinical trial. It is of utility in genetic 
studies as it permits comparison of aa, aA and AA genotypes. Technically, CATT 
remains an appropriate test even when HWE criteria are not met. 
I was able to use the same PLINK-DATA and –MAP matrices that I produced for HWE 
and χ2 testing, above. I wrote the necessary PLINK scripts for each gene. As an 
example, the script for ABCB11 is reproduced here: 
> plink --ped plinkabcb11dataccafricanandpscexclusion.txt --1 
--no-fid --no-parents --no-sex --allow-no-sex --map 
plinkabcb11mapccafricanandpscexclusion.txt  --model 
2.3.8.4 Haplotype analyses 
In complex phenotypic traits, combinations of SNPs may offer a more sensitive marker 
of modified risk. Each SNP cannot be fully studied in isolation as each is in linkage 
disequilibrium (LD) with the others. Each may represent a number of genetic 
polymorphisms. Haplotypes are combinations of different marker alleles on a single 
chromosome. A combination of SNPs, or the genetic polymorphisms that they 
represent, may be a more powerful indicator of risk. Haplotype analyses are required to 
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investigate this. However, in a diploid, human population individual genotyping results 
in unrelated subjects make it impossible to define an individual’s haplotype (unless that 
individual is homozygous in all the SNPs genotyped).  Statistical tools now permit the 
analysis of indirectly measured, or inferred, haplotypes. These methods assume that 
all subjects are unrelated and that the haplotypes are ambiguous due to unknown 
linkage phase of the SNPs. In such applications, the haplotypes are inferred using the 
assumptions implicit in HWE and application of an expectation-maximization (EM) 
algorithm. This uses a baseline set of haplotype frequency estimates to calculate a 
conditional distribution of haplotype pairs that each subject carries. This is known as 
the estimation step. Based on these conditional distributions, haplotype frequency 
estimates are updated - the maximization step. The EM algorithm switches between 
these two steps until the haplotype frequency estimates converge. The Haplo.stats 
software is an application of this type of EM algorithm and runs within the R statistical 
environment.  
2.3.8.4.1 Haplo.stats 
I undertook Haplotype analyses on the set of SNPs genotyped in each gene using 
Haplo.stats (V1.4.0 in R V2.10.1,).[318, 319]  
I reformatted the genotyping data into the required data matrices. One of these was 
required for each gene. The allelic calls for each SNP were listed in columns, in the 
order of the SNPs on the chromosome. Each row represented an individual subject. I 
made these matrices in Excel in a tab separated values format. As an example, part of 
the ABCB11 data matrix is presented in Figure 2.4.  
The Haplo.stats package (V1.4.4, Mayo Clinic, MA, USA)[320], containing the EM 
algorithm, was downloaded from the comprehensive R archive network 
(http://cran.ma.imperial.ac.uk/). I then wrote the required code to perform the analysis 
within R. I taught myself how to do this using online resources and trial and error. As 
an example, the code script that I wrote for ABCB11 is shown in Figure 2.5. 
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2.3.8.5 Correction for multiple testing 
There is an extensive literature on the most appropriate technique for correction for 
multiple testing in SNP association studies. Bonferroni correction is the most well-
known, and is a highly conservative technique. Permutation testing is a well-accepted, 
less conservative, approach. False discovery rate calculations are less conservative 
still, and therefore least likely to incorrectly discard a true positive result due to over 
correction. To explore the significance of my initial findings, I applied each of these 
techniques in turn.  
2.3.8.5.1 Bonferroni correction 
I first applied Bonferroni correction to the p-values obtained, using Excel (Microsoft). As 
73 SNPs had been genotyped, each nominal p-value was multiplied by a factor of 73 to 
generate the corrected value. As only 5 haplotype analyses were undertaken, their 
resulting p-values were multiplied by a factor of 5.  
2.3.8.5.2 Westfall and Young permutation testing 
This technique initially applies a  χ2 test to the case and control groups. A test statistic 
and p-value are thereby generated for each SNP. It then randomly reallocates each 
genotyped subject as a case or control and applies a  χ2 test to test between those 
allocated case and control status. This is reiterated many thousands of times, 
generating pseudo-p values and test statistics on the randomly generated cohorts. 
Assuming the null hypothesis is correct, all such iterations should have the same 
probability of showing a significant difference between the two groups as a matter of 
chance. The proportion of resampled data sets where the minimum pseudo-p-value is 
less than the original p-value is the adjusted p-value.  
I performed permutation testing using PLINK (V1.07). I did not perform permutation 
testing on the haplotype results. 
2.3.8.5.2.1 Permutation testing in PLINK 
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I had to combine the PLINK-DATA and PLINK-MAP matrices from all 5 genes for this 
analysis, and write further command line scripts. I set a maximum of 10000 
permutations per SNP. The PLINK script is reproduced here:  
>plink --ped plinkabcb11dataccafricanandpscexclusion.txt --1 -
-no-fid --no-parents --no-sex --allow-no-sex --map 
plinkabcb11mapccafricanandpscexclusion.txt --tdt --mperm 10000 
2.3.8.5.3 False discovery rate calculation (FDR) 
As a less conservative correction for multiple testing, a predicted FDR, which can be 
interpreted as the estimated proportion of false discoveries at a given p-value 
threshold, was calculated (R V2.10.1, QVALUE V1.0) with lambdalamda range set 
from 0.0 to 0.9 by 0.05, with both smoother and robust methods applied.[321] FDR 
calculations were not performed on the haplotype results, as it is not an appropriate 
application of this method. 
2.3.8.6 HapMap and NCBI dbSNP interrogation for associated SNPs 
If any true association exists between an individual SNP and risk of CC, this is highly 
unlikely to reflect a direct effect of that single polymorphism itself. Instead, the SNP is 
likely to represent a surrogate for changes in areas of the gene with which it shares 
close linkage disequilibrium. To explore this, I used HapMap to indentify all other, non-
genotyped, SNPs known to lie in strong LD (R2>0.8) with any genotyped SNPs found 
to be associated with altered susceptibility to CC. Each of the genotyped and 
associated individual SNPs, and those found to be in strong LD, were then examined in 
dbSNP[322] (NCBI, Bethesda, USA, Build 132) to explore potential functional 
consequences.  
2.4 Results 
2.4.1 DNA quality 
Blood samples were collected from a total of 172 subjects with CC and 256 control 
subjects. 44 samples were collected prospectively. 128 were obtained from archives. 
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As expected, the QIAGEN QIAamp blood mini DNA extraction technique was time 
efficient and effective. Although time consuming, the extraction protocol used on the 
clotted archive samples proved safe and effective.  
Germline leucocyte DNA was successfully extracted from all samples. Low volume 
spectrophotometry (LVS) confirmed high yields from most samples, and adequate 
yields from the rest. LVS also confirmed high DNA purity in the vast majority of 
extracted samples. DNA gel electrophoresis of the 15 least concentrated, least pure 
samples demonstrated reasonable quantities of large fragment DNA, certainly 
amenable to genotyping. 73 SNPs were successfully genotyped in samples from all 
172 subjects with CC. Of the 256 control samples, 2 failed genotyping resulting in 254 
to be included in the analysis.  
There were no differences in DNA quality between samples extracted with the 
QIAGEN™ blood mini kit and those extracted with the QIAGEN™ clotspin and 
PureGene system. There was no difference in genotyping success between the 
archived control samples, archived CC samples and the prospectively collected CC 
samples. 
2.4.2 Demographics of case and control groups 
8 of 172 CC cases were excluded after genotyping, but before analysis, as the cases 
had been identified as non-Caucasian (4), as PSC related CC (3) or both (1). This 
resulted in 164 cases to be included in the analysis. All cases included in the analysis 
were from Caucasian patients without PSC. The groups were well matched in terms of 
sex and age (Table 2.5).  
2.4.3 Hardy-Weinberg equilibrium (HWE) 
HWE was confirmed in all genotyped SNPs in case, control and combined groups. 
HWE results from the control group, for each SNP genotyped are presented in Table 
2.6. As none of these SNPs breached the defined p-value threshold, all genotyped 
SNPs were included in subsequent analyses. 
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2.4.4 Association testing 
The results of all association tests on all SNPs are reported in Table 2.7 in Appendix 2. 
For clarity, the results of allelic χ2 testing and CATT that yielded statistically significant 
associations are summarised in Table 2.8. 
2.4.4.1 Allelic frequency χ2 testing 
Allelic frequency testing demonstrated an association between 8 SNPs and altered risk 
of CC. None of the other 64 SNPs reached the p-value threshold of <0.05. 
2.4.4.2 Cochran-Armitage trend testing (CATT) 
CATT testing revealed a nominal association between genotype status and risk of CC 
in 7 SNPs and these are summarised in Table 2.8.  
2.4.5 Haplotype testing 
Haplotype testing revealed an association between haplotypes formed in ATP8B11 
and risk of CC. Haplotype testing in the other 4 candidate genes did not show any 
relationship with risk of CC. The haplotype findings are summarised in Table 2.9. 
2.4.6 Correction for multiple testing 
Although 8 of the individual SNPs and 1 of the haplotype analyses were nominally 
associated with altered risk of CC, it was necessary to correct the p-values for multiple 
testing.  
2.4.6.1 Bonferroni correction 
After Bonferroni correction, none of the initially associated SNPs retained significance. 
The corrected p-values are summarised in Table 2.8. The haplotype finding in ATP8B1 
did retain significance. Bonferroni corrected haplotype p-values are summarised in 
Table 2.9. 
2.4.6.2 Permutation testing 
Permutation testing generated p-values consistent with those found with allelic 
frequency χ2 testing, with 8 nominally associated SNPs. However, after permutation 
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correction for multiple testing, these p-values were >0.05 and none of the individual 
SNPs retained significant associations (data not presented). 
2.4.6.3 False discovery rate (FDR) 
The false discovery rate (FDR) q-value was calculated as 0.163, predicting <1.4 false 
positives amongst the 8 nominally significant SNPs and suggesting that the majority of 
these results are true positives. The respective q-value for each p-value is summarised 
in Table 2.8. 
2.4.7 HapMap interrogation for associated SNPs 
I searched for each of the 8 nominally associated SNPs in HapMap and identified 19 
other SNPs that lay in close LD (R2>0.8). Using dbSNP, I was able to identify the 
functionality of each of these 27 (8 plus 19) SNPs within each gene. Only one SNP 
(rs2287622) was directly associated with a known functional genetic polymorphism. All 
of the other 26 SNPs were intronic. These SNPs, and their function, are summarised in 
Table 2.11, below. 
2.4.8 Summary of results by gene 
2.4.8.1 ABCB11 
Allelic frequency testing in ABCB11 demonstrated that four individual SNPs were 
associated with altered susceptibility to CC (p<0.05); rs3770585G>A (OR 0.69, 95% CI 
0.52-0.93, p=0.013), rs2287622C>T (1.478, 95% CI 1.11-1.97, p=0.007), 
rs3770596T>A (OR 1.35, 95% CI 1.02-1.80, p=0.038), rs7605199G>A (OR 1.336, 95% 
CI 1.01-1.77, p=0.044). CATT also identified an association in these four SNPs, 
although with slightly higher p-values of 0.013, 0.009, 0.043 and 0.045 respectively.  
On searching dBSNP, One of these four associated SNPs - rs2287622 - was found to 
be directly associated with a genetic polymorphism (V444A or c.1331T>C). 
Using HapMap, 15 other SNPs within the ABCB11 gene were found that are known to 
lie in strong LD (R2>0.8) to the four associated SNPs.  All of these linked SNPs were 
reviewed in dBSNP. All are intronic and are not associated with any known functional 
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genetic polymorphism. Haplotype analysis of all 23 SNPs genotyped in ABCB11 
demonstrated no haplotype associations. 
Correction for multiple testing with both Bonferroni and permutation approaches 
abrogated the statistical significance of all significant findings in ABCB11. However, the 
false discovery rate calculation estimates that <1.4 of the 8 nominally associated SNPs 
are true false positives, meaning that the majority (>6.6) are likely to be genuine 
findings. 
2.4.8.2 ABCB4 
Allelic frequency testing in ABCB4 identified one SNP that was associated with altered 
susceptibility to CC - rs2097937A>G (OR 1.46, 95% CI 1.01-2.07, p=0.044). CATT of 
genotype frequencies also indicated a significant difference in this SNP, but with a 
slightly higher p-value (0.048). Rs2097937 is intronic. Four other SNPs within ABCB4 
were found to lie in strong LD (R2>0.8) to the associated SNP. Again, all of these four 
SNPs are intronic. Haplotype analysis of all 15 SNPs genotyped in ABCB4 
demonstrated no haplotype associations. Correction for multiple testing with both 
Bonferroni and permutation approaches abrogated the statistical significance of the 
single significant finding in ABCB4. The false discovery rate calculation estimates that 
<1.4 of the eight nominally associated SNPs are true false positives, meaning that the 
majority (>6.6) are likely to be genuine findings.  
2.4.8.3 ABCC2 
None of the individual SNPs genotyped in ABCC2 showed significant association with 
altered susceptibility to CC. The SNP rs3740066 was not associated with increased 
risk of CC. In fact, a trend towards association with decreased risk of CC was noted 
(OR 0.7854 95% CI 0.5852-1.054, p=0.09). Haplotype analysis of all nine SNPs 
genotyped identified no haplotypes to be associated with altered CC risk. 
2.4.8.4 ATP8B11 
Allelic frequency testing identified three SNPs in ATP8B1 to be significantly associated 
with altered susceptibility to CC; rs319454G>A (OR 1.37, 95% CI 1.01-1.86, p=0.04) 
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rs319448A>G (OR 1.375 95% CI 1.04-1.83, p=0.028), rs12456346A>G (OR 1.334, 
95% CI 1.002-1.776, p= 0.048). CATT of genotype frequencies also indicated a 
significant difference in two of these SNPs, with slightly higher p-values (0.042, 0.032), 
but did not reach the threshold for significance in the third (rs124563436), with a p-
value of 0.055.  
One other SNP within the gene was found to lie in strong LD (R2 >0.8) to the 
associated SNPs. The 3 associated SNPs are intronic, as is the one SNP that lies in 
close LD.  
Haplotype analysis of the 20 SNPs genotyped in ATP8B1 demonstrated a significant 
difference between case and control groups (global-stat score of 28, df 13, p = 0.0093) 
All 13 haplotypes contributing to the global-stat score finding are summarised in Table 
2.10. The haplotype effect was largely driven by a single protective haplotype, 
reference number 76, identified in 10% of healthy controls and 3% of CC cases (Hap 
score -3.22, p = 0.0013, OR 0.49 (95% CI 0.22 to 1.1), and a number of other 
haplotypes associated with decreased and increased risk of CC. Haplotype 76 included 
the wild-type, lower risk allele at all three loci identified by allelic association studies 
(rs319454, rs319448 and rs12456346), as did the base (i.e. OR 1) haplotype. 
Correction for multiple testing with both Bonferroni and permutation approaches 
abrogated the statistical significance of the 3 SNP findings in ATP8B1. However, the 
false discovery rate calculation estimates that <1.4 of the 8 nominally associated SNPs 
are true false positives, meaning that the majority (>6.6) are likely to be genuine 
findings. The statistical significance of the haplotype finding in ATP8B1 remained 
significant, even after Bonferroni correction (p=0.47). 
2.4.8.5 NR1H4 
None of the five individual SNPs genotyped in showed significant association with 
altered susceptibility to CC. Haplotype analysis identified no relationship between 
haplotypes of the 5 genotyped loci in NR1H4 and CC risk. 
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2.5 Discussion 
I have investigated the relationship of polymorphisms in genes encoding four major 
biliary transporter proteins and a nuclear receptor, FXR, to risk of CC. This is the first 
study to examine the role of variation in ABCB11 (BSEP), ABCB4 (MDR3), ATP8B1 
(FIC1) and NR1H4 (FXR). I have also investigated ABCC2 (MRP2), which has been 
examined before in a study of just 60 patients and 73 controls.[71]  
The case and control cohorts that I assembled were well matched. All subjects were 
Caucasian and did not have PSC. This minimised confounding factors and maximised 
the chance that case and control groups were directly comparable. However, this also 
means that any conclusions that may be drawn are not directly generalisable to non-
Caucasian populations, or to PSC patients - who are high risk of CC. Ethnic variation of 
genome and geographic risk factors for CC mean that entirely different gene 
polymorphisms may modify risk in other parts of the world. If validated, it would be 
particularly important to examine the polymorphisms that I have identified in a PSC 
related CC cohort, and an Asian cohort of controls and patients with OV associated 
CC. 
Although very well characterised, the CC cohort in my study did have some inevitable 
variation in phenotype that, due to subgroup sizes, it is not possible to investigate 
meaningfully. Such variables include intra- or extra-hepatic CC, operability, response to 
chemotherapy, rate of spread and survival. 
A crucial obstacle to overcome was successful extraction of DNA from archived clot 
from CC patients.  These samples represented 74% of my CC case cohort, and so 
failure to extract DNA would have rendered my study lamentably underpowered. My 
lab had not extracted DNA from clot before, and I was not permitted to use blade or 
ultrasonic techniques due to safety concerns. I expended some time identifying and 
learning the right DNA extraction method for the archived CC plasma samples. This 
was worthwhile, as the Clotspin basket method of clot disruption proved safe and 
highly effective – subsequent DNA yields were massive. 
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I did not undertake the extraction of the control DNA samples, or the KASPar 
genotyping, myself. Modern systems are almost fully robotised, and are highly efficient 
in terms of cost and time. Manually extracting the control samples would have 
occupied a disproportionate amount of my time. If I had genotyped the 73 SNPs in this 
number of samples it would have proven costly and time consuming. It is unlikely that I 
would have achieved as high a genotype call rate as a commercial robotic system.  
The statistical analyses that I undertook required the use of several software platforms 
with which I was unfamiliar. All of these were command line based packages, which 
need carefully constructed input matrices and programming scripts to run. I have no 
programming experience, nor did my colleagues. I therefore taught myself how to use 
them using online resources and trial and error with specimen datasets. I was able to 
reverse check my results, and they were also reviewed by a genetic statistician who 
concurred with my technique and results.  I am therefore confident that my statistical 
analysis has been robust. 
Eight of the SNPs genotyped are nominally associated with an altered risk of CC. I will 
consider the implications of these findings, gene by gene, in the subsequent sections. 
The approach used in this study, with multiple SNPs tested in each gene, means that 
p-value thresholds for significance must be corrected for multiple testing. None of the 
nominal SNP associations survived Bonferroni or permutation methods of correction for 
multiple testing. Both Bonferroni and permutation testing are expected to be rather 
conservative corrections, and I did observe a considerable excess of nominally 
significant results compared to the approximately 2 expected under the null. With this 
less stringent method of correction for multiple testing (FDR), individual SNPs retain 
significance, indicating a potential association. However, FDR analysis does not 
identify exactly which of the 8 findings are likely to ‘false discoveries’. However, the 
solitary finding of just 1 SNP in ABCB4 remains particularly tenuous. Interestingly, the 
only positive haplotype finding was sustained – even after Bonferroni correction. This is 
discussed in detail, along with the other findings in ATP8B1, below. 
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Apart from rs2287622, a non-synonymous polymorphism associated with a missense 
mutation in BSEP, all of the associated SNPs are intronic, as are all other SNPs that I 
identified as being in strong LD (R2>0.8) to them.  
As any gene mutation associated with any of these 8 SNPs cannot be deduced from 
my data, it is not possible to determine what mutation any influence is due to. Counter 
intuitively, the ‘wild-type’ allele in some SNPs is actually less common in the 
background population than the ‘mutant’ allele - most notably in rs2287622. To 
complicate interpretation of risk further, a differential in risk might be due to a protective 
effect associated with the ‘wild-type’ allele or a deleterious effect associated with the 
‘mutant’ allele, or even vice versa.  
It is important to note that the MAF of the SNPs selected for genotyping was 
intentionally set at a high level. This was necessary, as my relatively small cohort sizes 
could not be used to identify or exclude an influence of rare polymorphisms. This 
means that, in genes where I have detected no signal, it is highly unlikely that any 
common variation is associated with CC. In a cohort of this size, and with such a 
complex trait, testing rare polymorphisms would be futile. Therefore, it is not possible 
for me to exclude a powerful relationship between rare SNPs in the genes studied, and 
risk of CC. 
2.5.1 BSEP 
I identified four SNPs of interest in ABCB11, although I demonstrated no haplotypes 
that modified risk. Of the four, the strongest association was found in rs2287622, which 
is known to be associated with the V444A polymorphism (c.1331T>C, p <0.007, cor p 
0.52). This polymorphism has been positively associated with increased risk of a 
number of diseases, most compellingly with intrahepatic cholestasis of pregnancy 
(ICP) and drug-induced cholestasis.[323, 324] However, in my CC cohort, c.1331T>C was 
found to be associated with reduced susceptibility to disease. In ICP and drug-induced 
cholestasis, c.1331T>C is thought to contribute to reduced function of BSEP compared 
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to wildtype, reduced elimination of bile acids and therefore intrahepatic cholestasis and 
jaundice. 
It is tempting to conclude that the altered risk associated with this SNP must be related 
to the V444A mutation, but we cannot do so firmly from these data. Rs2287622 may be 
in LD with other, currently undefined, mutations in ABCB11. To confirm a link with 
V444A we would have to sequence the relevant part of the gene in the CC cohort and 
controls and directly demonstrate an association.  
It is plausible that reduced BSEP expression or function may be implicated in CC 
pathogenesis. BSEP is expressed on the apical membrane of hepatocytes and its 
principal function is the export of bile acids into the canaliculus. It is the major exporter 
of bile acids and reduction of its expression leads to increased levels of bile acids 
within the hepatocyte and cholangiocyte and reduced levels of bile acids in the 
canaliculi, with reduced overall bile flow. Very early onset of CC and HCC has been 
described in children with genetic disorders of BSEP. The risk of hepatobiliary 
malignancy was found to be highest as phenotypic expression of BSEP became 
minimal or absent.[50, 325] 
A further possible explanation lies in the ‘toxic bile theory’. This has been proposed by 
a number of authors and supported by studies of biliary transporter gene knockout 
mice.[299] Under normal conditions bile is already a considerably toxic fluid; toxicity to 
hepatocytes and bile duct epithelial cells is prevented by a number of physiological 
mechanisms, including micellar binding of bile acids and exogenous toxins. Bile acids 
form mixed biliary micelles with PtC and cholesterol, reducing the detergent activity of 
monomeric bile acids and activity of other toxins in the bile duct lumen. This prevents 
toxicity of high biliary bile acid and xenobiotic concentrations to cholangiocytes.[326, 327] 
Disturbances of bile composition may result in failure of this protective micellar system 
and subsequent hepatocellular and bile duct injury. Such changes may be due to the 
presence of exogenous toxins – or changes in the physiological constituents of bile. 
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Any change that leads to increased or decreased ratios of bile acid to PtC leads to 
reduced micellar stability.[294] Changes in this ratio and subsequent biliary damage 
have been shown in hereditary MDR3/Mdr2 defects, imbalance in BSEP/MDR3 
expression following liver transplantation and impaired MDR3 function due to absence 
of enteral nutrition, or use of total parenteral nutrition.[328, 329] This body of evidence 
suggests that biliary transporter polymorphisms (or combination of polymorphisms) that 
lead to disequilibrium of the bile acid to PtC ratio lead to unstable micelles - and bile 
duct injury. 
2.5.2 ABCB4 
I identified 1 SNP in ABCB4 that was associated with an increased risk of CC. Given 
that only a single SNP was identified, and that even the least conservative correction 
for multiple testing tends to abrogate its significance, this finding must be interpreted 
very cautiously. It may well represent a false positive. However, it is worth briefly 
considering how changes in MDR3 might impact risk of CC. A principal function of 
MDR3 is excretion of PtC into bile. Given the importance of PtC in stable micelle 
formation, discussed in 2.5.1, it is unsurprising that MDR3 dysfunction can lead to 
chronic bile duct injury. This has been demonstrated in progressive familial intrahepatic 
cholestasis 3 (PFIC3) where ABCB4 mutation confers absence of canalicular MDR3 
protein.[48, 301] These patients develop biliary cirrhosis and cholelithiasis syndromes, 
both of which are risk factors for CC. 
2.5.3 ABCC2 
No individual SNPs or haplotypes in ABCC2 were associated with change in risk of 
CC. An association between the SNP rs3740066 (c.3972 C>T) in ABCC2 and CC was 
previously reported by Hoblinger et al in a study of 60 CC cases and 72 controls with 
an OR of 1.83 (95% CI = 1.09-3.08, p=0.022).[71] Our, larger, study has not confirmed 
this finding. In fact, a non-significant trend in the opposite direction was detected with 
an OR of 0.79 (95% CI = 0.59-1.05, p=0.09). With the crucial role of MRP2 in toxin 
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excretion, it was a highly plausible candidate. However, given my comprehensive 
coverage of this locus, it is highly unlikely that common variation in this gene is 
implicated in CC risk. 
2.5.4 ATP8B1 
Haplotype analysis in ATP8B1 demonstrated a significant association between specific 
haplotypes and altered susceptibility to CC. This finding was sustained after Bonferroni 
correction for multiple testing (corrected p=0.047). The function of ATP8B1, and its 
dysfunction in patients with PFIC 1 or BRIC 1, is yet to be fully elucidated. A critical role 
in trafficking phosphatidylserine from the outer to the inner membrane leaflet has been 
demonstrated. Some authors have hypothesised mechanisms by which ATP8B1 
dysfunction may lead to cholestasis. Reduced ATP8B1 function causes disordered 
phosphatidylserine distribution, leading to membrane instability and vulnerability to lipid 
extraction by hydrophobic bile acids. Marked depletion of membrane lipids abrogates 
the function of abcb11 and abcc2 (and potentially other membrane bound transporter 
proteins) in mouse models, thereby leading to cholestasis, the hallmark of PFIC 1 and 
BRIC 1.[330] Other authors have proposed a further function of ATP8B1 in the formation 
of the cellular cytoskeleton in polarised apical cells, where a reduction in ATP8B1 
function results in the reduction of microvilli formation in Caco-2 cells. It is proposed 
that the resultant reduction of the apical surface area of hepatocytes limits the bile salt 
excretory capacity of the liver in patients with ATP8B1 deficiency.[331] A variety of 
potential roles in CC risk modification may also be postulated. ATP8B1 is expressed on 
both hepatocyte and cholangiocyte apical membranes. In the cholangiocyte, decreased 
membrane stability and increased vulnerability to lipid extraction may increase 
apoptosis and cell turnover. Abnormality in apical membrane structure may impact the 
function of other cholangiocyte transporter proteins, leading to reduced efflux, or 
increased influx, of mutagenic species into the cholangiocyte cytoplasm. In the 
hepatocyte, reduced ATP8B1 function may result in depressed function of other 
transporter proteins. The resultant reduction in the principal physiological constituents 
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of bile may result in reduced bile flow, increasing the concentration of exogenous 
mutagens in bile and the exposure of the cholangiocytes to such species. Furthermore, 
such direct and indirect effects might result in unstable micelle formation in the bile, 
impairing the protective mechanisms of the biliary tract and leading to increased 
exposure of the cholangiocytes to damaging toxins. 
2.5.5 NR1H4 
No relationship between NR1H4 polymorphisms and CC was demonstrated. It is highly 
unlikely that common variation in this gene plays a strong role in risk of sporadic CC.  
2.5.6 Conclusion 
This is the largest study to date of biliary transporter proteins as susceptibility factors 
for CC. This study has demonstrated an association between polymorphisms in 3 
genes encoding biliary transporter proteins and altered susceptibility to CC. A total of 8 
SNPs have been associated with increased or decreased risk of CC. These findings 
might be accounted for by the over or under expression of BSEP, FIC1 or MDR3 
leading to a variety of possible biliary abnormalities.   
The functional consequences of these polymorphisms in terms of protein expression or 
function are not known and cannot be deduced from these data. Given the findings in 
ABCB11 and ATP8B1, and their biological plausibility as risk modifiers for CC, further 
study of these genes in a validation cohort is warranted.  
A validation cohort would be highly desirable. The genotyping of the 8 candidate SNPs 
in a new CC cohort would add power to my findings, or refute them. If replicated, deep 
re-sequencing of the implicated regions of the genome in affected subjects would be 
indicated. As genetic susceptibility to CC is likely to be highly complex and involve 
many genes, a genome wide association (GWAS) approach would offer substantial 
advantages. However, CC is a relatively rare disease and such a study will require a 
multi-centre, international collaboration. Subsequent to my work in this area, I have 
visited the cholangiocarcinoma group at the Mayo Clinic, Minnesota, USA. Plans are 
Chapter 2 – Biliary transporter genetics 
 93 
well advanced for them to undertake validation of my biliary transporter findings in their 
own CC cohort. This will be as a prelude to an ongoing collaborative GWAS study into 
CC. 
A range of biliary transporter polymorphisms that cause or modify diseases has already 
been discovered in progressive familial cholestasis, gallstone disease and cystic 
fibrosis. Discovery of genetic polymorphisms that modify the risk of CC would offer a 
major insight into its pathogenesis. If a panel of genetic polymorphisms that modifies 
risk was confirmed and validated in a PSC or OV cohort, risk stratification for 
development of CC might be possible. Low risk patients could be reassured. OV 
patients considered to be at high risk could be subject to concerted efforts to eradicate 
their infestation and monitor for OV relapse. In very high-risk groups, intensive 
monitoring and even prophylactic liver transplantation might be feasible before CC 
develops. 
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2.6 Chapter 2 Tables and Figures 
 
Table 2.1: Summary of biliary transporters, their pseudonyms, encoding genes, known functions, distribution in the liver and 
associated diseases 
Legend: PFIC, progressive familial intrahepatic cholestasis; BRIC – benign recurrent intrahepatic cholestasis 
Acronym Trivial name Full name Gene 
abbr. 
Known function Distribution in liver Associated 
diseases 
BSEP Bile salt exporter 
pump 
ATP-binding cassette, sub-
family B (MDR/TAP), member 
11 
ABCB11 Bile acid transport Hepatocyte apical 
membrane 
PFIC2, HCC, 
BRIC-2 
MDR3 Multidrug 
resistance protein 3 
ATP-binding cassette, sub-
family B (MDR/TAP), member 
4 
ABCB4 PtC transport Hepatocyte apical 
membrane 
PFIC3, Gallstone 
disease 
MRP2 Multidrug 
resistance-
associated protein 
2 
ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 2 
ABCC2 Conjugated bilirubin and 
organic anion transport 
Hepatocyte apical 
membrane 
Dubin-Johnson 
FIC1 Familial 
intrahepatic 
cholestasis protein 
1 
ATPase, aminophospholipid 
transporter, class I, type 8B, 
member 1 
ATP8B1 Translocation of acidic 
phospholipids in cell 
membrane 
Hepatocyte & 
cholangiocyte apical 
membranes 
PFIC-1 /Byler’s 
disease, BRIC-1 
FXR Farnesoid X 
receptor/bile acid 
receptor 
Nuclear receptor subfamily 1, 
group H, member 4 
NR1H4 Transcriptional 
regulation of ABCB4 and 
ABCB11 
Hepatocytes and 
cholangiocytes 
Cholestasis, 
Gallstone 
disease 
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Table 2.2: Commonly used values for cp,power   
Legend: Adapted from Machin, 1987[313] 
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Table 2.3: SNPs selected for genotyping in each candidate gene 
Legend: SNP - single nucleotide polymorphism; Ref - study SNP reference number; RS - reference SNP; BP - base pair 
ABCB11 - Chromosome 2  ABCB4 - Chromosome 7  ABCC2 - Chromosome 10  ATP8B1 - Chromosome 18 
Ref RS number BP location  Ref RS number BP location  Ref RS number BP location  Ref RS number BP location 
1 rs497692 169497262  1 rs31652 86867623  1 rs717620 101532568  1 rs7241054 53464481 
2 rs3755157 169500417  2 rs2097937 86868839  2 rs2756109 101548736  2 rs1968274 53465209 
3 rs6709087 169507256  3 rs31653   86870549  3 rs4148391 101556856  3 rs17685876 53468119 
4 rs853773 169522593  4 rs2373593 86874878  4 rs2073337 101557416  4 rs317826 53474943 
5 rs853772 169522901  5 rs31666 86890204  5 rs2002042 101577921  5 rs4308033 53485104 
6 rs3821120 169525182  6 rs31668 86891142  6 rs7476245 101584719  6 rs4306606 53485293 
7 rs16823014 169525959  7 rs8187799 86894112  7 rs3740066 101594197  7 rs317845 53486410 
8 rs4148797 169526281  8 rs31676 86907816  8 rs3740065 101595683  8 rs317838 53489654 
9 rs16856300 169526548  9 rs1149222 86911711  9 rs3740063 101600713  9 rs317837 53490222 
10 rs4148794 169529894  10 rs4148826 86912355      10 rs11659313 53503387 
11 rs17267869 169531654  11 rs2109505 86917342  NR1H4 - Chromosome 12  11 rs319454 53504713 
12 rs3770585 169532113  12 ABCB4_indel 86919500  Ref RS number BP location  12 rs7236365 53509688 
13 rs2287622 169538574  13 rs1202283   86920228  1 rs4764980 99409238  13 rs160993 53510410 
14 rs2058996 169542195  14 rs2302386 86929880  2 rs56163822  99411232  14 rs319448 53511146 
15 rs3770596 169548388  15 rs4148812 86939343  3 rs61755050  99450439  15 rs319440 53515528 
16 rs13416802 169550584      4 rs1030454 99469383  16 rs17686300 53519745 
17 rs2287618 169551055      5 rs35724 99479509  17 rs319457 53519863 
18 rs7605199 169564700          18 rs319406 53527210 
19 rs3815676 169578625          19 rs319409 53529582 
20 rs4148773 169582067          20 rs12456346 53546809 
21 rs3814382  169597234          21 rs9676158 53555113 
22 rs10930343  169598031             
23 rs7577650 169599456             
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Table 2.4: SNP DNA sequences for oligonucleotide primer design 
Legend: SNP - single nucleotide polymorphism, [x/z] - variable allele of SNP in preserved DNA sequence 
Gene SNP Sequence 
ABCB11 rs497692 
TATTTGGTCCTTTCCTGGCAGAACCAGGGCTAGATCCCCAAACTTCTGCCTTCAGGTCATCACACCAACCACGCCACCCTGCTCTCTTCCTGTGTGTCTGTCTGGTTACAGGGTGATCTCTGCAGTTGTACTGAGTGC[A/G]ACAGCTCT
TGGAAGAGCCTTCTCTTACACCCCAAGTTATGCAAAAGCTAAAATATCAGCTGCACGCTTTTTTCAACTGCTGGACCGACAACCCCCAATCAGTGTATACAATACTGCAGGT 
 rs3755157 
AATGCATCATCTGGGAATACAAAGACGTGGCTGGAGATCAACCCAACTGGACCACGAGACAATTTTTCAGTTAAATTCAAGTTTCCCTTAATTCTTATACTTGAGAAGTGTTTATGCTAC[C/T]ATCCCTCATTTACCCCCCAAGGACAAG
ATATTAATTAGAACACACTTTAAAATGTGTAGCTAAAACCTAAGTGTATCCAAAACCTAAACTGTAGTTCATAATTCTGGTTGGGAAAGACAC 
 rs6709087 
AAATGTATTAAAATAATTAACATCCAGAAATAGATAAGAGAATTTCGAAGAGGAAAAATTAGTGTGCAGGGATTTGCCTTACCAGATACTAAAATGTATCAAGTTATAAGAATTAAAACA[A/G]AGGGTGCAAAAAAAAAAATAGAAAGA
ATTAATAAGACATACTATTTGATAGCACAATAGAATGACTATAATAAATAATTTAATTGTACACTTAAAAATAACTAAGAGTGTAATTGGATTG 
 rs853773 
ACACAGCTGGACTAGCTTTCTTCTTCTCATACCTTTTATTTTATTATTTTGATAAGTCCGCTCTTTGTTTTCATGTATTTAGCTCTTTTCTGTTAGTTCATTTTTCTCATCTCTAAAGAA[C/T]GAAAAATTTCCTAAGCCTCCATCACACAGA
GGGTAAGAAGGCAAAGCTGAGAACTCTCATTTGGGCTCGCAGGGCACTCAGACAGTCATTGTACCTATAAAAAAGAAAATGGTACTGTCA 
 rs853772 
CAACCATATCCCATAGACATTTGAGGTCACTCATAACTAATCAAACTATGACTCTTAAATCTGTGAATGCCAAAGGATCTGCTGCAAAATGTCTTGAGTACATTTAGATGATTAATATAA[A/C]CCTCTCTCTGCTCAAGGACAAGGACAT
TCCTGTGCAGGAAGAAGTTGAACCTGCCCCAGTTAGGAGGATTCTGAAATTCAGTGCTCCAGAATGGCCCTACATGCTGGTAGGGTCTGTGGG 
 rs3821120 
GATGTGTCAGCTGTGCTGTACGTACCATCAAAGGGTAGGCTTTGGAACTTGTGAAGACTATTAGCACTCACTAAATTCTGCCAGCTTCCTTGTGACATTAAATACCAGCATTTTCTGGAAC[C/G]ATTGCCCCACAGGATGGTCCACCCA
CAGCCTGACATGATAGAAATTTTCCCAACCTTCTGATACCTGAAGTTATCCTTAACTCTAAACAACAACACTTAGGACATTTCAAAGCGATACAA 
 rs16823014 
TACAATCGATGTTTATGGGATAAAAGAATGAATGAAACTTTTATGTCCATGCTGCATACATGCAACAAGAGATTTATTTAAAATTGCTCATCTACTATGATGCATTCATAGTTCAATGCTA[A/G]ACACTGGGCTTTTCTGTTTCCTTTCTT
ACATCTTCTGTGTAGGCCAGAGGAAAAATAACCTCCGACTTAAATCTTAGGTCTTGCTTTCTATACTTTGTTACACTAATTTCTGCCTTCCAT 
 rs4148797 
ACAACATTAAGTTTAGGATTAGGGAAACCCACAGGCTAAAGGTTTTAGTCTCTAATATTTAGGCAATCTCTTTTGGTGAAACTAAAACACAAGGCAGAACATGTATGAGATCAAGTCAGG[A/G]TCAAATATTAGACACCCATAACTGCA
TCACAGATAACTTATGTGATAGGATTTAGGCATTGGTTAAGATAAGACAGAGATGGGACCCATAAAAATGGCTATCAGTATTAGTTCATTTGAA 
 rs16856300 
GTTTACAGGAGCTAAGAGTACTGCTTGGAGAGCAAGGATAAATGGGTATAGTCTCATCTCTGTCACCAACTAACCATGAGACCTTGGGTGAAAGCACAGACTTCTCAGGAAATGGTTCTA[A/C]GTTTTAGAGTCAATACTCCACAAGA
CCACAAGGTGGCGATAACTCCTTTGTGTGAATCGACCTTTAGCACCGTAAGAGAGTATTTCCCAATCTACAGAAAGTAAGGTTAGGCCTTTTCCA 
 rs4148794 
TGTACTCAGTATATTCAGCAAGCAACCCTGTCCTCCCCTGTCTCCATGCTTATGTTTATACATTCTCTCAGTCAGAAATGCTCTTTTCTATAGTCTACAAATCCCCATATCCTACCTTAG[C/T]CATCTCATCCATGAATCTTGCCTTGGTAA
CACCTGCCATACATTTCTTTTTCCTTTGACTTTCCATACTCTTTATTCAAACCTGCCTAATAGCACTTACCACATTCTTCTTTACCTTAGG 
 rs17267869 
ACTTTCATACTCAAATGTACAAATCTTTCTCTGCAGGAGGTTAATAGCTACTTTCTGTGTGTAGATCGTATTTCTGGATTTCTCATCCTAATCACCAAAA[C/T]GTAACATTTGTGAGAAATTATAGCCAAATTAATGTTCACATTAAAATG
GTTAACTAGTTCTAATAATAAACTGCAAATAAACTACTTAACATGAGTAGAA 
 rs3770585 
ATACCTTTTACATGACAGAGTAATGTGAAGCTATTGCTTTGTTATTTGCCAAATTCAGTAAATTCAGTCAAACTAGCATTTCTTAAAATTTGTTTGAATAAACTTGTTCTCAAGAAGAAA[A/G]ATAGGAAAACCCAAGTCTGAAAATTCAA
ACTGATAAGGAAAAGATATACTAGGGCCTGAAGTATTTATCTACATCTGAAAATAAATACACTACTTTTTGTGAGCTATTCTTTGAATATTT 
 rs2287622 
ACAAAGGCATCTGCACCTGTAGCCTAATTGTTTGATTTGGTAAACAGTGACAATCTGAACTTTGCTGTTTTCTTTCTTCTCCAGATTCTAAATGACCTCAACATGG[C/T]CATTAAACCAGGGGAAATGACAGCTCTGGTAGGACCCAGT
GGAGCTGGAAAAAGTACAGCACTGCAACTCATTCAGCGATTCTATGACCCCTGTGAAGGAATGGTGGGTGTCTTCCAGAA 
 rs2058996 
AGATGATGCTGGAGTGTTCTGGTAGCAGGAAGAGGCCCTCACTTTTCTCTGATTAACCAGAGTGGTTAAATTCTAGATTGGGCTTGTTGCTAGCAGAAGAGGTGAAATTCAGGACAACA[A/G]TTGAAAGTTGGTAGCATTTGAACACA
TCATTTAGGAACACTCAGTTTTAATCATCATCTACCATGGATACTCAAAAGAATACCCTCGGACCCCCGATTGGTTGACTAGTTGCCTGGTCTT 
 rs3770596 
AAACACATTAACCTGTATTATCATATTTATTTTCTTTAACAAAGTTCAAAAGATGTCAGCTGTTCATGCTGCCAAGATAAACTGAATTGAAAAAGTTGTTCTTTGTGTATTATCATGTTCTTAATGAAAT[A/T]AAGTCCGTGGTTTGGAATG
ATTATGGTTTGACCTCTGATAATCACTTCCATTTGCAAATCAAAATCCTACTCAATTTTCCCTGGCAATGTATTTATCTTAAAGCAGTAGATTTTGAATTT 
 rs13416802 
AGGAATGGAAAACCAAATATTGCATGTTCTCACTCATAAGTGGGAGCTAAGCTATGAGGATGCAAAGGCATAAGAATGATACAATGGACTTTGGGGACTCAGCGGAAAAGGGTACGAAGGCAGTGAAGGATAAAAGACCA[C/G]AGC
TTGGATTCAGTGTATACTGCTTGGGTGATGGGTGCACCAAAATCTCACAAATCACCACTAAAGGACTTACTCATGTAACTAAATACCACCTGTTTCCCAAAAAAATTATGGAAATAA 
 rs2287618 
TTTTCTCCCTGAAGCTGCTCTGTGTTTGCGATGATTTTATGATCATTTTGTAAAACCACTGCATCACGGCCTGTTTTAAACATTATAACTTGAGCTGTTTCTGCCGAAATTGACTCAAGC[A/G]TTTTGTCTTCACAGGTATGAGAAAAATC
TTGTGTTCGCCCAGCGTTGGGGAATTAGAAAAGGAATAGTGATGGGATTCTTTACTGGATTCGTGTGGTGTCTCATCTTTTTGTGTTATGCA 
 rs7605199 
TTCTCTGGAATAAATCCCCAAGAGTAGAAATGCTGAGTCATATGGTAGTTGAGTGTTTAGAATTTTTTTAATTACTAAACTGTTTTCCAGGATAGCTATGACATGGTTTGAATGGCATGAGTG[A/G]TGGTAGAGTGATCCAATTCTTCCA
CATCTTCATCAACATTTAGGGTTATCACTATTTTTAATTTTAGCCATTCCAATAAGTCTATAGTAATATCTCATTTTGATTTAATTTGCATTTCTC 
 rs3815676 
AGAAATTTTAAAGTATAGGTGTTTACTCCAAATTTTCTCAGGATGGAGGCATTTCTAGGCAGAAAYTGGCATTCTTCATAGTCACTATCAGTTCAACAAAACAATTTATAGTATTTCTCA[A/G]TGCCCCACACAGTTTATCTACTTGGCAA
TGGCATCAATGACAGTGATTATTTTCCCCTAAGTTGTAGATKAGYAGCTAAAAACKAAAGTCAGCTCCTGAAATAAACAGAATGAATTCAGA 
 rs4148773 
CATGCTTCTTTACTTTAATAAGAGTAAACAGGCATGATAGTGTTGAATGACAAAGCTCCCTAGTGGCTTCCTTACACCCCTGGCTATAATCACTGACTTTCACCTCCTGCCCTGCATCTATTCTGACCTA[C/T]ACTGGGGAAAACAGTAT
GTGGTCTCAATCCTATGGCTTCTACTAGTGTAGAAGTGTTAATGACATCTTGTTATTAACATCTTATTGTTAATTTGTGGTCTATATTTTAAACAGATAAATT 
 rs3814382 
GTCAACTCAGAAGTCAACCCATTCAGTTTGCATAGAGGAAACATCTAGAAATCTTGCTTTTCTTTGCTGACCTTGATATATTTGAGATTTGAACATATAATAACATATAAAATTATATGT[C/T]ATAATTTTGGGTTTTATGGGCTAAGTCAT
AAACCATCTTATACATAAATTCCAATAGAGAAAAAATGGTGGATGCTGAATTTTAATAAAAAATTTATGACAGAGAAACCTAAAATTGAGA 
ABCB4 rs31652 
TTTGTAAAAGAGTGGGCACAGAGGGCATGATTATGGGTACTATAGCAATCTGCCAGACATTTTAATATATGTAAAGATTACATCATACTCAGGGTACTGATTCTATACATCCCTTTTAA[A/G]AAACATGTACGCTCTGAATTTGATAAGA
CTGGTTTATTGCTAACAATTAAGCCCTTTACACTGTGCCAGCCTCTGTCCTGAAAAGCATCAGTACTATTTCTCTGTGAAAACATTCAGAGT 
 rs2097937 
TAAAACTTTAAAAAAATACTTAATGATAGGGCTCTTTCTTGCTTTATGGAACCGATATGTGCTTTCAGAGTTAGCTC[A/G]GTAGGGCAATTTCATTTTCTCTTGATGTTGGATGATAAAGCTGGAAATTCATTCATTTAAAAAACTTTGAT
TCCACAATAGAATGATTTAGAAAATTACCAAGAGAGATGAGGCTATTGA 
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Gene SNP Sequence 
ABCB4 
cont’d rs31653 
CAGGAGGATTTGAGGTTGTCTGATGAGGGCTCGGGCAATAGCAATCCTCTGTTTTTGACCTCCTGAGAGCTGAGTCCCCTTATCTCCCACTCTTGTTTCATATTTCTGCAAGTTAACCAA[A/G]TTATAAATATGTTGAATGAACTGTTGC
TTAACAGTTGACAGTTCTATTTACAAGAAAAACATTTAGAGTCAATAACAGTTTCTATAACGTTGTTTCAACTTAACAGAGTGTTTATTTTCA 
 rs2373593 
TTATAAAGGTGAACTACAGACTCCTGCCCAAATTCAAAGCTGACTTCCAAAACAGGGTGCTACCTGCTTATTGCCTCCCCACCGCTTTCAGTTTTGCTGCCTTCTCTTACCTTGAATTCT[A/C]GGCTCTCGAACTTTGACTTTGATCCTC
AACCTCCAGCCCTTTCATATTTGGCTTTTGTCATTGATTTTCTAGCATGTAGCCCCGTGGCTCTCTTCCTTGAGTGAAGACCAACTCTTACTG 
 rs31666 
TTTGTTTGTCCATTGCATGTCTTCCCCGACAGAAACCGCTGTTTGAGGGCACAACTTGGTTTATTTGTGTACCACTGTATCTCCAGTGCCTGGAGCAGCACTAGGCAGA[C/T]AGATGCCCCAAAATATATAGTCCACATTGCCTTGAAT
TGCAAGAGAGCCAGAGCTTGCTTTGTTTTGAAACTTTAAAAGATTTGGAGGAGGATCTTTTCTAATTTATTTATTTTTTGGCT 
 rs31668 
AGGACTTTGGCTTAGTTTAATTTAAGGCTGCTTAATCCCAGAATGGAGCCAGTCAGTGAGGTTGGGAGAAGCAGCAGCTGATGAATTGATCTAATTCAGGCTGTTATGTG[A/G]TGTTTGCAAACTTACCGCTATGATCTCTGAGAATA
TGACTGAAAATGCCGGCTGAAGCCCCCCATTGGCAATGGCACATACTGTTCCCACGACAAAGTAGGGCCATTCTGTTTTATTCAG 
 rs8187799 
ACACACACACACACACACACACACACACACACACACTTTAATGTCTTGATATTCTTTCAGACATCAGGAAGCCAGATCCAGTCAGAAGAATTTGAACTAAATGATGAAAAGGCTGCCACT[A/G]GAATGGCCCCAAATGGCTGGAAATC
TCGCCTATTTAGGCATTCTACTCAGAAAAACCTTAAAAATTCACAAATGTGTCAGAAGAGCCTTGATGTGGAAACCGATGGACTTGTAAGTTGTT 
 rs31676 
CATTCATGAAAAACATCCTACCTAATATTTAACTTGGTTCAGTGTTTAGAAATAATAATTAGAAATAAACAGCAATATGCAAGAACAAAAATAAAAAGCT[C/T]ATGCTCTCTCCTGATATTTATTTTCATATATACAGTTTTTTCGTGGAAG
GATTATTTGCCATAAACAATTTTGGGTTTTATGTTTTTGGCATACCATTATTTTTATGTTCC 
 rs1149222 
ATATTTGAATGCAGTGACTTACTTTTTTACGTCAAAACTTTTTCTTTTTCACTGTAGTCAGTTTATTTAATGTAGTTTATTTAAAATCATACCAAACATGCAGTGATAATTTTTTGGAGA[G/T]GGGGAACCACAGCAAAATATACTGTCAAT
TTTGGTCCCACCGATAATTTATCTACCCCCCATCCCATATAGAAATCATAAGATTCTCAGTCTGGCTACAACATGAAAGTGAAAAAGATAA 
 rs4148826 
AAATAGGTTTGAAAAATCTTTTTAACTCTGTATGTATTCAGGAGAACAATAGGTAGTTTGAGAAAATAGACCCACTCAGGCAATAAAATGCTATATTAGCCTTGCAAATGTTGCTCTTCC[A/G]CAAAAAAAAAAGGAAAGGATAAACCTA
AACTTAATCCTTTATGTACTATGTTACATATACATCACATTTTAGATAATAATGAATGCCAGAATGTGACTTAAACTTTTCCTCATGTTATTT 
 rs2109505 
TTCCAGCTCTTTGTTCTGGCCCCCGAAAGCTATCACAGTCCTGATGGCCCCCAGAGCCTCTTCTGCCACGGCGCCTGCTTTTGCATAAGCAGCTAGTTCTTTGTCACTAAATGCCGAGAG[A/T]ATCTGGACAGAAAAGAAACAGTGAT
CACTTTTGTATAGGGAGAAAAGTTTAAAGGCACTCTGGTCAACCCTTTAACCTACTTTTTCTTCCCAAACCCTCTCCTTTAACAAATATTAAAGT 
 ABCB4_indel 
CGGGAGGCTGAGGCAGGAGAATCACTTGAATCCAGGAGGCGGAGGTTGCAGTGAGCTGAGATGGTGCCACTGCACTCCAGCCTGGGTGACAGAGTGAGACTCAGTTTC[-
/AGAAA]AGAAAAGAAAAGAAAAAAGAAAAGAGAAGGTATTTAATAGAGCCTTTCTCTTTTTTTTCAGATATGCATATTACTACTCAGGATTGG 
 rs1202283 
AACATTTTTCATTTAAAATCTTTCCTTGACATATTTTCACACAGTAATTAATTTCTATATGAAAGTGTGACATTAACAATGTACCTACTCTGTTAGCCGCGTATTGAGTTCAGTGGTGTC[A/G]TTGATGTCAAACCATCCTATTTCCTGTCG
TAGAATAGCATGAAAAAACTTCTGCCTAATTTTCCTGATCTGTCGACCAGCTGCCAAAGTCCAAAATGAAACTTGTATATAGGCAGCAACA 
 rs4148812 
CTGTCTGCAGACAGCAATAAATTGTCCTTGCTGCACCTGTGCTGTATAAGTTTGGCTTATTATAGTCAATGACCCACATTCTTAAGATGGATGATTTTTTAAAAAGTAGAGACAGGCTGGCGAT[C/G]ACACCGGACAGAGCTAACTGGT
GTGCAAGGAAAGTGAAAATGGGAATTGTGTTAGTAGCACAATGCAAACTCAACAATTTCAAGAAAATGCATTTCTGCATTTGCTTCACAGACCCCCAC 
 rs2302386 
ATTTCCTTCACCTGTATTAAAAGTCAAACAACAATACACATATTTCTTTAAATTTAAACGAGTATTTGAACAATTTTCTGAGAATTTTACAACTCCTTCT[A/G]TGATATCTGGAGTCAACCAGATATCCAAATCATTAAATAAGATGGTAAT
GAATAGCAAAATCAACTCCCAAATTTTTACCCAGTTAAAGAAATGCTATGGATTTTTTTAAAAGGTAAAGA 
ABCC2 rs717620 
TAACTAACTACCACTTGTTCTGAGTCTGAGAAGAGTCAATATGAAGATAAATGTAATTTCTCACCCAAAAAGTAGAGTTGCAGAACTTCTCCAGCATGATTCCTGGACTGCGTCTGGAAC[A/G]AAGACTCTTCTATTAATATGATTGTGT
TGTTTCTTCTTTACTTGTTTCATCAAAGAAAGTGGAACAGGAATTATCTACCATTCTGATGTTCTCCGTAAAGGATGACCTTTCATCCCAACC 
 rs2756109 
TGAAAAGAACAGAAAGGACCTCTCAGCATCATGCCCAGGCCCTTCACTCTCAGGACTGCCCCTCAGGCCCCCACGCAGATGGGTCTCTCTTTTTACATGGGACTCTTACCAGCTTAGTT[G/T]CCTGGTTTTCTAATCTAAAATAGATTA
CAAGTATCAGTTAGGAGCGGGAGAGTGGAACAGTGAAGGCAGCTAGAAGGGCAGAAGCAACTAGGCCAGGGAGAGATGATCAAAACCTGTACA 
 rs4148391 
GGCAAGGTTCCCTTGCCTCTCTCAACTTGTTTCCTTATAGTTTAAATGAAGATAATAACTCTACAAATGTAAGGTGACTAACTCAACTCAATTTGCCCAGAACTTTTTAAGTCTTAAGAC[A/T]GGAAGGCCTGTGTCCTAGGCAGCCCTT
TAGTCCCAGGCAAACTGGAACAGTTAGTCATACTAAGGTTGTTATAAAGTGAGATAATGTATTTAAAATGCTTTGTACATAGTAGGTTGTCAA 
 rs2073337 
TCAGCTTCCTGAAGAGGAAGTTCACTTTTGATAGACTAGCTGGCATCTCTAGGCCTGACCGCAAGATCCAGGGGACTTGTCCCTCTCACCGCCCCATGCC[A/G]CTTTTCCTCCTTTGTACCATACCCCCAGCTCTAGTTTCACCTTCGT
GTACTGTACGATGGTCTGGCTCCCAGAGCAACTTTTCAGGATGCACAGCAAGAATGTGGTATCAGGAAGGATTG 
 rs2002042 
TCAGTCAACCACATCACCATGGTTACCGTAAGAAAATTGGGCAGTTTTCCCATACTAATGGTAAACATTTTTTTCTGATTAGCCTGGATCTGAGTTTCTGGATTCTGTTATAAACCA[C/T]TTCTCCTTTGAAGAATCCTGTCTTTAATGTA
CAAAGAACAGTTTGCAAAACATCCCCGTAAGCCCTTTTTCTGGTGAACACTGAGAGAACATTTCTGAGCAGTTTTGTAAGCTCCAGAGC 
 rs7476245 
TTGCAGCTCCATAAGAACCCCCATGACGATTAGGTCGGTTCCAGAAGAGCCATGCTATGGTGCTTCCTTGGTTGACTTTGGACAGGCATAGCTGCTTGGAGATGTCTCTCAGCAGCAGCT[A/G]GGTCTTTCTTTTTACTTCGGCAAAG
TTCTAGTTTCACTGGGGTGTCTGTGGGTGGTTTAGGCTCAATTCCAGTGTATTCTTCGAGGGAATGTGCAGCTTGAAAGCAAAACAGGGAAACTG 
 rs3740066 
CCTCCATCCAAATGATGAAGGCTTAGGGCCCAGCTGCTCTCCACTCTGTCCAATTGTTGTTTGATCACAAGGCCTCCCATCCAGGCCTTCCTTCACTCCACCTACCTTCTCCATGCTACC[A/G]ATGTCACAAGTGATCCCTCTGAGGAC
CAGATCCAGCTCAGGTCGGTACCGCACTTGGTAGTTGTTAAACTGGATCTTGCCTTTGCTGGGCCAATCTGGCGGAGGCCTCTTATCAGTCACC 
 rs3740065 
GGCTATAGCAACGCTAAAGAATCGTCTGCTGTACTTGACTTCTGTTGTGTTGCTGCCACCTAGTGGTCAGATACAGGCAGCCACAAATGCATATTACCAAACATTTCAAAGTTCTGGAAA[C/T]GACGTGTCCATCCTAGGGAACTAGCT
CAAGTATCCCGAGTAGACCGTGGAATTGACAGTGCTGACTGAACAGACATCAAGAAGAAGCTGCATATGTTTCCTGTAAAACAAGCTGCTCCCC 
 rs3740063 
ACATCTGCCTCTCACGGCTTGAGCTTCCACCTCCCCATACCCAGTTAATTGTTACAACACACAGTTTCCTATTTTGCCCTCAAGATATGAATAGTTCCCTTAACCTTGTTCGTTTTCATT[C/T]GCGTGATGTAAAATTTTGGCCAGATTAC
TTGACATCTCTAAGTCTCAGTTTCTTCATCAGTAATGTGGTGGTGGTTAAACCTTCTGCCATCAGGTGTTTCCCGGCTGACACTGTTACTGT 
 rs2756105 
AAATGCAATTCAGTTTTTTTCAGTATATTAACACATATGTGCAACCATCACCACAGTCAATTTTAGAACATTTCATTATCTTTAACCCCGTCTCCTCCTTCCCCTTATCCTTAGCAAC[C/T]GCTAAATCTCTTTTCTGTCTTTATAGATTTCC
CTGTTCTAGACATTTCATATGAATGGAATTATATAATATGGTTCTTTTTTGATTGGCTTCTTTCACTTAGCACAATGTGTTCAAGGTT 
 rs11595888 
TAGCTTGATTAGATTTTTTTGTAGATACTTTAACTCCCCCTCTTTTTAAAAGAATTTTAATAAAGCTGAGATAAGAGGCATATTTACTTTTAATTTTACTTTTAGTTTGC[C/T]CCATTATTACCCTAGCTTCTTCCGAGCTCACAAGCTTACC
GTACGGCTGACTGTATATGTACTCGGGATCTCTCGTCGACTTGTGCTCAATGACCACGCTCGAGCGTACCTTCACCCTAG 
ATP8B1 rs7241054 
TTGCCCAGGCTGGTCTCAAACTCCTGGCCTCAAGTGATTCTCCTGCCTCAGCCTTCCAAAGTACTGGGATTACAGGCGTGAGCCACAGTGCCCGGTCCTGATCACCTTTTCTCCATCAC[C/T]TTTTCCCTAACACTTAGTTTCCCTTTCT
CCATCACTTCTTCCCTAACACTTAGTTTCCCTGTCCCCGACTTTCTCACTACTAAAGGACCCCTACATTCCTCTAGAAACCTTGTGGGACTA 
 rs1968274 
CAATGGTAAAAAACAGAATTCTCGAACTATGGAAACTAGTGTGTGAAAGACACAGAATGAGAAAAATGTCTGGAAAAAAATTACTTTCTCCTCTTTGAGGAGTTTCCATAATTACCTAAAGT[C/T]ATCTTCAAATTTAAAAGGACACACC
ATTCCCCAGTCTTAGGAATGTGGCTGCCAATAACCTTTTCTCTCGACATAAGACAAGTGAAAAAGAGTGAGGTCTTTGTTCAAGTCCCTGATAAA 
 rs17685876 
TGATAGGTCAGGAAGTGATACCCAGAACTGCTCTGGCCATCTTCCAGCATCCATATGAAGCTAATAATGAAGGTTTCTGAGAGAAGAGATGGCAAGAACC[A/G]GCCCAATCCTTTCTTGACAACATTAAATTGCTCAATCAACTGGGC
CTGAAGCCTACTAATGATTAATGATGACGCACTACTGTAGAGATGTTTTGAGTCA 
Chapter 2 – Biliary transporter genetics 
 99 
Gene SNP Sequence 
ATP8B! 
cont’d rs317826 
TTGTCCAGGCAGGCCTTGAACTCCTGAACTCAGGTGATCCACCTGCCTTGGCCTCCCAAAGTGCTAGGATTACACACATGAACAACTGTGCCTGGCCGAAATAGATATATTTCTTCCTGAAGATTTCTAAGGG[A/G]CAGAGAAATAAA
GTAGTGGGGAGAGAGGGGTGGGGAGGAGGGAGAGAATGGAGGGAGAGAATGGGGGGAGAGAAGAGTGGGGAGAGAAGAGTGGGGAGAGAAGGGAGGGAGGGGAGAGAG 
 rs4308033 
ATATGAAGAAATAGGGGTTACGATGTGTCACTTGGGGCAGTTTCCTCATGTTTAAATGAGGCAAGACAACAACAGGCAGTTCCAAGTAATCAAGGTGCAGCCTAAATTTGAGCAGATTTTACTTTTAGGGAAACTTGGGG[A/C]CCTTC
AGAGGCCATTTTTCTCCATTCCTTCTCAGCTCAGGCCAGGCGCAGTGGCTCATGCCTGTAATCCCAGCCCTTTGGGAGGCCGAGGCGGGTGGATCACCTGAAGTCAGGAGTTCTA 
 rs4306606 
CTATTGTAGAAACTGCTGAAAATATAGGATTTGCTTGTGAACTTCTGACTGAAGACACCACCATCTGCTATGGGGAGGATATTAAGTGAGTAAAAGCCTGCAGTATGAAATTA[C/T]GTAATAGCTCATCTTTGCAAATGCAAGACTGTC
TGTAGAAGATAGCAGATATGAAGAAATAGGGGTTACGATGTGTCACTTGGGGCAGTTTCCTCATGTTTAAATGAGGCAAGACAACAA 
 rs317845 
TTTTTCTGAGAAACCCTCCTCTGTTTTTCCAGCACATCCTTCTGCATCCTTTCCTGATCCCCCTCAGTAGCAGTTTCTTCCTTATAATTTAGCTCCTGGCCATGTCTTGCTGATTATAAT[C/T]GGTCTTATCTCTCCAGCCAGACGTGGGT
TCCCGTCCTGAAAGGGCCATCCCTCTTGTCCCTCTGTCCTTCCAGTGCTTTGACATTTGGTGGGCACAGAGTAGAACAATACAAAGTACTGA 
 rs317838 
AAGGTGCTGACACTGTTATTTATGAACGGTTACATCGAATGAATCCTACTAAGCAAGAAACACAGGATGCCCTGGATGTAAGTTTCACTTTTATTCTTTCTGCAAGGGATTCTGAACTTA[C/T]TCTCTGATGCTGTCTGTTAAGTTTGCA
TGAAAGCTGTATGTTAACTGCTGACCCTCCCTTTGCTTTGCAATAGTTGGGGTGGAAAGAGCAGTAAAGTAGGAATACAGCCACCTGGGTCCC 
 rs317837 
AGAGCTGACTGTGAAGGAATCTTTTTATATTTATTTCACTATTACATTCAATGTAGATAATGACTTACCAGTTTTGTTGAAGGCAACACTTTTCTAGAGGAACTGATGGTTTTAAGCTAA[C/T]AGTGAATTATGAGATAGTAACATTTCAA
ATTAACTTTATAAATGTAGTTTTCTATTAAAAAATCAAACTTAGCTGGGTGTGGTAACTCACATCTGTAATCCCAGCATTTTGGGAGGCTGA 
 rs11659313 
GCATCCCAAACGATTCTTCGGCTTAAAGGTCTTACCTCTATTTTGTTGTGGTTGTGTTGAGAGGCATCCCGATGGTCCCCTGAGAAACAAACAGGACAAAACAAATTGATTCTACACCTA[C/T]GTCCAGAGGCCCCTCCTTACCTGGCT
TTGCTTATATAGTGATGGTGGTAAGACCATATACGGCCTGGACAGGCTAAAATATTTATTATCTGGCACTTTACAGAAAACGTTAGATGACCCC 
 rs319454 
GGTTTCACTCTGTCACCCAGGCTGGAGTGCAGTGGTGCAAACCCAGCCCACAACAGCCTCGACGTACCCAGGCTCAGGTGATCCTACCTCAGCCTCTCAAGTAACTGGAACTACAGGCACAC[A/G]CAATTTTGCTCACTGCAACCTC
CACCTCCCGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCTGAATAGCTGGGACTAGAGGCATCCACCACCACGCCCAGGTAATTTTTGTACTTTTAGT 
 rs7236365 
TCCTACTAGGAGGTAGTGGCCGGAAAGCACAAGTTCTCCACCTTGGGTGTGGCAGATGATAATAAAGGCTCAGATAAGAGGTGAGGACCACTTCCAAAAGGGAAAACTAAGTTTTTCCAT[C/T]ACCTGCTAAATCTTCCCCTCCTCCC
AGTCCCTTTCTGAAGTCTGGGCTTTGGAACCCGGT 
 rs160993 
TAACCTTACTCAATACTTCATATGATTGAGAATTTAGTAGTCTGAAAAATAATATATGTCAAATAAAAACAGCACTATCATAACGCTTTGAAAGTCTATTTGATTGCTGC[A/G]ATTGACTGATGTATCCTACATCTCCCATAGAAGGTAAG
GTTTTGTTCCCAAAATTATCTCTCCAAAGAGAAGGTGGTGTCTTATATTCAAATCCTTGAAGAATCTTATATTACAGGGCAT 
 rs319448 
AAGTATTGCATGACATTGTAAAATAAGATCACTTAAGAAGCAATATGATAAGTATTATGTTGTAGAAGTTATGAGCATATATTTATGGAAGGAATAAAAAGTCAACCATCCTAGTG[A/G]TACTTGGAGATTCGCAAGTGGGAATAAAATT
TCCAGAGACAAATTTAAATTTCTGGACATGGAGTCCAAAAGTGCTATATCTCACAACTTTGTCGTGGAAAGAGCAGAGTGCCAAACAGG 
 rs319440 
TTGAACCCAGGGGGTGTGGAGGTTGCAGTGAGCTGAGATAGCACCACTACACTCCAGCCTGGGCGACAGAGTGAGACTCTGTCTCAAAAATAAATAAATAAATTGCCTATTGGTAAAGAC[C/T]TTAAAAATCTGTTCCTTTCTCTGAC
ACAGATAATAACCTCGATATTATTCATATCTGTCTGGACGCTGCTCAGCAGTTGATAAAGGGCTCAGACACATATGCTCCTGTCTGATCCTTTTA 
 rs17686300 
CTAATTCCAAGTCTCATCACCGTCATCACATAAGTCTACATCCTGCAGAGTATATAGGAAAGGCTCTTCAAGCATTTGGACAACCTCCTTCTAGTGGTTCTCTCTAGCTTCTGGATACCT[A/G]GAACAGAGCCTAGAGGGCAGTGGCTC
CTGAAATTATCTCATTGCAAACTTAACTGGACACCAAGGAAGTTTTGTATTATGATACCTAAAAAAGAGTTGCTCTAAATCTTTTGTGAAAATC 
 rs319457 
ACTGCACTCCAGCCTGGGTGACAGAGGGAGACTCTGTCTCAAAAAAAAAAAAAGAAAAAAAAAGTTAAGACGAGACTTCTCCCTTGCCACTCCTACCCCCTCACCCCCAGTTAAATATGA[C/T]TTTCACAAAAGATTTAGAGCAACTCT
TTTTTAGGTATCATAATACAAAACTTCCTTGGTGTCCAGTTAAGTTTGCAATGAGATAATTTCAGGAGCCACTGCCCTCTAGGCTCTGTTCCAG 
 rs319406 
GATTACTTGACTGCAGTCAGATTTCTAAAATTGAGTAAAAACGTGTTTGCGGTTCAATTGCAGACAAAGACATACTGGTTACTTTCTCCAGGCTCCCCACAGTATTGGCAGAAGTGT[A/G]AAATTAAGAGATCAAGGTCATTTCTGGTA
ACCCCTCACTGCACCTACTCGAGGTCTGATGCCACCCTCTCTGTCTGAATCATCCAAATCAAAATTGGCCAGGGATGAGGGTATAGTGCTG 
 rs319409 
GTGTGTACATATATGCATTCATATTGTGTATGAATTCTATGCATCACACAGCTGAAAGCACAAGATGGTAGATACCCTTCTGCTTTTGTCTCTTAACAGTGTAATTTGGAGGT[A/C]ATTCCTACCATATTTATGGGGTCACCTCATTCTTT
TTTTGCTGACTGCATAGGCTATCATTGTAATCGTGTTTAACTGGCTGTTCCCAGTAGGCATTTGGGTTGTTTCTAGTCGTTCTGA 
 rs12456346 
TGAAGAGGGCAAAGAGAGGAAGGGAGGAAAGAAGGAGAGCAGACTGGCTGTGAGGGAGGCAGGGCACATGGGAAATGGGAGGAAAGAGGTCTGGCATTTACTGAACATCATCTGTGTGCTTGGGAAGGGC[A/G]CAGAGAGGTA
TTAGAATAAGAATTTTTGTAAAAAGTCACAGGCAAAGTCATTTGATATGGGTTTTGAGAAGCGAGAACCACCCAAATCCCCTAGGAATATAAATCACCCTTGGAAAACAT 
 rs9676158 
CCATCTTGAGTTGACTTTTGTGTATGGTGAGAGACAGGGGCCCAGTTTCATTCTTTAGCATGTGGGGATTTATTTCTGGGTTCCCTATTCTGTTCCATTGGTTTATGTGTCTGTTTTTAG[C/T]CCATATTATGTTTTGGTTACTACAGCCT
TGTTATATATATATGTATCAAGGTGACTGTGAAGGTACTATATGGAAACATTTTTTATTGTTGTAAAATATATGTACATAAAATTTACCATT 
NR1H4 rs4764980 
AACTAAGTCTGCTCTGGCTGTTCCTTCCACTCCATTTTGTGTCCATGGGGCAGAGCAGTGCCCAACCAGTAGTCATGATTCCTCTGCTGGGCACCTCTGCTGCCCAGCCCTCTTGGGTTC[A/G]GAGTTCCACTGTGATATATGGCATA
GTTGTTTGAGGATGAGGGTGAGGTTGAAGTGAGTTCTCTCTCTCTTCTGCTTGTTGCATTGGACGGATCTGCCTTATACCTCAATGTTTCCAGAC 
 NR1H4_001 
CCCCAGCTCTCCTAACCAACCCTTCCCGCATTCCCACAGTCACAAACTATTTATTTTCCTTTCAGGAGTTTTTTTTGAAGACCACCATAAAGAAAGTGCATTTCAATTGAAAAATTTG[G/T]ATGGGATCAAAAATGAATCTCATTGAACAT
TCCCATTTACCTACCACAGATGAATTTTCTTTTTCTGAAAATTTATTTGGTAAGTTGTCAAGTTCATTTGAATATCAATAAGAACAAACT 
 NR1H4_003 
GAGAAGCTGTGAGAGGACTTTTTACACTTTTCAGTGTTTCTCCCACAGGTTTCTTCAGGAGAAGCATTACCAAAAACGCTGTGTACAAGTGTAAAAACGGGGGCAACTGTGTGATGGATA[T/C]GTACATGCGAAGAAAGTGTCAAGAG
TGTCGACTAAGGAAATGCAAAGAGATGGGAATGTTGGCTGAATGTATGTATACAGGTATTCACTTCAAGCAATTACATTTCACTAAAAATCTC 
 rs1030454 
CCTTTTCAGCTTGCACAAAATGAAAACAGTTACCAGAACTATGTTTTCCAAAGATGCAAATCTAAGCTGATTATCAGTTCAGATACTGTCTTTGAGAGGGGTTAGAAATGTAAAGAAACAAATGATAGACT[A/G]TTTATAAGAAGGGTA
AATGCTTTAGTTAAATTTAGAAATCTTAACACCTCTACTTTTGCTTTTGAAAGTG 
 rs35724 
AAGACAATCAGTTGACAAAATTCTCAAAATATAGCCAAAACAATGAGTGTAATGAGTGTATGTCTAATTTTGTCAGTGTCTTTGTTTCAGTCACTACTAATAATCAATGATAATGCTCTT[C/G]AATTGCCAAAAGAATCTCAAAAACGTCT
CCATTTTCCAGATGGGATTTAGTGAATCTTTTGAATATGACTATCGATAATTAAGGCAGAGATCACATCTTAAACAACTAACAAAAAGTGGT 
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Table 2.5: Number, sex and ages of case and control subjects 
 n Female (%) Male (%) Median age 
(range) 
Controls 254 119 (46.8%) 135 (53.1%) 66.1 (55-80) 
Cases 164 71 (43.4%) 93 (56.7)% 68 (30-92) 
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Table 2.6: Hardy-Weinberg equilibrium results  
Legend: Results from control cohort only shown. Calculated using Pearson’s χ2 test. P-value 
threshold for non-conformity to HWE set at 0.001. Abbreviations: SNP, single nucleotide 
polymorphism; A1, allele 1; A2, allele 2; GENO, genotype distribution; ObHet, observed 
heterozygosity; ExpHet, expected heterozygosity; p, p-value. 
Gene SNP A1 A2 GENO ObHet ExpHet p  
ABCB11 rs497692 A G 60/108/85 0.4269 0.4951 0.03082 
 rs3755157 T C 2/45/203 0.18 0.1768 1 
 rs6709087 G A 15/85/153 0.336 0.3512 0.4763 
 rs853773 T C 58/109/83 0.436 0.495 0.07312 
 rs853772 C A 61/112/79 0.4444 0.4974 0.09959 
 rs3821120 C G 44/115/94 0.4545 0.4805 0.4321 
 rs16823014 A G 2/34/214 0.136 0.1404 0.6397 
 rs4148797 G A 25/96/133 0.378 0.4096 0.2216 
 rs16856300 C A 44/110/97 0.4382 0.4777 0.1884 
 rs4148794 C T 43/104/106 0.4111 0.469 0.05993 
 rs17267869 C T 8/64/180 0.254 0.2671 0.4763 
 rs3770585 A G 59/127/64 0.508 0.4998 0.8993 
 rs2287622 T C 39/103/112 0.4055 0.4587 0.07478 
 rs2058996 A G 39/134/77 0.536 0.4884 0.1542 
 rs3770596 A T 51/104/89 0.4262 0.4879 0.04953 
 rs13416802 C G 4/50/199 0.1976 0.203 0.7535 
 rs2287618 A G 30/91/131 0.3611 0.4197 0.03471 
 rs7605199 G A 65/125/64 0.4921 0.5 0.8026 
 rs3815676 G A 0/15/239 0.05906 0.05731 1 
 rs4148773 T C 2/34/216 0.1349 0.1394 0.6383 
 rs3814382 T C 43/120/88 0.4781 0.4839 0.8962 
 rs10930343 G A 52/113/89 0.4449 0.4894 0.1585 
 rs7577650 A G 42/117/94 0.4625 0.4789 0.6002 
ABCB4 rs31652aa G A 2/44/201 0.1781 0.1754 1 
 rs2097937 G A 4/71/176 0.2829 0.2652 0.472 
 rs31653aa A G 2/38/209 0.1526 0.1544 0.6869 
 rs2373593 C A 2/38/212 0.1508 0.1528 0.6837 
 rs31666aa C T 6/54/190 0.216 0.2292 0.4021 
 rs31668aa G A 1/30/222 0.1186 0.1185 1 
 rs8187799 G A 3/32/217 0.127 0.1394 0.1534 
 rs31676aa T C 15/73/164 0.2897 0.3252 0.08305 
 rs1149222 G T 15/80/156 0.3187 0.3422 0.2708 
 rs4148826 G A 17/69/168 0.2717 0.3233 0.01808 
 rs2109505 A T 17/68/168 0.2688 0.3219 0.01083 
 ABCB4_indel :- AGAAA 0/9/243 0.03571 0.03508 1 
 rs1202283 G A 60/120/74 0.4724 0.4985 0.4498 
 rs4148812 C G 16/101/133 0.404 0.3905 0.7456 
 rs2302386 G A 9/64/179 0.254 0.2725 0.2544 
ABCC2 rs717620 T C 12/79/159 0.316 0.3271 0.5646 
 rs2756109 G T 52/113/89 0.4449 0.4894 0.1585 
 rs4148391 A T 4/61/185 0.244 0.2379 1 
 rs2073337 G A 39/124/91 0.4882 0.479 0.7948 
 rs2002042 T C 13/87/153 0.3439 0.3469 0.8572 
 rs7476245 A G 0/30/221 0.1195 0.1124 1 
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Gene SNP A1 A2 GENO ObHet ExpHet p  
ABCB2  
cont’d rs3740066 A G 33/128/92 0.5059 0.4728 0.2902 
 rs3740065 C T 7/49/194 0.196 0.2202 0.08516 
 rs3740063 C T 47/139/67 0.5494 0.4969 0.102 
ATP8B11 rs7241054 T C 64/126/62 0.5 0.5 1 
 rs1968274 C T 11/89/154 0.3504 0.3415 0.854 
 rs17685876 G A 12/102/138 0.4048 0.375 0.2425 
 rs317826 A G 12/104/137 0.4111 0.3779 0.1866 
 rs4308033 A C 37/125/91 0.4941 0.4772 0.6924 
 rs4306606 T C 16/98/138 0.3889 0.3828 0.8705 
 rs317845 C T 11/103/140 0.4055 0.371 0.176 
 rs317838 T C 26/125/99 0.5 0.4574 0.1674 
 rs317837 C T 11/105/138 0.4134 0.375 0.1317 
 rs11659313 C T 7/67/179 0.2648 0.2689 0.8148 
 rs319454 A G 19/102/128 0.4096 0.4042 1 
 rs7236365 T C 40/125/86 0.498 0.4832 0.6957 
 rs160993 A G 5/56/189 0.224 0.2292 0.7805 
 rs319448 G A 38/118/96 0.4683 0.4735 0.8942 
 rs319440 C T 50/127/72 0.51 0.4961 0.7028 
 rs17686300 A G 15/93/142 0.372 0.371 1 
 rs319457 T C 5/44/202 0.1753 0.192 0.1797 
 rs319406 G A 33/127/90 0.508 0.474 0.2877 
 rs319409 A C 51/131/72 0.5157 0.4966 0.6134 
 rs12456346 G A 40/109/104 0.4308 0.468 0.2264 
 rs9676158 T C 0/30/217 0.1215 0.1141 1 
NR1H4 rs4764980 G A 66/120/68 0.4724 0.5 0.3814 
 rs56163822 T G 0/15/236 0.05976 0.05798 1 
 rs61755050 C T 0/2/247 0.008032 0.008 1 
 rs1030454 G A 4/64/182 0.256 0.2465 0.7965 
 rs35724aa G C 29/114/111 0.4488 0.4479 1 
 
Table 2.7: Results from allelic association testing, Cochran-Armitage trend 
testing, dominant and recessive modelling for all SNPs 
Legend: This table can be found in Appendix 3 
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Table 2.8: Summary of SNPs nominally associated with altered risk of CC by gene  
Legend: With allele frequency in each group, allelic association odds ratio and Cochran-Armitage trend test results. SNP, single nucleotide 
polymorphism; A1, allele 1; A2, allele 2; Freq A, frequency of allele 1 in affected group; Freq UnA, frequency of allele 1 in unaffected group; OR, odds 
ratio; SE, standard error; L95 and U95, lower and upper limits of OR 95% confidence interval; allelic 'allelic association testing result; p, p-value; 
cor p, Bonferroni corrected p value; FDR, false discovery rate Q value; CATT, Cochran-Armitage Trend Testing result; bold text - p-value less than 
0.05. 
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Table 2.9: Haplotype testing results 
Legend: Global stat - global score statistic, df - degrees of freedom, p - p-value, cor-p - Bonferroni corrected p-value, bold text - p-value less than 
0.05 
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Table 2.10: Haplotypes in ATP8B1 associated with altered susceptibility to CC  
Legend: Hap Ref - allocated haplotype reference, Hap-Score - score statistic for association of haplotype with the binary trait, p-val  - p-value for the 
haplotype score statistic (based on a chi-square distribution with 1 degree of freedom), pool hf  - estimated haplotype frequency for cases and 
controls pooled together, control hf - estimated haplotype frequency for control group subjects, case hf  - estimated haplotype frequency for case 
group subjects, glm.eff - the haplo.glm function modeled haplotype effects as: baseline (Base) or additive haplotype effect (Eff), OR. lower  - lower 
limit of the Odds Ratio 95% Confidence Interval, OR - Odds Ratio based on haplo.glm model estimated coefficient for the haplotype, OR upper  - 
Upper limit of the  95% odds ratio confidence interval. Individual SNPs nominally associated with altered susceptibility to CC are shown in bold. 
 
Hap 
ref 
       Genotyped alleles contributing to haplotype     Hap 
score 
p-val Pool 
hf 
Control 
hf 
Case 
hf 
glm.eff OR 
lower 
OR OR 
upper 
 rs7241054 
rs1968274 
rs17685876 
rs317826 
rs4308033 
rs4306606 
rs317845 
rs317838 
rs317837 
rs11659313 
rs319454 
rs7236365 
rs160993 
rs319448 
rs319440 
rs17686300 
rs319457 
rs319406 
rs319409 
rs1245634
6 
rs9676158 
   
 
     
 
76 T C A G A C T C T T G T G A T G C G C A C -3.22 0.001 0.075 0.101 0.0324 Eff 0.220 0.490 1.1 
56 C T G G C C T C C T G C G A C G C A A A C -1.75 0.079 0.128 0.150 0.1073 Base NA 1 NA 
119 T T A G C C T T T C G C A G T G T A A A C -1.61 0.107 0.059 0.068 0.0347 Eff 0.340 0.76 1.7 
23 C T A A C C C T T T G C G A C G C G C G C -1.31 0.189 0.047 0.056 0.0356 Eff 0.340 0.85 2.1 
81 T C A G C C C T T T G C G A C G C G C A C -0.42 0.671 0.032 0.033 0.0262 Eff 0.390 1.05 2.8 
101 T T A G A T T C T T A T G G T A C A C G C -0.39 0.695 0.059 0.061 0.0652 Eff 0.510 1.08 2.3 
85 T C A G C C T C C C A C A G T G C A A G C -0.34 0.734 0.020 0.024 0.0183 Eff 0.460 1.41 4.3 
50 C T G G C C T C C T A T G G T A C A A A T -0.15 0.878 0.023 0.02 0.0217 Eff 0.440 1.36 4.2 
18 C T A A C C C T T T G C G A C G C A A A C 0.37 0.709 0.022 0.02 0.0255 Eff 0.480 1.57 5.2 
78 T C A G C C C T T T G C G A C G C A A A C 0.41 0.683 0.028 0.027 0.0262 Eff 0.620 1.65 4.4 
113 T T A G C C C T T T G C G A C G C A A A C 0.53 0.599 0.044 0.038 0.0509 Eff 0.690 1.62 3.8 
10 C T A A A T T C T T A T G G T A C A C G C 0.98 0.325 0.035 0.029 0.0399 Eff 0.830 2.19 5.8 
12 C T A A A T T C T T A T G G T A C G C G C 1.08 0.279 0.073 0.064 0.0821 Eff 0.940 1.83 3.6 
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Table 2.11: Genotyped and associated SNPs, with linked SNPs and 
functional classification  
Legend: LD - linkage disequilibrium, R2 - correlation coefficient of two SNPs in LD 
Gene Genotyped SNP, associated 
with CC 
SNPs in close LD 
(R>0.8) 
LD 
(%) 
Function 
ABCB11 rs3770585 - - Intronic 
 rs2287622 - - Missense 
  rs2287623 100% Intronic 
  rs2389605 100% Intronic 
  rs2241340 100% Intronic 
  rs4140386 100% Intronic 
  rs2287621 95% Intronic 
 rs3770596 - - Intronic 
  rs3770594 84% Intronic 
  rs4148782 87% Intronic 
  rs3770591 100% Intronic 
  rs3770590 87% Intronic 
  rs3770589 84% Intronic 
  rs12692889 81% Intronic 
  rs2287620 81% Intronic 
  rs13384680 81% Intronic 
  rs6761690 81% Intronic 
  rs13430236 93% Intronic 
 rs7605199 - - Intronic 
ABCB4 rs2097937 - - 3’ 
Intronic 
  rs6465112 100% 3’ 
Intronic 
  rs1526090 100% Intronic 
  rs12154399 100% Intronic 
  rs4148830 100% Intronic 
ATP8B1 rs319454 - - Intronic 
 rs319448 - - Intronic 
 rs12456346 - - Intronic 
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Figure 2.1: Hepatobiliary transport systems in hepatocytes and cholangiocytes.  
Abbreviations: ABCG5/G8, two-half transporter for cholesterol; AE2, chloride–bicarbonate anion exchanger isoform 2; ASBT, apical sodium-
dependent bile-salt transporter; BCRP, breast cancer resistance protein; BS-, bile salts; BSEP, canalicular bile-salt export pump; CFTR, cystic 
fibrosis transmembrane regulator; Cl-, chloride ions; GSH, glutathione, HCO3-, bicarbonate ions; MDR1, multidrug export pump; MDR3, 
phospholipid export pump; MRPs, multidrug-resistance-associated proteins; MRP2, canalicular conjugate export pump; Na+, sodium ions; NTCP, 
basolateral sodium taurocholate cotransporter; OA-, anionic anions or conjugates; OATPs, organic anion transporting proteins; OC+, cationic 
drugs; OST, organic solute transporter; PC, phosphatidylcholine. (Adapted from Geier et al, 2006[295])  
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Figure 2.2 Specimen fragment of PLINK-DATA matrix for analysis of ABCB11 results 
Legend: Showing 10 subject IDs in column 1, disease status in column 2, allelic genotyping calls in 4 SNPs in columns 4-10.  
 
 
10101D9 0 G G C C G A C C
10188D9 0 G G C C G A C C
10218D9 0 G A C C G A T C
10278D9 0 A A C C A A T T
10346D9 0 G A C C A A T C
10380D9 0 G G C C G A C C
10398D11 0 G G C C G G C C
10477D9 0 G A C C G A T C
10544D9 0 G A C C G A T C
10577D9 0 G G C C A A C C
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Figure 2.3 Specimen PLINK-MAP matrix (from ABCB11) 
Legend: Column 1 - chromosome; column 2 - SNP reference; column 4 - base pair location on chromosome.  
 
 
2 rs497692 0 169497262 
2 rs3755157 0 169500417 
2 rs6709087 0 169507256 
2 rs853773 0 169522593 
2 rs853772 0 169522901 
2 rs3821120 0 169525182 
2 rs16823014 0 169525959 
2 rs4148797 0 169526281 
2 rs16856300 0 169526548 
2 rs4148794 0 169529894 
2 rs17267869 0 169531654 
2 rs3770585 0 169532113 
2 rs2287622 0 169538574 
2 rs2058996 0 169542195 
2 rs3770596 0 169548388 
2 rs13416802 0 169550584 
2 rs2287618 0 169551055 
2 rs7605199 0 169564700 
2 rs3815676 0 169578625 
2 rs4148773 0 169582067 
2 rs3814382 0 169597234 
2 rs10930343 0 169598031 
2 rs7577650 0 169599456 
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Figure 2.4 Specimen data matrix for Haplo.stats 
 
Subject Disease Control rs497692.a1 rs497692.a2 rs3755157.a1 rs3755157.a2 rs6709087.a1 rs6709087.a2 rs853773.a1 rs853773.a2
10101D9 0 1 G G C C G A C C
10188D9 0 1 G G C C G A C C
10218D9 0 1 G A C C G A T C
10278D9 0 1 A A C C A A T T
10346D9 0 1 G A C C A A T C
10380D9 0 1 G G C C G A C C
10398D11 0 1 G G C C G G C C
10477D9 0 1 G A C C G A T C
10544D9 0 1 G A C C G A T C
10577D9 0 1 G G C C A A C C
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Figure 2.5 Specimen programming script for Haplo.stats 
library(haplo.stats) 
data(haploabcb11dataccafricanandpscexclusion) 
names(haploabcb11dataccafricanandpscexclusion) 
attach(haploabcb11dataccafricanandpscexclusion) 
geno <- haploabcb11dataccafricanandpscexclusion[,c(6:51)] 
label <-c ("rs497692", "rs3755157", "rs6709087", "rs853773", "rs853772", "rs3821120", "rs16823014",  
"rs4148797", "rs16856300", "rs4148794", "rs17267869", "rs3770585", "rs2287622", "rs2058996", "rs3770596", 
"rs13416802", "rs2287618", "rs7605199", "rs3815676", "rs4148773", "rs3814382", "rs10930343", "rs7577650") 
geno.desc <- summaryGeno(geno, miss.val=c(0,NA)) 
print(geno.desc) 
table(geno.desc[,3]) 
miss.all <- which(geno.desc[,3]>10) 
haploabcb11dataccafricanandpscexclusion.updated <- haploabcb11dataccafricanandpscexclusion[-miss.all,] 
library(haplo.stats) 
data(haploabcb11dataccafricanandpscexclusion.updated) 
names(haploabcb11dataccafricanandpscexclusion.updated) 
attach(haploabcb11dataccafricanandpscexclusion.updated) 
geno <- haploabcb11dataccafricanandpscexclusion.updated[,c(6:51)] 
label <-c ("rs497692", "rs3755157", "rs6709087", "rs853773", "rs853772", "rs3821120", "rs16823014",  
"rs4148797", "rs16856300", "rs4148794", "rs17267869", "rs3770585", "rs2287622", "rs2058996", "rs3770596", 
"rs13416802", "rs2287618", "rs7605199", "rs3815676", "rs4148773", "rs3814382", "rs10930343", "rs7577650") 
#haplo.cc# 
y.bin <- 1 * (haploabcb11dataccafricanandpscexclusion.updated$Disease == "1") 
cc.haploabcb11dataccafricanandpscexclusion <- haplo.cc(y = y.bin, geno = geno, locus.label = label, control 
= haplo.glm.control(haplo.freq.min = 0.02)) print(cc.haploabcb11dataccafricanandpscexclusion, nlines = 25, 
digits = 2) names(cc.haploabcb11dataccafricanandpscexclusion) 
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3. Polymorphisms in Natural Killer cell receptor protein 2D 
(NKG2D) as a risk factor for cholangiocarcinoma 
3.1 Background 
3.1.1 Natural Killer (NK) cells 
Natural Killer cells are cytotoxic lymphocytes that form a critical component of the 
innate immune system. One important role is in the direct recognition and killing of 
virally infected, or malignantly transformed, cells.[332] NK cells are present in the 
circulation, reticuloendothelial system and other tissues of the human body. They 
patrol, forming synapses with individual target cells and surveying that cell’s surface for 
activating and inhibitory ligands. Receptors that suppress NK cell activation include 
those activated by ligands of MHC class I. The expression of MHC class I ligands is 
decreased in stressed or transformed cells. Activating receptors respond to ligands 
expressed only by stressed cells, including RAET1 and MICA.  In addition, NK cell 
activation can be stimulated by a number of interferons and cytokines, including IL-15, 
although simultaneous activation by other pathways is also required.[332, 333]  
After the integration of these various signals, the target cell is either released by the NK 
cell undamaged or is killed via the release of perforin granules and proteases into the 
synapse. The apposed abnormal cell is perforated and penetrated by the released 
granzymes, triggering apoptosis or osmotic cell death. Activated NK cells also release 
cytokines that contribute to the general inflammatory process in infection and tumour 
killing.[334-336] 
3.1.1.1 Normal function of NKG2D receptor 
NKG2D is a major activating receptor expressed on the surface of CD8+, γδs T cells 
and NK cells. It is a C type lectin-like receptor formed of a type II transmembrane 
anchored glycoprotein. It is encoded by a single gene, NKG2D, which is located on 
chromosome 12 and which shows relatively little polymorphism. Even murine and 
human forms of NKG2D show 70% homology.[337] 
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NKG2D is activated by an unusually large and diverse range of ligands. These include 
MIC (A and B), ULBP (1, 2, 3 & 4), RAET1G and RAET1L. These ligands are 
expressed on the surfaces of stressed cells that are subject to intracellular infection, 
malignant transformation and heat shock. In human cells exposed to ionizing radiation 
or genotoxic chemicals, the subsequent DNA damaging pathways have been shown to 
upregulate the expression of many NKG2D ligands.[338] In NK cells, inhibitory signals 
generally dominate over activating signals. However, activating signals transmitted 
through NKG2D cannot be overcome by inhibitory signals, allowing NKG2D to function 
as a master switch in determining activation of NK cells.[339] 
Activated NKG2D associates with the DAP10 adaptor molecule in the cell membrane. 
In NK cells, this induces cytolytic granule release and target cell death. Activation of 
the NKG2D pathway also leads to cytokine release by the NK cell. Human NK cells 
treated with high concentrations of NKG2D ligands secrete cytokines including 
interferon γ, CSF and MIP-1β. These contribute to further activation of inflammatory 
and immune pathways, including the recruitment of further NK cells.[340] 
There is strong evidence of NK cell importance in the immunosurveillance of cancer 
cells. However, tumours eventually evade NK cell action and proliferate. This is thought 
to be due, in part, to very high levels of cell bound NKG2D ligands eventually leading to 
down regulation of NKG2D expression. Indeed, in advanced tumours, very large 
concentrations of soluble NKG2D ligands have been demonstrated – further 
attenuating NK function. Therefore, it is thought that NKG2D activity plays an important 
role in early tumour detection and control but with a diminishing role as the tumour 
progresses.[341-343]  
3.1.1.2 Dysfunction and carcinogenesis 
Mouse models of carcinogenesis have demonstrated reduced tumour surveillance and 
increased tumour progression in NKG2D receptor knock out mice, as illustrated in 
Figure 3.1.[344, 345] In an attempt to quantify the importance of cytotoxic immunity in 
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tumour surveillance, a prospective Japanese cohort study was started in 1986. This 
recruited normal subjects, with no known immunological defect. Circulating cytotoxic 
lymphocyte activity was quantified and the cohort divided in to low, medium and high 
activity tertiles. At an 11-year follow up, subjects with low cytotoxic immunity had 
increased risk of cancer compared to those with medium or high cytotoxic immunity. A 
subsequent study of the same Japanese cohort considered whether the differences in 
cytotoxicity could be attributed to lifestyle – smoking, exercise and similar factors. This 
concluded that only 30% of the difference between the groups could be explained by 
such factors. Therefore, the same investigators went on to explore genetic 
susceptibility factors in this cohort. They genotyped a 270kb region of natural killer 
complex gene region on chromosome 12, which includes CD94 and NKG2D genes, 
and identified NKG2D haplotypes that were associated with lower cytotoxic lymphocyte 
activity. Finally, a case-control study was performed to study those in the original 
cohort who had developed a malignancy (n=102) with matched control subjects with 
high (n=204), medium (n=204) and low (n=204) cytotoxic activity. They genotyped 20 
SNPs in the NKC region, covering CD94, NKG2D, NKG2F, NKG2E, NKG2A and Ly49 
genes. Eight of the 20 SNPs were associated with altered susceptibility to cancer and 
seven of these were found to lie within NKG2D.[346]  
3.1.1.3 NKG2D and CC in PSC 
This finding led to a study of NKG2D polymorphisms as a risk factor for 
cholangiocarcinoma. Melum and colleagues selected 7 SNPs across NKG2D and 
compared the genotype frequencies of 46 subjects with PSC and CC with 319 control 
subjects with PSC and no CC. Two of these SNPs were associated with increased risk 
of CC, and this finding persisted after correction for multiple testing. The two SNPs 
implicated were rs11053781 with an OR of 1.95 (CI 1.23-3.07) and rs2617167 with an 
OR 2.20 (1.40-3.44). The authors concluded that common genetic variation in the 
NKG2D receptor may be associated with increased susceptibility to CC in PSC 
patients. They suggest that, in patients with PSC, good NK cell function may be critical 
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in the detection and abolition of premalignant biliary cells.[72] They did not genotype any 
non-PSC related, sporadic CC cases and so no conclusions can be drawn on a 
potential role in this group. The majority of CC is sporadic, and it is therefore important 
to seek to validate the Norwegian findings in this group.  
3.1.2 Rationale for this study 
Genetic variation in the NKG2D receptor has been associated with reduced receptor 
function and impaired NK cell activation. Such genetic variation has been associated 
with increased risk of a number of malignancies, including PSC related CC. The same 
genetic variation may reduce tumour immunosurveillance in non-PSC patients, 
permitting survival and proliferation of transformed cholangiocytes and so progression 
to advanced malignancy. 
3.2 Hypothesis and study aim 
3.2.1 Hypothesis 
I hypothesised that variation in the gene encoding natural killer cell protein G2D 
(NKG2D) is associated with altered susceptibility to sporadic CC. 
3.2.2 Study aim 
I aimed to investigate the relationship between common polymorphisms in NKG2D and 
sporadic CC. 
3.3 Materials and methods 
3.3.1 Ethics 
The study protocol conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki. Approval from the local Research Ethics Committee and NHS R&D 
Department was sought and obtained for this study (Ref 09/H0712/82). 
3.3.2 Power calculation 
I undertook an a priori power calculation using statpages (Statpages) using the same 
method detailed in 2.3.4.[311, 347] I set a desired α (p-value) of ≤0.05, power of 80% and 
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case to control ratio of 1:2. The allele frequencies of the SNPs positively associated 
with CC in the Norwegian study, rs11053781 (case group MAF 0.66, control group 
MAF 0.50) and rs2617167 (case group MAF 0.39, control group MAF 0.22), were used 
as a surrogate for pilot data. This generated required group sizes of 112 cases and 223 
controls for rs11053781 and 95 cases and 191 controls for rs2617167.  
This confirmed that my proposed study had adequate power to detect a difference of 
the magnitude found in the Norwegian study. Indeed, with the cohort sizes available to 
me, it had power to detect the predicted difference in rs11053781 and rs2617167 of 
88.4% and 95.1% respectively. 
3.3.3 DNA resource 
I used the same DNA resource that I collated for my biliary transporter study (sections 
2.3.2-2.3.5) for this study of NKG2D polymorphisms. Therefore, the methods of sample 
collection, DNA extraction and DNA quality control will not be reiterated here. 
3.3.4 SNP selection 
I used HaploView (V 4.2, Broad Institute) to search HapMap (V3 Build R2, NCBI) data 
from genomic regions of interest within, and 5KB up and down stream of, NKG2D. The 
polymorphisms selected were relatively common with a minimum mean allele 
frequency (MAF) of >5%. Markers with a MAF of less than 5% were excluded. I then 
used the application tagger within Haploview to select SNPs that captured the 
maximum genetic variation in NKG2D, with the minimum number of SNPs. The two 
SNPs identified to be of interest in the Norwegian study were force included. Pair-wise 
comparisons only were used with an R2 cut-off of >0.8, a measure of linkage 
disequilibrium (LD) between two SNPs. This resulted in a total of 7 SNPs to be 
genotyped in NKG2D. These SNPs are listed in Table 3.1. Due to LD, the SNPs 
selected represent far more variation around the candidate gene than the absolute 
number of single nucleotide polymorphisms genotyped.  
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3.3.5 Primer design and genotyping 
I performed primer design by collating the corresponding DNA sequence from the 
NCBI dbSNP database for each SNP shortlisted. These are listed in Table 3.2. I 
reverse checked all DNA primer sequences by searching the NCBI basic local 
alignment search tool (BLAST). I then input these sequences into ‘PrimerPicker’ 
(KBioscience). This is proprietary, web-based software that generates designs for the 
oligonucleotides necessary for the KASPar genotyping process. 
KBioscience performed the genotyping on the same KASPar system used for my 
biliary transporter study, discussed in section 2.3.7.  
Raw data from the genotyping process were returned to me in comma separated 
values (csv) format.  
3.3.6 Statistical analysis 
I managed and manipulated the raw genotyping data with MS Excel (Microsoft). 
Differences were considered significant if p <0.05.  
3.3.6.1 Hardy-Weiberg Equilibrium (HWE) 
I confirmed HWE in all 7 genotyped SNPs using Pearson’s χ2 test in PLINK (V1.07). I 
used a p-value threshold of 0.001, in line with standard practice and the HWE p-value 
criteria set in the tagger algorithm during SNP selection. I determined that any SNPs 
that breached this HWE threshold in the control cohort would be excluded from further 
analysis.  
I prepared a PLINK-DATA matrix and a PLINK-MAP matrix of the NKG2D data, using 
the technique described in 2.3.8.1.1. I produced a programming script to run the HWE 
analysis, which is reproduced here: 
>plink --ped plinknkg2ddataccafricanandpscexclusion.txt --1 --
no-fid --no-parents --no-sex --allow-no-sex --map 
plinknkg2dmapccafricanandpscexclusion.txt   --hardy 
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3.3.6.2 Allelic association testing (χ2) 
I used the following script to execute χ2 allelic association testing and calculate 
associated odds ratios, with 95% confidence intervals: 
>plink --ped plinknkg2ddataccafricanandpscexclusion.txt --1 --
no-fid --no-parents --no-sex --allow-no-sex --map 
plinknkg2dmapccafricanandpscexclusion.txt --assoc --ci 0.95 
3.3.6.3 Cochran-Armitage Trend Testing (CATT) 
I used the following script to execute CATT on the NKG2D data: 
> plink --ped plinkNKG2Ddataccafricanandpscexclusion.txt --1 -
-no-fid --no-parents --no-sex --allow-no-sex --map 
plinkNKG2Dmapccafricanandpscexclusion.txt  --model 
3.3.6.4 Haplotype analysis 
I used haplo.stats (R V2.10.1, Haplo.stats V1.4.0 [319]) to perform a haplotype analysis 
on all 7 SNPs genotyped in NKG2D. 
3.3.7 Correction for multiple testing 
Any p-values of <0.05 were to be corrected for multiple testing. In this case, correction 
was required for 7 independent tests in the SNP association tests. No correction would 
be required for a positive haplotype test as only one haplotype test was to be 
performed.  
I planned to apply Bonferroni correction to all calculated p-values of <0.05 using MS 
Excel (Microsoft). I would also perform permutation testing (PLINK V1.07) and a 
predicted false discovery rate calculation (FDR, R V2.10.1, QVALUE V1.0[321]) as 
alternative, less conservative corrections for multiple testing. 
3.3.8 HapMap and NCBI dbSNP interrogation for associated SNPs 
I planned to use HapMap to identify all other, non-genotyped, SNPs known to lie in 
strong LD (R2>0.8) with any genotyped SNPs found to be associated with altered 
susceptibility to CC. Each of the genotyped and associated individual SNPs, and those 
Chapter 3 – NKG2D genetics 
 119 
found to be in strong LD, would then examined in dbSNP[322] (NCBI, Bethesda, USA, 
Build 132) to explore potential functional consequences.  
3.4 Results 
3.4.1 DNA extraction 
For this experiment, I used the same DNA resource that I prepared for my biliary 
transporter study. Details of the DNA extraction and QC are as previously described in 
section 2.4.1.   
3.4.2 Demographics of case and control groups  
All samples were successfully genotyped. Data from 164 CC subjects and 257 controls 
were included in the analysis. All cases included in the analysis were from Caucasian 
patients without PSC. The two groups were well matched in terms of sex and age 
(Table 3.3). 
3.4.3 Harvey-Weinberg equilibrium (HWE) 
HWE was confirmed in all genotyped SNPs in case, control and combined groups. 
HWE results from the control group, for each SNP genotyped are presented in Table 
3.4. As none of these SNPs breached the defined p-value threshold of <0.001, all 
genotyped SNPs were included in subsequent analyses. 
3.4.4 Alellic and Cochran-Armitage trend testing 
Allele frequency and Cochran-Armitage trend testing results for each SNP are listed in 
Table 3.5. None of the SNPs genotyped were associated with altered susceptibility to 
CC. Dominant and recessive models were also tested, with no significant difference 
between groups. 
3.4.5 Haplotype analysis 
I undertook a haplotype analysis, to detect association between different combinations 
of SNPs in NKG2D and altered susceptibility to CC. The haplotype analysis result is 
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summarised in Table 3.6. There was no evidence to suggest any haplotype differs in 
frequency between cases and controls (p > 0.1). 
3.4.6 Correction for multiple testing 
As none of the statistical tests demonstrated a significant difference, correction of p-
values was not required.  
3.4.7 HapMap and NCBI dbSNP interrogation for associated SNPs 
As I found no SNPs to be associated with altered susceptibility to CC, this was not 
performed. 
3.5 Discussion 
In the recent Norwegian study by Melum and colleagues, polymorphisms in the gene 
encoding natural killer cell receptor G2D (NKG2D) identified two SNPs that were 
associated with altered susceptibility to CC in patients with PSC.[72] The same genetic 
variation may reduce tumour immunosurveillance in non-PSC patients, permitting 
survival and proliferation of transformed cholangiocytes and so progression to 
advanced malignancy.  
My study is the first to examine NKG2D polymorphisms in sporadic CC. The study had 
adequate a priori power. I found no relationship between common genetic variation in 
NKG2D and susceptibility to CC. This is in contrast to the prior finding of the study by 
Melum and colleagues of an association between rs11053781 and rs2617167 and CC, 
in their study. The SNPs tested in my study, and those associated in the Norwegian 
study are illustrated in the LD plot in Figure 3.2. Although this proved to be a clear 
negative study, the findings are of importance none the less. 
The failure to reproduce the association may reflect an important difference between 
the pathogenesis of sporadic CC and that of PSC-related CC. PSC, unlike risk factors 
such as cholelithiasis and hepatitis C, is a strong risk factor for CC - with a lifetime 
incidence of CC of around 15% in PSC patients. PSC is an autoimmune disease that 
remains poorly understood but is associated with other autoimmune diseases. There 
Chapter 3 – NKG2D genetics 
 121 
are clear genetic associations between PSC and variation in the HLA genetic region.[65] 
PSC-related CC has significant clinical differences to sporadic CC, including a much 
earlier age of onset, frequent multifocal high-grade dysplasia and a particularly poor 
prognosis.[348-351] It is therefore conceivable that NK cell killing plays a more important 
role in PSC than its does in CC patients with otherwise normal bile ducts.  
The populations of the Norwegian study were recruited from Norway and Sweden. My 
cohort and controls were Caucasians residing in the UK. It is possible that a genetic 
influence in the Scandinavian population may not be present in the UK.  
Alternatively, my study may present a false negative. Although it was well powered to 
detect differences of the magnitude observed in the Norwegian study, I cannot exclude 
the possibility of smaller effects in non-PSC-related CC. Confidence intervals from my 
study suggest any such effects must have OR <1.5 and considerably larger studies 
would be needed to detect, or exclude, effects of this magnitude. Finally, although 
executed with statistical rigour and with strong positive results, the Norwegian study 
may have reported a false positive in PSC-related CC. 
I can conclude that common genetic variation in NKG2D does not contribute 
substantially to sporadic cholangiocarcinoma risk. My findings cannot refute those of 
Melum and colleagues, as my study excluded patients with PSC-related CC.  This 
could be elucidated in an additional candidate-gene validation study in further cohorts 
of patients with sporadic CC and PSC-related CC, along with appropriate control 
groups. However, as genetic susceptibility to CC is likely to be highly complex and 
involve many genes, a genome wide association study (GWAS) would offer the 
advantage of being an unbiased screen for associated genes. With increasing 
availability and affordability, a GWAS may also prove a more cost-effective method for 
further exploring such genetic factors. CC is a relatively rare disease and such a study 
would require a multi-centre, international collaboration to collate adequate numbers of 
well-characterised cases and controls. 
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3.6 Chapter 3 Tables and Figures 
Table 3.1: SNPs in NKG2D selected for genotyping 
Legend: By gene, RS number and location on chromosome. SNPs force added as associated in Norwegian PSC/CC study in bold. 
Ref RS number Chromosome BP location 
1 rs7397310 12 10412260 
2 rs10772271 12 10415387 
3 rs1049172 12 10417007 
4 rs11053781 12 10428536 
5 rs12819494 12 10442808 
6 rs2617165 12 10445197 
7 rs2617167 12 10450498 
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Table 3.2: SNP DNA sequences in NKG2D for oligonucleotide primer design 
Legend: SNP - single nucleotide polymorphism, [x/z] - variable allele of SNP in preserved DNA sequence 
SNP Sequence 
rs7397310 AAAATTTAATTTAACCAACTGTTGCCTAGAAATCGATGATAATGGTTGAGCTGTCATGGAAATCACCGCTAGAATGCACACATTGGCCCATATTCCAGTTCAGACTTGGTCTGGGTGGTCCCCGGATTCCTTGTTTGGAGGATG
GTTCTCAGCCTTTAGAGGATTCAAAAGCCTCATTGGTGGGTTCTTGGTTATTCTTGGCATCTGCCTCATCCTCCCTTGCCTTTTACCCCTGTTTATTAGAAGTATTCAGTCAACTATGGAGGCAATAGTGGCCTGATACACTAC
CATGCAGATGATGGCATTAACCAGATATCAGTCGCTGCTGGTAGAAGCAGCAGCTCAGCTCCACGAAGACGTGGCAAATAGTGGTGCTTTCTGTTAACACATTTGTTATAAAAAGCACCAAAGGGGGGAATGGAACAGGAATTA
AAAGAAATTAAAGAATGTGTAAGCAAAAACTCAGTTGTATGTAAGAAAACCCAATTCCCCCTGAGGAAGAGAAAGAACTGGAGTCCTTTAAAAATTAACTGCCTGTTTTTCCGTGGCTAGTGAGCCTTATCTCTCCCTTTCCCA
GGCATTGTGAAGACCCTGTTTCTCTAGCTGTGCAGCTGCAAGGTCACTAGACAGACAAACTCAAGTCATAAAACATGCTTTTCCTTGAAAAGTAAGAAACAATGTAATGTATGTCTCAATTGAATAACTGTCTTTGTTTCTTGC
TTCTGTAATATGCTTCCCCCTGCACAAATCTTCCCCCACAGACAAAATACTTAAAAGATAACTTGACTCTTTGTTCAGGGCTCAGTCATTTGGATGTTAATCCAACTGGGCCAGTGCACCTAAATAATAAAAATCCTCCTCAAC
CCCTTGGTGTTCCTGA[C/T]TCCTTATCAATCCTGCTACAGGTGGAGAAAAAAGAAAGACCAGCAGAAAAGAAAAAAACTAGGAGAGGAAGTCAGAGGGAAAGAAAGCAAAAACAGCAAGCATAGAGCCAAACAGCCAGGCAG
GCACGCCAAGGGGTAAGTCCCTCTCCCCAAAGAGCTTGGGGACTGGTGCCGGGAGGAGAGCAGAGGAGGTGAAAGGGCATAATTCTTGCAATTTGCGGCAGGCATCTGCCAATCCTCTGGGCCGGTGACTGCCTGGGGCCCAGA
CTA 
rs10772271 TGGAGTGTATGGTGGTTCTTTTTCAAAATCCCACTGCTTGGGATAATCCATCATACTGAGCGCTCTCTGCTATTTCCTGAAATTCAACACCCTGCGGGTCAGCCTCCGAGGGCAATCCAGCTTCCACCTCTAAATGCCAAGTTTACTTTGTGCCTCTCATGGCAGGAGGAAAATTTGGCGTTCCTTGAAAGCATAAAAGGATACAAGAAGCCCAAGCCTTTCCAAGAACTTGCCCATCAGTCCATGCTTAGCCATCCCCAAGCAAATGTATAGTGGTACTGTGGAAGA
CCTTTACTGGACACTCGGCCAAATAACTGGAGCAGTACTTGTGCTCTAATCCAATTGGCTATCCGCTTCACGCTGGCATTTCGTCAATCTAAAAAGGTAAAAACAAAACACCGCAGGCCAAAGGAAACTCCTTGAGTCCTTTAA
TCCTCAGGTTTACGTAAATGTTATTAAGGTCCGTGAGAAGTGCCAAATAAGTTTAAAGCACAAAAATCAAATAGCTGCAAAATTTAAATCCATGTTGGTCTGGTAGGTAACCATAAATTAAAAAAAAATTTAACTTCAATTCAA
TTCTCACCTCGTTT[A/G]CCCTTACTATTGGTGTACTTATTCTTGTAGACTGTTATATTATGCCCTGCCTTCAAGGTTTTATGCAAAAACTTGTCTCTGCTGCTCTTACAGAGTTAACTCCTAACTATCCTCCACCCTATTGA
AAAAAAATTACCTCTCTTAGAAGGACAAAGAATTAAGTCAAAACATATTAAACAAGACTGAGGAGGAATTATGAAATAAAAAAAGGGGGAATATTGTAAAAAGTAAAGTAGAGGTTCCTCTTCAAAGACTTTCCTCCCCATCTA
ATTAGAAATAAACAGTAACTTCTCTTAGAAGCAAAATTTATTCAAAGACCTGTGCTCCTAAATATTTGCCCTGGCATGCTTATACTGGTCCAAGCAAGCGTTAGGTCATAGCCTGTTCCTCTTCCTTATTTAAAAGTGTTTTTA
TCTTTCTCAGCATTCCACAAGTTACTTCCTCCTTCCTTTGTTCTCCTCTACCTTTGCCTCTTTTAAAAAGTTCTAAGTTGCTAGCCAATCGGGACAAATACAGAATGTGAGGTCCCGTTCCAGCCAGTGGAAACCGGACACAGC
AGTAGTGTGGACATGTCAGGTTATAAATGACCCTGTCTCCTTTGTTCGGTGTACTCTCATGGCAGAACTGCTAGTGAGTG 
rs1049172 TCCTAAAATGGTATTAAGTTCCTGTATTTGAAGTTCAATAGGTATGATTCATTTTTATTTTCCCGCGTTAATAAAATCATGTATGTAATTTGTAATTGTCTCTCCTCTAGACTAACAATAATTGAAATGCAGAAGGGAGACTGT
GCACTCTATGCCTCGAGCTTTAAAGGCTATATAGAAAACTGTTCAACTCCAAATAC[A/G]TACATCTGCATGCAAAGGACTGTGTAAAGATGATCAACCATCTCAATAAAAGCCAGGAACAGAGAAGAGATTACACCAGCGGT
AACACTGCCAACTGAGACTAAAGGAAACAAACAAAAACAGGACAAAATGACCAAAGACTGTCAGATTTCTTAGACTCCACAGGACCAAACCATAGAACAATTTCACTGCAAACATGCATGATTCTCCAAGACAAAAGAAGAGAG
ATCCTAAAGGCAATTCAGATATCCCCAAGGCTGCCTCTCCCACCACAAGCCCAGAGTGGATGGGCTGGGGGAGGGGTGCTGTTTTAATTTCTAAAGGTAGGACCAACACCCAGGGGATCAGTGAAGGAAGAGAAGGCCAGCAGA
TCACTGAGAGTGCAACCCCACCCTCCACAGGAAATTGCCTCATGGGCAGGGCCACAGCAGAGAGACACAGCATGGGCAGTGCCTTCCCTGCCTGTGGGGGTCATGCTGCCACTTTTAATGGGTCCTCCACCCAACGGGGTCAGG
GAGGTGGTGCTGCCCCAGTGGGCCATGATTATCTTAAAGGCATTATTCTCCAGCCTTAAGTAAGATCTTAGGACGTTTCCTTTGCTATGATTTGTACTTGCTTGAGTCCCATGACTGTTTCTCTTCCTCTCTTTCTTCCTTTTG
GAATAGTAATATCCATCCTATGTTTGTCCCACTATTGTATTTTGGAAGCACATAACTTGT 
rs11053781 
TCATATGACTCAAAGCAATCTACAGATTCAGTGCAATTCCTAACACGATACCAGTAACATTCTCTACAGAAATAGAAAAATATCTTAAAATTTATATGGTACCACAAAAGACTGAATAGCCAAAGCAATCTTGAACAAAAATGA
AGAAAACTGGTGGCATCACGTTACCTGACTTCAATATATACGACAAAACTACAACAACCAAAACAGTATGGCATTGATATAAAAATAGACACCTAGACCAATAAAACAGAATAGACAACCCAGGAATAAATCCATGTATTATAG
CCAACTGATTTTTCCAGAAAGTCACCAATAACATACACTGGGAAAGGAGAGCCTCTTCAATAAATGAAGCTGAAAAAACTGGATATCCACATAGAGGAATGAAATTAGACCCTCATCTCACACCATATACAAAAATCAACTCAA
AATGGATTAATGACTTAAATATAAGAACTGAATCTATAACACTACTAGAAGAGATAAGAGAAACACCA[C/T]AGGACATTAGTCTAGGCAAAGATTTTATGGGTAAGAATTCAAAAGTACAGGCAACAAAAGCAAAAAGAAAC
AAATGAGATTGTATCAAACTAACACACTTCTCTACTGCATAGGAAACAATTGACAGAGTGAAGAGACAACTTGTAGAATAAGAGAAAATACTCGCAAACTATTCCTCTAACAAGAGACCAATATCCAGAATATACAAGGAATTC
AAACAACTCAACAGCAACAACAAAAACTGATTTGAAAATGAGCAAAGGATCTGAATAGATATTTCTGAGAAGATATACAAATAGCCACAGATATATTTTTTGAAATTCAACATCATTCATCATCAAGAAGATGAAAATCAAAAC
CACAATGAATATCATCTCACCCTAGTTAGAATAGCTATTATTTAAAAAGACAAAAAATAACAAATGACAGTGAGGATGCAGGGAAAGGCTAATGTTTATACAATTTTGGTGGGAATGTAAATTAGTATAGCCATTATGGAA 
rs12819494 
AAATAATATATTGGCTGACAACCAAGCTATGCAATTCACAAGGGCAATCCCTAGGAAATGGGGCTAAAAAATAAAAATAAAAAATTAGAATTTGAAACAAAAACATCAGCAAATGCATTTTAAAGGAGAAAGATTCTGCAGTAA
AATTTTATGTAAGTTACCCCCCCAAAATCTTTATAAACCCCCCAAATTTATTTGTATGATACTATATTATAAAAAATGTCTATTATAAGAAATTAGAAAACATGCAGAAACTGGAAAATGTCTTCCATACTTGGAGGGAAAGAC
AATCAGTCAATAAAATCTGACTTTTTCTGGGACAAGATGGTAGATTTATCAGAAAATATATTTTAAAGTAACTATTATAAATGTACTTAAATTATACAGAAAAGTATGTTCAATTAATTAAATGAAAATATGATGGCAATGAGA
AAACAAGTAGGAAATTTTGTCAGAGAAATGAAAACCAAGAAATAAACCAAATTCTGAGTTGAGAAGTA[C/T]ATTACTTGAAACGAAAAATTCACTAAATTGGCTAGAAAAAAAATTGAGATTCAAAAGGAAGAATTCATCAA
CTTTGGGATATATTAATAGAAATTATTCATCCCAGAGAAAAAGAGAATACAGAAAGATGTAGAAAAATAATATTAAGACAAAACTGACTTAAAAACTTTTCAAATTTGCTTTTTTAAAAATGTATACATCCAAGATGCTAAGCA
AACTAATGACTAATAGAATCAGCATGTAGAAATCCCCATCTCAAAACATCATAATCAAATGATTGAAGAGGATTTTAAGACAAAGACCCTGAGATAATCTTGTGGAACAGGTAGGACGGATTATGAGATGACTTGAGTCTGTGT
GAATGCCAGGGAATGGTTGAGGTATCCCCCACCAGCAGGAGTATTTTGACCACATTACCTTCCAGAGAACCCACATTTGCCCTGAATACTATTCTAGATTGGAAGGAGGCAACATCAACAAGATAGAGGAATAGCATACCC 
Chapter 3 – NKG2D genetics 
 124 
rs2617165 TTGTAAAATGTGAATATAGTTAACACTACTGACCTGTTCACTTAAAAATGGTTGAGATATATGATATGGTTAAGATGTAATGGCTCAGATGTAACATACTGTATGAGTTCAACTATATGACATTCTGGAAAAGTAAACAACTAT
GGAGACAGTACAAAAATCGATGCTTGCCATGTGTTTGAAGGAGGAAAGGATGAATG[A/G]GCAGAGCACAGAAGATTTTCAGGGCAATGCAATTATTCTGTATGATCTATGATGATAAAGACATGTCATTATCATTATATATT
TGGCCAGACCCATAAAGTGTAAAACACTGAGTGAAACTTAACATAAGCTATGGTCTTTCAATAATAATGATGTTTCAATTGTAACAAATATACCATGCTGATGGGGGATATTGATCA 
rs2617167 TTCTCCAGATATTCTGATTAAATAAATGTATTTTTCCACTATGTGTCTCATAGTGGAACTTTTCCTCCTTGAAGTTTAGAAGGAAATTGAAAGGTTGCCATTGAGGAAATAAATGACACAGCAGCCAAAAATTGGCTTTTCTGGGCACCACACCACTCTCTAACTAGATAAGCCCTCACTTTTATCTGATTTGGTTTTGGTGGAATAACAATGGTCTTGACCAGGTACATGGACTCCTTTTTCTCTGCTACTCCCTAATAAATACAACTCTAAACTCTGCAAGTAATG
AAAGACACACAG[A/G]AAAACTCTGAAAGGTGGAAAGAGGAAGGCAAAATAGTTTGGGACCCCAGAATCAGGGATCAACAGAGTGTCCGGGCATCTTCAGTCCCCCACTCAGCAGAAGAAAGTGATCTAGTCCTCTGTTTCTC
AGAACCAAATCTGGTAACAGGAGGTGGGTCAGCTAAGCCCATTCCCACTCTGTATTGAAAGGGAGTCCTGCCAGCAACATTAGGCAAGCCTGGTACCACTGGCAAGGATGACCTACCAGGAGGCCTGCTACCAGTTAGGAGCTA
GAGGAAGTGCTTCTCCTCCCAAACCAAAA 
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Table 3.3: Demographics of case and control groups 
Legend: n – number in group 
 n Female (%) Male (%) Median age 
(range) 
Controls 257 121 (47%) 136 (53%) 66.1 (55-80) 
Cases 164 71 (43.4%) 93 (56.7)% 68 (30-92) 
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Table 3.4: Hardy-Weinberg equilibrium results for SNPs tested in NKG2D  
Legend: Using Pearson’s χ2 test. P-value threshold for non-conformity to HWE set at 0.001. Abbreviations: SNP, single nucleotide polymorphism; 
A1, allele 1; A2, allele 2; GENO, genotype distribution; ObHet, observed heterozygosity; ExpHet, expected heterozygosity; p, p-value. Results 
from control cohort only shown.  
 
SNP A1 A2 GENO ObHet ExpHet P 
rs7397310 T C 12/71/167 0.284 0.3078 0.2191 
rs10772271 G A 33/129/85 0.5223 0.4778 0.1826 
rs1049172 G A 22/99/129 0.396 0.4084 0.6428 
rs11053781 T C 53/119/73 0.4857 0.4967 0.7968 
rs12819494 T C 2/60/190 0.2381 0.2217 0.3909 
rs2617165 A G 6/63/175 0.2582 0.2601 0.8091 
rs2617167 A G 19/92/140 0.3665 0.3838 0.5102 
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Table 3.5: Results from allelic association testing, Cochran-Armitage trend testing, dominant and recessive modelling for all 
SNPs genotyped in NKG2D 
Legend: Abbreviations: SNP - single nucleotide polymorphism; A1 - allele 1; A2 - allele 2; Freq A - frequency of allele 1 in affected group; Freq 
UnA - frequency of allele 1 in unaffected group; OR - odds ratio; SE - standard error; L95 and U95 - lower and upper limits of OR 95% confidence 
interval; allelic allelic association testing result; p - p-value. 
SNP A1 
Freq A Freq 
UnA A2 
OR L95 
OR 
U95 
OR  χ2 TEST Freq A Freq UnA χ2 DF P 
rs7397310 T 0.1925 0.19 C 1.017 0.7122 1.451 ALLELIC 62/260 95/405 0.00822 1 0.9278 
        TREND 62/260 95/405 0.00762 1 0.9304 
        GENO 8/46/107 12/71/167 0.008457 2 0.9958 
        DOM 54/107 83/167 0.005106 1 0.943 
        REC 8/153 12/238 0.006038 1 0.9381 
rs10772271 G 0.4317 0.3947 A 1.165 0.8759 1.549 ALLELIC 139/183 195/299 1.1 1 0.2942 
        TREND 139/183 195/299 1.127 1 0.2884 
        GENO 33/73/55 33/129/85 4.004 2 0.1351 
        DOM 106/55 162/85 0.002734 1 0.9583 
        REC 33/128 33/214 3.661 1 0.0557 
rs1049172 G 0.2625 0.286 A 0.8886 0.6481 1.218 ALLELIC 84/236 143/357 0.5383 1 0.4632 
        TREND 84/236 143/357 0.5219 1 0.4701 
        GENO 12/60/88 22/99/129 0.5229 2 0.77 
        DOM 72/88 121/129 0.4527 1 0.5011 
        REC 12/148 22/228 0.2168 1 0.6415 
rs11053781 T 0.4938 0.4592 C 1.149 0.8669 1.523 ALLELIC 159/163 225/265 0.9335 1 0.334 
        TREND 159/163 225/265 0.9504 1 0.3296 
        GENO 36/87/38 53/119/73 1.959 2 0.3756 
        DOM 123/38 172/73 1.876 1 0.1708 
        REC 36/125 53/192 0.03005 1 0.8624 
rs12819494 T 0.1415 0.127 C 1.133 0.752 1.708 ALLELIC 45/273 64/440 0.3577 1 0.5498 
SNP A1 Freq A Freq A2 OR L95 U95  χ2 TEST Freq A Freq UnA χ2 DF P 
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UnA OR OR 
        TREND 45/273 64/440 0.3447 1 0.5571 
Cont’d        GENO 7/31/121 2/60/190 NA NA NA 
        DOM 38/121 62/190 NA NA NA 
        REC 7/152 2/250 NA NA NA 
rs2617165 A 0.1398 0.1537 G 0.8946 0.5998 1.334 ALLELIC 45/277 75/413 0.2986 1 0.5848 
        TREND 45/277 75/413 0.2867 1 0.5923 
        GENO 5/35/121 6/63/175 0.9733 2 0.6147 
        DOM 40/121 69/175 0.5815 1 0.4457 
        REC 5/156 6/238 0.1535 1 0.6952 
rs2617167 A 0.2112 0.259 G 0.7661 0.5486 1.07 ALLELIC 68/254 130/372 2.454 1 0.1173 
        TREND 68/254 130/372 2.353 1 0.125 
        GENO 8/52/101 19/92/140 2.356 2 0.3079 
        DOM 60/101 111/140 1.955 1 0.1621 
        REC 8/153 19/232 1.083 1 0.2979 
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Table 3.6: Summary haplotype results in NKG2D 
Legend: Hap Ref - allocated haplotype reference, Hap-Score - score statistic for association of haplotype with the binary trait, p-val  - p-value for 
the haplotype score statistic (based on a chi-square distribution with 1 degree of freedom), control hf - estimated haplotype frequency for control 
group subjects, case hf  - estimated haplotype frequency for case group subjects, glm.eff - the haplo.glm function modeled haplotype effects as: 
baseline (Base) or additive haplotype effect (Eff), OR. lower  - lower limit of the Odds Ratio 95% Confidence Interval, OR - Odds Ratio based on 
haplo.glm model estimated coefficient for the haplotype, OR upper  - Upper limit of the  95% odds ratio confidence interval. 
Hap ref Genotyped alleles contributing to haplotype Hap score p-val Control hf Case hf glm.eff OR lower OR OR upper 
 rs7397310 
rs10772271 
rs1049172 
rs11053781 
rs12819494 
rs2617165 
rs2617167 
  
 
     
 
17 C G G C T G G -1.15 0.25 0.0981 0.0706 Eff 0.43 0.76 1.3 
2 C A A C C G A -1.05 0.29 0.0651 0.0507 Eff 0.43 0.84 1.7 
1 C A A C C A A -0.93 0.35 0.1399 0.1215 Eff 0.53 0.85 1.4 
10 C G A C C G A -0.83 0.41 0.0349 0.0226 Eff 0.23 0.63 1.7 
20 T G G C C G G -0.37 0.71 0.1823 0.1739 Eff 0.64 0.96 1.4 
5 C A A T C G G -0.18 0.86 0.3533 0.3434 Base NA 1 NA 
7 C A A T T G G 1.4 0.16 0.0238 0.0386 Eff 0.81 1.87 4.3 
13 C G A T C G G 1.61 0.11 0.0595 0.0901 Eff 0.85 1.6 3 
3 C A A C C G G NA NA 0.0055 0.0034 R 1.09 1.98 3.6 
4 C A A T C A A NA NA 0.012 0.0142 R 1.09 1.98 3.6 
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Figure 3.1: Postulated mechanism for increased tumour progression in NKG2D receptor knock out mice  
Legend: NK cells lacking expression of the activating receptor NKG2D fail to recognise transformed epithelial cells expressing Rae-1 proteins. 
Transformation of normal epithelium and other cell types often leads to the expression of ligands for the activation receptor NKG2D. In mice, such 
ligands belong to a family of several Rae1 as well as H60 and MULT1 proteins. This figure illustrates the destruction of tumor cells expressing 
NKG2D ligands by NK cells. In the absence of the NKG2D receptor, these cells cannot be rejected by NK cells or other NKG2D-expressing 
immune cells. The result is aggressive tumour development[346, 352]  Adapted from Ljunggren et al, Immunity, 2008 
 
 
Overleaf:  
Figure 3.2: LD Plot, NKG2D 
Legend: SNPs genotyped in current study (blue), and prior Norwegian PSC/CC study (green) are circled (HaploView V 4.1, HapMap data V3 build 
R2, CEU, Chr12, 10410KB-10460KB.) 
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Figure 3.3: Haplo.stats script for NKG2D haplotype analysis 
>library(haplo.stats) 
data(haplodatankd2ccallafricanandpscexclusion) 
names(haplodatankd2ccallafricanandpscexclusion) 
attach(haplodatankd2ccallafricanandpscexclusion) 
geno <- haplodatankd2ccallafricanandpscexclusion[,c(6:19)] 
label <-c ("rs7397310", "rs10772271", "rs1049172", "rs11053781", "rs12819494", "rs2617165", "rs2617167") 
geno.desc <- summaryGeno(geno, miss.val=c(0,NA)) 
print(geno.desc) 
table(geno.desc[,3]) 
miss.all <- which(geno.desc[,3]==7) 
haplodatankd2ccallafricanandpscexclusion.updated <- haplodatankd2ccallafricanandpscexclusion [-miss.all,] 
library(haplo.stats) 
data(haplodatankd2ccallafricanandpscexclusion.updated) 
names(haplodatankd2ccallafricanandpscexclusion.updated) 
attach(haplodatankd2ccallafricanandpscexclusion.updated) 
geno <- haplodatankd2ccallafricanandpscexclusion.updated[,c(6:19)] 
label <-c ("rs7397310", "rs10772271", "rs1049172", "rs11053781", "rs12819494", "rs2617165", "rs2617167") 
#haplo.cc# 
y.bin <- 1 * (haplodatankd2ccallafricanandpscexclusion.updated$Disease == "1") 
cc.haplodatankd2ccallafricanandpscexclusion <- haplo.cc(y = y.bin, geno = geno, locus.label = label, control = 
haplo.glm.control(haplo.freq.min = 0.02)) 
print(cc.haplodatankd2ccallafricanandpscexclusion, nlines = 25, digits = 2) 
names(cc.haplodatankd2ccallafricanandpscexclusion) 
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4. Proteomic profiling of blood plasma in CC 
4.1 Background 
The inadequate performance of current CC tumour markers has led to investigation 
of alternatives. Biomarkers have been sought in CC tissue, bile and the blood. 
Biomarker discovery in tissue and bile may inform our knowledge of CC 
pathogenesis, and the search for down-stream biomarkers in the plasma or serum. 
However, circulating markers of disease offer the greatest clinical, diagnostic 
potential as the blood may be accessed safely, easily and cheaply. 
4.1.1 Protein biomarkers for CC 
4.1.1.1 Tissue markers 
Studies of CC tissue have mainly utilised immunohistochemistry techniques and 
have focused on the histopathological diagnosis of CC and its differentiation from 
other types of malignancy. Combinations of cytokeratin stains have shown some 
promise in differentiating CC from metastatic cancer,[353] and in predicting poor 
prognosis in CC.[354] Mucin staining also has some discriminatory power, MUC1 being 
expressed by 70%, and MUC5AC by 50%, of CCs but not by HCC.[355] Other markers 
that have shown promise in differentiating CC from other malignancies include the 
glucose transporter GLUT-1 and p63. Those that have been associated with variation 
in prognosis include the adhesion molecules CD24 and CEACAM6, the cell-surface 
transmembrane heparin sulphate proteoglycan syndecan 1, connective tissue growth 
factor, and the cyclin-dependent kinase inhibitor P27Kip1.[356] Transcriptomic studies 
of CC tissue have demonstrated upregulation of many genes. Increased expression 
of survivin, p-cadherin, DNA replication complex GINS protein PSF2 and insulin like 
growth factor-binding proteins 1 & 2 has been shown.[357, 358] 
Proteomic studies have been performed on CC tissue and cells. In one study, 2D-
PAGE and mass spectrometry was used to analyse protein from a CC cell line 
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(HuCCA-1) in comparison with breast cancer and HCC lines. Cytokeratin 7 and 19 
were only expressed by the CC cell line. Calgizzarin, exrin, moesin, radixin and 
hippocalin-like protein 1 were also only expressed in the HuCCA-1 cell line.[359] In 
another study, surface enhanced laser desorption/ionisation time of flight mass 
spectrometry (SELDI-TOF MS) was performed on 22 samples of CC and adjacent 
normal duct tissue. With this technique, mass spectra (a plot of signal intensity 
against mass-to-charge ratio (m/z)), are produced. Differentiating m/z peaks were 
identified and a panel of three of these offered sensitivity and specificity of 93% and 
92% and a ROC of 0.96. The proteins represented by these peaks were not 
identified.[360]  
4.1.1.2 Bile markers 
Bile is an attractive target for biomarker discovery as all CCs are in intimate contact 
with the biliary tree and bile flow. However, the high lipid, bile salt and inorganic ion 
content of bile make analysis difficult. Collection of bile also requires ERCP, an 
invasive procedure with significant risks. In an early bile study, Mac-2-binding protein 
(Mac-2BP), in combination with CA19-9, offered increased accuracy in diagnosis of 
CC.[361] Biliary fibronectin is elevated in the bile of CC patients, but also in gallstone 
disease and PSC. A pilot study found that biliary levels of insulin-like growth factor 
were highly accurate in discriminating extrahepatic CC from pancreatic cancer and 
benign biliary abnormalities.[163] Proteomic studies have been undertaken on bile 
samples from CC patients. A variety of pre-fractionation strategies have been 
employed, including delipidation and immunoglobulin depletion of the most abundant 
proteins. In the first, one-dimensional sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (1D SDS-PAGE) and liquid chromatography followed by tandem 
mass spectrometry (LC-MS/MS) was performed. Although only one CC sample was 
analysed, the detection of CEACAM1, CA125, Mac-2BP and lipocalin 2 was 
achieved.[361, 362] A similar, more recent study of bile from 3 patients with CC 
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demonstrated over expression of CEACAM6 and MUC1.[363] Recent work from the 
Imperial College London cholangiocarcinoma group, to which I contributed, utilised a 
label-free proteomic approach (GeLC-MS/MS) on bile from patients with CC. We 
demonstrated and then validated increased levels of neutrophil gelatinase-
associated lipocalin (NGAL) in bile from patients will pancreatobiliary malignancy, 
including CC.[364] This is addressed in more detail in Chapter 5. 
4.1.1.3 Circulating markers 
Experimental circulating biomarkers have been evaluated alone and in combination 
with CA19-9.  Other carbohydrate antigens (CA 50, 95, 242, 195, 125) individually or 
in panels, contribute a minimal amount to diagnostic accuracy.[161] Receptor-binding 
cancer antigen on SiSo cells (RCAS1), cytokeratin fragment 19 (CYFRA 21-1) and 
MUC5AC all show more promise, although replicative studies are required.[365-367] 
Interleukin 6 may improve sensitivity in combination with CA19-9, but is also elevated 
in benign biliary disease and HCC, reducing specificity further.[368] The same group 
that performed a SELDI-TOF MS proteomic study of CC tissue compared serum 
from 20 patients with CC with that from 20 patients with benign biliary disease and 25 
healthy volunteers. Four of 31 peaks with m/z lower than 20kDa were differentially 
expressed. The most differentiating peak, of m/z 4462Da, was up regulated in 
CC.[360] The proteins were not identified and only a single type of interactive chip was 
used. The sample size was small and further, independent validation of these 
findings is outstanding. 
4.1.2 Plasma proteomic profiling 
The proteome is the functional protein output of the genome, including any post-
translational modifications. The total protein complement of a specified fluid or sub-
cellular compartment can be considered its proteome.[369] The human proteome is 
considered to be a rich source of potential disease biomarkers. Proteomic profiling of 
plasma has been used to study biomarkers in various malignancies, including CC.[163, 
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356] In common with other types of rare cancer, our limited knowledge of the 
pathogenesis of CC limits systematic investigation of candidate protein markers in 
specific pathways. However, proteomic techniques permit the rapid analysis of large 
sections of the proteome in multiple samples. A range of analytical techniques are 
utilised, but the same overall strategy is applied. Samples are selected to address 
the research question, proteins are separated to focus on a proportion of the 
proteome, results are analysed to identify differentially expressed proteins, an assay 
is developed, the potential biomarker is confirmed in further samples and, finally, 
validatory clinical trials are undertaken.[356] The huge number of proteins in plasma, 
and the massive relative abundance of a few of these, can hamper the resolution of 
proteomic techniques for low abundance proteins. In biomarker discovery, the target 
proteins are likely to be in low abundance and therefore depletion of the most 
abundant proteins (such as albumin) is often attempted first. Frequently, multiple 
protein separation techniques need to be performed serially. 
4.1.2.1 GeLC-MS/MS 
LC-MS/MS combines the physical separation capabilities of liquid chromatography 
with the accuracy of mass spectrometry and has been used widely in proteomic 
research.[370] Despite the excellent peptide separation capability of LC-MS/MS, a 
further, pre-LC, fractionation of the proteome is desirable. Simple 1D SDS-PAGE can 
be used to achieve this in complex protein samples. The strategy of SDS-PAGE 
followed by LC-MS/MS has been termed GeLC-MS/MS. A typical workflow for GeLC-
MS/MS is shown in Figure 4.1. SDS-PAGE first separates proteins according to their 
size-dependent electrophoretic mobility (a function of the length of polypeptide chain 
or the molecular weight). The resulting gels are cut into 20-30 bands, which are 
analysed separately by LC-MS/MS. After trypsin digestion of the fractionated protein 
samples, the resulting peptides are separated by reverse phase liquid 
chromatography before undergoing tandem mass spectrometry (Illustrated in Figures 
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4.2 and 4.3). Once the peptide MS/MS spectra are obtained, protein identification is 
achieved by searching for each peptide against a reference database. To permit 
quantitative results, this technique sometimes utilises heavy isotope labelling of the 
protein samples before analysis. However, label-free approaches, avoiding this need 
for expensive heavy isotopes, have been developed. Label free GeLC-MS/MS has 
been used successfully in the detection and identification of new biomarkers in other 
diseases.[370, 371] The advantages of GeLC-MS/MS include the contemporaneous 
identification and quantification of the proteins detected, as well as relatively high 
sensitivity for high molecular weight proteins. However, it is a relatively labour 
intensive technique, with manual production of gel fragments required for tryptic 
digestion and LC-MS/MS. Although automated, LC-MS/MS itself, and the analysis of 
the data generated, is a time consuming process.  
4.1.2.2 Surface-enhanced laser desorption/ionization time-of-flight mass 
spectrometry (SELDI-TOF MS) 
In this technique, the protein mixture is applied directly to a chip, the surface of which 
is modified with a chemical functionality. Some proteins in the sample bind to the 
surface, while the others are removed by washing. This equates to a highly effective 
initial fractionation step, as those hugely abundant proteins that are not bound are 
almost entirely excluded from subsequent analytical steps. The subset of proteins 
that bind to the specific surface are easier to analyse and resolve in the spectra 
generated. Common chip surfaces include CM10 (weak-positive ion exchange), H50 
(hydrophobic surface, similar to C6-C12 reverse phase chromatography), IMAC30 
(metal-binding surface), and Q10 (strong anion exchanger). The range of different 
chip surface properties is illustrated in Figure 4.4. The commonest surfaces used to 
most success in biomarker discovery studies are CM10 and H50, the biochemical 
function of which is illustrated in Figure 4.5. An energy absorbing matrix (EAM) 
solution is applied to the chip surface, which releases the bound protein component 
and co-crystallizes with it as it dries. Proteins retained within the matrix on the SELDI 
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chip surface are analysed using time-of-flight mass spectrometry. A laser desorbs 
and ionizes the proteins from the crystals of the sample/matrix mixture. The ions are 
accelerated through an electric potential and fly down a field-free flight tube. A 
detector measures ions as they reach the end of the tube (Figure 4.6). The mass-to-
charge ratio of each ion can be determined from i) the kinetic energy given to ions by 
the electric field, ii) the length of the tube and iii) the time taken to travel the length of 
the tube. SELDI-TOF MS has been used to successfully identify malignant protein 
patterns in plasma from ovarian, hepatocellular, pancreatic, prostate and breast 
carcinomas.[371, 372] SELDI-TOF MS does not require initial time-consuming manual 
separation stages. It is relatively sensitive in the low molecular weight range and the 
instrument itself processes samples quickly and is highly automated. There is no 
significant obstacle to analysing large numbers of samples on this system. SELDI-
TOF MS does not identify proteins from the peaks generated, and is less sensitive 
for higher mass peptides.  
4.2 Hypothesis and study aim  
4.2.1 Hypothesis 
Plasma proteomic profiles can differentiate patients with cholangiocarcinoma from 
those with benign biliary disease, and from healthy control subjects. 
4.2.2 Aims 
1) To compare the plasma proteomic profile of patients with CC to that of patients 
with benign disease and healthy controls utilising: 
i) GeLC-MS/MS to compare plasma protein profiles of patients with CC to those 
with gallstone disease of the bile duct 
ii) SELDI-TOF MS to compare plasma protein profiles of patients with CC to 
those of PSC patients and those of healthy controls 
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2) To identify specific protein peaks for further investigation as potential clinical 
biomarkers of CC 
4.3 Materials and Methods 
4.3.1 Ethics 
The study protocol conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki. Approval from the local Research Ethics Committee and NHS R&D 
Department was sought and obtained for these studies (Ref 09/H0712/82). All 
participants provided written, informed consent. 
4.3.2 Subjects 
4.3.2.1 CC patients 
I recruited subjects with CC from the gastroenterology clinics and ERCP lists at 
Imperial College London Healthcare NHS Trust (ICH) and University College 
Hospitals NHS Trust (UCH). CC patients were considered for recruitment if their 
diagnosis was secured on the basis of a) pre- or post-operative histology or b) 
multidisciplinary team consensus on the basis of ≥2 imaging modalities, clinical 
course and plasma markers. 
4.3.2.2 PSC and gallstone disease patients 
I recruited PSC and gallstone disease patients in a similar fashion, from specialist 
hepatology clinics at ICH and UCH. The diagnosis of gallstone disease was made on 
the basis of clinical course, imaging findings and liver function tests. The diagnosis of 
PSC was determined on the basis of clinical course, prior imaging, consistent 
autoantibody titres and, where available, biopsy results. Patients with advanced 
cirrhosis (Child-Pugh B or C, according to standard criteria, Table 4.1) were 
excluded, as were patients who had undergone previous liver transplant. Patients 
currently being investigated for suspected cholangiocarcinoma were excluded. 
However, PSC patients with dominant strictures that had been fully investigated and 
characterised were included. To reach an adequate cohort size, I approached 
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collaborators at the Norwegian PSC Research Center (NoPSC), Rikshospitalet, Oslo, 
Norway. They were able to provide plasma samples from well-characterised PSC 
patients, with appropriate on-going consent in place for use in studies of liver 
disease.  
4.3.2.3 Healthy controls 
Healthy volunteers were recruited at ICH and UCH. After completing a short, 
confidential health questionnaire, individuals with no current inflammatory or 
malignant disease, or liver disease of any sort, were recruited. 
4.3.3 Sample collection and processing 
The plasma proteome is vulnerable to modification during sample collection and pre-
processing. For these proteomic studies, a total of 8mL of blood was collected into 
EDTA tubes, placed onto ice immediately and centrifuged within one hour. 200μL 
aliquots were placed into Eppendorf tubes (Eppendorph, Histon, UK) and frozen at -
80oC. Where samples were collected prospectively, I used my sample collection 
standard operating procedure (SOP) (Appendix 1).  
I collected demographic data, including age, sex, ethnicity, and short medical history 
onto my case record form (CRF, Appendix 2). Where available, the most recent 
routine clinical laboratory indices were also documented, including white cell count, 
C-reactive protein (CRP), CA19-9, alanine transferase (ALT), albumin, alkaline 
phosphatase (ALP), bilirubin, urea and creatinine. As healthy control volunteers were 
not undergoing routine laboratory blood testing, these parameters could not be 
collected for those subjects. Where available for CC cases, I collated imaging 
information to determine the anatomical location of the CC. 
Plasma samples from the NoPSC archive had been collected and processed 
according to a strict protocol that did not diverge from my SOP significantly. 
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4.3.4 Method, GeLC-MS/MS study 
All reagents used were from Sigma-Aldrich (Gillingham, Dorset, UK), unless stated 
otherwise.  
4.3.4.1 Subjects included  
Plasma samples from eight CC patients and seven gallstone disease patients were 
included. All 15 of these samples were collected at ICH. 
4.3.4.2 Protein depletion 
I first carried out depletion of the high abundance plasma proteins in each sample, 
using a Plasma IgY partitioning column (Mixed Seppro, Genway Biotech, US). This 
process depletes the 12 most abundant plasma proteins, including fibrinogen, IgG, 
transferrin and albumin. The workflow undertaken is detailed here and illustrated in 
Figure 4.7. 
i) 490 µL of dilution buffer (100mM ammonium formate, pH 7.4) and 10 µL of 
plasma were applied to the Ig-Y spin column 
ii) The column was incubated on a rotor for 15 min at 4°C 
iii) The column was centrifuged at 400g for 30s and the eluate collected and 
retained  
iv) Steps (i) to (iii) were repeated with a further 500µl of dilution buffer  
v) 500µl of stripping buffer (1M glycine, pH 2.5) was applied to the column and 
incubated with mixing on a rotor for 3 min 
vi) The column was centrifuged at 400g for 30s and this eluate (containing the 
unwanted, high abundance 12 proteins) was discarded 
vii) The IgY column was immediately neutralised with 600µL of 1x neutralizing 
buffer (1M tris-HCl, pH 8.0)  
viii) Steps i-vii were repeated for each sample  
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ix) The retained eluate from steps iii and iv was fully dehydrated in a vacuum 
centrifuge and frozen at -20oC pending SDS-PAGE 
4.3.4.3 1D SDS-PAGE 
1D SDS-PAGE was the second protein separation technique that I applied to each 
plasma sample.  
4.3.4.3.1 1D SDS PAGE methodology 
i) Each of the depleted, dehydrated protein samples were rehydrated in 13μL of 
H2O 
ii) Sample proteins were then denatured by addition of 5μL of 4x lithium dodecyl 
sulphate (LDS) buffer (Invitrogen, Paisley, UK) 
iii) The samples were then reduced by adding 2μL of 0.5M DTT and heating at 
100oC for 2 min 
iv) Samples were cooled and further diluted with 8μL H20 and 52μL of 4x LDS 
buffer 
v) Samples were then alkylated with 5μL of 1M iodoacetamide (IAA) in the dark 
for 30 min, resulting in a total volume of 85μL 
vi) 20µl of each sample was then applied to Novex 10% bis-tris gels (Invitrogen) 
in 2-(N-morpholino)ethanesulfonic acid (MES) buffer with 500μL NuPAGE 
antioxidant (Invitrogen) in the inner chamber 
vii) PageRuler pre-stained protein ladder marker mix (Fermentas, St. Leon-Rot, 
Germany) was placed in lanes 1 & 10 of each gel, plasma samples in lanes 
2-9 
viii) Gels were subject to electrophoresis at 200V for 30min  
ix) Gels were stained with Coomassie brilliant blue (CBB) (InstantBlue, Novexin, 
UK) overnight 
Chapter 4 – Plasma proteomics 
 143 
 
 
4.3.4.3.2 Confirmation of protein depletion 
To confirm efficacity of protein depletion, I initially performed 1D SDS PAGE on 
samples from 4 subjects: benign samples 1 & 2 and CC samples 1 & 2. A pre-
depletion ‘raw’ plasma sample and a post-depletion sample from each of these 4 
subjects were included on a single gel. The depleted, dehydrated sample was 
reconstituted and prepared to a total volume of 85μL using the steps detailed in 
4.3.4.3.1, above. Samples of equivalent volume and concentration of ‘raw’ plasma 
were achieved by adding only 3μL of H2O to 10μL of raw plasma at step (i). 
Corresponding raw and depleted samples from each of the 4 subjects were run on a 
gel in lanes 2-9, according to the parameters in 4.3.4.3.1, above. 
4.3.4.3.3 Preparation of gels for LC-MS/MS study 
Once protein depletion had been confirmed, I prepared two gels with the 8 CC 
samples and 7 benign samples. 
i) Samples were prepared as per 4.3.4.3.1, above, and were applied to the two 
gels according to the template shown in Figure 4.8. The gels were then run 
according to the parameters outlined in 4.3.4.3.1 
ii) After completion of 1D SDS-PAGE, all gel lanes were sliced into equivalent 
regions, illustrated in Figure 4.9. Gel regions were defined by the protein 
standard included in lanes 1 & 10, with each gel slice having the same mass  
iii) Gel slices were kept in dry conditions in a multiwell plate overnight  
iv) Slices were destained with 1mL 100mM ammonium bicarbonate in 50% ACN 
overnight 
v) Each slice was washed with 1mL of water and dehydrated in 1mL ACN 
overnight 
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vi) Gel slices were transferred to low-binding Eppendorf tubes and kept chilled 
pending tryptic digestion 
vii) The proteins in each slice were digested in 0.3mL 50mM ammonium 
bicarbonate containing 1ng/µl trypsin at 37oC overnight  
viii) After digestion, trypic peptides were extracted with 0.3mL 0.1% formic acid in 
2% ACN 
ix) 400µl of the supernatant was dried and then dissolved in 30µl of water 
containing 0.1% TFA 
4.3.4.4 Liquid chromatography MS/MS 
Samples extracted from equivalent gels regions from all 15 samples were batched 
for LC-MS/MS and each batch required circa 20h to process through the LC-MS/MS 
system. An Agilent LC series system was used (Agilent Technologies UK Ltd, 
Berkshire, UK). 8µL of each peptide solution was applied to ProteCol traps (SGE Ltd, 
Milton Keynes, UK) and separated by nano-LC using 75um ID x 15 cm C18 PepMap 
columns (Dionex, Leeds, UK) at a flow rate of 250nL/min over a linear gradient of 2–
45% ACN (LC-MS grade, Sigma) containing 0.1% formic acid (Sigma) for 30 min. 
MS analyses of eluted peptides was performed on-line using an LTQ linear ion trap 
MS (Thermo) connected to the nano-LC effluent through an electrospray interface. 
Dynamic activation time was set at 30s with scans every 2µs. Data-dependent 
MS/MS spectra were obtained. 
4.3.4.5 Protein identification 
Progenesis software (Nonlinear Dynamics Ltd, Newcastle, UK) was used to match 
LC and m/z data between equivalent gels regions from each subject. SEQUEST 
software was used to match peaks from each tandem mass spectrum to the NCBI 
human RefSeq peptide database. Peptides with acceptable tandem mass spectra 
quality were included in further analysis (Xcorr values >1.5 for single charged, >2.0 
for double charged and >2.5 for triple charged peptides). Proteins that were identified 
Chapter 4 – Plasma proteomics 
 145 
by 2 unique peptides were included in further analysis. Where proteins were 
identified in more than one gel region, the region in which the most unique 
associated peptides were identified was used. Finally, Progenesis software 
(Nonlinear Dynamics) was used to compare normalised intensities of component 
peptide ions of interest and thereby quantify the protein concentration in each gel 
region.  
4.3.4.6 Statistical analysis, LC-MS/MS study 
Statistical analyses were performed using Excel (Microsoft), Prism Version 5 
(Graphpad Software, San Diego, USA) and SYSTAT (Chicago, US). In calculating a 
normalised abundance for each protein in each gel region, Progenesis software log 
transforms the abundance of all component peptides before summing. Student’s t-
test (on arcsin transformed data) and linear regression analysis were used to identify 
differentially expressed proteins. Proteins were considered to be differentially 
expressed when abundance was ≥1.5 fold different between groups and Student’s t-
test p-value was <0.05. ROC-AUC analysis was then performed on any protein that 
was differentially expressed between the two groups. Finally, a general discriminant 
function analysis was undertaken to assess the discriminatory utility of combinations 
of the putative protein markers. 
4.3.4.7 Further investigation of identified proteins 
Any candidate proteins identified were investigated further by searching in the 
Universal Protein Resource Unit Knowledge Base (UnitProtKB) database (v61, 
European Bioinformatics Institute, Hinxton, UK) and the PubMed (National Center for 
Biotechnology Information, U.S. National Library of Medicine, Bethesda, USA) 
protein database.  
4.3.5 Method, SELDI-TOF MS studies 
All reagents were sourced from Sigma-Aldrich, unless stated otherwise. This study 
comprised three phases: 
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i. Preliminary optimisation studies – identifying the conditions under which the 
best resolution and magnitude of protein m/z peaks could be obtained 
ii. Discovery study – performing SELDI-TOF MS under a shortlist of chip 
conditions to identify any discriminatory m/z peaks of interest and determine 
the best conditions under which to conduct a validation study 
iii. Validation study – performing SELDI-TOF MS on further, larger cohorts of 
CC, PSC and healthy controls, but under a reduced number of conditions, to 
validate the m/z peak findings from the discovery SELDI-TOF MS study 
4.3.5.1 Subjects included 
In total, plasma samples were included from 99 CC patients, 64 PSC patients and 
107 healthy controls. In the preliminary optimisation studies, a single healthy control 
sample, ‘N’, was used. In the initial discovery SELDI-TOF MS experiment 18 CC, 10 
PSC and 18 healthy control samples were used. In the final, validation, experiment 
81 CC, 54 PSC and 90 healthy control samples were used. 
4.3.5.2 Selection of chip surface 
As discussed in Section 4.1, a wide range of SELDI chip surface properties are 
available. However, the chips are single use and are expensive to purchase. Given 
my budget and the number of samples I intended to investigate, it was necessary to 
narrow the number of different surfaces to two. Previous work by our group, and 
work published by others, has found that H50 and CM10 chips have yielded the best 
number, and resolution, of peaks when investigating crude plasma with a hypothesis 
free, non-biased approach. I therefore elected to use CM10 and H50 chips in my 
experiments. 
4.3.5.3 Preparation of samples 
Each plasma sample was denatured and diluted using the following protocol: 
i) 10μL of 500mM DTT was added to 1mL of 9M urea/2% CHAPS to make 
a 9M urea/2%CHAPS/5mM DDT solution 
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ii) 20μL of each plasma sample was added to 180μL of the solution from 
step (i) to achieve a 1:10 dilution 
iii) Samples were left at room temperature for 30 min to denature  
4.3.5.4 Preparation of buffers and binding solutions 
A range of buffers and binding solutions was required for initial condition 
optimisation, my discovery SELDI-TOF MS study and validation SELDI-TOF MS 
study. I made up adequate volumes of each buffer and binding solution to complete 
all the anticipated experiments, with a margin for error. Based on previous successful 
work within my group, and that reported by other groups, I prepared the following 
buffers and binding solutions. 
4.3.5.4.1 pH buffers for CM10 chip conditioning 
All buffers were made up to 100mM. I prepared and experimented with the following 
buffer solutions on CM10 chips: 
i. pH3: 0.1M glycine and hydrochloric acid  
ii. pH4:   0.1M sodium acetate solution and 100% acetic acid  
0.1M ammonium acetate and 100% acetic acid  
iii. pH6:  sodium phosphate buffer 
0.1M citric acid and sodium hydroxide 
iv. pH7: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
v. pH8:  Tris (hydroxylmethyl) aminomethane and hydrochloric acid  
4.3.5.4.2 Binding solutions for H50 chip conditioning 
I prepared and experimented with the following acetonitrile (ACN) binding solutions 
on H50 chips: 
i. 10% ACN with 0.1% TFA 
ii. 20% ACN with 0.1% TFA 
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iii. 20% ACN with 0.1% TFA plus 100mM NaCl 
iv. 50% ACN with 0.1% TFA  
4.3.5.5 Preparation of energy absorbing matrices (EAMs) 
4.3.5.5.1 Sinapinic acid (SPA) 
A saturated solution of SPA in 50% acetonitrile, 49.50% HPLC grade H2O and 0.50% 
trifluoroacetic acid (TFA) was made up. The saturated solution was centrifuged 
briefly, to remove any non-dissolved SPA particles, and the supernatant extracted for 
use. 
4.3.5.5.2 Alpha-cyano-4-hydroxycinnamic acid (CHCA) 
A saturated solution of CHCA was made up in 50% acetonitrile, 49.75% HPLC grade 
H2O and 0.25% TFA. The saturated solution was centrifuged briefly, to remove any 
non-dissolved CHCA particles, and the supernatant extracted for use.  
4.3.5.6 Application of samples to SELDI chips 
Each SELDI chip array can accommodate up to 12 chips (1-12) with 8 spots (A-H) 
per chip giving a total of 96 spots per array.  
4.3.5.6.1 CM10 
i) An appropriate number of CM10 chips were assembled within the SELDI 
bioprocessor, forming a well over each spot 
ii) 200μL of appropriate buffer was applied to each well/spot and left on the 
shaker for 5 min 
iii) The buffer was discarded from each well 
iv) Steps (ii)-(iii) were repeated, to complete conditioning of spots 
v) A further 135μL of buffer was applied to each well, with addition of 15μL 
of sample, prepared in 4.3.4.5.1, above 
vi) The samples were covered with an adhesive acetate sheet and incubated 
on the shaker at room temperature for 60 min 
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vii) The buffer/sample mix was discarded from each well 
viii) 200μL of buffer was applied to each well, left on the shaker for 5 min, 
before discarding. Repeated 2 more times 
ix) 200μL deionised water was applied to each well, left on the shaker for 5 
min, before discarding. Repeated 1 more time 
x) The bioprocessor was disassembled and the spots on the array allowed 
to air-dry for 10 min 
xi) 0.5μL of saturated EAM (SPA or CHCA) was applied to each spot and 
allowed to dry. Repeated 1 more time 
xii) The samples were then processed through the SELDI instrument 
4.3.5.6.2 H50 chips 
i) An appropriate number of H50 chips were assembled within the SELDI 
bioprocessor, forming a well over each spot 
ii) To pre-condition the chips, 100µL of 50% acetonitrile (ACN) solution was 
applied to each spot and left for 5 min. This step was repeated once 
iii) 200µL of appropriate ACN binding solution was applied to each well/spot 
and left on the shaker for 5 min 
iv) The buffer was discarded from each well 
v) Steps (iii)-(iv) were repeated, to complete conditioning of spots 
vi) A further 135μL of ACN binding solution was applied to each well, with 
addition of 15μL of sample, as prepared in 4.3.4.5.1, above 
vii) The samples were covered with an adhesive acetate sheet and incubated 
on the shaker at room temperature for 60mins 
viii) The buffer/sample mix was discarded from each well 
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ix) 200μL of ACN binding solution was applied to each well and left on the 
shaker for 5 min, before discarding. Repeated 2 more times 
x) 200μL deionised water was applied to each well, left on the shaker for 5 
min, before discarding. Repeated 1 more time 
xi) The bioprocessor was disassembled and the spots on the array allowed 
to air-dry for 10 min 
xii) 0.5μL of saturated EAM (SPA or CHCA) was applied to each spot and 
allowed to dry. Repeated 1 more time 
xiii) The samples were then processed through the SELDI instrument 
4.3.5.7 Protein and peptide standard 
I made up a protein and peptide standard solution that was included on two spots 
within each array of chips, to permit calibration of the SELDI-TOF MS instrument. 
The constituent proteins and peptides of the protein/peptide standard are listed in 
Table 4.2. In addition, a standard healthy control sample (‘N’) was applied to 2 spots 
on each array to confirm inter-assay consistency.  
4.3.5.8 SELDI-TOF MS 
All chips were analysed by SELDI-TOF MS using a Protein Biology System IIc 
Reader (Ciphergen Biosystems Inc., Freemont, CA, USA). Chips were processed 
through the SELDI-TOF MS device under the same settings (Table 4.3).  
4.3.5.9 Preliminary study to select optimum chip conditions  
It was not considered necessary, or good practice, to run all samples under all 
possible conditions. Initially, I investigated a single, standard sample (‘N’) under 
numerous conditions. I selected these initial chip/condition combinations based upon 
previous experience of successful SELDI-TOF MS experiments on plasma in my 
group. As discussed in Section 4.1, above, the chemical and physical conditions at 
the chip surface can vary the milieu of bound protein dramatically. The selection of 
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conditions under which the samples are applied to the SELDI chip is therefore 
crucial, as this fundamentally affects the results produced. The CM10 chip surface 
includes negatively charged carboxylate chemistry and therefore acts as a weak 
cationic exchanger and binds proteins that are positively charged at the prevailing pH 
(Figure 4.5A). To modulate the sensitivity and range of proteins binding, the pH of 
the buffer may can be increased or decreased. With decreased pH, a greater number 
of proteins within the sample become positively charged, increasing protein binding. 
With increased pH, a greater number of proteins become negatively charged, 
resulting in less binding (and therefore greater specificity). In the case of H50, the 
concentration of ACN applied can be modulated. Only the most hydrophobic proteins 
will be retained with wash buffers containing a high organic solvent and so increasing 
the concentration of organic solvent in the binding solution will increase the 
selectivity of the surface (Figure 4.5B). The SELDI chip manufacturer also suggests 
that to increase the salt concentration, and thereby the hydrophobic interactions on 
H50 chips, additional sodium chloride can be included in the binding solution. Finally, 
it is possible to modify the energy-absorbing matrix (EAM) that co-crystallises with 
the proteins applied to each spot. Varying the EAM used on the SELDI chip modifies 
the spectra achieved. Generally, CHCA is considered best for small proteins and 
peptides (1-30kDa). SPA is considered to have broader utility and permits detection 
of larger proteins as well as many peptides (10-150kDa). 
4.3.5.9.1 Selection of buffer solution and EAM for CM10 chips  
The standard control sample ‘N’ was applied to multiple spots on CM10 chips 
according to the protocol detailed in 4.3.5.6.1. The seven buffers listed in 4.3.5.4.1 
were each used in the preparation of four spots, two of which were treated with SPA 
and two with CHCA as the EAM (i.e. 7x4=28 spots). The chip, buffer and EAM 
combinations trialled are detailed in Table 4.7. Chips were subjected to SELDI-TOF 
MS as per the protocols and settings detailed in 4.3.5.8. Initial data management and 
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analysis was with the Biomarker Wizard function that is integrated into the SELDI-
TOF MS control software (Ciphergen). The Biomarker Wizard generates the spectra, 
identifies and matches peaks between spectra and assigns intensity values to each 
peak.  Spectra were inspected manually for number of peaks, amplitude of peaks, 
SNR and resolution of peaks. 
4.3.5.9.2 Selection of binding solution and EAM for H50 chips 
Standard sample ‘N’ was applied to multiple spots on H50 chips according to the 
protocols detailed in 4.3.5.6.2. The four different binding solutions detailed in 
4.3.5.4.2 were each used in the preparation of four spots, two of which were treated 
with SPA and two with CHCA as the EAM (i.e. 4x4=16 spots). The chip, binding 
solution and EAM combinations trialled are detailed in Table 4.7. Chips were 
subjected to SELDI-TOF MS as per the protocols and settings detailed in 4.3.5.8, 
above. The spectra generated were inspected manually and analysed within the 
Biomarker Wizard software for number of peaks, amplitude of peaks, SNR and 
resolution of peaks. 
4.3.5.10 Discovery SELDI-TOF MS study  
4.3.5.10.1 Subjects included, discovery study 
Three cohorts were analysed and compared. Plasma from 18 CC subjects, 10 PSC 
subjects and 18 healthy control subjects were included in the discovery study. 
4.3.5.10.2 Chips and conditions used, discovery study 
The selection of the chip conditions used was informed by the results of the 
preliminary studies, 4.3.5.9, above. The following 4 chip and condition combinations 
were used: 
i. CM10 chip, pH 4 sodium acetate buffer, SPA EAM 
ii. CM10 chip, pH 6 sodium phosphate buffer, SPA EAM 
iii. CM10 chip, pH8 Tris buffer, SPA EAM 
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iv. H50 chip, 10% ACN binding solution, CHCA EAM 
4.3.5.10.3 SELDI-TOF MS, discovery study 
All samples were prepared from the raw plasma aliquots in one batch, according to 
the protocol in 4.3.5.3. Samples, the protein standard solution and the ‘N’ standard 
plasma samples were all applied to two spots each on a 96 spot chip array, 
according to the protocol in 4.3.5.6. The various combinations of chip and condition 
used are detailed in 4.3.10.2. SELDI-TOF MS was then undertaken on each sample, 
using the protocol and settings in 4.3.5.8. 
4.3.5.10.4 Statistical analyses, discovery study 
The Biomarker Wizard software was used to auto-detect all peaks within the 
specified m/z range and with a signal to noise ratio (SNR) of 3. Peaks were aligned 
within 0.3% of mass error. Data were further manipulated in MS Excel and statistical 
analyses were undertaken in STATISTICA (StatSoft Inc., Tulsa, USA). Peak 
intensities at each m/z point were averaged between the paired spots for each 
sample. Where any spot failed to generate a spectrum, the spectrum from its 
duplicate was used in isolation. Where neither paired spots generated spectra, the 
subject was excluded from further analysis. After testing whether peak intensities 
were normally distributed, values were subjected to either Mann-Whitney U test (not 
normally distributed) or Student’s t-test (normally distributed) to compare groups. 
Initially, CC subjects were compared to PSC subjects; CC subjects were then 
compared to healthy control subjects. P-values of <0.05 were considered significant. 
Those peaks identified as significantly different were examined manually in the 
Biomarker Wizard (Ciphergen). Those peaks that were found to be misaligned, those 
shouldered on a dominant adjacent peak and those that had been misclassified as a 
peak rather than noise were manually excluded from further analysis. The two 
combinations of chip and conditions that produced the most discriminatory peaks in 
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this discovery SELDI-TOF MS study were determined. These were then used in the 
subsequent, validation SELDI-TOF MS study. 
4.3.5.11 Validation study, SELDI-TOF MS  
4.3.5.11.1 Subjects included, validation study 
Three cohorts were investigated, to validate the peaks of interest identified in the 
preceding discovery study. Samples from 81 CC subjects, 54 PSC subjects and 90 
healthy control samples were subjected to SELDI-TOF MS analysis.  
In parallel, I subjected fresh samples from the original discovery cohorts (18 CC, 10 
PSC, 17 healthy controls) to repeat SELDI-TOF MS analysis. This was to confirm 
reproducibility of the findings.  
4.3.5.11.2 Chip conditions used, validation study 
The selection of chip conditions for the validation study was informed by the results 
of the discovery study. Two chip/condition combinations were selected: 
i. CM10 chips, Tris buffer - pH 8, SPA as EAM 
ii. H50 chips, ACN 10% solution binding solution, CHCA as EAM 
4.3.5.11.3 SELDI-TOF MS 
All samples were freshly sourced and processed from the primary raw plasma 
aliquots according to the protocol in 4.3.5.3. Samples, the protein standard solution 
and the ‘N’ standard plasma samples were all applied to two spots each on a 96 spot 
chip array, according to the protocol in 4.3.5.6. The two combinations of chip and 
condition used are detailed in 4.3.5.11.2, above. Samples from all cohorts were 
applied to randomly allocated spots across all arrays. The two spots used for each 
subject were always applied to separate chips. SELDI-TOF MS was then undertaken 
on each sample, using the protocol and settings in 4.3.5.8. 
4.3.5.11.4 Statistical analyses, validation study 
4.3.5.11.4.1 Initial analysis, validation samples only 
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Initial analysis, using the Biomarker Wizard, was as in section 4.3.5.10.4. M/z peaks 
corresponding to the seven identified as of interest in the discovery study were 
matched according to m/z (within 0.15% of each other) and peak characteristics. 
Once the seven peaks had been identified, the groups were compared. P-values of 
<0.05 were considered significant. Initially, the new validation cohorts were studied, 
seeking to validate the findings from the original discovery study. CC subjects were 
first compared to PSC subjects, CC subjects were then compared to healthy controls 
and PSC subjects were then compared to healthy controls. Where possible, 
subgroup analyses of subjects recruited at ICH and UCH were undertaken, to 
investigate reproducibility of the findings on both sites. Peak intensity values were 
compared between the UK PSC cohort and Norwegian PSC cohort, to identify any 
geographical variation. 
4.3.5.11.4.2 Repeat analysis of samples from discovery study 
Subsequently, the new dataset on the original discovery cohort was analysed, 
seeking to demonstrate reproducibility of the original significant peaks in the same 
subjects; CC subjects were first compared to PSC subjects; CC subjects were then 
compared to healthy control subjects. 
4.3.5.11.4.3 Combination of cohorts 
Only those peaks identified in the discovery study and confirmed as significantly 
different in the validation study were subject to further analysis. To maximise cohort 
size, this was performed on the pooled cohorts, i.e. 99 CC samples, 64 PSC and 107 
healthy controls. Only data from the validation study and the parallel repeat SELDI-
TOF MS analysis of the discovery samples were used. Demographic data on the 
combined cohort were collated and descriptive statistics were generated. Sex, age 
and ethnicity were compared between groups using χ2 testing or Kruskal-Wallace 
ANOVA as appropriate. 
4.3.5.11.4.4 Anatomical subtype of CC 
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The CC cohort was further characterised by collating details of anatomical subtype of 
the primary malignancy (i.e. intrahepatic, hilar or distal CC). Peak intensities were 
compared between these subtypes using Kruskal-Wallace ANOVA (GraphPad 
Prism). 
4.3.5.11.4.5 Routine lab parameters 
Where available, routine laboratory test results of CC and PSC patients were collated 
for the combined cohort. These parameters were not available for healthy controls. 
Descriptive statistics on each parameter were generated for each cohort. CC and 
PSC cohorts were compared using Mann-Whitney U test (GraphPad Prism). 
4.3.5.11.4.6 ROC-AUC analysis 
ROC-AUC analysis was performed for each of the validated peaks (GraphPad 
Prism). Diagnostic utility in discriminating CC from PSC, and then CC from healthy 
controls, was tested.  
4.3.5.11.4.7 Correlation matrix 
A correlation matrix of all validated peaks was generated, to identify any potential 
correlation between each of them (STATISTICA).  
4.3.5.11.4.8 Correlation of discriminatory peaks with routine lab parameters 
Where they were known, routine laboratory parameters from all subjects were 
correlated with the intensity of the seven peaks of interest. Pearson’s correlation was 
used (STATISTICA). 
4.3.5.11.4.9 Multiple linear regression (general discriminant analysis) 
Multiple linear regression (MLR) was used to perform a general discriminant analysis 
to identify the peaks generated under both chip conditions that maximally 
discriminated the study groups with f to include set at 3.5, and f to exclude to 3.4 and 
maximum steps to 100 (STATISTICA). CC and PSC groups were analysed, then CC 
and healthy controls. ROC-AUC analysis was then used to assess the performance 
of these models. 
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4.3.5.11.4.10 Combination of peaks with CA19-9 
MLR was then used to determine whether the addition of CA199 would enhance the 
model or displace any of the previously included peaks. Again, ROC-AUC analysis 
was performed to assess performance. 
4.3.5.11.4.11 Potential confounding factors analysis 
MLR was repeated, offering only the seven peaks for inclusion but sequentially 
weighting for each of the following potential confounding factors: age, sex, ethnicity 
and site of collection. The following laboratory indices were also corrected for: ALT, 
albumin, CRP and CA19-9. Again, ROC-AUC analysis was performed to assess 
performance. 
4.3.5.11.4.12 Post hoc analysis of PSC and CC group 
Although none of the 99 CC patients in the discovery and validation cohorts had PSC 
and CC, I subjected samples from six such subjects to SELDI-TOF MS in parallel to 
the validation cohort. Mann-Whitney U test was used to simply analyse any peaks 
that showed utility in discriminating CC from PSC in the larger study, comparing 
these six subjects with the 64 PSC subjects. 
4.3.5.11.5 Database search for m/z peak matches 
All m/z peaks confirmed to be of interest in the validation study were researched 
further. The online TagIdent tool (ExPASy, Swiss Institute of Bioinformatics, Geneva 
Switzerland) was used to search the UniProtKB database v61 (NCBI). The search 
was restricted by species of origin homo sapiens. All previously registered proteins 
within 0.1% of the m/z of the validated peaks of interest were sought. Each of these 
proteins was then explored manually in the UniProtKB database. 
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4.4 Results  
4.4.1 Results of GeLC-MS/MS study 
4.4.1.1 Demographics of subjects 
Eight patients were included in the CC group, five were male (63%) and the median 
age was 60y. Four members of the CC cohort were Caucasian (50%), with four of 
other ethnicity. Seven patients were included in the control group, two were male 
(39%) and the median age was 55y. All benign control subjects were Caucasian. All 
benign control cases had uncomplicated gallstone disease. There was no significant 
difference in age, sex or ethnicity between the two groups. Further details are 
included in Tables 4.4 and 4.5.  
4.4.1.2 Routine laboratory markers 
Routine laboratory indices were collected for each patient. Individual and median 
values are detailed in Table 4.6. Tumour marker values were generally not available 
for gall stone disease cases. No blood test results were available for one of the 
benign control cases. There were no significant differences between CC and benign 
control groups in any of the laboratory indices collected (p-values 0.3-0.91).  
4.4.1.3 Confirmation of depletion 
The gel prepared and run to confirm efficacity of the IgY column protein depletion 
step (Figure 4.10) demonstrated clearly that the most abundant proteins (e.g. 
albumin, arrowed) was partially depleted from the sample. However, it was also clear 
that a substantial fraction of such proteins remained after the depletion step. 
4.4.1.4 Proteins identified and differentially expressed 
128 different non-redundant proteins were identified from the peptides detected in 
the samples analysed. These are listed in Table 4.8. 
Student’s t-test of the logarithmically transformed normalised abundances identified 
six proteins that were differentially expressed between CC and the gallstone disease 
groups. These are highlighted in bold text in Table 4.8 and summarised in Table 4.9. 
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One of the six was found to be in reduced abundance in CC, five were at increased 
abundance. ROC-AUC analysis demonstrated good diagnostic performance in all six 
of these individual proteins, with ROC-AUCs of between 0.87 and 0.98 (Table 4.10). 
After three steps, multiple linear regression included two of these proteins in the 
optimum model generated. No benefit was achieved by including the other putative 
protein markers. This model achieved a ROC-AUC of 0.998 (95% CI 0.99-1.0). 
4.4.1.5 Further investigation of identified proteins 
Each of the six candidate proteins was investigated further by searching in the 
UniProtKB database (v61) and PubMed search. Where known, functions and 
disease associations of the identified proteins are summarised in Table 4.11. 
4.4.2 Results of SELDI-TOF MS studies 
4.4.2.1 Results of preliminary optimisation studies 
This investigation of chip, buffer and EAM combinations resulted in a short list of 4 
chip/condition combinations for the subsequent discovery SELDI-TOF MS 
experiment.  
4.4.2.1.1 Selection of CM10 chip buffer and EAM 
Several buffers produced no or attenuated spectra and were therefore not utilised in 
subsequent experiments. Glycine and citric acid based buffers (at pH3 and pH6) 
produced no spectral peaks al all. HEPES (pH7) and ammonium acetate (pH 4) 
buffers produced some spectral signal, but peaks were markedly less abundant and 
intense than the three best performing buffers. Three buffers, sodium acetate (pH 4), 
sodium phosphate (pH 6) and Tris (pH8) generated the best spectra (Figure 4.11). At 
low to mid mass range, SPA produced the highest resolution of peaks (Figure 
4.11A). High mass range detection was non-existent with CHCA (spectra not 
presented). With SPA, multiple peaks were detectable in the high mass range at all 
three pH conditions (illustrative spectra can be found in Figure 4.11B). Therefore, the 
Chapter 4 – Plasma proteomics 
 160 
following three CM10 chip/condition combinations were selected for the discovery 
SELDI-TOF MS experiment: 
i. CM10 chip, pH 4 buffer sodium acetate buffer, SPA EAM 
ii. CM10 chip, pH 6 sodium phosphate buffer, SPA EAM 
iii. CM10 chip, pH8 Tris buffer, SPA EAM 
4.4.2.1.2 Selection of H50 chip binding solution and EAM 
10% ACN with 0.1% TFA resulted in the most peaks with the greatest amplitude 
(illustrative spectra can be found in Figure 4.12). Increasing the concentration of 
ACN reduced spectral resolution and peak intensity. Those spots that were treated 
with the NaCl supplemented ACN binding solution generated no spectra whatsoever. 
At low mass ranges, CHCA EAM outperformed SPA (Figure 4.12A). High mass 
range peak detection was almost non-existent with both EAMs (Figure 4.12B). The 
fourth and final chip/condition combination selected for inclusion in the discovery 
experiment was therefore: 
iv. H50 chip, 10% ACN binding solution, CHCA EAM 
4.4.2.2 Results of discovery SELDI-TOF MS study 
I performed this experiment on three cohorts: samples from 18 CC subjects, 10 PSC 
subjects and 18 healthy control samples. 
4.4.2.2.1 Demographics of subjects, discovery study 
Of the 18 subjects with CC, nine were collected at ICH and nine from UCH. All ten of 
the samples from PSC patients were from NoPSC Biobank, Norway. Of the 17 
healthy controls analysed, 9 were from ICH and 8 from UCH. There were significant 
differences in the male to female ratio between the three groups. There was a 
significant difference between the age of the CC cohort (median age 68y) and the 
age of the PSC (39y) and HC (42y) cohorts. The majority of subjects in all three 
groups were Caucasian, however there were significantly more non-Caucasians in 
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the CC (17%) and healthy control groups (16%) than in the PSC groups (0%). More 
detailed demographic data is presented in Table 4.12. 
4.4.2.2.2 CM10 chips, discovery study 
The SP060 sample failed on both spots under all three conditions and was excluded 
from further analysis. It was subsequently reanalysed successfully in the validation 
cohort. In a further seven cases a single spectrum was generated and analysed. In 
all other cases peak magnitude was calculated as a mean value from two adequate 
spectra.  
4.4.2.2.2.1 pH4 
A total of 51 peaks were detected and assigned an m/z value by the Biomarker 
Wizard. No peaks were found to be significantly different between CC and PSC or 
between CC and healthy control groups. 
4.4.2.2.2.2 pH6 
39 peaks were detected and assigned an m/z value. One peak was found to be 
significantly different between CC and PSC or CC and healthy control groups. M/z 
4631 was differentially expressed in both comparisons (p=0.03 and 0.007 
respectively).  
4.4.2.2.2.3 pH8 
61 peaks were detected and assigned an m/z value. One peak was found to be 
significantly different between CC and PSC or CC and healthy control groups. M/z 
4630 was differentially expressed in both comparisons (p=0.036 and 0.001 
respectively). 
4.4.2.2.3 H50 chips, discovery study 
A total of 28 peaks were detected and assigned an m/z value. Six peaks were found 
to be significantly different between CC and PSC or CC and healthy control groups; 
m/z 4297 (CC vs. PSC), m/z 5768 (CC vs. healthy controls), m/z 8572 (CC vs. PSC 
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and CC vs. healthy controls), m/z 8701 (CC vs. PSC and CC vs. healthy controls), 
m/z 11520 (CC vs. healthy controls) and m/z 17313 (CC vs. PSC). 
Results from of all seven significantly different peaks are summarised as ‘Primary 
analysis discovery cohort’ in the first rows of Table 4.13.  
4.4.2.2.4 Decision on chip conditions for validation study 
CM10/pH4 was excluded as no significantly different peaks were identified in the 
discovery study and pH4 was expected to be the least selective condition (i.e. most 
proteins able to bind), thereby reducing resolution. pH6 was excluded as the only 
significantly different peak, m/z 4630, was also detected at pH8 (as m/z 4631). The 
greatest absolute number of peaks was detected at pH8 on the CM10 chip. The 
significantly different peak, m/z 4631, correlated with the positive finding at pH6. pH8 
was the most selective condition used on the CM10 chip yet had yielded the only 
peak of interest. The H50 chip had yielded a substantial number of significantly 
different peaks (six) with good spectral amplitude and SNR. The use of two different 
surfaces was considered complimentary, as they are highly likely to bind different 
proteins. Therefore, CM10/pH8 and H50/ACN 10% were selected as the 
chip/condition combinations for the validation study. 
4.4.2.3 Results of validation SELDI-TOF MS study 
Spectra were successfully generated from all subjects under all conditions. 98% of 
spectra were averages between 2 spots, 2% were from an isolated spot (due to 
paired spot failure). 
4.4.2.3.1 Demographics of subjects, validation study 
Samples from 81 patients with CC (48 from ICH, 33 from UCH), 54 patients with PSC 
(1 ICH, 12 UCH, 41 Norway) and 90 healthy controls (65 ICH, 25 UCH) were 
included. The characteristics of these patients are summarised in Table 4.14. There 
were significant differences in age between the CC cohort (median age 66y) and the 
PSC (42y) and healthy control (42y) cohorts. There were significant differences in 
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ethnicity between the PSC group, which was 89% Caucasian, and the CC (65% 
Caucasian) and healthy control (57% Caucasian) cohorts. There were also 
significant differences in the male to female ratio between the PSC cohort (76% 
male) and the CC (57%) and healthy control (53%) cohorts. Samples from all 
subjects from the discovery study also underwent repeat SELDI-TOF MS analysis, 
but were subject to separate statistical analysis initially. The demographic details of 
the discovery cohort can be found in Table 4.12. 
4.4.2.3.2 Matching of peaks from discovery and validation studies 
The m/z values of each of the seven peaks from the discovery study, and the m/z 
value of matched peaks in the validation study are summarised in Table 4.15. All 
seven peaks were matched within the 0.15% range.  
4.4.2.3.2.1 CM10 chips, validation study 
A total of 41 peaks were detected and assigned an m/z value by the Biomarker 
Wizard. A single peak, m/z 4630, was sought and identified within 0.1% of m/z 4631. 
This peak was examined within the Biomarker software and had similar appearances 
to the m/z 4631 peak identified as of interest in the discovery study.  
4.4.2.3.2.2 H50 chip, validation study 
A total of 34 peaks were detected and assigned an m/z value by the Biomarker 
Wizard. Peaks corresponding to the six identified of interest in the H50 discovery 
study were identified within 0.15% of their m/z value. These peaks were examined 
manually and validated within the Biomarker software.  
4.4.2.3.3 Statistical analysis of validation study cohorts 
Results of analysis of all seven peaks of interest are summarised in Table 4.13. Each 
of the seven peaks was initially analysed in isolation:  
4.4.2.3.3.1 New CC cohort vs. new PSC cohort  
Three peaks had strongly significant (p<0.0001) differences between CC and PSC 
cohorts: m/z 4631, m/z 5768 and m/z 11526, all of which were more intense in CC 
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subjects that PSC subjects. A significant difference was detected in two other peaks: 
m/z 8699 (p=0.03) and m/z 17287 (p=0.02), both of which were relatively less 
intense in CC than PSC groups. The two remaining peaks showed no difference in 
peak intensity. 
4.4.2.3.3.2 New CC cohort vs. new healthy controls 
Significant differences were detected in all seven peaks. Four peaks were 
significantly (p<0.0001) less intense in CC: m/z 4291, m/z 8701, m/z 17287 and m/z 
8577. Three peaks were significantly higher intensity in CC: m/z 11526 and m/z 4630 
(p<0.0001) and m/z 5768 (p=0.001). 
4.4.2.3.3.3 New PSC cohort vs. new healthy controls 
Significantly lower intensity was found in four peaks: m/z 4291, m/z 8572, m/z 8699 
and m/z 17287 (p<0.05). Two peaks were increased in PSC: m/z 4631 m/z 11526. 
4.4.2.3.3.4 New Norwegian PSC vs. UK PSC cohort 
No peaks were found to vary between the Norwegian PSC subjects and the UK PSC 
subjects (p=0.30 to 0.75). 
4.4.2.3.3.5 New ICH CC vs. new ICH healthy controls 
The significant differences in all seven peaks detected in the full cohorts were all 
sustained when only the ICH subgroups were analysed (p=2.0x10-7 to 0.007). 
4.4.2.3.3.6 New UCH CC vs. new UCH healthy controls 
The significant differences in six of seven peaks detected in the full cohorts were 
sustained when only the UCH subgroups were analysed (p=1.2x10-7 to 0.028). There 
was no difference found in m/z 5765 (p=0.35). 
4.4.2.3.4 Analysis of repeat SEDLI-TOF MS in discovery cohorts 
The new results for the original discovery cohorts were then subject to analysis, 
comparing CC to PSC and then CC to healthy control cohorts. There was little 
consistency in the CC to PSC comparison; only one of five peaks originally found to 
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be different remained so (m/z 4631, p=0.02). There was much better consistency in 
the CC to healthy control comparisons where five of the six peaks originally found to 
be different remained so in the repeat study (p=0.016 to 3.0x10-4). 
4.4.2.3.5 Combined cohort 
The results from the repeated SELDI-TOF MS analysis of the discovery cohort were 
then merged with the validation study results to form a combined cohort. All 
subsequent analyses were performed on this combined cohort. 
4.4.2.3.5.1 Demographics of combined cohort 
There were samples from 99 CC subjects (58% from UCH, 42% from UCH), 64 PSC 
subjects (31% UCH, 69% Norway) and 107 healthy control subjects (69% ICH, 31% 
UCH) in the combined cohort. A summary of demographic data for this combined 
cohort can be found in Table 4.16. Similar differences persisted. The median age 
was higher in the CC cohort (median 68y) than in the PSC (42y) and healthy control 
groups (42y). There were more men in the PSC cohort (78%) than in CC (59%) and 
healthy control cohorts (52%).   
4.4.2.3.5.2 Anatomical subtypes within combined CC cohort 
The anatomical subtype was confirmed in 89 of the 99 CC subjects. The majority 
were hilar (66%) or distal (23%). 11% were intrahepatic. A breakdown is shown in 
Table 4.18. There was no significant difference in any of the seven peak intensities 
between different anatomical subtypes.  
4.4.2.3.5.3 Laboratory blood results of combined cohort 
Routine blood parameters were collated for the combined cohorts and can be found 
in Table 4.17. Laboratory data were not available for healthy controls. Mann-Whitney 
U test confirmed that there were no significant differences in bilirubin, ALP, white cell 
count and AFP between the CC and PSC cohorts. There were significant differences 
(<0.0001) in ALT, albumin, CRP, Cea and CA19-9. Creatinine and urea could not be 
compared. 
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4.4.2.3.6 ROC-AUC analysis of each peak 
Each peak was subject to ROC-AUC analysis. Four individual peaks had some utility 
in discriminating CC from PSC (ROC-AUC of 0.62 to 0.75). The best peak was m/z 
4631. When CC and healthy control groups were compared, all seven peaks had 
some utility in discriminating CC and healthy control groups (ROC-AUC of 0.58-
0.82). The joint best peaks were m/z 8572 and m/z 11526. The ROC-AUC results, 
with derived optimum sensitivities and specificities, are summarised in Table 4.19. 
4.4.2.3.7 Correlation matrix, between significant peaks 
This matrix can be found in Table 4.20. There was strong correlation between two 
pairs of peaks: m/z 8572 with m/z 4191 (R2 0.89) and m/z 5765 with m/z 11526 
(R2=0.70). There was moderate correlation between two other pairs of peaks m/z 
4291 with m/z 8699 (R2=0.51) and m/z 8572 with m/z 8699 (R2=0.52). There were no 
other correlations seen.  
4.4.2.3.8 Correlation matrix, between peaks and routine laboratory indices 
This matrix can be found in Table 4.21. There was no significant correlation between 
any of the peaks and any of the routine laboratory indices.  
4.4.2.3.9 Multiple linear regression (general discriminant analysis) 
4.4.2.3.9.1 CC vs PSC 
After four steps, three peaks were included in the optimum model: m/z 11526, m/z 
17287, and m/z 4631. β-values, f-to include and f-to exclude values for each of these 
are included in Table 4.22. When this model was applied to the combined cohort the 
ROC-AUC reached 0.76, with sensitivity of 75% and specificity of 64%. 
4.4.2.3.9.2 CC vs HC 
After six steps, the optimum model reached included five peaks: m/z 8572, m/z 4291, 
m/z 11526, m/z 5765, m/z 4631. β-values, F-to include and f-to exclude values for 
each of these are included in Table 4.22. When this model was applied to the 
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combined cohort the ROC-AUC reached 0.90, with sensitivity of 95% and specificity 
of 74%. 
4.4.2.3.9.3 Combination of peaks with addition of CA19-9 
Making CA19-9 values available to the MLR did not displace any of the three protein 
peaks from the CC vs. PSC model. CA19-9 was included and there was marginal 
improvement in the ROC from 0.76 to 0.77. Sensitivity was 75% and specificity 69%. 
No CA19-9 values were available for the healthy control group and so this analysis 
could not be repeated on the CC vs healthy control model. 
4.4.2.3.9.4 Weighting for potential confounders using MLR 
Weighting for age, sex, ethnicity and site of collection made no difference to the 
protein peaks selected for inclusion in the MLR, and no significant changes to the β 
values occurred. 
4.4.2.3.10 Post hoc analysis - patients with PSC and CC 
In parallel with the validation cohort, I also subjected 6 samples from patients with 
PSC and CC to SELDI-TOF MS. These were compared only to the PSC cohort 
(n=64) and only using the three peaks found to be of most utility in discriminating CC 
from PSC in the main study. MW-U testing identified a significant difference in m/z 
4631 (p=0.01) but not in m/z 11526 or m/z 17287 (Table 4.23). 
4.4.2.3.11 UniProtKB database search 
A total of 46 proteins fell within the search parameters (Table 4.24). Between 3 and 
13 m/z matches were found within 0.1% range each of the seven peaks of interest. 
After consideration of known subcellular location of expression (principally secreted 
proteins), known function (tumour suppressor or biliary functions) and known 
malignant disease associations (functional or association as a plasma biomarker), 
matched proteins that were empirically considered to be of logical interest as CC 
biomarkers are highlighted in bold in Table 4.24.  
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4.5 Discussion 
I have employed two fundamentally different, but complimentary, proteomic 
techniques to undertake a unbiased search for potential new protein biomarkers of 
CC. GeLC-MS/MS offers optimal performance at high mass ranges and offers direct 
identification of proteins. SELDI-TOF MS offers optimal performance at lower mass 
ranges, is high throughput and does not require multiple protein separation steps.  
In the following sections, I will summarise the work I have undertaken with these 
techniques. Each of the identified proteins, and unidentified protein peaks of interest, 
will be considered in turn. In the case of unidentified m/z peaks, this will include 
exploration of the potential identity of the protein in the current literature. I will then 
consider the relative merits and weaknesses of the experimental approaches that I 
took. Finally, I will consider the further work that might be undertaken to expand upon 
the work presented in this chapter. 
4.5.1 GeLC-MS/MS 
Plasma samples from eight patients with confirmed CC and samples from seven 
patients with benign, gallstone related biliary disease have been subjected to GeLC-
MS/MS. Six proteins that significantly differentiated CC from gallstone disease 
patients were identified. In combination, two of these six proteins had maximal utility 
in discriminating CC from gallstone disease, with a ROC-AUC approaching 1.0.  
4.5.1.1 Proteins identified 
4.5.1.1.1 Carboxypeptidase N subunit 2 (CPN2) 
This protein was identified on the basis of four tryptic peptides specific to CPN2. It 
was expressed at lower levels in the plasma of CC patients (0.77 fold). It is an 83kDa 
protein and is a regulatory subunit of Carboxypeptidase N (CPN), binding the 
catalytic subunit and keeping it in circulation. CPN is a plasma zinc metalloprotease 
that cleaves carboxy-terminal arginines and lysines from peptides found in the 
bloodstream such as complement induced anaphylatoxins, kinins, and creatine 
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kinase MM. CPN is constitutively expressed in the liver and secreted into the 
bloodstream.[373] Very low constitutional levels of CPN have been rarely associated 
with cases of hereditary angioedema.[374] There is no published evidence of reduced 
plasma levels of CPN or CPN2 in other diseases, or utility as a cancer biomarker. 
4.5.1.1.2 C-reactive protein (CRP) 
CRP was identified on the basis of seven tryptic peptides specific to CRP. It was 
three-fold higher in the CC cohort than the benign group. In the study cohort it had a 
favourable ROC-AUC of 0.91. CRP is a 25kDa acute phase protein. It is synthesised 
in the liver in response to factors released by macrophages and secreted into the 
plasma. CRP is thought to have physiological function, binding to the phosphocholine 
expressed on the surface of dying cells, and some types of bacteria, thereby 
activating the complement system through the C1Q complex.[375] There is limited 
evidence from one study that modest elevation of CRP predicts poorer prognosis in 
patients undergoing curative or palliative therapy for hilar CC.[376] There is more 
compelling evidence of elevation of CRP in asymptomatic subjects who subsequently 
develop colorectal carcinoma.[377] Whether the increased level of CRP noted in my 
cohort is due to low-grade biliary infection, a tumour related inflammatory response 
or other inflammatory cause is not clear. It is interesting to note that the median CRP 
level in the routine laboratory analyses was actually higher (15 mg/L) in the benign 
cohort than in the CC cohort (7.5 mg/L). Although this was not a significant 
difference, the trend is in the opposite direction of that seen in the LC-MS/MS 
analysis. Direct pair-wise correlation of the laboratory CRP and the result from LC-
MS/MS showed no correlation between the results. 
4.5.1.1.3 Glutathione peroxidase 3 (GPX3) precursor 
This protein was identified from four tryptic peptides specific to GPX3 and was two-
fold higher in the CC group. The ROC-AUC of 0.98, and inclusion in the ideal panel 
of proteins in the multiple linear regression model, suggests very good diagnostic 
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function in these small groups of subjects. GPX3 is a secreted protein that protects 
cells and enzymes from oxidative damage, by catalysing the reduction of hydrogen 
peroxide, lipid peroxides and organic hydroperoxide by glutathione.[375] There is 
limited evidence of disease associations with GPX3. Relatively old studies have 
shown low plasma levels in patients with breast, GI and various childhood 
cancers.[378, 379] Furthermore, low levels of GPX3 have recently been described in 
patients with ovarian cancer.[380] There is experimental evidence, in pancreatic 
cancer cell lines, that glutathione peroxidase may have a tumour suppressant 
effect.[381] The fact that my study has shown increased levels of the precursor 
molecule is interesting and, perhaps, may point to increased production due to an 
upstream consumptive process. 
4.5.1.1.4 Leucine-rich α-2-glycoprotein 1 (LRG1) 
LRG1 was identified from two tryptic peptides specific to LRG1 and found to be 2.2-
fold higher in the CC group. It had good individual diagnostic performance with a 
ROC-AUC of 0.93. LRG1 is a secreted protein and involvement in protein-protein 
interaction, signal transduction, and cell adhesion and development has been 
demonstrated.[375] A Japanese proteomic study (utilising multi-dimensional liquid 
chromatography and two-dimensional difference gel electrophoresis) of pooled 
plasma from 5 pancreatic cancer patients and five control subjects showed 
upregulation of LRG1. This was confirmed by Western blotting in validation 
cohorts.[382] A UK group, using a two dimensional difference gel electrophoresis and 
tandem mass spectrometry proteomic approach, has recently reported increased 
plasma LRG1 in biliary tract cancer patients. 37 biliary tract cancer patient, 11 PSC 
patients and 7 autoimmune pancreatitis patients were studied. They verified their 
finding in the same subjects using ELISA. In combination with plasma CA19-9 and 
IL-6, a ROC-AUC of 0.98 was attained.[383] LRG1 is also elevated in various 
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autoimmune conditions, ovarian cancer, appendicitis and ulcerative colitis, perhaps 
raising questions about its specificity as a pancreatobiliary tumour biomarker.[384-388] 
4.5.1.1.5 Serum amyloid A4 (SA4) 
SA4 was identified from two tryptic peptides specific to SA4 and was 1.7-fold higher 
in the CC cohort than the benign groups. Its ROC-AUC 0.93 suggests good 
performance in this cohort of patients. SA4 is an apolipoprotein of the HDL complex 
and an acute phase protein. It is expressed by the liver and secreted into the plasma. 
A number of small LC-MS/MS plasma proteomic studies have identified SA4, at 
elevated levels, in breast cancer, hepatocellular carcinoma and pancreatic 
cancer.[389-391] It has also been identified in proteomic studies of a host of other 
disparate diseases, including traumatic brain injury and infective exacerbation of 
COPD.[392, 393] Despite its frequent elevation as known an acute phase protein, a 
number of experimental studies have indicated a directly tumour related increase of 
SA4.[394]  
4.5.1.1.6 Zinc finger protein 844 (ZFP844) 
This zinc finger protein was identified by two tryptic peptides specific to ZFP844 and 
was two-fold higher in the CC group. It had an excellent ROC-AUC of 0.98 and was 
one of the two proteins included in the multiple linear regression optimum model. 
ZFP844 is expressed in the nucleus and is likely to be a transcription factor.[375] I was 
not able to identify any previous associations between this protein and disease, 
benign or malignant.  
4.5.1.1.7 Combinations of identified proteins 
The multiple linear regression (MLR) discriminant function analysis identified a panel 
of two of these proteins, GPX3 and ZFP844, which had a 100% sensitivity and 
specificity in these cohorts. Given the small cohort sizes, and the very high ROC-
AUC (up to 0.98) of two of the individual markers, this does not serve as any 
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indicator of which of these six proteins is a priority of further investigation and which 
should be discounted. 
4.5.1.2 Experimental technique 
A major advantage of GeLC-MS/MS is the integral identification and quantification of 
the proteins detected, and this was achieved in my study. The technique was 
expected to be somewhat laborious, limiting the number of samples that can be 
processed in a reasonable timeframe, and this also proved to be the case. The first 
stage of the protocol, using an IgY column to deplete the most abundant plasma 
proteins, proved technically challenging. It required repetition after several 
optimisation experiments to achieve success. Initially, the column became 
progressively less effective with each sample depleted, with comparative 
overabundance of albumin in later samples, representing a clear potential 
confounding factor. I ran gels comparing the stripped and eluted fraction of each 
specimen, and concluded that the dilution buffer was attenuating the acid conditions 
required to strip the bound protein fraction. A second stripping cycle, with 
reapplication of an acidic buffer, solved this issue. The performance of the protein 
depletion was confirmed, and appeared to meet the manufacturer’s claim of 95% 
efficacity. However, the difference between the most abundant proteins and the least 
abundant proteins currently detectable in plasma is of about nine to 12 orders of 
magnitude. This has been described as ‘equivalent to the difference between the 
height of an ant and the distance from the Earth to the moon’.[386, 395] It is clear that 
the partial, even 95%, depletion of albumin and other high abundance proteins will 
only mitigate the masking effects on moderately abundant proteins. Furthermore, in 
removal of these proteins I may also have removed other proteins of potential 
interest – including proteins that bind to albumin, or proteins that undergo unintended 
binding to the IgYs in the depletion column due to antibody cross-reaction. 
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Gel electrophoresis, the LC-MS/MS and statistical analyses proceeded without 
undue complication. The design of the study completed, with a single (discovery) 
phase testing two small groups of samples, is vulnerable to Type I error due to 
multiple testing. Therefore, the results can only be regarded as exploratory. The 
verification of findings in the current cohorts using a different technique, and 
validation in new samples, would have addressed this. The results of ROC-AUC 
analyses on these small groups must also be treated with caution and simply give an 
indication of the degree of separation in the cohorts that are under investigation. The 
results cannot be extrapolated beyond this. 
4.5.1.3 Cohorts recruited 
This study was conducted at the beginning of my research period, when I had 
collected a small number of samples. The cohort sizes of eight and seven are 
comparable with most recently published proteomic studies that have utilised a gel 
and tandem MS based approach. Many studies still employ the strategy of pooling all 
the case and all the control samples and then passing just two samples through the 
analytical technique. This has obvious advantages if time and resources are short 
but, with an n of one in each group, results can only be regarded as exploratory at 
best. Perhaps more significantly in my study, the limited samples available meant 
that the demographics of the case and control groups were not as consistent as I 
would have liked for such small cohorts. Although age was well matched between 
the groups, the case and control groups were significantly different in terms of 
ethnicity and sex. These factors may impinge on any conclusions that can be drawn 
about the differentially expressed proteins. If more samples had been available I 
would not have necessarily included more in each group, but would certainly have 
endeavoured to match the subjects included more closely for sex and ethnicity. As all 
differentially expressed proteins are rapidly identified by this technique, any protein 
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differences that were obviously attributable to female sex, for example, could have 
been be promptly excluded from further investigation. 
There were no significant differences in the known standard laboratory indices 
between the two groups. In one benign case, all of the standard laboratory indices 
were unavailable. No tumour marker results were available for all but one of the 
benign control group. It is likely that tumour markers, especially CA19-9, would have 
been different between the groups. Having the values would have permitted me to 
explore combinations of traditional CC biomarkers with the six putative protein 
markers identified with MLR. However, the fact that two of the putative markers had 
individual ROC-AUCs of 0.98 means that such a MLR analysis would be very 
unlikely to offer further insight. 
The CC samples in my study were from patients with symptomatic, fully diagnosed 
disease. They therefore have, by definition, relatively late CC. Extrapolation of my 
findings to early, asymptomatic disease is not possible. A control disease group were 
chosen, over a healthy control group, to mitigate the potential confounders of 
cholestasis and biliary epithelial inflammation on the proteome. The similarity of the 
normal plasma markers of cholestasis and inflammation in the two groups suggest 
that this was at least somewhat successful. However, gallstone disease is not a 
close corollary of PSC, a group in which accurate diagnosis of CC is of particular 
importance and difficulty. I cannot extrapolate my findings to PSC related CC without 
further work in appropriate new cohorts.  
4.5.1.4 Further work warranted 
The number of peptides on which the identification is made is an indicator of the 
certainty of that identification. The veracity of the protein identifications in my study is 
robust, with at least two specific peptides identifying each, but internal verification 
within the current cohort is required. Secondly, the limited cohort sizes in the study 
mandate that any verified protein differences be validated in further patients. Current 
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standard best practice in proteomic studies would be to confirm the presence and 
concentration of each protein identified in the current samples using Western 
blotting. If the identification and differentiation of the proteins is verified, validation of 
the findings in a further, larger cohort of patients is indicated. GPX3 and ZFP844 
were the two strongest biomarkers in this discovery study. There is relatively little 
known about any disease associations of GPX3, and nothing about associations with 
ZFP844. These two candidate proteins warrant formal verification in the current 
cohorts with Western blotting, before validation in a large new cohort with Western 
blot, or preferably ELISA. At first sight, SA4 seems rather a non-specific candidate to 
warrant consideration as a CC biomarker, but it has also been found to be elevated 
in the plasma in HCC and pancreatic cancer studies. Confirmation in a further cohort, 
alongside the other potential markers could therefore be warranted. CRP seems 
highly unlikely to represent a specific marker of CC but would be amenable to simple 
further investigation as it is available in all clinical labs. It could easily and cheaply be 
performed in a study of patients with indeterminate biliary stricture, or in a 
longitudinal study of patients with PSC. A quick, cheap retrospective analysis might 
also be feasible. CPN2 is the inactive, stabilising subunit of an enzyme and has no 
known disease associations. It was reduced in CC patients, but only moderately so 
(0.77-fold). It therefore seems a less attractive potential marker for further 
investigation. However, it was firmly identified with four specific peptides and could 
simply be investigated in a further cohort, alongside GPX3 and ZFP844. LRG1 has 
now been shown to be elevated in bile duct cancer by two separate research groups 
using different techniques - at University College London using two-dimensional 
difference gel electrophoresis and tandem mass spectrometry and then verified in the 
same cohorts with ELISA, and now in my study using SELDI-TOF MS. It seems that 
study of this protein in a larger, clinical trial may now be warranted. 
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4.5.2 SELDI-TOF MS 
SELDI-TOF MS has been applied to plasma samples from a total of 99 CC patients, 
64 PSC patients and 107 healthy control subjects, initially divided into a smaller 
discovery cohort and a larger validation cohort. After identifying the optimum 
conditions under which to analyse the samples, a discovery cohort was investigated 
and seven individual m/z peaks, each representing an as yet unknown protein, were 
detected that were differentially expressed between cohorts. All seven of these were 
confirmed in the subsequent validation study. All seven peaks exhibited some 
diagnostic utility in discriminating CC subjects from PSC patients, or CC subjects 
from healthy controls.  The discriminatory function of combinations of these peaks 
was assessed for two key comparisons: CC subjects compared to PSC subjects and 
CC compared to healthy control subjects. A combined panel of three of these seven 
peaks demonstrated substantial utility in discriminating CC from PSC, with a ROC-
AUC of 0.76, sensitivity of 75% and specificity of 64%. In discriminating CC from 
healthy controls, a combined panel of five peaks demonstrated very good diagnostic 
function, with a ROC-AUC of 0.90, sensitivity of 95% and specificity of 74%.  
4.5.2.1 Peaks identified as of interest 
All peaks identified as of interest were singly resolved, of good (>20%) relative 
intensity and had no interference from neighbouring peaks. 
4.5.2.1.1 m/z 4291 
This peak was significantly less intense in CC and PSC groups than in healthy 
controls. This peak had no function in discriminating PSC from CC but was useful 
when CC and healthy controls were compared (ROC-AUC 0.76), where it was 
included in the calculated optimum peak panel. Peak m/z 4291 was closely 
correlated (R2 0.90) with peak m/z 8572, with which it also shared the same pattern 
of discriminatory characteristics. The expected m/z of a doubly charged ion of m/z 
8572 is 4286 and it is therefore highly likely that these peaks represent the same 
protein. Peak m/z 4291 did not correlate with any routine laboratory indices. 
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4.5.2.1.2 m/z 4631 
This peak was the only one of the seven peaks that was identified using the CM10 
chip surface. It was found to be at increased intensity in both PSC and CC patients. It 
was the most effective individual peak at discriminating both CC from PSC subjects 
(ROC-AUC 0.74), and CC from healthy controls (ROC-AUC 0.82), and was included 
in the optimum panel of proteins calculated for both comparisons. This peak was also 
elevated in a small additional group of six patients with CC and PSC that I was able 
to analyse and compare to the PSC only group as a post hoc analysis. M/z 4631 was 
not correlated with any of the other peaks, or with any routine laboratory results. 
4.5.2.1.3 m/z 5765 
This peak was significantly more intense in CC patients than in PSC subjects and 
healthy controls. It had moderate function as a potential diagnostic test in identifying 
CC from PSC subjects (0.63) and CC from healthy controls (0.59). It was included in 
the optimum panel of peaks to discriminate CC from HC cohorts. M/z 5765 was 
strongly correlated with another peak, m/z 11526 (R2 0.70), with which it shared a 
similar pattern of discriminatory characteristics. The expected m/z of double charged 
version of 11526 is 5763. It is therefore highly likely that these two peaks represent 
the same protein. M/z 5765 was minimally correlated with CRP (R2 0.15).  
4.5.2.1.4 m/z 8572 
This peak was less intense in both CC and PSC cohorts. It had no significant utility in 
discriminating CC from PSC subjects, but good performance in discriminating CC 
from healthy controls (ROC-AUC 0.82), where it was included in the optimum model. 
As discussed above, it is likely to represent a singly charged version of the same 
protein detected as peak m/z 4191. M/z 8572 was also moderately correlated with 
m/z 8699 (R2 0.51), but not with any laboratory parameters. 
4.5.2.1.5 m/z 8699 
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This peak was significantly less intense in CC and PSC groups. Differentiation of CC 
and PSC (ROC-AUC 0.69), and CC and healthy controls (ROC 0.74), was good.  
However, it was not included in the optimum discriminatory panel for either of these 
key comparisons. M/z 8699 was moderately correlated with both m/z 4291 and m/z 
8572, with which it shares the same pattern of variation in intensity. It is not clear why 
this is. It did not correlate with any lab parameters. 
4.5.2.1.6 m/z 11526 
This peak was more intense in both CC and PSC groups. Discrimination of CC from 
PSC (ROC 0.73) and CC from HC (ROC 0.83) were both good. This peak was 
included in the optimum panel of peaks for both key group comparisons. As 
discussed above, it was correlated with m/z 5765 and these are likely to represent 
differently charged versions of the same protein. There was very modest correlation 
between this peak and plasma CRP (R2 0.20). 
4.5.2.1.7 m/z 17287 
This peak was of lower intensity in CC and PSC groups. Discrimination of CC 
subjects from those with PSC was modest (ROC 0.61) and somewhat better when 
comparing CC with healthy controls (ROC 0.72). In multiple linear regression this 
peak was included in the optimum panel of proteins that discriminated CC from PSC. 
There was no correlation between this peak and any others, or the laboratory 
indices. 
4.5.2.1.8 Combinations of peaks 
Multiple linear regression analyses allowed me to explore combinations of peaks. 
Doing so achieved improved diagnostic performance. The model differentiating CC 
and PSC included three peaks and achieved a ROC of 0.76. This is somewhat 
disappointing as the best individual peak had a ROC-AUC of 0.74. The panel 
differentiating CC from healthy controls included five peaks and reached a ROC-AUC 
of 0.90. When CA19-9 was offered for inclusion in the CC vs. PSC, all three peaks 
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were retained in the model. Addition of CA19-9 enhanced the CC vs. PSC panel 
slightly, achieving a ROC of 0.77, with sensitivity of 75% and specificity of 69%. No 
CA19-9 values were available for healthy controls and so addition of CA19-9 to that 
panel could not be undertaken. 
4.5.2.1.9 Potential identity of m/z peaks 
4.5.2.1.9.1 Published SELDI-TOF MS studies 
I reviewed published work that has previously utilised SELDI-TOF MS on plasma 
from patients with CC, pancreatic cancer or hepatocellular carcinoma. The peaks of 
interest from these nine studies, and any subsequent protein identifications, are 
summarised in Table 4.25. Of the 43 peaks identified of interest in the nine studies 
considered, four fall within 0.15% of the seven peaks that I have identified. Three of 
these matched peaks were reported in the Scarlett paper, the first to report 
application of SELDI-TOF to plasma from CC patients.[360] The differences shown by 
Scarlett between CC and non-CC subjects in each of these three matching peaks are 
contiguous with the findings of my SELDI-TOF MS experiment. One of the matching 
Scarlett peaks, m/z 11535, was the one found to be of most value in discriminating 
CC from healthy controls (ROC-AUC 0.87) in that study. The fourth matching peak, 
m/z 8560, is from a very recent Chinese study of pancreatic cancer. In this case, the 
direction of difference conflicts with my findings, with increased peak intensity in CC 
compared to controls. The matching peaks are summarised in Table 4.26. Neither 
investigating groups identified any of the four matched peaks, nor have they 
published any subsequent work on these peaks. The correlation between the 
findings in Scarlett and colleagues and my study are of interest, and certainly support 
the need to identify the proteins that these m/z peaks represent.  
4.5.2.1.9.2 Search for m/z values in protein TagIdent database 
Of the 46 protein matches on the TagIDent database, several bear some scrutiny as 
potential biomarkers. However, this is entirely exploratory and many of the promising 
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matches are actually expressed at counter-intuitively increased or decreased levels. 
One of the hits, MHC class I polypeptide-related sequence, has previously been 
shown to be shed from epithelial cell tumours, including HCC, into the blood plasma 
and could represent the peak at m/z 4291. However, m/z 4291 is reduced in CC in 
my study, which would make little sense. As a further example, the serum amyloid 
A1 (SAA1) could represent the m/z peak at 11526, which I have shown to be 
increased in CC.  This would also correlate with my finding of increase in another 
serum amyloid, SAA4, in the GeLC-MS/MS study. However, SAA1 is also in the 
short list of proteins at m/z 8572, which is reduced in CC. Speculative examination of 
this database was worthwhile, but I am doubtful that any reasonable conclusions can 
be drawn. 
4.5.2.2 Experimental techniques 
The sample processing and SELDI-TOF MS process itself were relatively 
straightforward and reliable, and processed large numbers of specimens quickly, 
when it was up and running. The choice of two chip surfaces did prove worthwhile 
as, despite it being the only significant chip identified on CM10, m/z 4631 proved to 
be the strongest individual peak found, and did not correlate at all with any of the six 
peaks of interest found on H50 chips. Several of the buffers that I used in the 
optimisation experiments failed to generate any spectra and I did not reach an 
explanation for this. One sample failed to generate spectra, in both replicate spots. A 
sample from the same subject (prepared as a fresh sample from the raw plasma 
aliquot) was included in the validation cohort and generated normal, adequate 
spectra. In the validation cohort, spectra were achieved from all samples included. 
The significant differences seen in the discovery cohort were mitigated, and in some 
cases abrogated, when the same samples were subjected to repeat SELDI-TOF MS. 
However, the candidate peaks were confirmed in the validation cohorts. The design 
of the study, with discovery and validation phases, adds strength to the findings and 
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minimises the risk of type I error due to multiple testing. Once differences had been 
confirmed in the validation cohort, I elected to combine the results from the validation 
cohort results with the repeated SELDI-TOF results from the reanalysed discovery 
samples. This permitted analysis of the maximum sized cohorts in the subsequent 
ROC-AUC and MLR analyses, with consequent strengthening of the findings. 
4.5.2.3 Cohorts recruited 
The size of cohorts that I was able to assemble for this study compare very 
favourably with previously published SELDI-TOF MS biomarker discovery studies. 
My study included substantially more CC subjects than any of the nine summarised 
in Table 4.25.  I elected to study three groups – with PSC as a disease control group, 
excluding those with advanced cirrhosis or previous liver transplantation. Although 
this complicated recruitment, simply comparing patients with cancer to completely 
healthy controls would not be adequate. Potential confounding factors such as biliary 
obstruction could not be investigated if the only control group all, by definition, had 
normal liver function tests. Diagnosing PSC related CC poses a very specific, 
frequent and very important clinical dilemma. It was therefore appropriate to use PSC 
as the primary control group, with secondary comparisons to healthy controls. 
However, this decision was not without ramification. PSC is an uncommon disease 
and neither of the UK centres at which I was recruiting patients have large PSC 
practices. Although I was able to identify over 60 potential recruits, successfully 
calling them in to consider participation and give blood proved difficult. Non-cirrhotic, 
non-transplanted PSC patients are generally young, and frequently have full time 
jobs and young families. They are not ideal targets for the research fellow’s 
telephone calls and, as generally well, are not frequent attenders in outpatient clinics. 
I therefore had to enter into collaboration with colleagues at the Oslo based NoPSC 
Biobank. They were in a position to help, have a large resource of well-characterised 
PSC patient’s samples and their sample processing is in line with our SOP.  
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Even with access to the NoPSC Biobank, there was an unavoidable preponderance 
of young, male, Caucasian patients in the PSC control group. This cohort was not a 
good match for the older, more gender balanced, ethnically diverse CC group. I 
endeavoured to collate a healthy control group that was better matched to the CC 
group and this was generally achieved in terms of sex and ethnicity. However, an 
age difference persisted. A final important factor was my decision to collect samples 
at two UK hospitals, ICH and UCK along with the Norwegian site. This afforded 
quicker recruitment of minimum cohort sizes and eventually bigger cohorts for 
comparison, but could become a confounding factor. All three institutions have long 
established, high quality clinical and research governance standards. All three 
collaborating groups are very experienced in clinical research and have undertaken 
proteomic studies, so understand the importance of consistent, careful sample 
treatment. Compatibility of sample collection and processing SOPs was ensured.  
It was very likely that there would be significant differences in other factors between 
the three cohorts. Some degree of biliary inflammation, cholestasis and cholangitis is 
a frequent, if not universal, feature of CC and PSC. In patients with malignancy, and 
a lesser extent PSC, nutritional status and renal function are also likely to be 
impaired. However, the severity of these features is highly variable and therefore and 
the impact on the proteome is likely to also vary. The routine laboratory indices that I 
was able to collect offer insight into some of these factors. Importantly, the principal 
markers of cholestasis, ALP and bilirubin, were not significantly different between CC 
and PSC groups. ALT and albumin were significantly higher in the PSC group. CRP 
and CA19-9 were significantly higher in CC. There were no differences in white cell 
count or AFP between the two groups. Renal function could not be compared, as 
these numbers were not available for the PSC cohort. It is worth noting that none of 
the CC or PSC patients recruited were known to have renal failure. It was not 
possible to make the same comparisons between CC and healthy control groups as I 
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did not have laboratory data for the healthy controls, although it seems reasonable to 
assume that routine lab indices in this groups would fall in a normal distribution 
within, and just out of, the laboratory defined normal range. 
The subgroup analyses and other statistical investigations that I was able to perform 
also offer some reassurance about potential confounding factors. The pattern of 
significantly increased or decreased intensity in CC groups for all but one of the 
seven peaks was the same when UCH and ICH samples were analysed in isolation. 
Each of the seven peak intensities in the Norwegian PSC cohort was not different to 
the UK PSC cohort. All laboratory indices were correlated with all seven peaks of 
interest. Apart from minor correlation between CRP and peaks m/z 5765 and m/z 
11526, no correlation was found. Multiple linear regression (MLR) is able to offer 
some correction for potential confounding factors. I repeated the principal MLR 
analysis with correction for age, sex, ethnicity (Caucasian or non-Caucasian) and site 
of collection, in case any of these factors were affecting my findings. In all cases, 
such correction had no more than a negligible positive or negative effect on the 
diagnostic performance. Finally, the MLR model discriminating CC vs. PSC model 
was repeated with correction for the various differential laboratory blood indices: 
ALT, albumin, CA19-9 and CRP. Such analyses are reassuring but are not a 
substitute for better-matched groups. Certainly my study would have been 
strengthened if CC and healthy control samples had been available from the 
Norwegian group. 
The CC group recruited had heterogeneity in the extent and primary location of their 
cancer. I investigated this with analysis of the three anatomical subgroups of CC and 
found no difference in the peak intensities between them. All patients had fully 
diagnosed symptomatic CC and so results cannot be extrapolated to those with 
early, asymptomatic disease. None of the discovery or validation CC groups had 
PSC. However, I had a small additional cohort of six CC patients who did have 
Chapter 4 – Plasma proteomics 
 184 
underlying PSC. A post hoc comparison of m/z 11526, 17287 and 4631 between this 
small group and the 64 PSC patients confirmed a significant difference in 4631 
(p=0.01). 
4.5.2.4 Further work warranted  
Given the large sample sizes and strong validation of my discovery findings, I believe 
that it is appropriate to pursue identification of the seven peaks of interest. This will 
be pursued by other members of our group. For each of the seven peaks, we have 
identified four samples that generate particularly intense signal and pooled them. 
Protein purification, using sequential ion exchange, reverse-phase chromatography 
and SDS-PAGE, will be undertaken. Subsequent protein identification will be 
achieved by nanoflow liquid chromatography tandem MS analysis of trypsin-digested 
peptides.[371, 396] 
4.5.3 Conclusion 
In the course of this work, I have come to understand some of the challenges that 
proteomic studies all face. Clearly appropriately matched control groups are of critical 
importance. However, the heterogeneity of HPB diseases, and CC in particular, 
makes matching the groups particularly challenging. In clinical studies, some degree 
of compromise is necessary but careful thought must be given if reasonable 
comparisons and conclusions are to be drawn. Proteomic studies are particularly 
vulnerable to patient, sample collection and sample processing variation. The huge 
relative abundance of proteins that are of no interest, and the miniscule 
concentration of those that are, makes biomarker discovery a technically demanding 
challenge, one that is perhaps not readily appreciated. The volume of data that 
modern analytical devices can generate on single specimens is huge, and is 
compounded by the number of specimens that can be processed rapidly. This offers 
great opportunity but could become overwhelming if adequate bioinformatics 
software and support are not applied. I was not able to personally complete 
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validation of the proteins identified in the GeLC-MS/MS study or identification of the 
SELDI-TOF MS peaks during my PhD programme, and this limits some of the 
conclusions that I can draw. 
The findings of the GeLC-MS/MS study that I undertook have identified a number of 
proteins that, when considered in the context of other published work, do look of 
interest and worthy of further investigation. The contemporaneous, provisional 
identification of the proteins detected is a huge advantage of this technique. 
However, the statistical significance of these findings in such small cohorts requires 
cautious interpretation. The proteins identified require careful validation before any 
conclusions can be drawn. Since my work was completed, other members of my 
group have sought to validate one of the markers, Carboxypeptidase N, in a fresh 
cohort of CC patients. 
The SELDI work that I have undertaken has delivered strong positive results with 
large validation cohorts studied. Combination of three of these peaks discriminated 
CC from PSC patients with sensitivity of 75% and specificity of 64%. Combination of 
five of these peaks discriminated CC from healthy control patients with sensitivity of 
95% and specificity of 74%. Again, it was pleasing to find some supportive, 
corresponding results from a different group along with some unique new peaks to 
report. The collaboration with the NoPSC Biobank, Oslo proved fruitful and highlights 
the importance of well curated, disease specific Biobanks. I believe that all seven of 
the m/z peaks have been subjected to robust testing and all warrant further study. It 
is likely that these seven peaks represent five unique proteins. Peaks corresponding 
closely with three have these have been identified in another SELDI-TOF study of 
CC, supporting my findings. My strongest peak, m/z 4631, appears to be a novel 
finding, never previously identified in SELDI-TOF MS studies of HPB cancer.  
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4.6 Chapter 4 Tables and Figures 
Table 4.1: Child-Pugh classification of cirrhosis 
Legend: Child-Pugh (C-P) classification is a scale of severity of cirrhosis that predicts 
survival. A score is calculated based on a total of 5 laboratory and clinical features. 
Using the second part of the table, a categorization and predicted 1 and 2 year 
survival are calculated. No PSC patients with C-P B or C disease were included in 
my PSC cohort.[397, 398] INR – international normalized ratio of prothrombin time.  
Measure 1 point 2 points 3 points 
Total bilirubin, umol/l <34 34-50 >50 
Plasma albumin, g/l >35 28-35 <28 
INR <1.7 1.71-2.30 >2.30 
Ascites None Mild Moderate to 
Severe 
Hepatic 
encephalopathy 
None Grade I-II Grade III-IV 
 
Points C-P classification  1 year survival 2 year survival 
5-6 A 100% 85% 
7-9 B 81% 51% 
10-15 C 45% 35% 
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Table 4.2: Constituents of protein standard, SELDI-TOF MS study 
Legend: A standard calibrant solution with an appropriate range of MW peptides and 
proteins was required to calibrate the SELDI-TOF MS. Two spots on every 96 spot 
array were reserved for this protein standard. 
 Molecule MW (kDa) Concentration (μM) 
Peptides Angiotensin 1.2965 1 
 [Glu1] fibrinopeptide B 1.570.6 1 
 Dynorphin A 2.1475 1 
 ACTH 2.9335 1 
 B-endorphin 3.465 1 
 Insulin, bovine 5.7336 1 
 Ubiquitin, bovine 8.5648 1 
Proteins Cytochrome C 12.360 1 
 Lysozyme 14.307 1 
 Carbonic anhydrase 29.095 1 
 Ovalbumin 44.287 1 
 Bovine serum albumin 66.393 1 
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Table 4.3: SELDI-TOF MS instrument settings 
Legend: The same instrument settings were used for all studies. Standard settings 
differed according to which energy absorbing matrix (EAM) was in use. SPA – 
sinapinic acid, CHCA - α-cyano-4-hydroxycinnamic acid. Unless otherwise specified, 
units are arbitrary to the instrument. 
Setting Value set  
 SPA as EAM CHCA as EAM 
High mass (kDa) 100 20 
Optimum range (kDa) 10,000-100,000 1,500-20,000 
Laser intensity 240 180 
Detector sensitivity 8 8 
Lag time (Da) 7.5 20 
Deflector  1500 3000 
Transients per position (n) 20 20 
Start position 20 20 
End position 80 80 
Moving 5 5 
Warm up shots (n) 2 2 
Laser intensity for warm up 190 250 
Include warm up shots? No No 
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Table 4.4: Demographic data, GeLC-MS/MS study 
Legend: Details of sex, age and ethnicity of cases in the malignant (CC) group and 
benign gallstone disease (GSD) group 
Ref Sex Age Ethnicity Diagnosis 
CC1 M 78 Caucasian CC 
CC2 M 60 Caucasian CC 
CC4 M 59 Asian CC 
CC5 F 62 Caucasian CC 
CC6 M 66 Afro Caribbean CC 
CC8 F 59 Asian CC 
CC9 M 59 Caucasian CC 
CC10 F 48 Asian CC 
BB1 M 78 Caucasian GSD 
BB2 F 86 Caucasian GSD 
BB3 F 51 Caucasian GSD 
BB4 F 55 Caucasian GSD 
BB5 F 51 Caucasian GSD 
BB6 M 78 Caucasian GSD 
BB7 F 50 Caucasian GSD 
Table 4.5: Descriptive statistics of demographic factors, GeLC-MS/MS 
study 
Legend: CC and benign gallstone disease cohorts 
 CC Benign 
n 8 7 
Male n (%) 5 (63%) 2 (29%) 
Median age (IQ range) 60 (59-66) 55 (51-80) 
Ethnicity   
  Caucasian (%) 4 (50%) 7 (100%) 
  Afro-Caribbean 1 (13%) 0 
  Asian 3 (37%) 0 
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Table 4.6: Standard laboratory indices for each patient, LC-MS/MS study 
Legend: Median and range for each parameter is shown for both groups. P-value 
shown is from M-W U test between malignant (CC) and benign (stone disease) 
groups. Where value unavailable, field is hyphenated. 
Ref CRP Alb WCC Bili ALT ALP CeA CA19-9 
Malignant         
CC1 - 20 10.6 102 86 359 1 54 
CC2 7 35 25 5 17 152 2 131 
CC4 35 29 19 15 68 299 3 42 
CC5 8 35 14 9 23 108 4 24 
CC6 147 29 1.1 7 81 126 10 885 
CC8 8 34 6.2 15 15 109 1 92 
CC9 - 29 3.6 44 49 454 1 266 
CC10 21.7 31 8.5 11 15 102 - 9 
Median 7.5 30 9.6 13 36 139 2 73 
(range) (6-147) (20-35) (1-25) (5-102) (15-86) (108-454) (1-10) (9-885) 
Benign          
BB1 24 27 11.9 10 8 173 - - 
BB2 5 42 7 11 27 131 - - 
BB3 - - - - - - -  
BB4 26 36 7.6 4 15 102 - - 
BB5 6 37 - 17 35 362 14 132 
BB6 5 29 53 26 131 234 - - 
BB7 9 35 7.1 9 265 111 - - 
Median 14.8 34.5 9.45 10.5 17.5 152 - - 
(range) (5-26) (27-37) (7-53) (4-26) (8-265) (102-362)   
         
P-value 0.29 0.3 0.9 0.91 0.56 0.86 - - 
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Table 4.7: Shortlist of chip, condition and EAM combinations for 
preliminary optimisation study 
Legend: A total of 14 different CM10, and 8 different H50, combinations were trialled. 
Chip Buffer Matrix 
CM10 Glycine and HCl, pH 3 SPA 
CM10 Glycine and HCl, pH 3 CHCA 
CM10 Sodium acetate, pH 4 SPA 
CM10 Sodium acetate, pH 4 CHCA 
CM10 Ammonium acetate, pH 4 SPA 
CM10 Ammonium acetate, pH 4 CHCA 
CM10 Sodium phosphate, pH 6 SPA 
CM10 Sodium phosphate, pH 6 CHCA 
CM10 Citric acid, pH 6 SPA 
CM10 Citric acid, pH 6 CHCA 
CM10 HEPES, pH 7 SPA 
CM10 HEPES, pH 7 CHCA 
CM10 Tris, pH 8 SPA 
CM10 Tris, pH 8 CHCA 
H50 ACN 10% + 0.1% TFA SPA 
H50 ACN 10% + 0.1% TFA CHCA 
H50 ACN 20% + 0.1% TFA SPA 
H50 ACN 20% + 0.1% TFA SPA 
H50 ACN 20% + 0.1% TFA + NaCl CHCA 
H50 ACN 20% + 0.1% TFA + NaCl CHCA 
H50 ACN 50% + 0.1% TFA SPA 
H50 ACN 50% + 0.1% TFA CHCA 
 
Chapter 4 – Plasma proteomics 
 192 
Table 4.8: Non-redundant proteins identified, GeLC-MS/MS study 
Legend: All proteins identified from their peptide fingerprint are listed. The NCBI 
(National Center for Biotechnology Information, U.S. National Library of Medicine, 
Bethesda, USA) reference is a unique identifier used in the collation of proteomic 
data in international databases. Proteins found in different abundance between CC 
and healthy control subjects are highlighted in bold within this table. Proteins are 
listed met minimum degrees of certainty (Xcorr value >1.5 for single charge, >2.0 for 
double charge and >2.5 for triple charge. Minimum number of unique peptides: 2.) 
NCBI number Approved protein name 
NP_000005.2 alpha-2-macroglobulin precursor   
NP_000020.1 angiotensinogen preproprotein   
NP_000030.1 apolipoprotein A-I preproprotein   
NP_000031.1 apolipoprotein C-III precursor  
NP_000032.1 apolipoprotein E precursor   
NP_000033.2 apolipoprotein H precursor   
NP_000053.2 serpin peptidase inhibitor, clade G, member 1  
NP_000055.2 complement component 3 precursor   
NP_000056.2 complement component 6 precursor  
NP_000087.1 ceruloplasmin precursor   
NP_000177.2 complement factor H isoform a precursor  
NP_000195.2 complement factor I preproprotein  
NP_000217.2 keratin 9   
NP_000362.1 transthyretin precursor   
NP_000375.2 apolipoprotein B precursor   
NP_000403.1 histidine-rich glycoprotein precursor  
NP_000412.3 keratin 10   
NP_000414.2 keratin 2   
NP_000415.2 keratin 5   
NP_000437.3 paraoxonase 1 precursor   
NP_000468.1 albumin preproprotein   
NP_000473.2 apolipoprotein A-IV precursor  
NP_000474.2 apolipoprotein C-II precursor   
NP_000479.1 serpin peptidase inhibitor, clade C, member 1  
NP_000497.1 coagulation factor II preproprotein  
NP_000499.1 fibrinogen, alpha polypeptide isoform alpha-E prep 
NP_000500.2 fibrinogen, gamma chain isoform gamma-A precursor 
NP_000509.1 beta globin   
NP_000510.1 delta globin   
NP_000517.2 keratin 14   
NP_000542.1 von Hippel-Lindau tumor suppressor isoform 1  
NP_000549.1 alpha 1 globin   
NP_000558.2 C-reactive protein, pentraxin-related  
NP_000574.2 vitamin D-binding protein precursor  
NP_000578.2 complement component 7 precursor  
NP_000597.2 complement component 8, gamma polypeptide  
NP_000598.2 orosomucoid 1 precursor   
NP_000599.1 orosomucoid 2   
NP_000604.1 hemopexin   
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NP_000629.3 vitronectin precursor   
NP_000706.1 complement component 4 binding protein, alpha chain 
NP_000884.1 kininogen 1 isoform 2   
NP_000925.2 alpha-2-plasmin inhibitor   
NP_001002029.3 complement component 4B preproprotein  
NP_001007526.2 NACHT and WD repeat domain containing 1  
NP_001035519.1 protocadherin 17 precursor  
NP_001054.1 transferrin  
NP_001073871.1 coiled-coil domain containing 61  
NP_001073982.1 carboxypeptidase N, polypeptide 2, 83kD  
NP_001076.2 serpin peptidase inhibitor, clade A, member 3 pre 
NP_001092877.1 hypothetical protein LOC55184  
NP_001107854.1 tuberous sclerosis 2 isoform 5  
NP_001121134.1 gelsolin isoform b   
NP_001121179.1 serine proteinase inhibitor, clade A, member  
NP_001124.1 afamin precursor   
NP_001129973.1 zinc finger protein 844  
NP_001138422.1 hypothetical protein LOC284297  
NP_001139.3 ankyrin 2 isoform 1  
NP_001176.1 alpha-2-glycoprotein 1, zinc   
NP_001613.2 alpha-2-HS-glycoprotein   
NP_001624.1 alpha-1-microglobulin/bikunin preproprotein  
NP_001630.1 serum amyloid P component precursor  
NP_001634.1 apolipoprotein A-II preproprotein  
NP_001638.1 apolipoprotein D precursor   
NP_001701.2 complement factor B preproprotein  
NP_001724.3 complement component 1, r subcomponent  
NP_001726.2 complement component 5 preproprotein  
NP_001728.1 complement component 9 precursor   
NP_001804.2 centromere protein E   
NP_001822.2 clusterin isoform 1   
NP_002069.2 golgi autoantigen, golgin subfamily a, 4  
NP_002075.2 glutathione peroxidase 3 precursor   
NP_002105.2 human immunodeficiency virus type I enhancer 
NP_002206.2 inter-alpha (globulin) inhibitor H1  
NP_002207.2 inter-alpha globulin inhibitor H2 polypeptide 
NP_002208.3 inter-alpha (globulin) inhibitor H3 preproprotei 
NP_002209.2 inter-alpha (globulin) inhibitor H4  
NP_002263.2 keratin 4   
NP_002266.2 keratin 15   
NP_002606.3 serine (or cysteine) proteinase inhibitor, clade 
NP_002955.2 S100 calcium-binding protein A8   
NP_002956.1 S100 calcium-binding protein A9   
NP_003269.2 C-type lectin domain family 3, member B  
NP_003310.3 titin isoform N2-B  
NP_004039.1 beta-2-microglobulin precursor   
NP_004229.1 thyroid hormone receptor interactor 12  
NP_004961.1 insulin-like growth factor binding protein, acid l 
NP_005132.2 fibrinogen, beta chain preproprotein  
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NP_005134.1 haptoglobin isoform 1 preproprotein  
NP_005546.2 keratin 6B   
NP_005568.2 lipoprotein Lp(a) precursor   
NP_006112.3 keratin 1   
NP_006253.2 peripherin  
NP_006503.1 serum amyloid A4, constitutive  
NP_006653.2 Snf2-related CBP activator protein  
NP_006735.2 retinol-binding protein 4, plasma precursor  
NP_009117.2 centrosomal protein 2 isoform 1  
NP_009224.2 complement component 4A preproprotein  
NP_036192.2 dynamin 1-like protein isoform 1  
NP_036375.1 solute carrier family 35 member 3A   
NP_055542.1 myeloid/lymphoid or mixed-lineage leukemia 4  
NP_055704.2 metalloprotease 1  
NP_055836.1 zinc finger protein 292  
NP_055861.3 senataxin  
NP_055907.3 PI-3-kinase-related kinase SMG-1  
NP_059672.2 MAP/microtubule affinity-regulating kinase 2 isoform 
NP_060719.4 CDK5 regulatory subunit associated protein 2 isoform 
NP_065076.2 akt substrate AS250  
NP_066275.3 haptoglobin-related protein   
NP_079052.2 NKF3 kinase family member   
NP_110381.2 serum amyloid A2 isoform a  
NP_443204.1 leucine-rich alpha-2-glycoprotein 1  
NP_473375.2 fibronectin 1 isoform 7 preproprotein  
NP_510880.2 myosin 18A isoform a  
NP_570602.2 alpha 1B-glycoprotein precursor   
NP_653247.1 immunoglobulin J chain  
NP_705694.2 keratin 13 isoform a  
NP_835260.2 PDZ domain containing 2  
NP_853512.1 keratin 25  
NP_938073.1 kelch-like 17  
NP_954630.1 serum amyloid A1 preproprotein  
NP_958850.1 complement component 1, s subcomponent  
NP_997639.1 fibronectin 1 isoform 6 preproprotein  
XP_001714007.1 PREDICTED: similar to 22kDa peroxisomal membrane 
XP_001719048.1 PREDICTED: similar to hCG2042722  
XP_001719515.1 PREDICTED: hypothetical protein, partial  
XP_001724477.1 PREDICTED: similar to kappa immunoglobulin  
XP_001724484.1 PREDICTED: hypothetical protein  
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Table 4.9: Identified, differentially expressed proteins, GeLC-MS/MS study 
Legend: Summary of the six differentially expressed proteins identified. UniProtKB reference refers to the Universal Protein Resource database 
and is a unique protein identifier. The number of unique peptides used in the identification of the protein, the expected MW of the protein, the 
gel region in which I detected the protein in maximal abundance, the fold change between in CC compared with gallstone disease cohorts are 
listed. The p-value relates to the t-test between CC and gallstone disease groups. 
Approved protein name  UniProtKB  Unique peptides MW (kDa) Gel region (kDa) Fold change (CC) P-value 
Carboxypeptidase N CPN2_HUMAN 4 58.3 95-110 0.77 0.02 
C-reactive protein CRP_HUMAN  7 25 24-30 2.9 0.009 
Glutathione peroxidase 3 GPX3_HUMAN  4 25.5 24-30 2.0 0.001 
Leucine-rich α-2-glycoprotein 1 A2GL_HUMAN  2 38.2 53-60 2.2 0.002 
Serum amyloid A4 SAA4_HUMAN 2 14.8 18-22 1.7 0.002 
Zinc finger protein 844 ZN844_HUMAN  2 77 250-276 2.2 <0.0001 
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Table 4.10: Results of ROC-AUC and PCA analyses, GeLC-MS/MS study 
Legend: The utility of each identified protein as a diagnostic marker was assessed. The ROC-AUC value is shown, along with 95% confidence 
intervals and the ROC-AUC derived p-value. In the principal components analysis (PCA) only two of the proteins were required to reach the 
optimum model. The β-value of each of these is included in the final column. 
Protein name  ROC-AUC 95% CI p-value β-value 
Carboxypeptidase N 0.87 0.69-1.0 0.015 - 
C-reactive protein 0.91 0.76-1.0 0.008 - 
Glutathione peroxidase 3 0.98 0.93-1.0 0.002 0.363 
Leucine-rich alpha-2-glycoprotein 1 0.93 0.80-1.0 0.005 - 
Serum amyloid A4 0.93 0.81-1.0 0.005 - 
Zinc finger protein 844 0.98 0.93-1.0 0.002 0.626 
 
Chapter 4 – Plasma proteomics 
 197 
Table 4.11: Results of database search for known function and disease associations 
Legend: Summary of database and literature review. UniProtKB v61 was interrogated for each of the six identified proteins. 
PubMed was searched for any combination of each proteins name and the word ‘cancer’.  
Protein Subcellular 
location 
Known function Known disease associations 
Carboxypeptidase N Secreted The 83 kDa subunit binds and stabilizes the catalytic subunit at 37 
degrees Celsius and keeps it in circulation. Under some circumstances 
it may be an allosteric modifier of the catalytic subunit. Important in the 
regulation of peptides like kinins and anaphylatoxins 
Rare cases of hereditary 
angioedema 
C-reactive protein Secreted Promotes agglutination, bacterial capsular swelling, phagocytosis and 
complement fixation through its calcium-dependent binding to 
phosphorylcholine. Can interact with DNA and histones and may 
scavenge nuclear material released from damaged circulating cells. 
Acute phase response to tissue 
injury, or other inflammatory stimuli. 
Non specific elevation in some 
malignancies 
Glutathione 
peroxidase 3 
precursor 
Secreted Protects cells and enzymes from oxidative damage, by catalyzing the 
reduction of hydrogen peroxide, lipid peroxides and organic 
hydroperoxide, by glutathione. 
Low levels have been described in 
a number of malignancies 
Leucine-rich alpha-2-
glycoprotein 1 
Secreted Has been shown to be involved in protein-protein interaction, signal 
transduction, and cell adhesion and development. LRG1 is expressed 
during granulocyte differentiation 
High in acute appendicitis, several 
malignancies – including pancreatic 
Ca and CC. 
Serum amyloid A4 Secreted Apolipoprotein of the HDL complex. Expressed by the liver, secreted 
into plasma 
Major acute phase reactant. Non 
specifically elevated in some 
cancers 
Zinc finger protein 
844 
Nucleus May be involved in transcriptional regulation - 
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Table 4.12: Subject demographics, discovery SELDI-TOF MS study 
Legend: p-values represent the result of χ2 testing of age and ethnicity, K-W ANOVA 
for age.  
 CC PSC HC P-value 
n 18 10 17  
Male n (%) 12 (67%) 9 (90%) 9 (47%) 0.14 
Age (IQ range) 68 (56-74) 39 (30-59) 42 (38-64) <0.01 
Ethnicity     
 Caucasian (%) 15 (83%) 10 (100%) 14 (82%) 0.37 
 Other 3 0 3 0.37 
  Asian 2 0 3  
  African 1 0 0  
  Unknown 0 0 0  
Institution      
 ICH (%) 9 (50%) 0 9 (50%) - 
 UCH (%) 9 (53%) 0 8 (47%) - 
 Norway 0 10 (100%) 0 - 
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Table 4.13: Principal results of SELDI-TOF MS experiments.  
Legend: P-values from the initial discovery (1o) study for each significantly different m/z peak are shown first. P-values from the new cases 
analysed in the validation cohort are then shown. P-values from the repeated analysis of the discovery cohort (2o) are then shown. Where 
possible, subgroup analyses of UCH and ICH cohorts are shown. Comparisons between UK and Norwegian PSC samples are also shown. CC 
– cholangiocarcinoma cohort, PSC – PSC cohort, HC – healthy control cohort, SI – signal intensity, rSI – relative signal intensity.  
Cohort Comparison 4297/4291 4630/4631 5768/5765 8577/8572 8701/8699 11520/11526 17313/17287 
1o analysis CC vs PSC (p) 0.046 0.036 0.317 0.0176 0.049 0.209 0.022 
discovery cohort CC vs HC (p) 0.054 0.001 0.038 0.0033 0.023 0.034 0.169 
Validation Mean SI CC (rSI) 17.15 2.273 3.032 22.1 36.0 0.850 0.441 
cohort Mean SI PSC (rSI) 17.62 0.899 1.731 25.3 42.4 0.252 0.639 
 Mean SI HC (rSI) 25.49 0.750 1.923 35.9 48.6 0.147 0.838 
 CC vs PSC (p) 0.785 9.7x10-7 2.6x10-4 0.113 0.03 2.6x10-5 0.018 
 CC vs HC (p) 1.2x10-7 1.3x10-11 0.001 9.4x10-13 1.4x10-7 4.2x10-7 9.8x10-8 
 PSC vs HC (p) 4.5x10-6 0.024 0.25 1.3x10-7 0.0168 0.029 0.03 
 Nor PSC vs UK PSC (p) 0.461 0.46 0.37 0.56 0.75 0.34 0.30 
 ICH CC vs ICH HC (p) 5.0x10-4 3.6x10-6 0.007 2.0x10-7 4.5x10-4 7.5x10-5 3.6x10-5 
 UCH CC vs UCH HC (p) 7.0 x10-4 1.2x10-7 0.354 1.5x10-4 0.006 0.028 0.014 
2o analysis CC vs PSC (p) 0.1747 0.02 0.266 0.203 0.58 0.19 0.54 
discovery cohort CC vs HC (p) 3.0x10-4 0.001 0.104 5.9x10-4 0.016 0.044 0.129 
Summary  ↓CC, ↓PSC ↑CC, ↑PSC ↑CC ↓CC and ↓PSC ↓CC, ↓PSC ↑CC, ↑PSC ↓CC and ↓PSC 
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Table 4.14: Subject demographics, validation SELDI-TOF MS study 
Legend: p-values represent the result of χ2 testing of age and ethnicity, K-W ANOVA 
for age.  
 CC PSC HC p-value 
n 81 54 90  
Male n (%) 46 (57%) 41 (76%) 48  (53%) 0.02 
Age (IQ range) 66 (58-78) 42 (31-51) 42 (33-55) <0.001 
Ethnicity     
 Caucasian (%) 53 (65%) 48 (89%) 51 (57%) <0.001 
 Other 28 6 39  
  Asian 16 5 36  
  African 8 0 3  
  Unknown 4 1 0  
Institution     
 ICH (%) 48 (59%) 1 (2%) 65 (72%) <0.001 
 UCH (%) 33 (41%) 12 (22%) 25 (28%) <0.001 
 Norway (%) 0 41 (76%) 0 - 
 
Table 4.15 Matching of discovery m/z peak values with validation m/z 
peak values 
Legend: The calculated permissible +/-0.15% range is shown for each peak from the 
discovery study. Δ – actual difference between m/z peak identified in discovery study 
and its matched partner in validation study. 
m/z discovery 4297 4630 5768 8577 8701 11520 17313 
+/- 0.15% (Da) +/-6 +/-6 +/-9 +/-13 +/- 13 +/-18 +/- 26 
m/z validation 4291 4631 5765 8572 8699 11526 17287 
Δ (Da)  6  1  3  5  2  6  26  
Δ  (%) 0.14% 0.02% 0.05% 0.06% 0.02% 0.05% 0.15% 
 
  
Chapter 4 – Plasma proteomics 
 201 
Table 4.16: Subject demographics, combined SELDI-TOF MS cohorts 
Legend: p-values represent the result of χ2 testing of age and ethnicity, K-W ANOVA 
for age.  
 CC PSC HC p-value 
n 99 64 107  
Male n (%) 58 (59%) 50 (78%) 57 (53%) 0.005 
Age (IQ range) 68 (55-74) 42 (31-52) 42 (34-57) <0.001 
Ethnicity     
 Caucasian (%) 68 (69%) 58 (91%) 65 (61%) <0.001 
 Other 31 6 42  
  Asian (%) 18 (18%) 5 (8%) 39 (36%)  
  African 9 (9%) 0 3 (3%)  
  Unknown 4 (4%) 1 (1%) 0  
Institution      
 ICH (%) 57 (58%) 1 (2%) 74 (69%) <0.001 
 UCH (%) 42 (42%) 12 (18%) 33 (31%) <0.001 
 Norway (%) 0 51 (80%) 0  
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Table 4.17: Routine laboratory indices, combined SELDI-TOF MS CC 
cohort 
Legend: Routine laboratory values were not available for healthy control subjects. 
Where adequate number of values permits, p-value from a M-W U test between CC 
and PSC groups is shown. NS – not significant. 
 CC PSC p-value 
Ur (mmol/L) 5.9 (3.9-8) 5.2 (-) - 
Cr (μmol/L) 70 (62-81) 82 (-) - 
Bili (μmol/L)  20 (10-77) 24 (12-41) NS 
ALP (IU/L) 263 (143-607) 217 (124-395) NS 
ALT (IU/L) 46 (24-80) 91 (52-131) <0.00001 
Alb (g/L) 30 (27-35) 40 (36-43) <0.00001 
CRP (mg/L) 38 (14-83) 3.9 (1.7-11) <0.00001 
WCC (x109/L) 6.6 (5.5-10.5) 6.3 (4.8-7.7) NS 
AFP (ng/mL) 5 (2.5-5.5) 4 (3-5) NS 
Cea (μg/L) 3 (1.9-10.5) 1.45 (1.2-2.0) 0.00200 
CA19-9 (IU/mL) 216 (24-1000) 22 (17-39) 0.00040 
 
Table 4.18: Anatomical location of tumour, combined SELDI-TOF MS CC 
cohort 
Legend: Breakdown of the 99 CC subjects by site of primary biliary malignancy. % is 
of total where anatomical location known. 
Site of disease n (%) 
  Intrahepatic CC 10 (11%) 
  Hilar CC 59 (66%) 
  Distal CC 20 (23%) 
Total known 89 
  Indeterminate location CC 10 
Grand total 99 
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Table 4.19: ROC-AUC analysis of 7 peaks of interest 
Legend: P-value derived from ROC-AUC analysis. Sens – sensitivity, spec - 
specificity 
Peak 4291 4631 5765 8572 8699 11526 17287 
P-value CC/PSC 0.7851 <0.001 <0.001 0.1139 <0.001 <0.001 0.018 
AUC-ROC 0.55 0.76 0.63 0.61 0.69 0.73 0.61 
Sens/Spec (%) 65/51 83/57 63/52 65/51 70/51 79/56 63/56 
P-value CC/HC <0.001 <0.001 <0.001 < 0.001 <0.001 <0.001 <0.001 
AUC-ROC 0.76 0.82 0.59 0.82 0.74 0.83 0.72 
Sens/spec (%) 88/54 89/57 65/49 91/63 89/54 83/64 75/56 
 
Table 4.20: Correlation matrix of the seven significant peaks 
Legend: Values in matrix are R2 for the correlation between the pair of m/z peaks. 
Values in in the matrix in bold text represent significant correlation (p<0.05) 
m/z 4291 4631 5765 8572 8699 11526 17287 
4291 1       
4631 0.03 1      
5765 0.01 0.01 1     
8572 0.89 0.01 0.03 1    
8699 0.51 0.01 0.01 0.52 1   
11526 0.00 0.00 0.70 0.00 0.00 1  
17287 0.06 0.00 0.00 0.06 0.06 0.01 1 
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Table 4.21: Correlation matrix of the seven significant peaks and routine 
laboratory indices 
Legend: Number in matrix represent R2 values. Pairwise exclusion of missing data. 
 4291 4631 5765 8572 8699 11526 17287 
Ur 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
Cr 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Bili 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Alp 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
Alt 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Alb 0.01 0.05 0.05 0.02 0.02 0.07 0.00 
CRP 0.00 0.04 0.15 0.01 0.00 0.20 0.00 
WCC 0.00 0.00 0.01 0.00 0.00 0.02 0.00 
AFP 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Cea 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
CA199 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
Table 4.22: Summary of multiple linear regression analysis of the seven 
significant peaks 
Legend: Settings: F to include 3.5, F to exclude 3.4, max number of steps 
100. 
Peak (m/z)  Β-value F to exclude No. of steps ROC-AUC (95% CI) 
CC vs. PSC   4 0.76 (0.68-0.82) 
11526 .236 9.97179   
17287 -.17 5.19979   
4631 .141 3.51676   
CC vs. HC   6 0.90 (0.85-0.94) 
8572 -.91 27.33   
4291 .563 10.99   
11526 .793 18.38   
5765 -.62 11.81   
4631 .119 4.46   
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Table 4.23: Analysis of six subjects with CC and PSC  
Legend: Limited analysis of six additional subjects with CC and PSC. Comparison is 
only between these six cases and 64 PSC only subjects in the three peaks of 
principal interest in discriminating CC from PSC in the principal study. 
 
Peak MW-U test p-value ROC-AUC ROC 95% CI ROC p-value 
4631 0.01 0.82 0.70-0.94 0.01 
11526 0.10 0.70 0.50-0.94 0.10 
17287 0.44 0.60 0.37-0.82 0.44 
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Table 4.24: Results of m/z database search for seven peaks of interest, SELDI-TOF MS study 
Legend: Each of the seven m/z peak values, +/- 0.1%, was searched in turn in TagIdent (ExPASy, Swiss institute of bioinformatics). The 
number of protein hits for each m/z peak is give, the UniProt code, approved name and consensus molecular weight of the protein. The 
classification of each candidate protein, its known function and known disease associations are listed. Candidate proteins empirically 
considered of particular logical interest are highlighted in bold.  
m/z  ↑ /↓ in CC UniProt Code Approved name MW Classification Known function Known disease 
association 
4291 ↓ EDN1_HUMAN Big endothelin-1 4273 Secreted Endothelium-derived vasoconstrictor peptide - 
  MICB_HUMAN Isoform 3 of MHC class I polypeptide-related sequence 4276 Cell membrane Stress-induced s elf-antigento T cells Released from epithelial tumours, 
inc HCC 
  ADM2_HUMAN Intermedin-short (Potential) 4287 Secreted hormone Regulation of gastrointestinal function  
  DSCR8_HUMAN Isoform 4 of Down syndrome critical region protein 8  4287 Membrane - - 
4631 ↑ CCKN_HUMAN Cholecystokinin-39 4626 Secreted, hormone Induces gall bladder contraction  - 
  LST1_HUMAN Isoform 7 of Leukocyte-specific transcript 1 protein  4629 Cellular membrane Modulating B cell immune response - 
  RBMS1_HUMAN Isoform 4 of RNA-binding motif, single-stranded-interacti 4632 Nucleus DNA replication - 
5765 ↑ PRB2_HUMAN Basic proline-rich peptide IB-7 5737 Secreted - - 
  KTAS1_HUMAN Putative uncharacterized protein KTN1- AS1 5753 Dubious prediction - - 
8572 ↓ SAPL1_HUMAN Saposin B-Val-like (By similarity). 8569 Secreted Lysosomal degradation of sphingolipids - 
  LZTS1_HUMAN Isoform 7 of Leucine zipper putative tumour suppressor 1  8571 Cytoplasmic Tumour supressor - 
  U2AF1_HUMAN Isoform 3 of Splicing factor U2AF 35 kDa subunit  8572 Nuclear Mediating protein-RNA interactions - 
  NARG2_HUMAN Isoform 2 of NMDA receptor-regulated protein 2  8572 Nuclear - - 
  BAALC_HUMAN Isoform 4 of Brain and acute leukemia cytoplasmic protein 8573 Cytoplasmic interacting with CAMK2A Acute leukaemia 
  IGLL1_HUMAN Isoform 2 of Immunoglobulin lambda-like polypeptide 1  8574 Secreted Critical for B-cell development Agammaglobulinemia type 2 (AGM2) 
  SAA1_HUMAN Amyloid protein A 8575 Secreted Major acute phase reactant Amyloidosis 
  UBB_HUMAN Ubiquitin 8575 Cytoplasm/ Regulation of protein trafficking In tissue of neurodegenerative 
disease 
  ISK8_HUMAN Serine protease inhibitor Kazal-type 8. 8579 Secreted Serine protease inhibitor - 
  APOA2_HUMAN Truncated apolipoprotein A-II. 8580 Secreted HDL metabolism - 
8699 ↓ PAOX_HUMAN I12 of Peroxisomal N(1)-acetyl-spermine/spermidine 8685 Cytoplasm Polyamine conversion Low level in neoplastic tissues 
  CC078_HUMAN UPF0640 protein C3orf78 8695 Membrane -  
  SPIT4_HUMAN Kunitz-type protease inhibitor 4 8696 Secreted - - 
11526 ↑ LV101_HUMAN Ig lambda chain V-I region VOR 11515 Immunoglobulin - This is a Bence-Jones protein 
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  COBL1_HUMAN Isoform 5 of Cordon-bleu protein-like 1  11516 Not known - - 
  RT16_HUMAN 28S ribosomal protein S16, mitochondrial 11516 Mitochondrial - COXPD2): fatal neonatal metabolic 
acidosis 
  LV403_HUMAN Ig lambda chain V-IV region Hil. 11517 Immunoglobulin - Myeloma 
  MRAP_HUMAN Isoform 2 of Melanocortin-2 receptor accessory protein  11519 Cytoplasmic Intracellular trafficking pathways adipocytes - 
  CHCH7_HUMAN Isoform 2 of Coiled-coil-helix-coiled-coil-helix domain 11520 Mitochondrial - Benign epithelial tumours of the 
salivary gland 
  VPRE3_HUMAN Pre-B lymphocyte protein 3 11520 Immunoglobulin B cell maturation - 
  LV107_HUMAN Ig lambda chain V-I region BL2. 11522 Immunoglobulin Complement activation - 
  ATP7A_HUMAN Isoform 6 of Copper-transporting ATPase 1 11522 Golgi membrane - Menkes disease (curly hair 
syndrome) 
  SAA1_HUMAN Serum amyloid protein A(2-104) 11527 Secreted  - Major acute phase reactant 
  CD28_HUMAN Isoform 2 of T-cell-specific surface glycoprotein 11528 Membrane T-cell activation - 
  ENY2_HUMAN Enhancer of yellow 2 transcription factor homolog 11529 Nucleus Transcription factor - 
  CREM_HUMAN Isoform 20 of cAMP-responsive element modulator  11535 Nucleus Spermatogenesis - 
17287 ↓ BT3L4_HUMAN Transcription factor BTF3 homolog 4 17271 Nucleus Transcription factor - 
  XG_HUMAN Glycoprotein Xg. 17272 Cell membrane Xg blood group system - 
  3HAO_HUMAN Isoform 2 of 3-hydroxyanthranilate 3,4-dioxygenase  17275 Cytoplasm Fe2+ ion synthesis - 
  YV012_HUMAN Isoform 2 of Leucine-rich repeat-containing protein LOC40 17279 Cytoplasm - - 
  NTCP7_HUMAN Isoform 5 of Sodium/bile acid cotransporter 7 17283 Membrane Ion transport - 
  MSRB2_HUMAN Methionine-R-sulfoxide reductase B2, mitochondrial. 17288 Mitochondrial Reduction of methionine sulf. - 
  FXYD5_HUMAN FXYD domain-containing ion transport regulator 5 17292 Membrane Regulation of E-cadherin Promotes metastases 
  TMM80_HUMAN Isoform 2 of Transmembrane protein 80  17292 Membrane - - 
  MFAP5_HUMAN Microfibrillar-associated protein 5 17294 Secreted Component of the elastin-associated microfibrils - 
  CX038_HUMAN Isoform 3 of Uncharacterized protein CXorf38  17295 Uncharacterised - - 
  TTC32_HUMAN Tetratricopeptide repeat protein 32 17296 Repeat peptide - - 
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Table 4.25: Summary of m/z peaks previously identified as of interest in SELDI-TOF MS studies of HPB cancer 
Legend: Peaks of interest are listed and highlighted in bold where the study analysis identified it to be of particular interest. Panc Ca – 
pancreatic cancer. 
1st author[ref] Disease Year Country Journal Chip type Peaks of interest  Comment  
Scarlett[360] CC 2006 Australia Hepatology H50 4462, 4560, 5382, 17266,4462, 4560, 
5382, 5660, 5947, 6433, 6632, 6841, 
8528, 8691, 11535, 11697 
- 
Liu[399] CC 2008 China J cell biochem. Not known 1376, 1388, 1404 All 3 identified as transthyretin 
Navaglia[400]  Panc 
Ca 
2009 Italy Clin Chem Lab Med.  Imac 30 1526, 1211, 3519 - 
Zinkin[401]  HCC 2008 USA Clin Cancer Res.  CM10, IMAC30 and H50 13391 ID: cystatin C 
Okabe[402] IHCC 2012 Japan Cancer Research - 8360 Cell culture study. ID: epithelial 
cell-derived neutrophil-
activating peptide-78 
Wang[403] CC 2009 China Eur J Cancer Care IMAC30 28078  ID: apolipoprotein A-I (ApoA-I) 
Wang  CC 2010 China Cancers  
 
IMAC30 2170, 2967, 3300 3400, 4188, 4503, 
4906, 5630, 5681, 7598, 7797, 10875 
11167, 11242 
NB: Not on PubMed 
Kikkawa[404]  CC  2012 Japan International Journal 
of Proteomics 
 
Weak ion exchange 4204 Used MALDI. ID: prothrombin 
fragement 
Qian[405] Panc 
Ca 
2012 China Asian Pacific J 
Cancer Prev 
Weak ion beads, then 
plain gold chips 
7762, 8560, 11654 - 
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Table 4.26: Peaks from SELDI-TOF MS study matched with m/z peaks previously associated with CC or pancreatic CC in 
SELDI studies. 
Legend: Matched peaks fell within 0.15% of each other. Panc Ca – pancreatic cancer. 
My peak ↑ /↓ in CC Matched ↑ /↓  in CC Paper Disease m/z protein ID? 
8572 ↓ 8560 ↑ Qian[405] Panc Ca No 
8699 ↓ 8691 ↓ Scarlett[360] CC No 
11526 ↑ 11535 ↑ Scarlett CC No 
17287 ↓ 17266 ↓ Scarlett CC No 
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Figure 4.1: Standard workflow for GeLC-MS/MS studies 
Legend: Adapted from Griffiths et al 2009[370] 
 
 
 
Figure 4.2: Overview of label-free proteomics (I) 
Legend: Schematic of 1D SDS-PAGE and proteolytic digestion. Adapted from 
images provided courtesy of Dr V Horneffer-van der Sluis. 
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Figure 4.3: Overview of label-free proteomics (II)  
Legend: LC-MS/MS to protein identification. Adapted from images provided courtesy 
of Dr V Horneffer-van der Sluis. 
 
 
Figure 4.4: Illustration of available ProteinChip® active surfaces available 
for SELDI-TOF MS  
Legend: The crude plasma sample is placed onto the ProteinChip spot. Proteins bind 
to the chemical or biological ‘docking sites’ on the surface. Adapted from images 
provided courtesy of Dr V Horneffer-van der Sluis. 
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Figure 4.5: CM10 and H50 chip surface interactions 
Legend: The properties of the two surfaces that I selected for use in my SELDI-TOF 
MS experiments. (A) CM10. An anionic surface with carboxylate groups that interact 
with positively charged residues on proteins (e.g. lysine, arginine, histidine). (B) H50. 
A hydrophobic surface that binds to hydrophobic residues on the protein (e.g. 
alanine, valine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine). Adapted 
from images provided courtesy of Dr V Horneffer-van der Sluis. 
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Figure 4.6: Schematic diagram of the Ciphergen® SELDI-TOF mass 
spectrometer 
Legend: Showing the chip surface (Y), application of a laser and TOF MS measuring 
the molecular weights of the various proteins that are vaporised from the chip 
surface. The m/z ratios are represented in the spectra obtained. (Adapted from Issaq 
et al 2002)[406]  
 
 
Figure 4.7: Workflow for protein depletion using the IgY12 Seppro 
Column 
Legend: The 12 most abundant human plasma proteins are bound within the column, 
depleting the levels remaining within the plasma sample. 
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Figure 4.8: Layout of gels, GeLC-MS/MS study 
Legend: Mrker – marker (protein standard (PageRuler, Fermentas, UK)). * - empty 
lane. 
Gel 1             
 Lane 1 2 3 4 5 6 7 8 9 10  
 Sample Mrkr BB5 BB6 BB7 * CC6 CC8 CC9 CC10 Mrkr  
 Volume 5μL 20μL 20μL 20μL * 20μL 20μL 20μL 20μL 5μL  
             
Gel 2             
 Lane 1 2 3 4 5 6 7 8 9 10  
 Sample Mrkr BB1 BB2 BB3 BB4 CC1 CC2 CC4 CC5 Mrkr  
 Volume 5μL 20μL 20μL 20μL 20μL 20μL 20μL 20μL 20μL 5μL  
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Figure 4.9: Gel run to test efficacity of IgY depletion process 
Legend: Lanes 1 and 10 contain protein standard (PageRuler, Fermentas, UK). 
Paired samples of raw and depleted from 2 CC and 2 benign subjects were run in 
lanes 2-9. Substantial depletion of the albumin band (arrowed) can be seen. 
 
 
Figure 4.10: Image of gels from GeLC-MS/MS study  
Legend: Samples were applied according to the plan in Figure 4.8. Planned cut up is 
demarcated according to protein standard lines in lanes 1 & 10. 
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Figure 4.11: Representative results from preliminary SELDI-TOF MS 
CM10 condition optimisation experiments 
Legend: The same sample has been applied to multiple spots on CM10 chips. 
Different combinations of pH and energy absorbing matrix (EAM) have been used, 
permitting comparison of spectral peak resolution and signal intensity. 
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Figure 4.12: Representative results from preliminary SELDI-TOF MS H50 
condition optimisation experiments 
Legend: The same sample has been applied to multiple spots on CM10 ships. 
Different combinations of ACN concentration and EAM have been used, permitting 
comparison of spectral peak resolution and signal intensity. 
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5. Neutrophil gelatinase-associated lipocalin (NGAL) as a 
potential blood plasma biomarker for CC  
5.1 Background 
5.1.1 Current biomarkers 
As discussed in Chapter 4, biomarkers circulating in the blood of patients with CC 
offer an attractive theoretical target for new diagnostic and prognostic tests. Current 
clinical biomarkers of CC, such as CA19-9, have suboptimal sensitivity and 
specificity, particularly in early stage disease, or on the background of PSC and other 
benign biliary conditions. There is, therefore, a need for new biomarkers for earlier 
diagnosis of CC and potentially for screening in high-risk groups. Previous work from 
the cholangiocarcinoma group at Imperial College London, to which I contributed, 
has identified neutrophil gelatinase-associated lipocalin (NGAL) in bile as a potential 
biomarker of CC.  
5.1.2 Neutrophil gelatinase-associated lipocalin (NGAL) 
NGAL is also known variously as lipocalin-2, siderocalin, oncogene 24p3, migration 
stimulating factor inhibitor, alpha1-microgobulin related protein and uterocalin.[407] 
NGAL is a member of the lipocalin family of small, secreted glycoproteins that 
transport small hydrophobic ligands. An extensive body of literature has emerged 
over the last 10 years, demonstrating the considerable interest in the function of this 
molecule in health and disease and its potential as a biomarker of disease.  
5.1.2.1 Physiological functions of NGAL 
NGAL is a 25kDa protein that is expressed by activated neutrophils, and a wide 
range of other cells, including epithelial cells of the breast, bone marrow, kidney, 
liver, lungs, small intestine and prostate.[408, 409] Human cell line and in vivo mouse 
studies have elucidated important roles of NGAL in health and disease. The main 
known function of NGAL is the transport of iron particles into the cell cytoplasm via 
interaction with specific membrane receptors (24p3R).[410] NGAL has a strong affinity 
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for bacterial iron binding siderophores, which are critical for the proliferation of many 
gram-negative bacterial species. NGAL bound siderphores are transported into the 
host cell cytoplasm, reducing the free iron available to bacteria and thereby exerting 
a bacteriostatic effect.[411, 412]  Some authors have described NGAL as a stress 
protein or cytokine, as it appears to have pro-inflammatory effects. Increased 
expression in mouse and human models of lung injury has been demonstrated, as 
has a strong chemoattractive effect on neutrophils.[408, 413] After intravenous injection 
of E. coli into mice, NGAL levels in the plasma and liver rapidly become elevated.[414] 
In human cell line and in vivo murine experiments, NGAL seems to have strong 
antioxidant effects, counteracting oxidative stress and thereby increasing cellular 
resistance to cytotoxic species and apoptotic signals.[415-418]  
5.1.3 NGAL in benign disease 
NGAL has been shown to modulate several benign diseases. Its expression appears 
to promote inflammation in atherosclerotic plaques, likely through its association with 
MMP8 and MMP9, promoting proteolytic activity of MMP.[419] NGAL is known to 
mediate proliferation of renal tubules in mice and reduced NGAL expression has 
been implicated in some disorders of renal tubule proliferation.[420] NGAL has also 
been shown to suppress red blood cell production in models of anaemia.[421] 
Elevated NGAL levels have been demonstrated in human psoriatic skin, myocarditis 
and the plasma of patients with untreated HIV disease.[422-425] Elevation of plasma 
NGAL has also been demonstrated in patients with hypertension, severe adult 
respiratory syndrome (SARS), carotid atherosclerosis and acute myocardial 
infarction.[426-430] Obstetric studies have shown increased plasma NGAL levels in 
women with gestational diabetes and preeclampsia.[431, 432] NGAL levels rise after 
administration of some drugs, including alcohol and methamphetamine.[433-435] In a 
mouse study, deliberate administration of hepatotoxic agents caused an increase of 
NGAL in the hepatocytes, biliary epithelial cells, plasma and urine. The NGAL rise 
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was proportional to the degree of liver injury induced.[435] Some utility of plasma or 
urinary NGAL as a diagnostic or prognostic biomarker has been demonstrated in a 
variety of inflammatory conditions including peritonitis, sepsis of any cause and 
Crohn’s disease.[436-438] 
The role of NGAL in acute kidney injury (AKI), and its potential as a diagnostic and 
prognostic biomarker, has been most extensively investigated.[439] Animal studies 
demonstrate NGAL release from injured renal tubules, with subsequent transport into 
the blood stream and urine.[430, 440] Creatinine is the most commonly used index of 
renal function, but lacks sensitivity in early AKI.[441] Plasma and urinary levels of 
NGAL become elevated very early in the course AKI and correlate with degree of 
renal failure as well as poor 28-day survival – with diagnostic and prognostic 
performance superior to that of creatinine.[442-444] Plasma and urinary NGAL assays 
are now available commercially, in kit form, and are being utilised in clinical practice 
in some renal units.[445] 
5.1.4 NGAL in malignant disease 
The role of NGAL in carcinogenesis has been explored extensively and a variety of 
influences on tumour development have been shown. Some effects appear 
contradictory and many vary between cancer types. A pro-proliferative and anti-
apoptotic influence has been illustrated in in vivo murine experiments with thyroid 
cancer cells. Silencing of NGAL resulted in marked reduction in tumour clonogenic 
growth and tumour size. In vitro studies on the same NGAL deplete cells 
demonstrated marked increase in apoptosis.[446] Similar effects have been seen in 
models of endometrial cancer.[447] Rapid increased expression of NGAL in breast and 
lung cancer as a response to various different apoptosis inducing stimuli has been 
shown, with consequent significant reduction in the rate of apoptosis.[448, 449] In colon 
cancer cell lines and mouse models, NGAL expression appears to decrease 
invasiveness and liver metastasisation.[450, 451] 
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Elevated plasma NGAL has been investigated as a potential biomarker in a number 
of malignant conditions. In clinical studies of breast[452], ovarian[453, 454] colorectal[455], 
gastric[456] and renal cell carcinomas[457], plasma NGAL was significantly increased in 
malignant groups. In breast, colorectal and renal cancer studies, some utility in 
prognostication was also demonstrated. 
5.1.5 Biliary NGAL in hepatopancreatobiliary malignancy 
In vivo studies of murine models of HCC show that NGAL becomes markedly 
upregulated in the liver tissue early on in the process of malignant transformation.[458] 
Functional studies of HCC cells lines show that expression of NGAL actually 
decreases proliferation and invasiveness. NGAL expressing HCC cells implanted into 
mice show markedly reduced tumour growth.[459][55] 
Ectopic over-expression of NGAL in pancreatic cancer cell lines resulted in reduction 
of cell adherence and invasion. No effect on proliferation or sensitivity to 
chemotherapeutic drugs was seen in vitro. However, when implanted, pancreatic 
cancer cells expressing NGAL produced smaller tumours, with markedly reduced 
metastatic spread.[448]  
NGAL is expressed very weakly, or not at all, in normal pancreatic epithelial cells. It 
is universally expressed at high levels in pancreatic cancer.[460, 461] A study of NGAL 
in pancreatic juice from patients with pancreatic cancer or chronic pancreatitis and 
healthy controls was able to discriminate cancer patients from healthy controls with a 
receiver operator characteristic area under the curve (ROC AUC) of 0.9, and chronic 
pancreatitis from healthy controls with a ROC AUC of 0.87, but could not discriminate 
chronic pancreatitis from pancreatic cancer. Plasma NGAL levels were also elevated 
in pancreatic cancer and chronic pancreatitis, when compared to healthy controls 
(mean values of 103.5, 108.9 and 67.4 ng/mL respectively). Pancreatic cancer and 
chronic pancreatitis patients could be discriminated from healthy controls, but not 
from each other.[407][54] 
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5.1.6 Prior NGAL work by my group 
Recently published work from the Imperial College cholangiocarcinoma research 
group, to which I contributed, utilised a label-free proteomic approach on bile 
samples collected from patients with pancreatobiliary disease and identified a 
promising new biliary biomarker for malignancy. In a discovery cohort of 22 benign 
cases and 16 subjects with malignant disease, gel electrophoresis followed by LC-
MS/S was used to identify proteins that were differentially expressed in the malignant 
group. NGAL was found to be elevated, and this was confirmed with further 
immunoblotting studies. Our findings were then confirmed in a validation cohort of 14 
benign and 7 malignant cases. On its own, NGAL concentration had a ROC-AUC of 
0.76, sensitivity of 94% and specificity of 55%. PPV was 60% and NPV 92%. These 
findings were independent of plasma markers of pancreatobiliary disease such as 
CA19-9. Combining biliary NGAL levels with plasma CA19-9 levels improved the 
diagnostic performance with sensitivity of 85%, specificity of 82%, PPV of 79% and 
NPV of 87%.[364] 
5.1.7 Rationale for study 
The hypothesis free, proteomic study described above identified NGAL as a 
promising marker of pancreatobiliary malignancy in bile. Although potentially very 
useful, collecting human bile requires invasive, and expensive, procedures such as 
ERCP or PTC, which are not without risk to the patient. A blood test would be more 
acceptable to patients and healthcare funders, especially if it could be used in a 
screening context. NGAL is a small, well-conserved molecule. Plasma NGAL is now 
regarded as a robust clinical biomarker of acute kidney injury and some utility as a 
biomarker has also been demonstrated in a variety of malignant diseases. This offers 
clear evidence that NGAL can be shed from a primary disease site and then be 
usefully detected in downstream biofluids, such as blood (plasma). 
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5.2 Hypothesis and aim of study 
5.2.1 Hypothesis 
I hypothesised that plasma NGAL would be elevated in patients with CC, compared 
to healthy controls and to patients with PSC. 
5.2.2 Aim 
To determine the potential utility of plasma NGAL concentrations in the diagnosis of 
cholangiocarcinoma. 
5.3 Materials and methods 
5.3.1 Ethics  
The study protocol conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki. Approval from the local Research Ethics Committee and NHS R&D 
Department was sought and obtained for this study (Ref 09/H0712/82). All 
participants provided written, informed consent. 
5.3.2 Subjects 
5.3.2.1 CC patients 
I recruited subjects with CC from the gastroenterology clinics and ERCP lists at 
Imperial College London Healthcare NHS Trust (ICH) and University College 
Hospitals NHS Trust (UCH). CC patients were considered for recruitment if their 
diagnosis was secured on the basis of a) pre- or post-operative histology or b) 
multidisciplinary team consensus on the basis of ≥2 imaging modalities, clinical 
course and plasma markers. 
5.3.2.2 PSC patients 
I recruited PSC patients in a similar fashion, from specialist hepatology clinics at ICH 
and UCH. The diagnosis of PSC was determined on the basis of clinical course, prior 
imaging, consistent autoantibody titres and, where available, biopsy results. Patients 
with advanced cirrhosis (Child-Pugh B or C, Table 4.1) were excluded, as were 
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patients who had undergone previous liver transplantation. Patients currently being 
investigated for suspected cholangiocarcinoma were excluded. However, patients 
with known dominant strictures that had been fully investigated were included. To 
reach an adequate cohort size, I approached collaborators at the Norwegian PSC 
Research Center (NoPSC), Rikshospitalet, Oslo, Norway. They were able to provide 
plasma samples from well-characterised PSC patients, with on going consent in 
place for use in studies of liver disease.  
5.3.2.3 Healthy controls 
Healthy volunteers were recruited at ICH and UCH. After completing a short, 
confidential health questionnaire, individuals with no current inflammatory or 
malignant disease, or liver disease of any sort, were recruited. Healthy controls had 
blood samples collected according to the same SOP and disease subjects. As these 
were healthy controls, undergoing no current investigation in the NHS, standard 
laboratory blood test results could not be collected. 
5.3.3 Sample collection 
Where samples were collected prospectively, I used my standard operating 
procedure (SOP, Appendix 1). For protein studies, 4mL of whole blood was drawn 
into an EDTA tube, immediately placed onto ice and processed within 1 hour.  
I collected demographic data, including age, sex, ethnicity, and short medical history 
onto my case record form (CRF, Appendix 2). Where available, the most recent 
routine clinical laboratory indices were also documented, including white cell count, 
C-reactive protein (CRP), CA19-9, alkaline phosphatase, bilirubin and creatinine. 
Where available for CC cases, I collated imaging information to determine the 
anatomical location of the CC. 
Plasma samples from the NoPSC archive had been collected according to a strict 
protocol that did not diverge from my SOP significantly. 
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5.3.4 ELISA  
Plasma NGAL (lipocalin-2) quantification was performed in duplicate on plasma from 
each subject using a Quantikine ELISA kit (R&D Systems, Minneapolis, USA). This is 
a quantitative sandwich enzyme immunoassay technique. 96 well plates, pre-coated 
with monoclonal antibody to NGAL, were used. Samples and standards were 
pipetted into the wells where any NGAL is bound. After rinsing, an alkaline 
phosphatase linked monoclonal antibody specific for NGAL was applied to the 
samples. After a further wash, a substrate solution (nitroblue tetrazolium) was added 
to each well and a colour change, proportional to the amount of NGAL initially bound, 
occurred.  
5.3.4.1 Preparation of reagents 
R&D Systems supplied all reagents, in kit form. I added deionised water to 40mL of 
wash buffer concentrate to prepare a total volume of 1L of wash buffer. I diluted 
40mL of calibration diluent concentrate in 160mL of deionised water to produce 
200mL of calibration diluent. I prepared a series of calibration solutions by initially 
diluting 100µL of a NGAL standard solution (100ng/mL) with 900µl of calibration 
diluent, followed by sequential dilutions with 500µL of diluent (Figure 5.1). I prepared 
my active substrate solution 5 min before use, by combining colour reagents A and 
B. The stop solution and assay diluent that I used were already prepared in the kit. 
5.3.4.2 Sample preparation 
I processed the ELISA plates in batches of two. As NGAL is found in saliva, I used 
gloves and mask when handling all samples and reagents. Aliquots of each sample 
to be assayed were thawed on ice. After placing 20µL of each plasma sample into a 
fresh Eppendorf tube (Eppendorf Ltd, Stevenage, UK), I added 380µL of calibration 
diluent to each sample, resulting in a 20-fold dilution. Samples were then kept on ice 
until applied to the ELISA plates. 
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5.3.4.3 Assay procedure 
i. 100µL of assay diluent was added to each well on the 8 (A-H) by 12 (1-
12) 96 well plates. Columns 1 and 12 of each plate were used for NGAL 
calibration standards. Each plasma sample was run in duplicate. 
Therefore, a total of seven plates were used 
ii. 50µL of each of the calibration standards were added to wells 1A-1G and 
12A-12G and 50µL of pure calibration diluent was added to wells 1H and 
12H 
iii. 50µl of each plasma sample was added to each of a pair of adjacent 
wells. A proforma was used to document the sample ID and 
corresponding wells 
iv. Once samples had been applied to each well, the plates were covered 
with an adhesive film and incubated at 4oC for 2h  
v. The contents of each well were then disposed of by removing the film and 
inverting the plate over a waste sink. All wells were washed 4 times by 
alternately filling with wash buffer and inverting the plate over the sink. 
After the fourth wash, the plates were blotted dry on clean paper towels 
vi. 200µL of NGAL conjugate was then applied to each well, the plates were 
recovered and incubated for a further 2h at 4oC 
vii. The 4x-rinsing step (step v., above) was repeated 
viii. 200µL of substrate solution was added to each well. The plates were 
again covered and incubated for 30min at room temperature in the dark 
ix. 50µL of stop solution was added to each well. The wells were gently 
agitated to ensure full mixing 
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x. The absorbance of each well was read within 10min. An optical 
calorimeter plate reader (Fisher Scientific UK Ltd, Loughborough, UK) set 
at 450nm was used 
5.3.4.4 Calculation of NGAL concentrations 
The absorbance recorded for each well was corrected by subtracting the averaged 
values from the zero wells (1H and 12H) on each plate. A standard curve was then 
produced, by plotting the absorbance value of each standard against its known 
NGAL concentration and defining a line of best fit (Excel, Microsoft). An example of 
such a standard curve, and its defining equation can be seen in Figure 5.2. The 
concentration of NGAL in each sample was determined by reading each absorbance 
value against this graph and multiplying by a factor of 20, to correct for the original 
twenty-fold dilution of each sample. 
5.3.5 Statistical techniques 
5.3.5.1 Descriptive statistics 
Median levels and interquartile range for NGAL, other laboratory values and 
demographic factors were calculated using GraphPad Prism v5 (GraphPad Software 
Inc, La Jolla, CA, USA). 
5.3.5.2 Comparison of NGAL levels 
As the results were from non-paired groups, and were not expected to be normally 
distributed, I used the two-tailed Mann-Whitney U test to compare groups. This is a 
non-parametric test, and was undertaken using GraphPad Prism v5. CC and healthy 
control cohorts were compared first. Differences between CC and PSC cohorts, and 
between PSC and healthy control cohorts, were then sought. Two combined cohorts 
were then investigated; the CC cohort was compared with a combined benign control 
group of PSC and healthy subjects and a combined disease cohort of CC and PSC 
cases was compared to the healthy control cohort. Finally, NGAL levels in the 
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different anatomical subgroups of CC (IHCC, hilar CC and distal CC) were 
compared. 
5.3.5.3 ROC AUC 
I performed a receiver operator characteristic, area under the curve (ROC AUC) 
analysis using GraphPad Prism v5. The area under a ROC curve quantifies the 
overall ability of a test to discriminate between those individuals with the disease and 
those without. The AUC has no units, but is the fraction of the maximum possible 
AUC.  The maximum possible AUC, that of an ideal test, is 1.0 and an entirely non-
discriminatory test has a ROC AUC of 0.5. CC and healthy control cohorts were 
compared first. Differences between CC and PSC cohorts, and between PSC and 
healthy control cohorts, were then sought. Two combined cohorts were then 
investigated; the CC cohort was compared with a combined benign control group of 
PSC and healthy subjects and a combined disease cohort of CC and PSC cases was 
compared to the healthy control cohort. 
5.3.5.4 Correlation with other laboratory indices 
I performed Pearson's correlation analysis to assess relationships between the levels 
of NGAL and other plasma markers, results of which were collected from clinical 
systems at the time of sample collection. Pearson’s generates an R squared (R2) 
value, termed the coefficient of determination. It has a value that ranges from zero to 
one, and is the fraction of the variance in the two variables that is shared. For 
example, if R2=0.32, then 32% of the variance in A can be explained by variation in 
B. Conversely, 32% of the variance in B may be explained by variation in A. The p-
value generated is the result of testing the null hypothesis that there is no correlation 
between A and B in the overall population. It is the chance that random sampling 
would result in a correlation coefficient as far from zero as is observed. Pearson’s 
correlation test was performed with GraphPad Prism v5.  
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5.3.5.5 Exploration of potential confounders 
Non-disease factors that differed between my CC, PSC and HC cohorts and might 
represent confounding factors were explored. Such factors included age, sex, 
ethnicity and site of collection. I conducted Pearson’s correlations of age with NGAL 
in each study cohort to investigate the influence of age on NGAL level. Where 
appropriate, I conducted M-W U testing or Kruskall-Wallace ANOVA as appropriate 
to seek any differences between NGAL across sex, ethnicity and site of collection 
subgroups. Finally, I repeated M-W U to confirm that any differences in NGAL levels 
between the principal cohorts were reproducible in subgroups that excluded each 
confounding factor in turn. These factors were further explored though multiple linear 
regression analysis, detailed in section 5.3.5.7, below. 
5.3.5.6 Performance of routine laboratory indices as biomarkers of CC 
I performed exploratory ROC-AUC analysis of each of the routine laboratory indices 
collected, to permit comparison with NGAL as a putative new marker. As no routine 
laboratory data existed for my healthy controls, I created a hypothetical data set 
using Excel (MS). For each parameter, random values were created that fitted a 
binomial distribution, within that parameter’s normal range. ROC-AUC analysis was 
performed for each laboratory parameter, comparing CC with HC, CC with PSC and 
then PSC with HC. 
5.3.5.7 Multiple linear regression 
5.3.5.7.1 Combination of NGAL with routine laboratory indices 
The hypothecated healthy control indices were also used for this section of analysis. 
I used multiple linear regression to perform a general discriminant analysis using 
STATISTICA (StatSoft Ltd., Milton Keyenes, UK). A forward stepwise technique was 
used with F1 of 1.1 and F2 of 1.0, with a maximum number of steps of 15. Included 
parameters were plasma urea, creatinine, CRP, ALT, ALP, bilirubin, CA19-9, white 
cell count, albumin and NGAL. The final model reached was then applied to the 
subjects in each cohort to create a set of values that could be subject to repeat ROC-
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AUC analysis (GraphPad Prism). The CC cohort was first compared to the HC 
cohort. The analysis was then repeated to compare the PSC and HC cohorts. 
5.3.5.7.2 Combination of NGAL and CA19-9 
Multiple linear regression was repeated with just two indices available for inclusion, 
NGAL and CA19-9, to assess the utility of these two in combination. 
5.3.5.7.3 Exploration of potential confounders 
I performed repeated multiple linear regression analyses, each time weighting for 
potential confounding factors (age, sex, ethnicity, site of collection). This technique 
compensates for any influence of the potential confounding factor on NGAL level. 
The β-value and p-value for NGAL at the end of each regression was noted to 
quantify any modification in the diagnostic utility of NGAL. 
5.4 Results 
5.4.1 Subjects recruited 
A total of 243 plasma samples were included in this study:  97 samples from patients 
with confirmed CC, 64 from patients with PSC and 82 from healthy controls with no 
CC or known liver disease.  
There were significant differences in age, male-to-female ratio and ethnicity between 
the three groups (Table 5.1).  
 5 (5%) of CC subjects had a prior diagnosis of PSC. Anatomical classification of CC 
was possible in 84 (87%) of CC cases; 9 IHCC, 59 hilar and 16 distal lesions. All the 
PSC patients had no cirrhosis, or fully compensated Child Pugh A cirrhosis, and 
none had a history of liver transplantation. 
Routine laboratory data were available on 64 (66%) of the CC cohort and 57 (92%) 
of the PSC cohort. These represented the most complete set of matched results that 
our collaborating sites could extract from their archives. As discussed in 5.3.2.3 
above, no routine laboratory data were available on the healthy control cohort. 
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5.4.2 Plasma NGAL levels 
Median NGAL concentrations (IQ range) in CC, PSC and healthy controls were 91 
(65-154), 83 (66-109) and 64 (52-78) ng/mL respectively (Table 5.2). The scatter plot 
in Figure 5.3 illustrates the distribution of NGAL values in all three cohorts.  
5.4.2.1 CC cohort vs HC cohort 
NGAL levels were significantly higher in plasma from CC patients compared with 
healthy controls (p<0.0001) (Table 5.3). The area under the ROC curve was 0.71 
(95% CI 0.64-0.79 p< 0.0001) (Figure 5.4a).  
5.4.2.2 CC cohort vs PSC cohort 
NGAL levels were not significantly higher in plasma samples from the CC cohort than 
those from the PSC cohort (p=0.17) with a ROC-AUC of 0.57 (95% CI 0.48-0.65, 
p=0.167) (Figure 5.4b).  
5.4.2.3 PSC cohort vs healthy control cohort 
NGAL levels were significantly higher in the PSC group (median 83.1, IQ range 65.7-
108.2), when compared to healthy controls (median 64.4, IQ range 51.4-77.7, 
p<0.0001). The ROC-AUC was 0.72 (95% CI 0.64-0.80, p<0.0001) (Figure 5.4c). 
5.4.2.4 CC cohort vs combined benign cohort 
NGAL levels were significantly higher in the CC group compared to the combined 
benign cohort (p<0.0001). The ROC-AUC was 0.65 (95% CI 0.57-0.72, p<0.0001). 
(Figure 5.4d) 
5.4.2.5 Combined CC and PSC cohort vs healthy controls 
NGAL levels were significantly higher in the combined disease cohort of CC and 
PSC (median 85.5, IQ range 65.2-128.1), when compared to healthy controls 
(median 64.4, IQ range 51.4-77.7, p<0.0001). The ROC-AUC was 0.71 (95% CI 
0.65-0.78, p<0.0001) (Figure 5.4e). 
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5.4.2.6 NGAL levels by anatomical subtype of CC 
Separate Kruskal-Wallis ANOVA testing of NGAL levels between anatomical 
subtypes of CC (hilar vs intrahepatic, distal or not known) demonstrated no 
significant differences (p= 0.17, 0.79, 0.14 respectively) (Table 5.4). 
5.4.3 Relationship between NGAL and other indices 
There were significant differences in ALT, albumin, CRP, CEA and CA19-9 between 
the CC and PSC cohorts. There were no significant differences in bilirubin, ALP, 
white cell count or AFP between the CC and PSC cohorts. (Table 5.5).  
There was no relationship between NGAL levels and bilirubin (R2=0.01), ALP 
(R2=0.02), urea (R2=0.07) or creatinine (R2=0.03). There was little or no correlation 
between NGAL and CRP (R2=0.14) and white cell count (R2=0.09) and moderate 
correlation with CA19-9 concentrations (R2=0.38) (Table 5.6). 
5.4.4 Exploration of potential confounders 
5.4.4.1 Age 
There were significant differences in age between the three cohorts (Table 5.1). Age 
positively correlated with plasma NGAL concentration in CC and HC cohorts. There 
was no correlation between age and NGAL in the PSC cohort. When all cohorts were 
combined, the correlation between age and NGAL level persisted (p<0.000001) 
(Table 5.7). 
5.4.4.2 Sex 
There were significant differences in the male to female ratio in the three cohorts 
(Table 5.1). There was no difference in plasma NGAL concentration between male 
and female subjects in the PSC and HC cohorts. However, NGAL levels were 
significantly lower in females in the CC group (p=0.03) (Table 5.8A). Despite this, the 
significant difference between CC and HC groups, and between PSC and HC 
groups, persisted in both male and female subgroups (Table 5.8B). 
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5.4.4.3 Ethnicity 
There were significant differences in the ethnicity of subjects in the three groups 
(Table 5.1). Plasma NGAL level did not vary significantly with ethnicity in the CC or 
PSC cohorts. However, plasma NGAL did vary significantly with ethnicity in the HC 
cohort (p=0.00002) (Table 5.9A). In the two ethnic subgroups that are big enough to 
analyse, Caucasian and Asian, the significant differences between CC and HC 
groups persists. However, any difference between PSC and HC becomes non-
significant in the Caucasian subgroup (p=0.08) (Table 5.9B). 
5.4.4.4 Site of sample collection 
There were no significant differences in plasma NGAL levels in CC and PSC 
subjects recruited at the three sites. However, there was a significant difference in 
plasma NGAL concentrations between HC subjects recruited at the ICH and UCH 
sites (p=0.0004) (Table 5.10A). In the ICH subgroups, the significant difference 
between CC and HC cohorts persisted. In the UCH subgroup, the difference between 
PSC and HC cohorts was sustained (Table 5.10B). However, this could not be tested 
in the ICH subgroup, as the number of PSC patients was too small. 
5.4.5 Performance of routine laboratory indices as biomarkers 
In discriminating CC from HC subjects, NGAL (ROC-AUC 0.72) was outperformed by 
bilirubin, ALP, ALT, albumin, CRP and CA19-9. It was underperformed by creatinine. 
Urea and white cell count were of no utility in discriminating these two groups. (Table 
5.11) 
In discriminating CC from PSC subjects, ALT, albumin, CRP and CA19-9 were of 
some utility. Like NGAL, bilirubin, ALP, white cell count proved to be of no utility in 
discriminating these two groups (Table 5.12).  
In discriminating PSC from HC subjects, NGAL (ROC-AUC of 0.73) was 
outperformed by bilirubin, ALP, ALT and CA19-9. NGAL was underperformed by 
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albumin and CRP. White cell count was of no utility in discriminating these two 
groups. (Table 5.13) 
5.4.6 Multiple linear regression 
5.4.6.1 Exploration of potential confounders 
Multiple linear regression was also used to further explore the potential confounding 
factors considered in 5.4.4. The uncorrected β-value for plasma NGAL alone as a 
discriminator of CC from HC subjects was 0.359. This was diminished, very slightly, 
by correction for age. It was unchanged by correction for sex and was enhanced, 
very slightly, by correction for ethnicity or site. (Table 5.14)  
The same analysis was performed to investigate the influence of confounders on the 
difference between NGAL in PSC and HC cohorts. The uncorrected β-value for 
plasma NGAL was 0.410. This was not changed by correction for sex, ethnicity or 
site of collection. It was diminished somewhat after correction for age (β=0.341) 
(Table 5.15). 
5.4.6.2 Combination of NGAL with routine laboratory indices 
A general discriminant function analysis was used to explore the utility of 
combinations of routine laboratory indices and NGAL in discriminating groups. The 
optimum model to discriminate CC from HC included 6 parameters: albumin, ALT 
WCC, CRP, NGAL and CA19-9. The relative β-values for each of the 6 parameters 
in the model are detailed in Table 5.16. Using this model, a ROC-AUC of 0.98 was 
achieved (95% CI 0.97-1.0, p<0.0001) (Figure 5.5). 
When just plasma NGAL and CA19-9 were subjected to multiple linear regression, 
the optimum model to discriminate CC from HC included NGAL only, with no added 
value for inclusion of plasma CA19-9. The ROC-AUC generated from this model was 
0.73, consistent with the ROC AUC from the raw NGAL data. 
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General discrimination analysis was also applied to the PSC and HC cohorts. The 
optimum model here was reached after 4 steps and comprised the following 4 
parameters: ALT, WCC, CA19-9 and NGAL. β -values and p-values for each of the 
parameters in this model are detailed in Table 5.17. Using this model, a ROC-AUC of 
0.98 was achieved (95% CI 0.97-1.0) (Figure 5.6) 
As there was no diagnostic utility in NGAL alone in discriminating CC from PSC, 
multiple linear regression analyses were not undertaken on this pairing of groups. 
5.5 Discussion 
This is the first reported study to investigate plasma NGAL levels in patients with CC 
and PSC. NGAL is expressed at significantly higher concentrations in blood plasma 
samples from patients with CC, when compared to plasma samples from healthy 
control subjects. NGAL is not significantly elevated in CC patients, when compared 
to patients with PSC. There appears to be no difference in the degree of elevation of 
NGAL between different anatomical subtypes of CC. NGAL is significantly elevated 
in PSC patients, when compared to healthy controls. Plasma NGAL appears to 
increase with age, regardless of disease status. 
5.5.1 Potential mechanisms of NGAL elevation  
As one would expect from its name, the initial discovery of constitutively expressed 
NGAL was in neutrophils, with marked increase in expression during neutrophil 
activation.[462, 463] Studies of activated neutrophils demonstrate 200 fold higher levels 
in the cell culture media than within the cells, suggesting a mechanism by which 
NGAL is actively secreted by neutrophils.[408] As already described in section 5.1, 
clinical studies have shown an increase in plasma NGAL during induced gram 
negative sepsis in mice, and in a host of human studies of acute infection or 
inflammation. None of the CC, PSC or healthy control subjects had current active 
sepsis or were receiving antibiotics at the time of sample collection. However, many 
of the patients in my CC cohort had undergone instrumentation of the biliary tree with 
Chapter 5 – Plasma NGAL 
 236 
biliary stenting and therefore had, probably invariably, some degree of post-
procedural cholangitis. Although much less likely to have been subject to ERCP and 
placement of biliary prosthesis, some of the PSC cohort had had instrumentation of 
the biliary tree, and secondary bacterial cholangitis is one of the known sequelae of 
PSC itself. None of the healthy control cohort had biliary prostheses or cholangitis of 
any sort. In my study, plasma NGAL is clearly elevated in both CC and PSC patients 
compared to healthy controls. The question therefore arises of whether this NGAL 
rise could simply be evidence of systemic neutrophil activation, due to low-grade 
sepsis from cholangitis, or a non-infective inflammatory response. The correlation 
analyses with CRP (R2=0.14, p<0.001) and WCC (R2=0.09, p<0.002), both of which 
are surrogate markers of neutrophil activation, are helpful here. The p-values 
certainly indicate significant correlation, although the R2 values suggest that this 
correlation is modest.  
Another factor that I anticipated would differ between my cohorts was the degree of 
biliary obstruction or cholestasis. Both CC and PSC are cholestatic diseases, but I 
expected the CC cohort to have more pronounced biliary outflow obstruction. In fact, 
no difference in the standard markers of cholestasis (bilirubin and ALP) was seen 
between CC and PSC cohorts. It is reasonable to assume that there would be a 
difference in bilirubin and ALP levels between CC patients and healthy controls, but 
the standard laboratory data on my healthy control specimens does not exist to 
confirm this. The fact that plasma NGAL was significantly elevated in both CC and 
PSC cohorts might fit with cholestasis being a common cause of the NGAL rise in 
both groups. However, there was no correlation between NGAL level and bilirubin 
(R2=0.01, p=0.53) or ALP (R2=0.02, p=0.15), suggesting that any NGAL rise is 
independent of cholestasis. 
Hyperbilirubinaemia, infection, cachexia and malignancy are all known risk factors for 
renal impairment. Clearly, all these factors are more common in CC patients than in 
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my healthy controls. Urinary NGAL (and to a lesser extent, plasma NGAL) have 
repeatedly been shown to be elevated early in acute kidney injury, and in chronic 
renal impairment, before a creatinine rise is seen. I was not able to perform formal 
creatinine clearance or urinary analysis on the subjects in my study, to definitively 
assess their renal function, and such tests do not form part of the routine clinical 
assessment of our patients. However, correlation of plasma NGAL and creatinine in 
my subjects was, if not non-existent, minimal (R2=0.03, p=0.27). Urea, which 
becomes elevated before the creatinine in hypovolaemic states but is a less specific 
marker of AKI than creatinine, was minimally correlated with NGAL (R2= 0.07, 
p=0.051). Very early kidney injury, without a creatinine rise, cannot be excluded as a 
potential confounder. However, it seems unlikely that early AKI would account for the 
NGAL rise seen in my CC cohort, without any association with the creatinine level 
being seen. 
Finally, NGAL may be higher in the plasma of CC patients because it is being shed 
from the site of biliary malignancy into the circulation. NGAL is a small, stable 
molecule and such a phenomenon has been demonstrated in a number of other 
malignancies.[407] The fact that, in my study, the laboratory marker with which NGAL 
most strongly correlates is CA19-9 (R2=0.38, p<0.0001) supports this. Although it has 
critical deficiencies, CA19-9 is the current best plasma marker for CC and is known 
to originate from the biliary tree itself. Our previous work in bile from patients with 
pancreatobiliary malignancy, where plasma and urinary NGAL levels were not 
elevated, also points to local biliary generation of NGAL in CC.[364] Whether NGAL is 
elevated in CC simply as a ‘bystander’, due to local biliary inflammation and 
neutrophil activation, or is constitutively expressed by malignant biliary cells 
themselves is not deducible from my data. Work on NGAL expression in CC cell lines 
and excision specimens would be required to elucidate this. Studies in the 
pathogenesis of pancreatic and hepatocellular cancers, which are both increasingly 
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shown to share common pathogenic features with cholangiocarcinoma, do suggest a 
functional role for NGAL in cancer development.[448, 459] A reduction in proliferation, 
invasion and metastatic activity of pancreatic cancer has been shown in mice, when 
NGAL is constitutively expressed by the cells.[55] However, given the range of 
conflicting effects of NGAL demonstrated in different malignancies, it cannot be 
assumed that tumour effects seen in HCC or pancreatic cancer can be extrapolated 
to CC. Investigation in CC cell lines, and CC tissue may elucidate this further, and 
permit investigation of the potential prognostic effects hinted at by mouse work on 
HCC and pancreatic cancer cells.  
5.5.2 NGAL as a discriminatory test 
The ROC AUC analysis suggests that NGAL discriminates between my CC and 
healthy control cohorts to a reasonable extent (ROC AUC=0.71, p<0.0001). NGAL 
performs very similarly in differentiating PSC from healthy control subjects (ROC 
AUC 0.72, p<0.0001). However, this does not extend to discriminating between CC 
and PSC cohorts (ROC AUC=0.56, p=0.17). As discrimination of benign from 
malignant strictures is the most difficult clinical challenge, this is perhaps a more 
important test of the potential utility of NGAL as a diagnostic biomarker, where the 
ROC-AUC of 0.56 suggests a very weak diagnostic test. Combination of NGAL with 
other markers, such as CA19-9, in a panel of tests might be expected to improve 
performance, as it did in our group’s earlier work on biliary NGAL. In that study, 
combining plasma CA19-9 and biliary NGAL improved diagnostic accuracy from a 
sensitivity of 94%, specificity of 55%, positive predictive value of 60% and a negative 
predictive value of 92% to a sensitivity of 85%, specificity of 82%, positive predictive 
value of 79%, and a negative predictive value of 87%. Unfortunately, I did not have 
routine laboratory data available for my healthy control cohort and so I could not 
explore this directly. Although I was able to look for association between parameters 
of infection, inflammation and renal failure and NGAL concentration, it was not 
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possible for me to look at the utility of combinations of NGAL with other markers. It 
may be reasonable to assume that all the healthy controls had normal blood 
parameters. Therefore I generated a hypothetical set of normal laboratory values for 
the healthy control cohort, to permit further exploratory analyses. I was first able to 
investigate routine laboratory markers as stand alone discriminatory tests, with some, 
such as ALT and albumin, performing substantially better than NGAL or CA19-9.  I 
was then able to undertake explorative multiple linear regression modelling to 
explore combinations of these markers with NGAL. In this analysis, NGAL proved 
slightly superior to CA19-9, with no added benefit in combining the two. A panel of 
six markers, including NGAL, was able to discriminate CC from healthy control 
subjects with a ROC-AUC of 0.98 (i.e. sensitivity and specificity approaching 100%). 
As there was no diagnostic utility in NGAL alone in discriminating CC from PSC 
(ROC AUC=0.56, p=0.17), multiple linear regression analyses were not undertaken 
on this pairing of groups, as such analyses would be futile. 
I subsequently undertook the same analyses on the PSC and healthy control 
cohorts. A panel of 4 parameters, including NGAL, was able to discriminate PSC 
from healthy controls – again with an impressive ROC-AUC of 0.98.  
5.5.3 Technical issues encountered 
The sample processing and ELISA techniques proved uncomplicated and reliable, 
with no significant variation between duplicate samples and minimal assay failures 
requiring repeat. The manufacturers of the ELISA kit recommended the use of 
heparinised samples over EDTA samples as EDTA has a theoretical chelating effect 
on NGAL. However, longstanding evidence exists suggesting that the stability of 
NGAL is reduced after collection using lithium heparin leading to degradation and 
subsequent reduced detectable NGAL levels.[436] Moreover, the archived PSC 
specimens were available only as EDTA-collected plasma. I therefore performed a 
small pilot experiment to confirm reproducibility of NGAL results in a dozen samples 
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where both EDTA and lithium heparin samples were available (results not shown). 
This confirmed reproducibility and concordance of NGAL measured in samples of 
both formats and I therefore elected to use EDTA specimens in my full experiment.  
5.5.4. Comparability of groups 
Significant differences existed in age, sex and ethnicity characteristics between my 
three cohorts. When comparing PSC patients (without cirrhosis or previous liver 
transplant), who are generally in their 3rd or 4th decade, with CC patients generally in 
their 6th or 7th decade, it is essentially impossible to age match. I demonstrated a 
correlation between plasma NGAL level and increasing age in both CC and healthy 
control groups. This was not the case in the PSC cohort, but this is likely to be a 
function of the lower, and narrower range, of age in the PSC subjects. Multiple linear 
regression with correction for age diminished the diagnostic power of NGAL 
negligibly in discriminating CC from healthy controls, and trivially in the discrimination 
of PSC subjects from healthy controls. Men are at much higher risk of PSC than 
women and a similar, but lesser, tendency exists in CC. It is therefore hard to collate 
fully sex-matched cohorts. Male and female subgroup analysis demonstrated the 
same significant findings found in the mixed sex groups and multiple linear 
regression, with correction of NGAL for sex, made no difference to NGAL’s 
performance. Subgroup analysis of Caucasian and Asian subjects demonstrated the 
same significant findings found in the combined groups and correction for ethnicity in 
the multiple linear regression analyses did not significantly weaken the finding. My 
CC cohort does broadly reflect the epidemiology of different disease phenotypes 
seen in the UK population, with a preponderance of hilar, extrahepatic lesions. 
Intrahepatic CC may be somewhat underrepresented. This is likely because my CC 
cases were recruited from medical gastroenterology clinics and ERCP lists, where 
cases tend to be those amenable to endoscopic therapy, and less IHCC is seen. 
Testing of NGAL levels between anatomical subgroups of CC demonstrated no 
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difference, suggesting that NGAL elevation is independent of CC anatomical 
subtype. Collection of samples at three different sites may also have introduced 
some bias, although strict, consistent sample collection protocols were observed at 
all sites. Analysing subgroups from ICH and UCH confirmed the strong significant 
difference between CC and healthy control cohorts in the ICH cohort. However, this 
was not a significant finding in the UCH subgroups. The PSC vs healthy control 
finding was also not demonstrated in the UCH subgroup, however this included only 
12 PSC subjects and so was a very limited analysis. It was not possible to make 
similar analyses of the Norwegian subgroup as I had neither healthy control nor CC 
subjects from that site. Correction of NGAL for site of collection in multiple linear 
regression modelling did not modify NGAL’s diagnostic performance.  
5.5.5 Ongoing and proposed work resulting from my study 
Further work resulting from my data is on going. I successfully applied for UKCRN 
adoption of our on going biomarker discovery programme and currently 6 UK HPB 
centres are prospectively recruiting CC cases, using our protocol, for inclusion in 
validation cohorts and further discovery studies. This covers tissue, bile, plasma and 
urine collection. 
Simply completing assays for routine clinical markers in the balance of my samples 
(principally healthy controls) would allow more complete analysis of confounding 
effects as well as permitting me to examine the diagnostic utility of combinations of 
more markers. Obtaining samples from healthy control and CC subjects from the 
NoPSC Norwegian archive and analysing their NGAL and routine biochemical levels 
would permit me to look more comprehensively at the confounding effect of the 
different sites of collection. 
We intend to examine the expression of NGAL in CC cell lines and human excision 
specimens. Given the elevation in PSC, investigation of NGAL expression in biliary 
tissue from PSC patients may also prove informative 
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5.5.6 The future of NGAL in clinical practice 
NGAL has already found a definite role in the diagnosis of acute kidney injury. The 
use of NGAL as a clinical biomarker in other diseases is subject to a significant 
amount of on going work around the world. A diagnostic role in pancreatic and 
hepatocellular carcinomas is emerging, and may also emerge in CC and PSC.  
Beyond use as a biomarker, a number of studies have investigated the potential 
imaging and therapeutic opportunities associated with NGAL’s discovery in tumours 
and other diseases. Antibody to NGAL conjugated with a near infrared dye 
(IRDye800CW) has been shown to be feasible in imaging in vitro and in vivo models 
of pancreatic adenocarcinoma cells.[464] A further murine study of atherosclerotic 
disease also demonstrated increased uptake of a labelled NGAL antibody in a 
carotid plaque model.[419] Although these studies have demonstrated internalisation 
of the NGAL-dye conjugate into the target cells, the avid uptake of NGAL into non-
target tissues, specifically the liver and urinary tract, have limited clinical application 
to date.[407]  
The therapeutic opportunities in down- or up-regulating NGAL expression have been 
speculated upon. There are currently no specific molecules known to directly 
modulate NGAL expression. However, recombinant human and mouse NGAL is 
available as are respective, highly specific antibodies.  Evidence that NGAL inhibits 
proliferation and invasion in HCC and pancreatic cancer offers a potential target for 
recombinant NGAL therapy.[459] The systemic effects of exogenous NGAL 
administration have yet to be explored, let alone any efficacy in treating disease 
states. Conversely, the upregulation of NGAL in the inflamed colonic mucosa of 
ulcerative colitis has led some authors to speculate that NGAL-antibody is worthy of 
investigation as a therapeutic agent, citing the efficacy of IL-2 in renal cell carcinoma 
and anti-TNF therapy in Crohn’s disease.[465] Such approaches may be limited by the 
generation of a host immune response to extrinsic antibodies to NGAL, or by 
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unintended consequences of NGAL suppression in the target or bystander tissues. 
To date, the conjugation of NGAL antibodies with chemoactive drugs, aiming to 
deliver high doses to tumour tissue, has not been investigated. Such an approach 
would increase dose delivery to tumour tissue whilst reducing systemic doses and 
toxicity. However, a weakness of such an approach may be the extensive expression 
of NGAL in diverse cells and it’s uptake by the liver and urinary tract – as illustrated 
by studies of NGAL antibody-IR marker conjugate imaging studies.  
Clearly NGAL plays a significant role in health and disease. A large body of in vivo 
and in vitro studies of global expression after gene knock in, knock out or 
modification of cytokine milieu, have confirmed that individual genes and proteins 
rarely function in isolation in either health or disease.[407] Genes and their proteins 
function in groups, and studies of NGAL within its wider group of associated genes is 
likely to prove more fruitful than study in isolation. With burgeoning data of utility as a 
biomarker in benign and malignant disease, the most exciting clinical opportunities 
may be yet to emerge from studies of the function of NGAL in disease - if they lead to 
functional imaging or even therapeutic applications. 
5.5.7 Conclusion 
This is the first study to examine the utility of plasma NGAL as a biomarker in CC. 
NGAL is elevated in the plasma of patients with CC, and patients with isolated PSC, 
compared to healthy controls. Elevation of NGAL appears to be generally 
independent of renal impairment, cholestasis or systemic inflammatory response, 
suggesting that NGAL could represent an independent plasma biomarker of CC and 
PSC. Due to the nature of the diseases under investigation, a number of confounding 
factors have been incurred whilst recruiting subjects for this study. I could, for 
instance, have restricted my cohorts to Caucasian subjects only, but this would have 
substantially reduced my sample sizes and generalisability of my findings. Age, sex 
and ethnic matching of cases and controls would have been advantageous, but 
Chapter 5 – Plasma NGAL 
 244 
proved impossible in practice. The impact of such factors was investigated as 
thoroughly as possible, with a range of statistical tools, without undermining any of 
the principal positive findings. Although my study involved prospective sample 
collection, all patients recruited had already been extensively investigated and 
followed up, ensuring clarity of diagnosis. This may mean that my CC cohort 
represent quite advanced disease and so cannot be directly applied to, say, patients 
with early, asymptomatic CC. In a PSC cohort, repeated longitudinal testing of 
plasma NGAL and correlation with the evolution of superadded CC would be 
required, if the potential as a screening test for CC in PSC were to be tested. On the 
basis of my findings of no difference in NGAL levels between PSC and CC subjects, 
it seems unlikely that plasma NGAL would form a useful test for identifying CC 
developing on a background of PSC. Assessment of the wider utility of plasma NGAL 
as a diagnostic test would be best achieved by prospective recruitment of all patients 
with a mass forming or stricturing biliary lesion at the outset of investigation. Serial 
measurement of NGAL with concomitant routine laboratory markers could then be 
related to eventual diagnosis and prognosis. This would be best undertaken as a 
multicentre study, including non-referral centres to reduce the risk of recruitment 
bias. 
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5.6 Chapter 5 Tables and Figures 
Table 5.1: Subject characteristics, plasma NGAL study 
Legend: n – number of subjects in cohort. Age shown is median value with 
interquartile (IQ) range in parentheses. CC – cholangiocarcinoma cohort, PSC – 
PSC cohort, HC – healthy control cohort. 
Cohort CC PSC HC 
n 97 64 82 
Age 65.8 (56.8-73.8) 42.2 (31.4-52.7) 48.3 (39.8-62.8) 
Sex (M : F) 1.6 : 1 3.6 : 1 1 : 1 
Ethnicity n (%)    
Caucasian 69 (71%) 58 (90%) 41 (50%) 
African 8 (8.3%) 0 1 (1.2%) 
Asian 15 (15.5%) 5 (8%) 38 (46.3%) 
Not known 5 (5%) 1 (1.6%) 0 
PSC n (%) 5 (5%) 64 (100%) 0 
 
Table 5.2: NGAL concentrations by cohort 
Legend: n - cohort size, the median value of NGAL concentration is given with IQ 
range in parentheses, CC – cholangiocarcinoma cohort, PSC – PSC cohort, HC – 
healthy control cohort. 
Cohort n Median NGAL concentration, ng/mL 
CC 97 91 (65-154) 
PSC 64 83 (66-109) 
HC 82 64 (52-78) 
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Table 5.3: Comparison of NGAL concentration between CC, HC and PSC 
groups 
Legend: Results of Mann-Whitney (M-W) U-test and receiver operator characteristic 
area under the curve (ROC-AUC) analyses. CC – cholangiocarcinoma cohort, PSC – 
PSC cohort, HC – healthy control cohort. 
 
Groups compared M-W U-test p-value ROC-AUC ROC p-value 
CC to HC <0.0001 0.71 <0.0001 
CC to PSC 0.17 0.56 0.17 
PSC to HC <0.0001 0.72 <0.0001 
CC to HC plus PSC  <0.0001 0.65 <0.0001 
CC plus PSC to HC <0.0001 0.71 <0.0001 
 
Table 5.4: Breakdown of CC cohort by anatomical subtype 
Legend: The number of subjects with each subtype of CC is shown, along with the 
median plasma NGAL level (IQ range in parentheses) for each subgroup. The p-
value shown relates to a Kruskal-Wallis ANOVA test comparing all subtype groups. 
 n (%) Median [NGAL], ng/mL p-value 
Hilar 59 (61%) 85.4 (64.4-140.7) 0.53 
IHCC 9 (9%) 128.6 (76.6-164.9) 0.53 
Distal CC 16 (16%) 94.6 (43.2-143.2) 0.53 
Not determined 13 (13%) 108 (67.4-184.9) 0.53 
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Table 5.5: Routine laboratory parameters by study group 
Legend: Quantitative data are shown as median values and interquartile range in 
parentheses. P-value from Mann-Whitney U test comparison of CC and PSC 
cohorts. No laboratory data were available for healthy controls.  
 
Parameter CC PSC p-value 
Ur 5.0 (3.7-7.6) n/a - 
Cr 68.5 (62-82.5) n/a - 
Bili 21.5 (11.0-77.0) 24 (12.3-41.0) NS 
ALP 287 (152.3-625.5) 216 (122.3-405.8) NS 
ALT 45.5 (24.0-80.0) 92 (51-131) 3x10-4 
Alb 30.0 (26.8-38.0) 40 (36-43) 1.3 x10-7 
CRP 47.5 (17.7-109) 4.25 (1.7-11) 1.5x10-6 
WCC 6.4 (5.5-9.6) 6.24 (4.7-7.7) NS 
AFP 5.0 (2.5-5.5) 4.0 (3.0-5.0) NS 
Cea 3.0 (2.0-15.3) 1.45 (1.2-7) 4.0x10-3 
CA125 51.5 (23.0-213) n/a - 
CA19-9 268 (21.5-1607) 24 (16.75-39) 1.8x10-3 
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Table 5.6: Pearson’s correlation analysis of NGAL concentration to 
routine laboratory parameters 
Legend: R2 – correlation coefficient 
Laboratory parameter R2 p-value 
Bilirubin 0.01 0.53 
ALP 0.02 0.15 
Creatinine 0.03 0.27 
Urea 0.07 0.05 
WCC 0.09 <0.002 
CRP 0.14 <0.001 
Ca19-9 0.38 <0.0001 
 
Table 5.7: Pearson’s correlation analysis of age with plasma NGAL 
concentration  
Legend: Values given for each cohort and for a combination of all three cohorts. Age 
given as median value with IQR in parentheses. NGAL concentration, [NGAL], given 
in ng/mL as median value with IQR in parentheses. 
 n Age [NGAL] R2 p-value 
CC 97 66 (57-74) 91 (65-154) 0.07 0.004 
PSC 64 42.24 (31-53) 83 (65-108) 0.00014 0.32 
HC 82 48 (40-63) 64 (52-78) 0.31 0.3x10-8 
Combined 243 55 (41-66.5) 75 (59-109) 0.1 0.000001 
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Table 5.8: NGAL concentrations in male and female subgroups 
Legend: (A): NGAL concentrations in male and female subgroups with p-value from 
M-W U test between male and female values in each row.  (B): Results of M-W U 
testing between CC, HC and PSC subjects within male and female subgroups. NGAL 
concentration, [NGAL], given in ng/mL as median value with IQR in parentheses.  
(A) 
 Male (n) [NGAL] Female (n)  [NGAL]  p-value 
CC 59 108.4 (70-165) 38 75.8 (55.4-118.6) 0.03 
PSC 50 82.4 (66-117) 14 84 (72-107) 0.38 
HC 41 71 (55-88) 41 63 (50-75) 0.09 
 
(B) 
 Male Female 
CC vs HC p-value <0.0001 0.01 
CC vs PSC p-value 0.04 0.66 
PSC vs HC p-value 0.005 0.001 
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Table 5.9: NGAL plasma concentrations by ethnicity and study cohort 
Legend: (A) NGAL plasma concentrations by ethnicity and study cohort, with non-parametric statistical comparison of NGAL concentration 
between ethnic subgroups. (B) Results of M-W U testing between CC, HC and PSC subjects within ethnic subgroups. NGAL concentration, 
[NGAL], given in ng/mL as median value with IQR in parentheses. Cauc – Caucasian.  
(A) 
 Caucasian (n) [NGAL]  African (n)  [NGAL] Asian (n) [NGAL] Not known (n) [NGAL] p-value Test used 
CC 69 93 (66-164) 8 60 (40-87) 16 118 (84-135) 5 91 (59-150) 0.13932 KW ANOVA 
PSC 58 83 (66-112) 0 - 5 76 (67-101) 1 115 (n/a) 0.99 M-W U 
HC 41 75 (63-89) 1 84 (n/a) 40 57 (44-65) 0 - 0.00002 MW-U 
 
(B) 
 Caucasian subgroup Asian subgroup 
CC vs HC P-value <0.002 <0.00001 
CC vs PSC P-value 0.19 0.07 
PSC vs HC P-value 0.08 0.02 
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Table 5.10: NGAL plasma concentrations by site of collection and study cohort 
Legend: (A) NGAL plasma concentrations by site of collection and study cohort, with M-W U test comparison of NGAL concentration between 
site of collection subgroups. (B) Results of M-W U testing between CC, HC and PSC subjects within site of collection subgroups. NGAL 
concentration, [NGAL], given in ng/mL as median value with IQR in parentheses. ICH – Imperial College Healthcare, UCH – University College 
Hospital.  
(A) 
 ICH (n) [NGAL] UCH (n) [NGAL] Norway (n) [NGAL] M-W U, p-value 
CC 49 108 (71-167) 48 87 (60-137) 0 - 0.12 
PSC 1 72 (n/a) 12 90 (69-115) 51 83 (65-110) 0.82 
HC 56 59 (48-73) 26 75 (70-93) 0 - 0.0004 
 
(B) 
 ICH subgroup UCH subgroup 
CC vs HC P-value <0.00001 0.38 
CC vs PSC P-value - 0.86 
PSC vs HC P-value - 0.34 
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Table 5.11: ROC-AUC analysis of routine laboratory markers, and NGAL, 
as discriminators of CC and HC subjects 
 CC (n) HC (n) ROC-AUC ROC-AUC 95% CI p-value 
Urea 42 82 0.61 0.50-0.72 0.05113 
Creatinine 42 82 0.68 0.58-0.78 <0.001 
Bilirubin 64 82 0.77 0.69-0.85 <0.0001 
ALP 63 82 0.94 0.90-0.98 <0.0001 
ALT 60 82 0.85 0.78-0.91 <0.0001 
Alb 43 82 0.94 0.90-0.98 <0.0001 
CRP 36 82 0.89 0.81-0.97 <0.0001 
WCC 52 82 0.55 0.44-0.66 0.32 
CA19-9 47 82 0.79 0.69-0.90 <0.0001 
      
NGAL 65 82 0.72 0.63-0.81 <0.0001 
 
Table 5.12: ROC-AUC analysis of routine laboratory markers, and NGAL, 
as discriminators of CC and PSC subjects. 
Legend: Urea and creatinine could not be included in this analysis as data were not 
available on the PSC cohort. 
 CC (n) HC (n) ROC-AUC ROC-AUC 95% CI p-value 
Urea - - - - - 
Creatinine - - - - - 
Bilirubin 64 57 0.51 0.41-0.62 0.79 
ALP 63 57 0.6 0.50-0.70 0.06 
ALT 60 56 0.72 0.63-0.82 <0.0001 
Alb 43 49 0.84 0.77-0.92 <0.0001 
CRP 36 48 0.86 0.78-0.94 <0.0001 
WCC 52 56 0.6 0.49-0.70 0.09 
CA19-9 47 51 0.72 0.60-0.84 <0.001 
      
NGAL 65 57 0.55 0.45-0.65 0.3233 
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Table 5.13: ROC-AUC analysis of routine laboratory markers, and NGAL, 
as discriminators of PSC and HC subjects 
Legend: Urea and creatinine could not be included in this analysis as data were not 
available on the PSC cohort. 
 CC (n) HC (n) ROC-AUC ROC-AUC 95% CI p-value 
Urea - - - - - 
Creatinine - - - - - 
Bilirubin 57 82 0.82 0.75-0.90 <0.0001 
ALP 57 82 0.91 0.85-0.97 <0.0001 
ALT 56 82 0.96 0.92-0.99 <0.0001 
Alb 49 82 0.69 0.59-0.78 <0.001 
CRP 48 82 0.52 0.40-0.64 <0.001 
WCC 56 82 0.65 0.55-0.75 0.002 
CA19-9 51 82 0.76 0.67-0.84 <0.0001 
      
NGAL 57 82 0.73 0.65-0.82 <0.0001 
 
Table 5.14: Multiple linear regression analysis, utilising plasma [NGAL] to 
discriminate CC from HC subjects  
Legend:!MLR settings: F1=1.1, F2=1.0, max steps 15. Uncorrected value is given with 
subsequent correction for various potential confounding factors.!
Corrected for β-value p-value  
Nothing 0.359 <0.0001  
Age 0.339 <0.0001  
Sex 0.359 <0.0001  
Ethnicity 0.366 <0.0001  
Site 0.36 <0.0001  
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Table 5.15: Multiple linear regression analysis, utilising plasma [NGAL] to 
discriminate PSC from HC subjects  
Legend:!MLR settings: F1=1.1, F2=1.0, max steps 15. Uncorrected value is given with 
subsequent correction for various potential confounding factors.!
Corrected for β-value p-value  
Nothing 0.410 <0.0001  
Age 0.341 <0.0001  
Sex 0.409 <0.0001  
Ethnicity 0.400 <0.0001  
Site 0.409 <0.0001  
 
Table 5.16: Multiple linear regression analysis, utilising plasma [NGAL] in 
combination with routine laboratory parameters, to discriminate CC from 
HC subjects  
Legend: MLR settings: F1=1.1, F2=1.0, max steps 15. This model was reached after 7 
steps. ROC-AUC analysis of this model’s performance can be found in Figure 5.5. 
Parameter β-value F to remove p-value 
Albumin 0.48 26.6 0.000001 
ALT 0.201 4.84 0.03 
WCC 0.25 12.03 0.0000763 
CRP 0.243 5.23 0.024 
NGAL 0.21 5.06 0.026 
Ca19-9 0.2 4.4227 0.037 
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Table 5.17: Multiple linear regression analysis, utilising plasma [NGAL] in 
combination with routine laboratory parameters, to discriminate PSC from 
HC subjects.  
Legend: MLR settings: F1=1.1, F2=1.0, max steps 15. This model was reached after 6 
steps. ROC-AUC analysis of this model’s performance can be found in Figure 5.5. 
Parameter β-value F to remove p-value 
ALT 0.49 1627 <0.0001 
WCC -0.19 462 <0.0001 
CA19-9 0.151 244 <0.0001 
NGAL 0.153 213 <0.0001 
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Figure 5.1: Workflow for dilution of calibration standards 
Legend: Sequential dilution of calibration standard resulted in 7 solutions, the ELISA 
results from which form 7 of 8 points on the subsequent calibration curve. The eighth 
calibration solution was plain calibration diluent (i.e. zero NGAL). 
 
 
Figure 5.2: Example calibration curve (from plate 1 analysis) 
Legend: Diamond points represent values derived using known concentration calibrant 
solutions. The line of best fit in shown, and is derived from the calculated polynomial 
formula shown. Unknown NGAL concentrations from study samples were subsequently 
calculated from the known absorbance value. 
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Figure 5.3: Scatter plot of plasma NGAL concentrations by group 
Legend:  - CC subject,  - healthy control subject,  - PSC subject. Red line shows 
median value. 
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Figure 5.4: ROC AUC curves for inter-group discrimination 
Legend: (A) CC vs healthy controls, (B) CC vs PSC, (C) PSC vs healthy controls, (D) 
CC vs combined benign groups, (E) Combined disease groups vs healthy controls. 
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Figure 5.5: ROC curve, using values calculated from multiple linear 
regression modelling, comparing CC and HC groups. 
Legend: The ROC-AUC is 0.98. This achieved by combining results from 6 laboratory 
parameters, including NGAL, in a multiple linear regression model.  
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6. Development of RF detector microcoils for MR imaging 
of the biliary tree 
6.1 Background 
6.1.1 1H MR physics 
Hydrogen nuclei (1H) are found very abundantly in water and, therefore, in the human 
body. As unpaired protons, hydrogen nuclei have two possible spin states, termed up 
and down. When placed in the magnetic field of a MRI scanner, the protons all align 
with, or against, that field. When exposed to radio-frequency (RF) energy, emitted by a 
transmitter coil in the scanner, the spin state of each proton changes. When the 
transmitter coil is switched off, the protons return to their original state, emitting RF 
energy as they do so. A RF detector coil can detect this emitted energy. The rate at 
which protons change spin state, and therefore emit this RF energy, varies with their 
chemical environment. This property permits the resolution of different tissues in 
human imaging studies.[466] The RF signal emitted by protons as they relax degrades 
exponentially with distance from the receiver coil. To maximise the signal to noise ratio, 
detector coils are therefore placed as close as possible to the tissue being studied. 
This permits collection of maximum signal and thereby maximum imaging data. 
Detector coils tend to be fitted closely around the body part being imaged but some are 
placed internal to the area of interest, for instance rectal and intravascular coils.[466, 467] 
6.1.2 Imaging of the biliary tree 
As discussed more extensively in Chapter 1, a range of imaging techniques is used in 
the investigation of CC. Current staging of CC is relatively poor, partly due to imperfect 
imaging resolution of the biliary tree and adjacent structures. Endoscopic ultrasound 
(EUS) has an established role in the assessment of pathology of the distal bile duct, 
ampulla and pancreas, with particular utility in the local staging of malignant HPB 
disease. Due to its limited range and resolution, surface ultrasound in unhelpful in the 
staging of CC. In EUS, the US probe is built into the tip of an endoscope that can be 
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passed into the upper gastrointestinal tract. The US system can then be closely 
apposed to the gastric or duodenal wall adjacent to the area of interest, including deep 
structures such as the pancreas, improving tissue visualisation. However, the 
resolution of endoscopic ultrasound remains intrinsically limited by available 
technology. ERCP offers the highest resolution cholangiographic images and the 
opportunity for therapeutic biliary intervention, such as stent placement, but gives no 
information external to the ducts and has the attendant risks of pancreatitis and 
visceral perforation. ERCP is technically demanding, as it requires selective 
cannulation of the common bile duct. This duct cannot actually be visualised until it is 
cannulated and radiopaque contrast is instilled. Its axis in a given individual is unknown 
and varies widely in the population. This leads to a relatively high procedural failure 
rate (circa 25%), and substantial risk of repeated pancreatic duct cannulation and 
subsequent pancreatitis.[468, 469] An MRI with MRCP is currently considered the first 
choice diagnostic imaging modality for malignancies of the biliary tree. It is very low 
risk, non-invasive and a detailed cholangiogram is obtained, along with high-resolution 
extraductal information such as tumour extent or hepatic metastases. Very high 
resolution biliary MRI is hampered by the distance of the duct from the surface of the 
patient’s body, and therefore from the surface RF detector coil. An RF detector coil 
placed within the bile duct would reduce this distance hugely, allowing better signal 
acquisition and thereby improving image resolution. If a further RF detector coil were 
integrated into a duodenoscope, offering real time MR imaging of the ampulla and 
distal bile duct during ERCP, diagnosis of distal disease and deep cannulation rates 
might also be improved. Integration of a microcoil into the scope tip would also provide 
additional opportunities for scope tracking within the MR scanner bore. 
6.1.3 ESPRC and Wellcome Trust Projects, overview 
In the first year of my research fellowship I worked on an ESPRC funded project. This 
was multifaceted, comprising development of a new catheter mounted RF detector 
microcoil, a MR compatible side-viewing duodenoscope, a novel system for motion 
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artefact correction and a new biliary tissue sampling system. I was principally 
responsible for clinical input into the development of the catheter mounted RF 
microcoil, its initial testing on phantom models and subsequent testing on ex vivo 
tissue. 
In the second and third years of my fellowship, I contributed to a Wellcome Trust 
funded project. Again, this had multiple subprojects including development of a 
somewhat larger RF detector microcoil and its integration into an MR compatible 
duodenoscope, robotised endoscope control systems and automated MR tracking 
systems. I was principally responsible for clinical input into the development of the 
detector coil, its testing in phantoms and ex vivo tissue, and initial integration of 
endoscopic and MR imaging in the MR scanner room. 
In this chapter I will briefly review previously published work in this field, and then the 
work that I have personally conducted as a collaborator in these two larger projects. 
6.1.4 Radiofrequency (RF) microcoils 
6.1.4.1 Previous microcoil catheter technology 
Small internal coils placed close to the field of view (FOV) of interest can have a much 
higher signal-to-noise ratio, demonstrated in vascular studies initially.[467] Catheters 
based on planar-loop, opposed-solenoid and twisted-pair coils have been developed 
for vascular imaging and catheter tracking.[470] Previous attempts have been made to 
develop receiver coils that might be placed into the biliary tree. High-resolution biliary 
images have been obtained with ‘loopless catheter antennae’, designed as vascular 
imaging coils, inserted into percutaneous transhepatic biliary drainage tubes.[471, 472] 
Microcoils have been produced on gallium arsenide, silicon and glass substrates but 
most demonstrations have been confined to the laboratory. These detectors have 
generally been handmade, bulky and rigid. Some examples of previous constructions 
are illustrated in Figure 1.1.[473] None of these could be adapted for per duodenoscope 
delivery. 
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6.1.4.2 Previous endoscope mounted RF detector coils 
A commercial MR-imaging endoscope designed for 1H imaging at 1.5 T and containing 
a single-turn RF detection coil embedded in its tip (the Olympus XGIF-MR30) was 
demonstrated in the 1990s.[474-478] A similar instrument, designed for research use at 
0.5T, has also been investigated. This instrument initially utilised a detached, projecting 
detector coil[479, 480] and then an inductively coupled saddle coil for intrinsic electrical 
safety, a prerequisite for clinical application.[481, 482] These systems were developed for 
the diagnosis and staging of colonic or oesophageal cancer and were therefore based 
upon forward viewing endoscopes. Furthermore, in several of these instruments the 
endoscope biopsy channel was occupied with the RF coil cabling, preventing biopsy 
channel use for other purposes.[479-482] Such approaches would not permit ERCP with 
simultaneous MR image capture. 
6.2 Devices tested 
The two devices investigated have been designed and built by Prof. RRA Syms in a 
collaboration between the Department of Electronic and Electrical Engineering and the 
Hepatology Section, Department of Medicine, Imperial College London. I contributed to 
the design specification of these devices, and have been involved in the appraisal of 
different iterations. 
6.2.1 Specification and design of catheter microcoil  
Knowledge of previous published attempts to develop microcoils, the physical 
constraints on endoscopically delivered catheter devices and patient safety 
requirements informed the specification of the catheter microcoil. Requirements 
included: 
• Introduction and removal through a 3.2mm endoscope channel 
• Reproducible and consistent performance 
• Economic to manufacture as a single use device 
• MR compatible 
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• Sterilisable before single-use 
• Watertight  
• Electrically safe: including induced currents in MR fields 
• Non-toxic 
• Flexible, to make turns within the endoscope and the bile duct 
• Maintain at least one internal catheter lumen  
The microcoil detector is 60mm in length and 2.7mm in diameter and the whole 
catheter is 2m long.  A prototype version is pictured in Figure 4.2. The detector coil is a 
two-turn planar coil with stacked windings. Both the detector coil and its output cable 
are printed lithographically as thin-film devices on a polyimide substrate of less than 
100µm thickness (Figure 6.3a). This allows application of the whole detection and 
transmission system to the outside of a catheter, with subsequent shrink-wrapping 
(Figure 6.3b). This preserves the internal lumens without excessively increasing the 
catheter’s diameter. Necessary capacitors are integrated into the printed components, 
maintaining the required smooth, narrow profile of the catheter tip. All materials are 
non-magnetic; the catheter is watertight and electrically safe. The catheter can be 
passed through an endoscope biopsy channel and is flexible enough to withstand 
deflection by the duodenoscope’s elevator bridge. It is non-toxic and the cost and 
difficulty of volume production would be small.  
6.2.2 Specification and design of an MR duodenoscope with integrated RF 
detector microcoil  
There were several further considerations that emerged during the design and 
integration of a microcoil detector into the tip of a duodenoscope: 
• Space within the shaft of the endoscope is already almost maximally exploited, 
with transmission of tip actuation forces, light, air, optics, suction and biopsy 
channels.  Transmission of signal from the RF coil could not displace any of 
these functions, or diminish the performance of the endoscope 
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• The scope tip is particularly crowded and there is very little space for integration 
of further detection systems 
• The scope is side viewing and the MRI field of view must encompass the 
endoscopic field of view 
• Integration of a fiducial in the scope tip is necessary to permit MR tracking of 
the scope tip with a proposed MR tracking system 
•  Electrical safety is of critical importance 
The duodenoscope design is based on a 13 mm diameter non-magnetic side-viewing 
duodenoscope previously developed by Endoscan (Endoscan Ltd, London, UK). Non-
ferrous materials such as polymers, titanium metal, and glass are to be used for the 
flexible elements, the actuation wires, pivots and fixtures, and the imaging 
components, respectively. Unlike current clinical endoscopes, illumination will be 
provided using a remote white-light source and a fluidic optical fibre, and viewing will 
be carried out using a coherent fibre bundle that routes the image back to an eyepiece 
or a video camera mounted on the operating handle. Other normal endoscope 
functions are to be preserved, including water/air, suction and the biopsy channel. In 
addition, a sub-miniature cable will be integrated into the shaft, with an RF connector 
on the endoscope’s handle.  
The endoscope tip is the principal area of modification. A simplified diagram is shown 
in Figure 6.4, highlighting its most significant mechanical and optical features. The only 
space available for additional internal components in the tip lies beyond its distal end. 
Significantly increasing the length of the tip would reduce its mechanical performance, 
and might also increase the risk of inadvertent visceral perforation during simultaneous 
scope torqueing and tip deflection. Therefore, the size of the additional space added 
was kept to an absolute minimum. 
The tip design includes two coils. The 1st is the primary detector coil. This is a saddle 
coil, based on the optimum Ginsberg-Melchner design.[483] It is fabricated as a thin-film 
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printed circuit board (PCB). Its configuration on the PCB is illustrated in Figure 6.5a. 
The entire circuit is formed into a sleeve by sandwiching the PCB between two 
cylinders of plastic, with an opening to allow a clear endoscopic view and passage of 
catheter tools through the biopsy channel. This first coil is designed to be temporarily 
applied to the outside of the endoscope, to be removable between procedures and 
potentially disposable. To achieve intrinsic electrical safety, there is no direct 
connection between this first coil and the rest of the MR system. The second, much 
smaller, ‘pick-up’ coil is located in the small extension to the scope’s tip. This is sealed 
within the scope, but can be accessed by unscrewing the tip cap. Mutual coupling 
between the two coils occurs through the tip. The signal induced in this second coil by 
the first is transmitted via the coaxial cable in the scope shaft to the scope handle, and 
then on to the MR system. The 2nd coil is another thin-film PCB, arranged as a two-turn 
thin-film saddle coil, and is illustrated in Figure 6.5b. The internal coil is wrapped 
around a cylindrical plastic shell. The shell also contains a volume of a polymer-based 
wet burn pad (Spenco Healthcare International, UK), which provides an internal signal 
source to act as a fiducial marker.[484] Overall placement of the two coils on the tip of 
the duodenoscope is as shown in Figure 6.5c. The external coil is arranged to overlap 
both the internal signal source and the internal coil. 
Final build of the purpose-designed endoscope is still underway. Scope tip coil 
experiments described here were performed with the detector coil built into dummy 
scope tips, or applied temporarily to the outside of a previously constructed MR 
compatible duodenoscope. 
6.3 Hypothesis & Aims 
6.3.1 Hypothesis 
Intraductal and intraduodenal MR detector coils will increase the resolution of MR 
imaging of biliary and peri-ampullary anatomical structures 
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6.3.2 Aims 
1) To confirm the utility of a catheter based RF microcoil by: 
i) quantifying the resolution of images obtained 
ii) defining the sensitive range and signal uniformity 
iii) proving that the coil can function in wet conditions  
iv) demonstrating high resolution imaging of ex vivo pancreatobiliary tissue 
v) comparing the images obtained with those from the standard MR coil 
vi) quantifying signal-to-noise ratios achieved 
 
2) To confirm the utility of a prototype duodenoscope tip RF microcoil by: 
i) defining the sensitive range and signal uniformity 
ii) demonstrating high resolution imaging of ex vivo duodenal tissue 
iii) comparing the images obtained to equivalent EUS images 
iv) assessing the impact of simulated unavoidable (respiratory) motion artefact 
v) performing simultaneous endoscopic and MR imaging 
6.4 Catheter mounted microcoil testing 
1H MR imaging was performed using was performed using a 1.5 T HD Signa Excite 
scanner (GE Healthcare, Little Chalfont, UK). The standard gantry body coil was used 
for transmission and the microcoil was connected to the auxiliary coil input for 
reception. 
6.4.1 Resolution testing 
6.4.1.1 Method 
The microcoil was placed at the isocentre in the coronal plane as shown in Figure 
6.6A. The microcoil was auto-tuned using a large spherical phantom, using a fast 
recovery fast spin echo (FRFSE) sequence, and the transmission gain was gradually 
increased to the maximum allowed by the system. 
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A glass cuvette containing a nylon nut and cheesehead bolt in copper sulfate solution 
was used as a resolution test subject. The pitch of the bolt thread was known to be 
0.7mm. The microcoil was placed between the cuvette and the spherical MR phantom, 
as shown in Figure 6.6B. Localising scans were used to centre the image. Images 
were acquired using a T2-weighted FRFSE sequence. Imaging was carried out using a 
relaxation recovery time (TR) of 33 ms, an echo time (TE) of 15ms, flip angle 10o, FOV 
of 80x40 and 1.2mm slice thickness. 
6.4.1.2 Results 
Images were acquired. Figure 6.7 shows a sagittal image, in which the 0.7mm pitch 
teeth of the bolt are clearly resolved. This demonstrates strongly sub-millimetre 
resolution imaging. The sensitive range was quantified as 15mm radius around the 
length of the microcoil. 
6.4.2 Field uniformity testing 
6.4.2.1 Method 
A test rig was constructed and used to hold the microcoil probe immersed in copper 
sulphate solution, Figure 6.8. A sagittal scout image was obtained before axial images 
were acquired along the length of the microcoil, using the MR settings detailed in 
6.4.1.1. 
6.4.2.2 Results 
The microcoil functioned well when immersed in liquid. Figure 6.9 shows a sagittal 
image from a localising scan. The microcoil can be seen running vertically, together 
with the support rod and co-axial wire. Figure 6.10 shows 28 consecutive axial slices 
along the microcoil. The central dark area represents the catheter. The signal is highly 
uniform along the length of the coil. Degradation is apparent in the early images, where 
the coil is attached to the rig. Two small defects can also be seen along the length of 
the coil, due to the the coil conductors. 
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6.4.3 Tissue contrast testing 
6.4.3.1 Method 
A number of different tissues were used. Butchered porcine material was obtained from 
a specialist supplier (Medical Meats, Rochdale, UK), so that en bloc specimens could 
be used. The MR settings from 6.4.1.1 were used. 
6.4.3.1.1 Specimens examined 
i) Bile duct. The cystic duct was incised and the microcoil placed within it, as 
shown in Figure 6.11. Axial images were obtained along the length of the coil.  
ii) Gallbladder fossa. The microcoil was placed on the surface of the liver, as 
shown in Figure 6.13A&B. Axial images were first obtained with the standard 
body coil. Imaging was then repeated with the same settings, but using the 
microcoil for detection. 
iii) A pancreas. The microcoil was placed alongside the specimen, with a cuvette 
phantom as a marker, as shown in Figure 6.16A and B. Axial images were first 
obtained with the standard body coil. Imaging was then repeated with the same 
settings, but using the microcoil for detection.  
6.4.3.1.2 Signal-to-noise ratio (SNR) 
In experiments ii and iii, the signal-to-noise ratio (SNR) was calculated. To calculate 
SNR, the scanner workstation and software were used (G.E.). Two 40-pixel diameter 
regions of interest (ROIs) were defined. The first ROI was selected within the most 
homogeneous area of the tissue scanned. An ROI was then defined outside the tissue, 
in the image background (i.e. air). The standard deviation of signal strength at this ROI 
was calculated. Where S is the signal mean from the ROI in the tissue and SDair is the 
standard deviation in the ROI in air:[485] 
SNR = S / SDair  
6.4.3.2 Results 
6.4.3.2.1 Biliary tree 
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Images were obtained. Features of the cystic duct, including its junction with the 
common bile duct could be discriminated. Extraductal features, including adjacent 
ducts and vessels could also be seen, Figure 6.12. 
6.4.3.2.2 Gall bladder 
Images were obtained. Figure 6.14A, B & C show images obtained with the standard 
body coil. Figure 6.15 shows representative images obtained with the microcoil. 
Resolution was substantially better in the microcoil images. SNR ratios were eight-fold 
greater in the microcoil images (260 vs 30). 
6.4.3.2.3 Pancreas 
Images were successfully obtained. Figure 6.17 shows images obtained with the 
standard body coil. Figure 6.18 shows representative images obtained with the 
microcoil. Resolution was substantially better in the microcoil images. SNR ratios were 
ten-fold greater in the microcoil images (300 vs 30). 
6.5 Duodenoscope coil testing 
Again, 1H MR imaging was carried out at 1.5 T using a GE Signa Excite clinical scanner 
at St Mary’s Hospital, London. The system body coil was used for excitation, and the 
test coil was connected to an auxiliary coil input for signal reception.  As the purpose-
designed duodenoscope with integrated detector coil and transmission was not 
complete, the detector coil was rigged on a number of different dummy scope tips to 
permit evaluation. The right hand side of Figure 6.19 shows such an arrangement. 
6.5.1 Sensitivity testing 
6.5.1.1 Method 
Initial evaluations were used to determine imaging sensitivity. To provide an internal 
fiducial, a 1.4 mm ID catheter was filled with Spenco and passed up the centreline of 
the coil. To provide an external signal source, the coil was mounted on a cuboid 
phantom filled with a solution containing 3.37 g/L NiCl2.6H2O and 2.4 g/L NaCl, with T1 
of 500-800ms and T2 of 100-200ms. Imaging was carried at the magnet isocentre, with 
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the coil at a variable angle with respect to the magnet bore. A gradient echo sequence 
was used, with a repetition time TR of 51 ms, an echo time TE of 2.692ms, a flip angle 
of 30o, a slice thickness of 1.2 mm, a slice separation of 2.2 mm, and a FOV of 120 
mm.  4 excitations were used to improve SNR.  Figure 6.20 shows the general 
arrangement; with the coil parallel to the MR scanner bore. 
6.5.1.2 Results 
A representative axial image acquired in shown in Figure 6.20. The Spenco fiducial is 
visible as a small bright circle, with a SNR of ≈ 85. It remained visible up to an angle of 
about 60o with respect to the bore, when the SNR fell to ≈ 40. At 80o, the SNR fell 
rapidly, to ≈10, although the fiducial was still visible within the image.  
6.5.2 Uniformity testing 
6.5.2.1 Method 
The scope tip coil was insulated and immersed in a tank fabricated from welded 
polyether ether ketone (PEEK) sheet. Water was used to fill the tank and the coil’s 
internal lumen. The tank was placed on the scanner trolley, with the coil parallel to the 
magnet bore. Imaging was carried out with 2D gradient echo sequence with TR = 
34ms, TE of 13ms, a slice thickness of 2 mm, a slice separation of 3 mm and a FOV of 
80mm. Eight excitations were used to improve SNR. The left hand side of Figure 6.21 
shows the experimental arrangement. Axial slices were obtained. 
6.5.2.2 Results 
A representative axial slice image is shown in the right of Figure 6.21. The surrounding 
water can be seen, together with a small central spot defining the fiducial. Four brighter 
regions indicate field concentrations near the four coil conductors. This image suggests 
that the coil response is highly uniform, with little angular variation and a gradual radial 
decay in sensitivity. 
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6.5.3 Porcine liver imaging 
6.5.3.1 Method 
The specimen was a butchered porcine liver, with the biliary ductal system and gall 
bladder intact, with a section of attached duodenum. The duodenum was opened with 
a scalpel to allow the tip coil to be located next to the ampulla of Vater. Imaging was 
carried out with a T2-weighted fast recovery fast spin echo sequence with TR of  33ms, 
TE of 15ms, a flip angle of 100 , a slice thickness of 1.2 mm and a FOV of 80 mm. 4 
excitations were used to improve SNR. The left side of Figure 6.22 shows the 
experimental arrangement. 
6.5.3.2 Results 
A representative axial image is shown in the right side of Figure 6.22. The central dark 
region again corresponds to the tube the coil is mounted on, while the surrounding 
bright tissue represents the duodenum. The biliary duct may be seen on the left-hand 
side of the duodenum. Excellent image detail is obtained up to a radius of at least 30 
mm. 
6.5.4 Motion artefact simulation 
To define the degree of image degradation caused by expected and unavoidable 
(respiratory) motion artefact, a simulator was designed and built.   
6.5.4.1 Method 
Motion artefacts were generated using a hydraulically driven stage consisting of a 
suspended table capable of carrying an in-vitro liver specimen and RF detector, which 
was remotely driven by a reciprocating syringe pump as shown in Figure 6.23 and 
6.24. The table of the motion generator consisted of a large movable stage supported 
on multiple balanced flexures. The table was driven using a large syringe arranged as 
a hydraulic ram. All table components were non-magnetic. The excursion of movement 
was ± 2cm with a load-bearing capacity of around 1 kg. This table was located on the 
patient trolley within the scanner bore. The hydraulic drive system was located in the 
scanner control room, remote from the magnet bore. It consisted of a linear actuator 
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(Portescap 57DBM10B2U-L, 88N, RS 340-6489 or RS 510-1120), which drove a 
similar syringe between variable limits. At maximum speed, full travel between limits 
could be achieved in around 3s, a reasonable simulation of respiratory motion. The 
actuator and driver were linked together using 10 m of water-filled flexible hydraulic 
line, which ran between the scanner control room and the magnet room. The hydraulic 
line was passed through the waveguide port into the magnet room. A porcine duodenal 
specimen was placed in the sample tray and an duodenoscope tip RF microcoil coil 
was placed inside the duodenum. The RF coil was arranged parallel to the magnet 
bore. 
Imaging was carried out using a standard 3D GRE biliary sequence. Slices were 
obtained in blocks of 28, with a FOV of 80mm, a slice thickness of 1.2 mm, a spacing 
between slices of 1.2mm, an echo time TE of 15ms, a repetition time TR of 33ms, and 
a flip angle of 10o. Multiple excitations (NEX of 4) were used to improve SNR, and the 
total acquisition time was around 5min 40s. This time corresponded to a very large 
number of table motion cycles. 
6.5.4.2 Results 
Images were obtained with and without activation of the motion generator.  
The images on the left of Figure 4.25 show coronal slice images obtained with the table 
stationary. The duodenum is running vertically, and bright tissue with good detail and 
high contrast may be seen one either side of a central dark band indicating the position 
of the RF detector. The images on right of Figure 4.25 show exactly corresponding 
images obtained with the table moving. All anatomical detail has now been completely 
destroyed, although the approximate location of the RF detector may still be identified. 
These results confirm the need for a tracking algorithm for in-vivo work, which is 
another part of the wider Wellcome project that was introduced in 6.1.3. 
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6.5.5 Comparison with EUS 
Endoscopic ultrasound (EUS) is the current gold standard for the local staging of distal 
CC and pancreatic cancer. To demonstrate any advantage of our MR system, we 
compared the images of a butchered porcine specimen obtained with those that can be 
produced at EUS. 
6.5.5.1 Method  
The imaged specimen comprised the distal 25cm of stomach, the duodenum, biliary 
tree and liver. The cystic duct was transected at the gallbladder neck and then 
cannulated. The ductal system was distended down to the ampulla with warm agar gel, 
which then cooled and solidified. Before imaging, the specimen was allowed to come to 
room temperature and was immersed in tap water in a large water bath.  
Clinical governance and infection control rules mean that we cannot perform EUS 
studies on non-human material using clinical endoscopes. Therefore, a dedicated 
research EUS system, which will never be used in human subjects, was obtained on 
loan from the manufacturer’s headquarters in Tokyo, Japan (Olympus KeyMed, 
Southend, UK). An Olympus GF-UM2000 EUS endoscope was used. This is a 
mechanical radial ultrasonic system that incorporates a HyperBand ultrasound 
transducer in its tip. This is able to scan at between 5 and 20 MHz with a field of view 
that can be set between 20 and 120mm. An Olympus EU-ME1 Universal Ultrasound 
Centre was used as the EUS image processor. Video image processing, air-water 
supply and suction were not connected to the endoscope, as these were not required 
for the conduct of this experiment. As in clinical practice, a water filled balloon was 
placed around the scope tip US transducer.  
To confirm correct operation of the system, preliminary imaging of air voids and 
volumes of water were undertaken. The porcine specimens were then imaged. Using 
direct vision and palpation of the specimens, the EUS tip was placed at different points 
in the duodenum (left side of Figure 6.26). In most images, the scope tip balloon was 
inflated to 1.5cm diameter with tap water. B-mode EUS images were obtained at a 
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variety of US frequencies and range settings. Images obtained were compared to 
those from earlier MR microcoil imaging of an identical specimen. 
6.5.5.2 Results  
Multiple images were obtained within the duodenum with visualisation of the distended 
bile duct seen. A representative image is presented in the right of Figure 6.26, where 
EUS settings were 20MHz, 6cm FOV. Comparative imaging from the prior MR 
microcoil duodenal imaging appeared superior (Figure 6.27). 
6.5.6 Integration of coil imaging with duodenoscope  
To simulate the planned purpose-built endoscope, the scope tip coil was applied to the 
end of the previously constructed MR compatible duodenoscope. This does not have 
the integrated induction coil and transmission line, but otherwise is highly similar to the 
design outlined in 6.2.2.  
The flexible light guide was made over-length, to allow the placement of a tungsten 
filament light source (SN LB-24, Welch Allyn, Skaneateles Falls, NY, USA) in the 
scanner control room. An eyepiece and then a MR-compatible video camera (WAT-
231S, Watec, Orangeburg, NY, USA) were used for viewing the endoscopic image. 
The umbilical was also made over-length, to allow connection to air and suction 
supplies on the wall of the magnet room rather than the standard, non-MR compatible 
endoscopy service stack. Water was delivered from a bottle (MD-431, Olympus 
KeyMed). 
The duodenoscope was evaluated cautiously in the magnet room, and no magnetic 
forces were observed. I obtained optical images of porcine specimens using the 
eyepiece and also using the video camera. The latter were successfully transmitted to 
a PC in the scanner control room and then projected on a screen in the magnet room. 
Figure 6.28 shows the instrument in use, and an optical image of a porcine ampulla 
obtained using the video camera. 
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Susceptibility effects and decoupling were observed by placing the instrument on a 
cuboid phantom, with the shaft parallel to the magnet axis, and obtaining MR images 
using the system body coil. No significant image disturbance was observed, suggesting 
that any perturbations caused by the duodenoscope and coil to the local magnetic field 
are minimal. MR imaging was then performed using the instrument itself. A 2D Axial T2 
sequence was used, with TR of 68ms and TE of 3.44ms, a flip angle of 30o, a 3 mm 
slice thickness and 3.3 mm slice separation. 6 excitations were used to improve SNR. 
Figure 6.29 shows the arrangement and an axial image in which the surrounding 
phantom and the internal fiducial may both clearly be seen.  
6.6 Discussion 
Two new RF detector microcoil devices have been developed and demonstrated. 
These devices are designed for 1H MR imaging at 1.5T magnetic field strength. The 
first is a catheter-mounted system for insertion into the biliary tree via a duodenoscope, 
with the intention of producing high resolution imaging of the bile duct and any 
strictures therein. The second device is a RF detector coil system for integration into 
the tip of an MR compatible duodenoscope. This scope tip coil is intended to enhance 
the MR imaging of adjacent hepatopancreatobiliary tissues, and afford data that can be 
integrated into other areas of the Wellcome project, including automated catheter 
tracking and robotic scope control. The design of an MR compatible duodenoscope 
with integration of the scope tip detector device has been completed and it is now 
being manufactured. 
6.6.1 Catheter mounted microcoil 
6.6.1.1 Catheter microcoil performance 
The catheter produced has an appropriate physical profile and handling characteristics 
for use through a duodenoscope. It is constructed of non-toxic materials and its 
electrical design is intrinsically safe, with no direct connection to any power source and 
built in decoupling to prevent large induced currents when used within the MR scanner. 
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We have demonstrated that this device can reliably produce images of a resolution of 
at less than 1mm, and field uniformity is excellent. The device is water resistant. The 
catheter microcoil can produce high quality images of ex vivo tissue, including biliary 
and pancreatic tissue. We have demonstrated interpretable anatomical detail with sub-
millimetre resolution. The images and signal-to-noise ratios demonstrated are superior 
to those obtained using a standard body coil. Imaging has been successful, even with 
the catheter microcoil passed through a duodenoscope biopsy channel within the 
scanner. 
A catheter-mounted microcoil has the potential to enhance clinical MR imaging of the 
bile duct, as well as a number of exciting research applications. A major advantage of 
the proposed technique is that it could provide cross sectional imaging of the diseased 
bile duct and adjacent tissue. This is not possible with techniques such as ERCP or 
choledochoscopy. The precise extent of invasion has shown to be the major predictor 
of survival after surgery for CC, and is poorly characterised by current imaging 
methods. In a clinical context, this new microcoil technology should provide very high-
resolution images of any hilar or distal biliary lesion, and delineation of invasion into 
adjacent tissues.  
6.6.1.2 Experimental techniques, catheter microcoil 
The imaging protocols used to date have required long (>5 minutes) acquisition times, 
and this would not be acceptable in a clinical study, unless a mechanism for motion 
artefact correction is determined. In early experiments, prototype coils would fail during 
some scans. Measurements taken during a test sequence demonstrated large currents 
induced in the microcoil during the scanner RF transmission pulses, beyond the 
tolerance of the coils. Further progress was hampered by the high microcoil attrition 
rate caused. A decoupling system was therefore integrated into the microcoil design. 
This breaks the microcoil circuit during RF transmission, reactivating it between such 
pulses. This allows detection of lower energy RF signal during proton relaxation but 
prevents damaging current induction during scanner RF transmission.  
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The imaging of ex vivo tissue is useful in demonstrating the proof-of-concept of the 
microcoil and refining it. However, the study of ex vivo tissue is an imperfect model of 
clinical imaging. Devitalised tissue deteriorates rapidly, affecting imaging 
characteristics and the differentiating properties of adjacent tissues. The lack of blood 
flow through the ex vivo models prevented the use of contrast agents, which are 
increasingly important to tissue contrast in clinical MR scans. Respiratory motion 
artefact is common in MR imaging and degrades images substantially, as 
demonstrated in the motion simulation testing of the scope tip coil. We have not yet 
directly assessed the effect it may have on the catheter microcoil images, but would 
anticipate substantial image degradation. A variety of strategies can be used to 
mitigate respiratory artefact including gated imaged acquisition and, experimentally, 
field shift coils. These approaches are being investigated by other subgroups in the 
Wellcome project. 
6.6.1.3 Further work warranted, catheter microcoil 
My studies of the catheter-mounted microcoil demonstrate the potential of this new 
approach to imaging of the biliary tree. It is also clear that applications within the rest 
GI tract, and beyond, should be possible. It is now necessary to demonstrate that 
comparable, or better, images can be produced in vivo. Introduction of the catheter via 
an endoscope into a sedated human subject in the MRI scanner, with 
contemporaneous MR imaging would be a substantial first experiment. This would be 
unlikely to gain necessary approvals. However, after appropriate safety assessments 
and research ethics approval, we plan a number of incremental studies to further 
confirm the proof-of-concept and patient safety.  
We will integrate a microcoil detector into a standard nasogastric (NG) tube. This could 
then be passed, without sedation or endoscopy, into a patient’s oesophagus. The FOV 
of the catheter should permit oesophageal MR imaging. This would constitute an initial 
human study, with only minimal risk to the volunteer. 
Chapter 6 – MR microcoils 
 280 
Introduction of the catheter into the biliary tree via existing clinical access could be 
achieved via the placement of a balloon anchored nasobiliary drainage catheter. The 
Cholangioscopy Access BalloonTM (Cook Medical, Bloomington, IL, USA) can be 
placed at ERCP and retained in the bile duct by an air filled balloon. For patient 
comfort, the access balloon catheter is then converted from a per oral route to a per 
nasal route. Once placed, this arrangement is entirely tolerable for a conscious 
patient.[486, 487] Once recovered, the patient could undergo MR scanning with the 
microcoil passed down the nasobiliary catheter that is already in situ – without the need 
for further sedation or an endoscopy within the MRI suite. Alternatively, a microcoil 
catheter could be passed down the lumen of a percutaneous biliary drainage system, 
as has been previously reported.[471, 472] 
Although simulations are possible, investigation of microcoil tracking and management 
of motion artefact will only be possible once in vivo studies can proceed. Furthermore, 
the administration of IV contrast to enhance tissue resolution would then also be 
feasible. The acquisition of high resolution MR spectroscopy data should be possible 
using the microcoil.[488] This remains to be confirmed in in vitro experiments, but may 
offer an exciting further research application of this microcoil. 
Animal studies could be considered for some of these steps. However, if patient safety 
can be assured then a research ethics committee may consider approving some initial 
human experiments without an animal phase. 
6.6.2 Duodenoscope with tip microcoil 
6.6.2.1 Scope tip coil performance 
A duodenoscope tip RF detector coil has been produced and tested, but has yet to be 
fully integrated into an MR compatible duodenoscope. The coil systems have been fully 
developed and tested on dummy scope tip rigs. The design of the scope tip coil was 
informed by experience with the prototype catheter based devices, and the literature. 
Part of the coil system will fit over the end of the modified duodenoscope and will be 
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disposable. The secondary coil is retained within the scope tip itself. The external coil 
is non-toxic and has intrinsic electrical safety, with no direct connection between the 
coil and any external systems. The coil arrangement permits high quality images to be 
obtained over a wide field of view. Sensitivity, uniformity and resolution testing have 
confirmed good performance. Simulation of respiratory motion artefact caused 
complete loss of tissue resolution. Images of porcine specimens obtained with this MR 
coil compared favourably with those obtained by a commercial clinical EUS system. 
Interpretable duodenal detail was demonstrated, with a wide field of view (diameter 
>3cm).  
The successful development of this coil, and its pending integration to the 
duodenoscope, are a critical part of the wider Wellcome funded project. This will permit 
progress with endoscope tip tracking within the magnet bore and the robotised control 
systems. If clinical imaging proves possible, the scope tip coil may offer improved 
resolution upper GI and hepatopancreatobiliary imaging, and has the theoretical 
potential to supersede EUS as the most sensitive staging test for cancers in these 
organs. 
6.6.2.2 Integration with MR compatible duodenoscope 
The duodenoscope, the design of which was considered in 6.2.2, is being constructed 
from MR-compatible materials, and will combine a coherent fibre bundle for optical 
imaging, an irrigation channel and a side-opening biopsy channel for the passage of 
catheter tools with the saddle coil for MR signal reception and an internal fiducial 
marker. The MR scope tip receiver coil will be magnetically coupled to an internal 
pickup coil for intrinsic safety, and the system will be tuned, matched and actively 
decoupled using the minimum of internal components.  
A simulation of the designed instrument, with a scope tip coil attached to an existing 
MR duodenoscope, has been evaluated in a conventional MR imaging suite, and 
allows optical and MR images to be obtained simultaneously without loss of 
functionality in either system.  
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6.6.2.3 Experimental techniques, scope tip coil 
As previously stated, the scope tip coil was never fully integrated into a duodenoscope 
during these experiments. Work has therefore focussed on rigs where the proposed 
coil system is built into dummy scope tips. This is an entirely reasonable approach, as 
getting the coil arrangements to work in isolation is likely to prove the most difficult part 
of the process. An external firm is building the duodenoscope itself and we could not 
await completion before commencing testing of the coils. Indeed, results from the initial 
testing of the scope tip coil arrangements have informed the duodenoscope design 
extensively, ensuring that the delivered device should function as required and 
expected. In obtaining the images to compare the EUS and MR systems, we used a 
butchered porcine model. As already considered in 6.5.1.2, ex vivo tissue is not 
necessarily an accurate model for normal tissue imaging. This may have caused 
relative disadvantage to the EUS system. However, it is likely that any deterioration in 
the tissue would disadvantage both techniques equally. The motion artefact generator 
worked as planned. It may not have represented a high-fidelity simulation of respiratory 
movement artefact, but our experiment is unlikely to have overestimated the impact of 
this type of movement. It is clear that motion detection and correction is going to prove 
critical to the successful in vivo application of this device. 
6.6.2.4 Further work warranted, scope tip coil 
The high quality of the images suggests that the duodenoscope tip coil will indeed 
provide useful in vivo performance. Once the integrated scope is in hand it will be 
further tested, but not on any non-human material as this would preclude its future use 
in human studies. Once the completed instrument has undergone safety testing on the 
bench top and in the MR scanner room, and ethical approval has been obtained, in 
vivo human imaging trials are planned.  
It has been confirmed that approval from the medicines and healthcare products 
regulatory authority (MHRA) is not required for the further investigation of either device 
in humans as they are not commercially exploited and remain the subject of academic 
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research at present. Ethical approval will be sought for incremental clinical studies, as 
explained in 6.5.1.3. With the scope tip device, straightforward upper GI endoscopy 
could be performed first, on a patient or healthy volunteer. This could be undertaken 
within the MR scanner, but without any attempt to cannulate the bile duct. MR scanning 
of extra-luminal structures could be undertaken, with and without contrast, with minimal 
risk beyond that of a standard upper GI endoscopy. 
Integration with other elements of the broader project will see the duodenoscope used 
in simulated procedures within the MR scanner, with MR tracking and robotic control 
systems in place. 
6.6.3 Conclusion 
Two new devices have been developed in collaboration between the Departments of 
Electrical & Electronic Engineering and Medicine, Imperial College London. In a variety 
of in vivo and ex vivo experiments, both devices have been shown to perform safely 
and produce high-resolution images.  
The work, in a multi-disciplinary research team of physicians, engineers and MR 
physicists, has offered me substantial insight into the different techniques and 
strategies used in developing a new device from scratch. This has contrasted and 
complimented the more traditional biomedical approaches of my other research 
studies.  
The work presented in this Chapter represents my contribution to two much larger 
projects, funded by the ESPRC and Wellcome Trust. Both of these projects have 
fulfilled their stated aims and have led to further successful project grants. 
Significant further work, with translation of these devices in to human studies is 
planned. This work may lead to development of a clinically applicable system.  
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6.7 Chapter 6 Figures 
Figure 6.1: State of the art in RF detector microcoils for MR 
Legend: Previous attempts to construct MRI microcoil detectors. All have demonstrated 
some function, but none are suitable for per-endoscope biliary imaging. (A) Hillenbrand 
2004[489], (B) Woytasik, 2007[490] (C) Uelzen, 2006[491], (D) Zuehlsdorff, 2004[492] 
(A) 
 
(B) 
 
(C) 
 
(D) 
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Figure 6.2: Prototype catheter microcoil 
Legend: This microcoil is mounted on a flexible biliary catheter 
 
 
Figure 6.3: Diagram of catheter microcoil design 
Legend: Thin film RF detection system: a) plan view and b) integration on catheter. 
Note preservation of both catheter lumens and only modest increase in diameter. CM 
and CT – integrated capacitors, LC – coil. Diagram courtesy of Prof RRA Syms. 
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Figure 1. Thin filmRF detection system: a) plan view and b) integration on catheter.
capacitorswerevulnerable tomechanicaldamage ina side-opening
gastroscope, and the need for joints made it difficult to seal the
assembly for use in a wet environment. The sub-miniature coaxial
cable used to transmit the detected signal back along the catheter
blocked one of the internal lumens, which are typically required
for use with a guide-wire or an actuation wire or for injection of
contrast agent.
In this paper, we attempt to provide a solution in the form of a
thin-film detector with integrated shunt matching capacitors and
a thin-film output cable as shown in Figure 1a. Thewhole structure
may be fabricated lithographically from non-magnetic materials
and wrapped around a catheter as shown in Figure 1b, avoiding
the need for additional components, simplifying sealing and leav-
ing the catheter free for its original use. Except near the coil ends,
the configuration is similar to a two-turn planar coil with stacked
windings, with a corresponding field of view. The target applica-
tion here is biliary imaging, which may require data to be acquired
for lengths 50–60mm along the duct. Similar approaches could be
used for vascular imaging.
Operation of the system is shown in the equivalent cir-
cuit of Figure 2a. Here, a source VS representing the signal
induced by nuclear magnetic dipoles in a resonator based on
a coil with inductance LC and resistance RC is to be matched
to a load RL at the angular frequency !S of the MRI system
using matching and tuning capacitors CM and CT. Generally, RL
should be matched to the series sum of RC and the sample
Figure 2. a) Electrical equivalent circuit and b) simplified equivalent.
loading RS. However, assuming that RS is small (as shown exper-
imentally later) and that the cable impedance Z0 matches RL,
the system operates as shown in the simplified equivalent of
Figure 2b.
Key to successful operation is development of impedance-
matched cables and resonant detectors containing suitable
matching circuits. Geometric constraints and the need for flex-
ibility make it difficult to achieve the desired impedance using
either a microstrip [33] or a coplanar waveguide [34]. Here we
use a microstrip with a periodically patterned ground plane. This
approach is commonlyused inphotonicbandgapdevices [35], but it
can also modify low-frequency impedance (a factor that was pre-
viously ignored in favour of filter applications). We use a simple
resonant detector with integrated capacitors that can be fabri-
cated using compatible processing, and demonstrate a convergent
method of identifying the component values needed for matching
and tuning. Combining these elementswedemonstrate external 1H
magnetic resonance imaging at 1.5 T using a 2 metre-long catheter
based detector, constructed entirely from thin film components.
A design for an impedance-matched thin-film cable is presented
in Section 2, and fabrication and measurements of transmission
characteristics in Section 3. A design for a compatible thin-film coil
with integrated capacitors is presented in Section 4, and fabrication
and matching and tuning are described in Section 5. Preliminary
MRI experiments are described in Section 6 and conclusions are
drawn in Section 7.
2. Thin-film cable design
In this Section, we consider possible cable formats, includ-
ing microstrip, coplanar waveguide and periodically patterned
microstrip, for an application such as a catheter-basedMRI detector
requiring very thin flexible layers of metals and dielectric.
2.1. Microstrip
Figure 3a shows one obvious possibility, a microstrip consist-
ing of two conducting layers separated by an insulator of relative
dielectric constant "r. One conducting layer is patterned into a strip
of width w, and the thickness of conductor and insulator are t and
h respectively. The characteristic impedance Z0 can be estimated
using Wheeler’s formulae [33]:
Z0 = ZFS c1 loge{1+ c2[c2c3 +
√
(c22c
2
3 + c4)]} (1)
Here ZFS =
√
(#0/"0) is the impedance of free space, and:
c1 = 1/{2!√[2(1+ εr)]} c2 = 4h/weff c3 = (14+ 8/εr)/11 c4 = !2(1+ 1/εr)/2
weff = w + t c5 loge{4e/
√
(c26 + c27)}
c5 = (1+ 1/εr)/2! c6 = t/h c7 = 1/{!(w/t + 11/10)}2
(2)
These expressions give the typical results shown in Figure 3a.
Here, we have assumed t =35#m and "r = 3.5, to model a Cu-
polyimide-Cu trilayer. Two curves are shown, for h=25#m and
h=50#m, and 50# impedance is only obtained for very small (<
100#m) strip widths, with w reducing as h decreases. The expla-
nation is the small separation of the conductors, which results
in low inductance and high capacitance per unit length. Reliable
lithographic fabrication in long lengths is therefore likely to be dif-
ficult. Larger inductance and/or smaller capacitance are required,
but using moderate (w ≈ 1mm) strip widths.
2.2. Coplanar waveguide
Figure 3b shows a second possibility, a coplanar waveguide
(CPW) consisting of a ground-signal-ground arrangement on a
dielectric backing. Z0 is found by evaluating the capacitance Cp per
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Figure 6.4: Diagram showing modified scope tip design 
Legend: The upper image shows the scope tip viewed en face to the optics and biopsy 
channel terminus. The lower is a side view of the bridge deflection system.  Diagram 
courtesy of Prof RRA Syms. 
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Figure 6.5: PCB layouts of scope tip coils 
Legend: Printed circuit board (PCB) layouts of (A) External scope tip saddle coil (B) 
internal ‘pick-up coil’. (C) is a 3D rendering of the coil once applied to the scope tip. 
C1A, C1B – capacitors of external coil, C2 – capacitor of internal ‘pick-up’ coil. L1 – 
external detector coil, L2 – internal ‘pick-up’ coil, PIN – PN diode. Diagram courtesy of 
Prof RRA Syms. 
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Figure 6.6: Arrangement of catheter microcoil for resolution testing 
Legend: (A) The coil is shown orientated in the axis of the bore (indicated by arrow B) 
of the MR scanner  (B) Cross-section of cuvette containing nylon bolt and copper 
sulphate solution 
 
 
Figure 6.7: Image acquired during resolution testing with catheter 
microcoil 
Legend: Thread pitch of bolt known to be 0.7mm 
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Figure 6.8: Uniformity testing set-up 
Legend: Lines through coil represent orientation of axial slices acquired.   B is the 
orientation of the magnet bore.   
 
 
Figure 6.9: Saggital scout image of microcoil 
Legend: The microcoil can be seen in saggital view with the coaxial wire extended out 
to the top left extreme of the field of view. 
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Figure 6.10: Axial images along length of microcoil  
Legend: Intensise signal was seen around the whole of the probe for almost its entire 
length, confirming good signal uniformity 
 
 
Figure 6.11: Experimental set up, porcine liver imaging 
Legend: The cystic duct has been incised at is junction with the common bile duct and 
the catheter mounted coil inserted, retrogradely, up the cystic duct 
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Figure 6.12: MR image porcine liver 
Legend: A representative axial slice through the catheter’s axis 
 
 
Figure 6.13: Arrangement of microcoil catheter on surface of liver 
specimen  
Legend: The catheter has simply been taped to the specimen, in the approximate axis 
of the gall bladder. 
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Figure 6.14:  MR images of liver specimen, obtained with standard body 
coil  
Legend: (A) the whole specimen, with microcoil seen as small, intense signal next to 
GB. (B) and (C) progressive magnification of body coil image of GB. Cf. MR microcoil 
images of same FOV in Figure 6.15. 
 
 
Figure 6.15: MR images of liver specimen, microcoil 
Legend: Microcoil acquired axial images showing high resolution of GB fossa 
structures 
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Figure 6.16: Arrangement of microcoil and pancreatic specimen 
Legend: The pancreas was arranged with a copper sulphate filled cuvette to act as a 
marker, as the volume of tissue was a relatively small target in the scanner bore. 
 
 
Figure 6.17: MR images of pancreas, obtained with standard body coil 
Legend: Axial images through pancreatic specimen and copper sulphate filled cuvette 
using the body coil. 
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Figure 6.18: MR images of pancreas, obtained with microcoil 
Legend: Microcoil images in the same orientation as those in 6.17. Resolution of 
structures approximate to the coil is substantially better. Note the screw head seen in 
some images. 
 
 
Figure 6.19: Thin film saddle coils before application to magrel 
Legend: The PCB arrangement of the cope tip microcoils is shown. The right hand side 
of the image shows the coils applied to a dummy scope tip. 
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Figure 6.20: Sensitivity testing of scope tip coil 
Legend: The left of the figure shows the experiment arrangement. The right of the 
figure shows the resulting axial MR image. Note the very high intensity spenco fiducial 
within the bore of the coil. 
 
 
Figure 6.21: Uniformity testing of scope tip coil 
Legend: Experimental arrangement is shown in the left of the figure, with the coil 
mounted in the PEEK tank, filled with water. The right of the figure shows the resulting 
axial MR image, with excellent uniformity. The tiny water fiducial can be seen in the 
centre of the coil, as can intense signal associated with the conductors. 
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Figure 6.22: Porcine liver/duodenal imaging with scope tip coil 
Legend: The left of the figure illustrates the positioning of the (covered) detector coil 
within the porcine duodenum. The right of the figure is a representative axial MR image 
showing good resolution of duodenal wall features. 
 
 
Figure 6.23 Motion artefact generator 
Legend: Schematic shows arrangement of the motion artefact generator located in 
separate areas of the MR suite. Diagram courtesy of Prof RRA Syms. 
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Figure 6.24: Photos of motion artefact experimental set up 
Legend: The test rig can be seen before and then after loading with the porcine 
specimen and placement in the MR bore. 
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Figure 6.25: Coronal images before and during motion simulations 
Legend: Images on the left are before activation of the motion generator, degradation 
of images once motion was generated can be seen in images on the right 
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Figure 6.26: EUS imaging of ex vivo porcine duodenum 
Legend: The arrangement of the EUS scope in the duodenum can be seen on the left. 
A representative axial EUS image is provided on the right. EUS settings were 20MHz, 
6cm FOV 
 
 
Figure 6.27: MR and EUS views of porcine duodenum 
Legend: Recapitulation of comparable MR microcoil (left) and EUS (right) images 
obtained from porcine duodenum scanning 
 
 
Chapter 6 – MR microcoils 
 300 
Figure 6.28: Integration of endoscopic and MR imaging 
Legend: The experimental set up is illustrated in the left side of the figure. A 
representative endoscopic video capture image is shown on the right. 
 
 
 
Figure 6.29: MR imaging with coil running through MR compatible 
duodenoscope 
Legend: The experimental set up is shown on the left, minimal artefactual distortion is 
seen in the representative axial image, shown on the right. 
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7. Summary and conclusion 
In pursuit of my stated overarching aim - ‘to improve understanding of the aetiology of 
cholangiocarcinoma and enhance its diagnosis and staging’ – I have undertaken 
experiments in three different fields.  
I have performed two genetic studies. The first investigated germline polymorphisms in 
five genes encoding biliary transporter proteins. Polymorphisms in three of these 
genes, ABCB11, ABCB4 and ATP8B1 were nominally associated with increased risk of 
CC. The positive findings in one gene, ATP8B1, persisted after Bonferroni correction 
for multiple testing. I believe that the positive findings in these three transporters 
warrant further investigation in a validation cohort. A collaboration between the 
Cholangiocarcinoma Group at Imperial College London and counterparts at the Mayo 
Clinic, MA, USA has been established. A multicentre, multinational genome wide 
association study for CC risk factors is planned. Validation of the biliary transporter 
associations presented in this thesis is to be attempted in their substantial Biobank of 
DNA samples from patients with sporadic CC. 
The second genetic study investigated polymorphisms in the NKG2D receptor as a risk 
factor for sporadic CC. Genetic polymorphisms in this his receptor have previously 
been implicated in PSC related CC.[72] The study presented here was more than 
adequately powered to detect the same effect seen in the prior study of PSC related 
CC, but the association was not replicated. This is an important negative finding and 
may point to important differences in pathogenesis between sporadic CC and PSC 
related CC. 
Three protein studies have been undertaken. The first utilised a GeLC-MS/MS 
proteomic approach to investigate and identify differentially expressed proteins in blood 
plasma from patients with CC and patients with benign, gallstone disease. Six proteins 
of interest were identified. Interestingly, several of these have previously been 
associated with malignancy. Of particular interest, the protein LRG1 has previously 
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been identified as elevated in the plasma of CC patients.[383] Several of the identified 
proteins warrant further investigation in validation cohorts, and this is being pursued.  
The second protein study employed a further proteomic technique, SELDI-TOF MS. 
This technique is high throughput and so large cohorts were investigated: 99 CC 
patients, 64 PSC and 107 healthy controls. To ensure avoidance of Type I error, 
separate discovery and validation studies were undertaken. Seven significant m/z 
peaks were found, all were validated in the second phase of the study. These seven 
peaks are likely to represent five unique proteins.  Three of those five unique proteins 
are close m/z matches with those identified in a previous SELDI-TOF MS study of 
plasma from CC patients.[360] The strongest of the five unique peaks appears to a novel 
finding in studies of hepatobiliary malignancy: m/z 4631. Given the strength of the 
findings, and partial replication of a previous high quality study, all five of these proteins 
warrant identification and further investigation. Again, this work is underway.  
The third protein study investigated a plasma protein, NGAL, as a biomarker for CC. 
This protein has previously been shown to elevated in bile samples from CC 
patients.[364] 97 CC patients, 64 PSC patients and 82 healthy controls were 
investigated. NGAL was not of utility in discriminating CC from PSC subjects in these 
cohorts. However, NGAL was elevated in both CC and PSC groups and showed 
reasonable utility in discriminating both disease groups from healthy controls. The 
difference between the groups was not attributable to sepsis, renal impairment, 
cholestasis or other factors investigated.  
In the final study presented in this thesis, the development of two new RF microcoil 
detector devices is described. One is catheter based and intended for insertion into the 
biliary tree via a duodenoscope at ERCP. The second is to be integrated into an MR 
compatible duodenoscope. Both devices act as detector coils for an attached MR 
system. They permit high-resolution radial imaging of tissues to which they are closely 
apposed. Results from in vitro and ex vivo testing of these devices are presented. Very 
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high-resolution imaging has been demonstrated, with favourable performance when 
compared to contemporaneous EUS imaging. These devices were developed as part 
of a wider project, investigating endoscopy within the MR scanner. Work is on going, 
and clinical studies are planned to confirm that the very promising ex vivo imaging can 
be replicated in vivo. 
The diversity of the studies I have undertaken and present in this thesis has required 
an understanding of a wide variety of analytical techniques, investigative strategies and 
scientific concepts.  The overarching aim has been to enhance the diagnosis of 
cholangiocarcinoma. In the course of the research period collaborations have been 
formed with a number of other UK and international institutions, which remain active. 
Biobank ethical approval has been put in place and a UK multicentre sample collection 
CC biomarker programme has received UKCRN support. This will offer the opportunity 
for validation studies of the positive findings in the genetic and proteomic studies 
presented in this thesis. 
Cholangiocarcinoma remains a relatively poorly understood disease, is an increasingly 
common diagnosis and carries a high mortality. Definitive diagnosis generally requires 
a multitude of investigations and treatment remains largely palliative. The complexity of 
diagnosis and management of patients with CC requires highly skilled surgeons, 
hepatologists, pathologists, radiologists, endoscopists and oncologists to collaborate 
as a multidisciplinary team. The clinical priority is to accurately identify the minority of 
patients who will benefit from prompt, curative resection and to optimise the palliative 
care of the majority who will not.  
International and national scientific collaborations are crucial if large studies are to be 
conducted into this uncommon disease, and new therapeutic and diagnostic 
techniques are to emerge. 
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Version 1.8 
 
BILIARY MALIGNANCY PROTEOMICS AND METABONOMICS STUDY 
 
Sample Collection SOP A: for subjects undergoing blood and urine collection only 
 
SAMPLE COLLECTION 
 
1. Confirm suitability, issue PIS, obtain informed consent. Copy of consent form to patient 
and notes 
 
2. Complete CRF including demographic details, clinical details, dietary and drug history 
 
3. A total of four tubes and 16mLs of blood is required. Note the time of blood collection on 
the CRF 
- Take one 4mLs EDTA tube (PURPLE TOP VACUTAINER) for proteomic and 
genomic studies 
- Take one 4mLs plain serum/no additive tube (BRIGHT RED TOP VACUTAINER) 
for metabonomic studies using MR spectroscopy 
- Take one 4mLs lithium heparin (GREEN TOP VACUTAINER) for metabonomic 
studies using MR spectroscopy 
- Take one 4mLs SST tube (YELLOW TOP VACUTAINER) for standard biochemical 
analysis 
 
4. Obtain ≥ 15mLs of urine in a plain, additive free universal container 
 
5. All samples (blood and urine) should be kept on ice with light excluded whilst processing 
is awaited 
 
6. Samples should be left for a minimum of 30 minutes before processing, but should be 
processed as soon as possible after this. Samples should be processed within a 
maximum of 2.5 hours. Collection and processing times should be documented on the 
CRF. 
  
SAMPLE PROCESSING 
 
7. Blood:  
‐ Keep blood samples on ice or in +4 oC fridge whilst processing awaited 
‐ Spin all blood samples at +4oC at 1000g for 10 minutes.  
- Store 200µL aliquots of each supernatant in Eppendorf tubes.  
- Please aim for a minimum of 4 aliquots from each vacutainer tube.  
- Note the time of centrifuging the on the CRF.  
- Remove the buffy coat layer from the EDTA sample and store in a cryovial or 
Eppendorph tube.  
- Discard all remaining cell layers in the vacutainers. 
 
8. Urine 
‐ Keep urine on ice or in +4oC fridge whilst processing awaited 
‐ Spin the urine sample at +4oC at 1000g for 10 minutes.  
‐ Store six 2mL aliquots of urine supernatant in Eppendorph tubes  
‐ Discard any remaining urine, cellular debris etc remaining in the urine tube 
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Version 1.8 
9. All samples should be stored at -80oC as soon as possible. However, short term storage 
in a standard -20oC freezer is acceptable, pending transfer to a -80oC freezer 
  
10. Allocate case number and record this on CRF  
 
11. Labelling 
 
- A unique case/subject identifier should be allocated in the site master file 
- Each aliquot should be labelled with a code.  
- This code starts with the allocated case/subject number, followed by an alphabetic 
code for the type of sample, followed by the aliquot number.  
- The coding for sample type is as follows: U = Urine, S = red cap serum, E = EDTA 
plasma, H = lithium heparin plasma, T = SST serum BC = buffy coat 
- E.g. for the third aliquot of EDTA plasma from subject HC1234 the label would 
read: ‘HC1234E3’ 
 
12. Record sample details in sample registry 
 
13. Archive consent form and CRF securely. 
 
Please direct any queries about this protocol to Dr Chris Wadsworth or Dr Mo Shariff 
Email:  c.wadsworth@imperial.ac.uk or m.shariff@imperial.ac.uk  
Office:  0208 383 8067 or 0208 383 5856 
Mobile: 07879811042 or 07971569850 
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VERSION 2.1 
 
BILIARY MALIGNANCY PROTEOMICS AND METABONOMICS STUDY - CRF 
Please complete as fully as possible. 
CASE NUMBER:   
DEMOGRAPHICS 
Patient initials:__________ Hospital number:_____________ Sex: M / F DoB:    /    / 
Ethnic origin:___________ Units of alcohol/day: __________ Cigarettes/day:______________ 
Occupation:____________ Rec drugs/betel nut:___________ LMP & cycle length:__________ 
Weight (kg):____________ Height (m):__________________ BMI:______________________ 
Exercise in last 24hrs: none / mild / moderate / hard 
MEDICAL HISTORY 
Principal current hepatobiliary diagnosis (circle all that apply):  
CC  / HCC / Liver Mets / PSC /  Pancreatic Ca  / Cirrhotic  / Healthy control / Other………… 
Diagnostic certainty: 
 Histologically proven  MDT consensus, fully investigated  Diagnosis likely, Ix pending 
Location of disease, if known:  
  
Previous therapy (tick all that apply, with date of last session) 
 Resection   /    /      Ablation   /   /      Chemotherapy    /   /     Radiotherapy   
 Biliary stent    /   /   TACE    /   /  PDT    /   /    Other…………   /   /  
 
OTHER CURRENT MEDICAL PROBLEMS 
List active diagnoses (esp malignant, inflammatory or infective processes): 
 
 Diabetes   Cholangitis   Systemic sepsis, any source 
 
DRUG HISTORY  
Please list all current medications (including herbal remedies and paracetamol/acetaminophen): 
 
 
 
 
 
 Diffuse process  Metastatic, extrahepatic disease  
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VERSION 2.1 
DIETARY HISTORY 
Time last ate ANYTHING ___ : ___  
Details of food and drink taken in the last 6 hours: 
 
List of other food and drink taken in last 24 hrs: 
 
Checklist of specific foods and drink taken in last 72hrs:  
Food   Details or comments Food   Details or comments 
Vegetarian  Vegan/non-vegan Nutrition drinks   
Meat  Red/white Cheese   
Fish  Type: Grapefruit   
Fizzy drinks   Berries   
Tea  Normal/herbal Liquorice   
Milk   Walnuts   
Cherries   Vanilla   
Yoghurt      
 
OTHER INVESTIGATIONS 
Most recent bloods on __ / __/ __ ALT:  ALP:  Bili:  Alb:  INR:
     AFP:  Ca 19-9: CeA:  Ur:  Cr: 
Summary of ERCP findings (if performed): 
Summary of most recent axial imaging findings (if performed): 
Samples placed on ice   Y / N 
Light excluded?    Y / N 
Samples processed by: 
Samples stored in which freezer?: 
Blood samples taken at:  __:__ 
Plain serum sample centrifuged at:  __:__ 
 
  All sections completed esp. time last ate, 
time of blood sample, time of centrifuge 
 
 
Pt. information sheet issued?  Y / N  
Informed consent obtained?   Y / N 
Samples taken: 
 2 x EDTA (Purple FBC tube) 
 1 x plain serum (Bright red cap tube) 
 15 ml urine   MSU    CSU 
 Bile, uncontaminated 
 Bile, with some saline 
 Bile, contaminated with contrast 
SAMPLE COLLECTION 
 
Please direct any queries about this CRF to Dr Chris Wadsworth or Dr Mo Shariff 
Email:  c.wadsworth@imperial.ac.uk or m.shariff@imperial.ac.uk  
Office:  0208 383 8067 or 0208 383 5856   
Fax:   0207 402 2796 
Mobile: 07879811042 or 07971569850 
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Table 2.7 Results from allelic association testing, Cochran-Armitage trend testing, dominant and recessive modelling for all 
SNPs 
Abbreviations: Chrom, Chromosome; SNP, single nucleotide polymorphism; A1, allele 1; A2, allele 2; Freq A, frequency of allele 1 in affected 
group; Freq UnA, frequency of allele 1 in unaffected group; OR, odds ratio; SE, standard error; L95 and U95, lower and upper limits of OR 95% 
confidence interval; allelic allelic association testing result; p, p-value; bold text - p-value <0.05. 
Gene 
Chrom SNP A1 Freq A Freq UnA A2 OR SE L95 OR U95 OR χ2 TEST AFF U-FF χ2 DF P 
ABCB11 rs497692 A 0.4908 0.4506 G 1.175 0.1423 0.8891 1.553 ALLELIC 160/166 228/278 1.288 1 0.2565 
Chrom 2          TREND 160/166 228/278 1.149 1 0.2838 
          GENO 43/74/46 60/108/85 1.361 2 0.5064 
          DOM 117/46 168/85 1.328 1 0.2492 
          REC 43/120 60/193 0.3779 1 0.5387 
 rs3755157 T 0.1108 0.098 C 1.146 0.234 0.7247 1.814 ALLELIC 35/281 49/451 0.3414 1 0.559 
          TREND 35/281 49/451 0.3268 1 0.5675 
          GENO 4/27/127 2/45/203 - - - 
          DOM 31/127 47/203 - - - 
          REC 4/154 2/248 - - - 
 rs6709087 G 0.2406 0.2273 A 1.077 0.1684 0.7745 1.499 ALLELIC 77/243 115/391 0.1959 1 0.6581 
          TREND 77/243 115/391 0.1994 1 0.6552 
          GENO 6/65/89 15/85/153 2.641 2 0.2669 
          DOM 71/89 100/153 0.95 1 0.3297 
          REC 6/154 15/238 0.9641 1 0.3261 
 rs853773 T 0.4905 0.45 C 1.177 0.144 0.8873 1.56 ALLELIC 155/161 225/275 1.277 1 0.2585 
          TREND 155/161 225/275 1.167 1 0.2799 
          GENO 40/75/43 58/109/83 1.625 2 0.4438 
          DOM 115/43 167/83 1.625 1 0.2025 
          REC 40/118 58/192 0.2376 1 0.6259 
 rs853772 C 0.5032 0.4643 A 1.169 0.1437 0.8818 1.549 ALLELIC 159/157 234/270 1.176 1 0.2781 
          TREND 159/157 234/270 1.064 1 0.3023 
Gene SNP A1 Freq A Freq UnA A2 OR SE L95 OR U95 OR χ2 TEST AFF U-FF χ2 DF P 
Appendices 
 340 
Chrom 
          GENO 44/71/43 61/112/79 1.066 2 0.5869 
          DOM 115/43 173/79 0.794 1 0.3729 
          REC 44/114 61/191 0.676 1 0.411 
 rs3821120 C 0.4099 0.4012 G 1.037 0.1451 0.7802 1.378 ALLELIC 132/190 203/303 0.06257 1 0.8025 
          TREND 132/190 203/303 0.06181 1 0.8037 
          GENO 25/82/54 44/115/94 1.185 2 0.553 
          DOM 107/54 159/94 0.5594 1 0.4545 
          REC 25/136 44/209 0.246 1 0.6199 
 rs16823014 A 0.06329 0.076 G 0.8215 0.2861 0.4689 1.439 ALLELIC 20/296 38/462 0.4737 1 0.4913 
          TREND 20/296 38/462 0.4577 1 0.4987 
          GENO 1/18/139 2/34/214 - - - 
          DOM 19/139 36/214 - - - 
          REC 1/157 2/248 - - - 
 rs4148797 G 0.3057 0.2874 A 1.092 0.1569 0.8028 1.485 ALLELIC 96/218 146/362 0.3139 1 0.5753 
          TREND 96/218 146/362 0.2953 1 0.5868 
          GENO 16/64/77 25/96/133 0.4405 2 0.8023 
          DOM 80/77 121/133 0.4274 1 0.5133 
          REC 16/141 25/229 0.01313 1 0.9088 
 rs16856300 C 0.4267 0.3944 A 1.143 0.1482 0.8545 1.528 ALLELIC 128/172 198/304 0.8092 1 0.3683 
          TREND 128/172 198/304 0.7869 1 0.375 
          GENO 25/78/47 44/110/97 2.777 2 0.2494 
          DOM 103/47 154/97 2.181 1 0.1397 
          REC 25/125 44/207 0.04911 1 0.8246 
 rs4148794 C 0.4399 0.3755 T 1.306 0.1458 0.9814 1.738 ALLELIC 139/177 190/316 3.359 1 0.06685 
          TREND 139/177 190/316 3.102 1 0.07819 
          GENO 31/77/50 43/104/106 4.35 2 0.1136 
          DOM 108/50 147/106 4.341 1 0.03722 
          REC 31/127 43/210 0.4537 1 0.5006 
Gene SNP A1 Freq A Freq UnA A2 OR SE L95 OR U95 OR χ2 TEST AFF U-FF χ2 DF P 
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 rs17267869 C 0.1338 0.1587 T 0.8184 0.2058 0.5468 1.225 ALLELIC 42/272 80/424 0.9507 1 0.3295 
          TREND 42/272 80/424 0.9713 1 0.3244 
          GENO 0/42/115 8/64/180 - - - 
          DOM 42/115 72/180 - - - 
          REC 0/157 8/244 - - - 
 rs3770585 A 0.4 0.49 G 0.6939 0.148 0.5192 0.9273 ALLELIC 120/180 245/255 6.122 1 0.01335 
          TREND 120/180 245/255 6.201 1 0.01277 
          GENO 23/74/53 59/127/64 6.202 2 0.04501 
          DOM 97/53 186/64 4.292 1 0.0383 
          REC 23/127 59/191 3.931 1 0.0474 
 rs2287622 T 0.45 0.3563 C 1.478 0.1456 1.111 1.966 ALLELIC 144/176 181/327 7.229 1 0.007173 
          TREND 144/176 181/327 6.801 1 0.009112 
          GENO 31/82/47 39/103/112 8.991 2 0.01116 
          DOM 113/47 142/112 8.991 1 0.002713 
          REC 31/129 39/215 1.13 1 0.2879 
 rs2058996 A 0.4903 0.424 G 1.307 0.1455 0.9823 1.738 ALLELIC 151/157 212/288 3.382 1 0.06591 
          TREND 151/157 212/288 3.619 1 0.05713 
          GENO 36/79/39 39/134/77 4.195 2 0.1228 
          DOM 115/39 173/77 1.396 1 0.2374 
          REC 36/118 39/211 3.812 1 0.05088 
 rs3770596 A 0.4968 0.4221 T 1.351 0.1457 1.016 1.798 ALLELIC 155/157 206/282 4.285 1 0.03846 
          TREND 155/157 206/282 4.096 1 0.04297 
          GENO 35/85/36 51/104/89 8.406 2 0.01495 
          DOM 120/36 155/89 7.951 1 0.004805 
          REC 35/121 51/193 0.1327 1 0.7156 
 rs13416802 C 0.1313 0.1146 G 1.167 0.2165 0.7634 1.784 ALLELIC 42/278 58/448 0.5092 1 0.4755 
          TREND 42/278 58/448 0.5098 1 0.4752 
          GENO 2/38/120 4/50/199 - - - 
Gene SNP A1 Freq A Freq UnA A2 OR SE L95 OR U95 OR χ2 TEST AFF U-FF χ2 DF P 
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          DOM 40/120 54/199 - - - 
          REC 2/158 4/249 - - - 
 rs2287618 A 0.3449 0.2996 G 1.231 0.1532 0.9118 1.662 ALLELIC 109/207 151/353 1.843 1 0.1746 
          TREND 109/207 151/353 1.713 1 0.1907 
          GENO 18/73/67 30/91/131 4.339 2 0.1142 
          DOM 91/67 121/131 3.569 1 0.05889 
          REC 18/140 30/222 0.02466 1 0.8752 
 rs7605199 G 0.4299 0.502 A 0.7483 0.1445 0.5638 0.9932 ALLELIC 135/179 255/253 4.038 1 0.04449 
          TREND 135/179 255/253 4.019 1 0.04499 
          GENO 28/79/50 65/125/64 4.151 2 0.1255 
          DOM 107/50 190/64 2.141 1 0.1434 
          REC 28/129 65/189 3.334 1 0.06786 
 rs3815676 G 0.02454 0.02953 A 0.8268 0.4437 0.3466 1.973 ALLELIC 8/318 15/493 0.1842 1 0.6678 
          TREND 8/318 15/493 0.1896 1 0.6633 
          GENO 0/8/155 0/15/239 - - - 
          DOM 8/155 15/239 - - - 
          REC 0/163 0/254 - - - 
 rs4148773 T 0.07669 0.0754 C 1.019 0.2679 0.6024 1.722 ALLELIC 25/301 38/466 0.004699 1 0.9454 
          TREND 25/301 38/466 0.004602 1 0.9459 
          GENO 1/23/139 2/34/216 - - - 
          DOM 24/139 36/216 - - - 
          REC 1/162 2/250 - - - 
 rs3814382 T 0.3549 0.4104 C 0.7906 0.1474 0.5923 1.055 ALLELIC 115/209 206/296 2.545 1 0.1106 
          TREND 115/209 206/296 2.555 1 0.1099 
          GENO 19/77/66 43/120/88 2.768 2 0.2505 
          DOM 96/66 163/88 1.359 1 0.2437 
          REC 19/143 43/208 2.253 1 0.1334 
 rs10930343 G 0.4815 0.4272 A 1.245 0.1429 0.9411 1.648 ALLELIC 156/168 217/291 2.36 1 0.1245 
Gene SNP A1 Freq A Freq UnA A2 OR SE L95 OR U95 OR χ2 TEST AFF U-FF χ2 DF P 
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          TREND 156/168 217/291 2.306 1 0.1289 
          GENO 34/88/40 52/113/89 5.408 2 0.06695 
          DOM 122/40 165/89 4.951 1 0.02608 
          REC 34/128 52/202 0.01601 1 0.8993 
 rs7577650 A 0.4472 0.3972 G 1.228 0.1443 0.9252 1.629 ALLELIC 144/178 201/305 2.022 1 0.1551 
          TREND 144/178 201/305 1.999 1 0.1574 
          GENO 31/82/48 42/117/94 2.388 2 0.303 
          DOM 113/48 159/94 2.353 1 0.1251 
          REC 31/130 42/211 0.4771 1 0.4897 
ABCB4 rs31652aa G 0.1335 0.09717 A 1.432 0.2234 0.9242 2.219 ALLELIC 43/279 48/446 2.603 1 0.1067 
Chrom 7          TREND 43/279 48/446 2.485 1 0.115 
          GENO 5/33/123 2/44/201 - - - 
          DOM 38/123 46/201 - - - 
          REC 5/156 2/245 - - - 
 rs2097937 G 0.2125 0.1574 A 1.445 0.1836 1.008 2.07 ALLELIC 68/252 79/423 4.045 1 0.04431 
          TREND 68/252 79/423 3.924 1 0.0476 
          GENO 11/46/103 4/71/176 - - - 
          DOM 57/103 75/176 - - - 
          REC 11/149 4/247 - - - 
 rs31653aa A 0.09938 0.08434 G 1.198 0.2464 0.7392 1.942 ALLELIC 32/290 42/456 0.5389 1 0.4629 
          TREND 32/290 42/456 0.4994 1 0.4798 
          GENO 4/24/133 2/38/209 - - - 
          DOM 28/133 40/209 - - - 
          REC 4/157 2/247 - - - 
 rs2373593 C 0.1104 0.08333 A 1.366 0.2392 0.8545 2.182 ALLELIC 36/290 42/462 1.707 1 0.1914 
          TREND 36/290 42/462 1.601 1 0.2057 
          GENO 4/28/131 2/38/212 - - - 
          DOM 32/131 40/212 - - - 
Gene SNP A1 Freq A Freq UnA A2 OR SE L95 OR U95 OR χ2 TEST AFF U-FF χ2 DF P 
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          REC 4/159 2/250 - - - 
 rs31666aa C 0.1437 0.132 T 1.104 0.207 0.7358 1.656 ALLELIC 46/274 66/434 0.2284 1 0.6327 
          TREND 46/274 66/434 0.2222 1 0.6374 
          GENO 3/40/117 6/54/190 - - - 
          DOM 43/117 60/190 - - - 
          REC 3/157 6/244 - - - 
 rs31668aa G 0.06707 0.06324 A 1.065 0.2865 0.6074 1.867 ALLELIC 22/306 32/474 0.04826 1 0.8261 
          TREND 22/306 32/474 0.04431 1 0.8333 
          GENO 3/16/145 1/30/222 - - - 
          DOM 19/145 31/222 - - - 
          REC 3/161 1/252 - - - 
 rs8187799 G 0.09451 0.0754 A 1.28 0.2532 0.7793 2.102 ALLELIC 31/297 38/466 0.9546 1 0.3286 
          TREND 31/297 38/466 0.8942 1 0.3444 
          GENO 2/27/135 3/32/217 - - - 
          DOM 29/135 35/217 - - - 
          REC 2/162 3/249 - - - 
 rs31676aa T 0.2075 0.2044 C 1.02 0.177 0.7208 1.442 ALLELIC 66/252 103/401 0.01209 1 0.9125 
          TREND 66/252 103/401 0.01071 1 0.9176 
          GENO 11/44/104 15/73/164 0.2028 2 0.9036 
          DOM 55/104 88/164 0.004664 1 0.9456 
          REC 11/148 15/237 0.1535 1 0.6952 
 rs1149222 G 0.1962 0.2191 T 0.8699 0.1781 0.6136 1.233 ALLELIC 62/254 110/392 0.6135 1 0.4335 
          TREND 62/254 110/392 0.5495 1 0.4585 
          GENO 11/40/107 15/80/156 2.037 2 0.3612 
          DOM 51/107 95/156 1.311 1 0.2523 
          REC 11/147 15/236 0.1583 1 0.6907 
 rs4148826 G 0.177 0.2028 A 0.8458 0.183 0.5908 1.211 ALLELIC 57/265 103/405 0.8389 1 0.3597 
          TREND 57/265 103/405 0.7209 1 0.3959 
Gene SNP A1 Freq A Freq UnA A2 OR SE L95 OR U95 OR χ2 TEST AFF U-FF χ2 DF P 
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          GENO 9/39/113 17/69/168 0.7571 2 0.6849 
          DOM 48/113 86/168 0.7373 1 0.3905 
          REC 9/152 17/237 0.2041 1 0.6514 
 rs2109505 A 0.1687 0.2016 T 0.8038 0.1848 0.5596 1.155 ALLELIC 55/271 102/404 1.399 1 0.2369 
          TREND 55/271 102/404 1.223 1 0.2688 
          GENO 7/41/115 17/68/168 1.374 2 0.5032 
          DOM 48/115 85/168 0.7846 1 0.3757 
          REC 7/156 17/236 1.072 1 0.3004 
 ABCB4_ind :- 0.02516 0.01786 AGAAA 1.419 0.4913 0.5419 3.718 ALLELIC 8/310 9/495 0.513 1 0.4738 
          TREND 8/310 9/495 0.5241 1 0.4691 
          GENO 0/8/151 0/9/243 - - - 
          DOM 8/151 9/243 - - - 
          REC 0/159 0/252 - - - 
 rs1202283 G 0.5127 0.4724 A 1.175 0.1437 0.8867 1.557 ALLELIC 161/153 240/268 1.261 1 0.2614 
          TREND 161/153 240/268 1.168 1 0.2798 
          GENO 46/69/42 60/120/74 1.637 2 0.4411 
          DOM 115/42 180/74 0.2718 1 0.6021 
          REC 46/111 60/194 1.634 1 0.2011 
 rs4148812 C 0.3281 0.266 G 1.348 0.1563 0.9921 1.831 ALLELIC 105/215 133/367 3.656 1 0.05588 
          TREND 105/215 133/367 3.594 1 0.05801 
          GENO 20/65/75 16/101/133 4.905 2 0.08608 
          DOM 85/75 117/133 1.562 1 0.2114 
          REC 20/140 16/234 4.532 1 0.03326 
 rs2302386 G 0.1419 0.1627 A 0.851 0.2057 0.5686 1.274 ALLELIC 42/254 82/422 0.6164 1 0.4324 
          TREND 42/254 82/422 0.5789 1 0.4467 
          GENO 4/34/110 9/64/179 - - - 
          DOM 38/110 73/179 - - - 
          REC 4/144 9/243 - - - 
Gene SNP A1 Freq A Freq UnA A2 OR SE L95 OR U95 OR χ2 TEST AFF U-FF χ2 DF P 
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ABCC2 rs717620 T 0.1957 0.206 C 0.9375 0.1788 0.6604 1.331 ALLELIC 63/259 103/397 0.1301 1 0.7183 
Chrom 10          TREND 63/259 103/397 0.1316 1 0.7167 
          GENO 4/55/102 12/79/159 - - - 
          DOM 59/102 91/159 - - - 
          REC 4/157 12/238 - - - 
 rs2756109 G 0.4395 0.4272 T 1.051 0.1448 0.7916 1.397 ALLELIC 138/176 217/291 0.1201 1 0.7289 
          TREND 138/176 217/291 0.111 1 0.739 
          GENO 33/72/52 52/113/89 0.1587 2 0.9237 
          DOM 105/52 165/89 0.1584 1 0.6906 
          REC 33/124 52/202 0.01768 1 0.8942 
 rs4148391 A 0.1442 0.138 T 1.052 0.2041 0.7053 1.57 ALLELIC 47/279 69/431 0.06227 1 0.8029 
          TREND 47/279 69/431 0.06373 1 0.8007 
          GENO 3/41/119 4/61/185 - - - 
          DOM 44/119 65/185 - - - 
          REC 3/160 4/246 - - - 
 rs2073337 G 0.375 0.3976 A 0.9089 0.1468 0.6816 1.212 ALLELIC 120/200 202/306 0.4234 1 0.5153 
          TREND 120/200 202/306 0.4442 1 0.5051 
          GENO 19/82/59 39/124/91 0.9946 2 0.6082 
          DOM 101/59 163/91 0.04668 1 0.8289 
          REC 19/141 39/215 0.9864 1 0.3206 
 rs2002042 T 0.2438 0.2233 C 1.121 0.1677 0.8072 1.558 ALLELIC 79/245 113/393 0.4671 1 0.4943 
          TREND 79/245 113/393 0.4884 1 0.4847 
          GENO 6/67/89 13/87/153 2.256 2 0.3236 
          DOM 73/89 100/153 1.245 1 0.2645 
          REC 6/156 13/240 0.4653 1 0.4952 
 rs7476245 A 0.07187 0.05976 G 1.218 0.2869 0.6944 2.138 ALLELIC 23/297 30/472 0.4754 1 0.4905 
          TREND 23/297 30/472 0.5106 1 0.4749 
          GENO 0/23/137 0/30/221 - - - 
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          DOM 23/137 30/221 - - - 
          REC 0/160 0/251 - - - 
 rs3740066 A 0.3281 0.3834 G 0.7854 0.1501 0.5852 1.054 ALLELIC 105/215 194/312 2.593 1 0.1073 
          TREND 105/215 194/312 2.802 1 0.09413 
          GENO 14/77/69 33/128/92 2.857 2 0.2396 
          DOM 91/69 161/92 1.884 1 0.1699 
          REC 14/146 33/220 1.792 1 0.1807 
 rs3740065 C 0.1415 0.126 T 1.143 0.2099 0.7578 1.725 ALLELIC 45/273 63/437 0.408 1 0.523 
          TREND 45/273 63/437 0.3696 1 0.5432 
          GENO 5/35/119 7/49/194 0.4113 2 0.8141 
          DOM 40/119 56/194 0.4113 1 0.5213 
          REC 5/154 7/243 0.04054 1 0.8404 
 rs3740063 C 0.4264 0.4605 T 0.8709 0.1432 0.6578 1.153 ALLELIC 139/187 233/273 0.9323 1 0.3343 
          TREND 139/187 233/273 1.013 1 0.3143 
          GENO 28/83/52 47/139/67 1.426 2 0.4902 
          DOM 111/52 186/67 1.426 1 0.2325 
          REC 28/135 47/206 0.1313 1 0.7171 
ATP8B1 rs7241054 T 0.4658 0.504 C 0.8584 0.1429 0.6487 1.136 ALLELIC 150/172 254/250 1.143 1 0.285 
Chrom 18          TREND 150/172 254/250 1.163 1 0.2808 
          GENO 33/84/44 64/126/62 1.38 2 0.5016 
          DOM 117/44 190/62 0.3826 1 0.5362 
          REC 33/128 64/188 1.312 1 0.2519 
 rs1968274 C 0.2044 0.2185 T 0.9189 0.1757 0.6512 1.297 ALLELIC 65/253 111/397 0.2319 1 0.6301 
          TREND 65/253 111/397 0.2311 1 0.6307 
          GENO 8/49/102 11/89/154 0.8216 2 0.6631 
          DOM 57/102 100/154 0.5145 1 0.4732 
          REC 8/151 11/243 0.1094 1 0.7408 
 rs17685876 G 0.2236 0.25 A 0.864 0.1687 0.6207 1.203 ALLELIC 72/250 126/378 0.7512 1 0.3861 
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          TREND 72/250 126/378 0.8131 1 0.3672 
          GENO 6/60/95 12/102/138 0.8131 2 0.6659 
          DOM 66/95 114/138 0.7197 1 0.3962 
          REC 6/155 12/240 0.2526 1 0.6153 
 rs317826 A 0.3057 0.253 G 1.3 0.1596 0.9512 1.778 ALLELIC 96/218 128/378 2.717 1 0.09926 
          TREND 96/218 128/378 2.88 1 0.08969 
          GENO 14/68/75 12/104/137 3.537 2 0.1706 
          DOM 82/75 116/137 1.579 1 0.2089 
          REC 14/143 12/241 2.842 1 0.09183 
 rs4308033 A 0.4359 0.3933 C 1.192 0.146 0.8954 1.587 ALLELIC 136/176 199/307 1.45 1 0.2286 
          TREND 136/176 199/307 1.473 1 0.2248 
          GENO 30/76/50 37/125/91 1.689 2 0.4298 
          DOM 106/50 162/91 0.6555 1 0.4182 
          REC 30/126 37/216 1.495 1 0.2215 
 rs4306606 T 0.307 0.2579 C 1.274 0.1589 0.9333 1.74 ALLELIC 97/219 130/374 2.332 1 0.1268 
          TREND 97/219 130/374 2.315 1 0.1281 
          GENO 16/65/77 16/98/138 2.572 2 0.2764 
          DOM 81/77 114/138 1.415 1 0.2343 
          REC 16/142 16/236 1.926 1 0.1652 
 rs317845 C 0.2437 0.2461 T 0.9876 0.166 0.7133 1.367 ALLELIC 78/242 125/383 0.005676 1 0.9399 
          TREND 78/242 125/383 0.005979 1 0.9384 
          GENO 10/58/92 11/103/140 1.279 2 0.5275 
          DOM 68/92 114/140 0.2261 1 0.6345 
          REC 10/150 11/243 0.751 1 0.3862 
 rs317838 T 0.3187 0.354 C 0.8538 0.1521 0.6337 1.15 ALLELIC 102/218 177/323 1.08 1 0.2987 
          TREND 102/218 177/323 1.175 1 0.2783 
          GENO 14/74/72 26/125/99 1.237 2 0.5387 
          DOM 88/72 151/99 1.17 1 0.2794 
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          REC 14/146 26/224 0.3017 1 0.5828 
 rs317837 C 0.2357 0.25 T 0.925 0.1679 0.6657 1.285 ALLELIC 74/240 127/381 0.2157 1 0.6423 
          TREND 74/240 127/381 0.2328 1 0.6294 
          GENO 8/58/91 11/105/138 0.8251 2 0.6619 
          DOM 66/91 116/138 0.5185 1 0.4715 
          REC 8/149 11/243 0.1287 1 0.7198 
 rs11659313 C 0.1437 0.1601 T 0.8809 0.2002 0.595 1.304 ALLELIC 46/274 81/425 0.4017 1 0.5262 
          TREND 46/274 81/425 0.4 1 0.5271 
          GENO 3/40/117 7/67/179 - - - 
          DOM 43/117 74/179 - - - 
          REC 3/157 7/246 - - - 
 rs319454 A 0.3491 0.2811 G 1.371 0.1542 1.014 1.855 ALLELIC 111/207 140/358 4.205 1 0.0403 
          TREND 111/207 140/358 4.139 1 0.04192 
          GENO 21/69/69 19/102/128 4.505 2 0.1052 
          DOM 90/69 121/128 2.493 1 0.1144 
          REC 21/138 19/230 3.413 1 0.06468 
 rs7236365 T 0.4245 0.4084 C 1.069 0.1453 0.8039 1.421 ALLELIC 135/183 205/297 0.2095 1 0.6472 
          TREND 135/183 205/297 0.2149 1 0.643 
          GENO 28/79/52 40/125/86 0.2349 2 0.8892 
          DOM 107/52 165/86 0.1059 1 0.7449 
          REC 28/131 40/211 0.1971 1 0.6571 
 rs160993 A 0.1595 0.132 G 1.248 0.2008 0.8419 1.85 ALLELIC 52/274 66/434 1.22 1 0.2694 
          TREND 52/274 66/434 1.183 1 0.2768 
          GENO 5/42/116 5/56/189 1.198 2 0.5492 
          DOM 47/116 61/189 1.005 1 0.3162 
          REC 5/158 5/245 0.4759 1 0.4903 
 rs319448 G 0.4625 0.3849 A 1.375 0.1447 1.035 1.826 ALLELIC 148/172 194/310 4.852 1 0.02761 
          TREND 148/172 194/310 4.576 1 0.03242 
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          GENO 39/70/51 38/118/96 5.789 2 0.05533 
          DOM 109/51 156/96 1.65 1 0.199 
          REC 39/121 38/214 5.565 1 0.01833 
 rs319440 C 0.4255 0.4558 T 0.8841 0.1442 0.6664 1.173 ALLELIC 137/185 227/271 0.7301 1 0.3929 
          TREND 137/185 227/271 0.7214 1 0.3957 
          GENO 32/73/56 50/127/72 1.723 2 0.4226 
          DOM 105/56 177/72 1.567 1 0.2106 
          REC 32/129 50/199 0.002557 1 0.9597 
 rs17686300 A 0.2932 0.246 G 1.272 0.1602 0.9288 1.741 ALLELIC 95/229 123/377 2.252 1 0.1334 
          TREND 95/229 123/377 2.193 1 0.1386 
          GENO 16/63/83 15/93/142 2.595 2 0.2732 
          DOM 79/83 108/142 1.228 1 0.2677 
          REC 16/146 15/235 2.123 1 0.1451 
 rs319457 T 0.1074 0.1076 C 0.9978 0.2297 0.6361 1.565 ALLELIC 35/291 54/448 8.89E-05 1 0.9925 
          TREND 35/291 54/448 8.84E-05 1 0.9925 
          GENO 0/35/128 5/44/202 - - - 
          DOM 35/128 49/202 - - - 
          REC 0/163 5/246 - - - 
 rs319406 G 0.3639 0.386 A 0.9101 0.1487 0.68 1.218 ALLELIC 115/201 193/307 0.4016 1 0.5263 
          TREND 115/201 193/307 0.4151 1 0.5194 
          GENO 22/71/65 33/127/90 1.397 2 0.4974 
          DOM 93/65 160/90 1.085 1 0.2975 
          REC 22/136 33/217 0.04352 1 0.8348 
 rs319409 A 0.4506 0.4587 C 0.9681 0.1428 0.7317 1.281 ALLELIC 146/178 233/275 0.05161 1 0.8203 
          TREND 146/178 233/275 0.05177 1 0.82 
          GENO 35/76/51 51/131/72 0.8721 2 0.6466 
          DOM 111/51 182/72 0.4668 1 0.4945 
          REC 35/127 51/203 0.1405 1 0.7078 
Gene SNP A1 Freq A Freq UnA A2 OR SE L95 OR U95 OR χ2 TEST AFF U-FF χ2 DF P 
Appendices 
 351 
Chrom 
 rs12456346 G 0.443 0.3735 A 1.334 0.1458 1.002 1.776 ALLELIC 140/176 189/317 3.916 1 0.04782 
          TREND 140/176 189/317 3.686 1 0.05486 
          GENO 32/76/50 40/109/104 3.964 2 0.1378 
          DOM 108/50 149/104 3.716 1 0.0539 
          REC 32/126 40/213 1.329 1 0.249 
 rs9676158 T 0.07372 0.06073 C 1.231 0.2871 0.7012 2.161 ALLELIC 23/289 30/464 0.5252 1 0.4686 
          TREND 23/289 30/464 0.5649 1 0.4523 
          GENO 0/23/133 0/30/217 - - - 
          DOM 23/133 30/217 - - - 
          REC 0/156 0/247 - - - 
NR1H4 rs4764980 G 0.4565 0.4961 A 0.8533 0.1428 0.645 1.129 ALLELIC 147/175 252/256 1.234 1 0.2666 
Chrom 12          TREND 147/175 252/256 1.166 1 0.2803 
          GENO 36/75/50 66/120/68 1.172 2 0.5566 
          DOM 111/50 186/68 0.8888 1 0.3458 
          REC 36/125 66/188 0.6981 1 0.4034 
 rs56163822 T 0.03988 0.02988 G 1.348 0.3858 0.6331 2.872 ALLELIC 13/313 15/487 0.6045 1 0.4368 
          TREND 13/313 15/487 0.5819 1 0.4456 
          GENO 1/11/151 0/15/236 - - - 
          DOM 12/151 15/236 - - - 
          REC 1/162 0/251 - - - 
 rs61755050 C 0.003049 0.004016 T 0.7584 1.227 0.06849 8.398 ALLELIC 1/327 2/496 0.05113 1 0.8211 
          TREND 1/327 2/496 0.05132 1 0.8208 
          GENO 0/1/163 0/2/247 - - - 
          DOM 1/163 2/247 - - - 
          REC 0/164 0/249 - - - 
 rs1030454 G 0.1677 0.144 A 1.198 0.1972 0.8139 1.763 ALLELIC 53/263 72/428 0.8399 1 0.3594 
          TREND 53/263 72/428 0.8491 1 0.3568 
          GENO 5/43/110 4/64/182 - - - 
Gene SNP A1 Freq A Freq UnA A2 OR SE L95 OR U95 OR χ2 TEST AFF U-FF χ2 DF P 
Appendices 
 352 
Chrom 
          DOM 48/110 68/182 - - - 
          REC 5/153 4/246 - - - 
 rs35724aa G 0.3926 0.3386 C 1.263 0.1472 0.9465 1.685 ALLELIC 128/198 172/336 2.519 1 0.1125 
          TREND 128/198 172/336 2.37 1 0.1237 
          GENO 31/66/66 29/114/111 4.671 2 0.09675 
          DOM 97/66 143/111 0.4188 1 0.5175 
          REC 31/132 29/225 4.657 1 0.03093 
 
  
